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Generally, β,γ-unsaturated carbonyls are thermodynamically less stable than their 
corresponding ,β-unsaturated isomers.  An investigation of SmI2-mediated deconjugation 
of ,β-unsaturated esters to provide β,γ-unsaturated esters is described herein.  Under 
almost neutral conditions, ,β-unsaturated esters bearing good leaving groups at the γ-
position were reductively deconjugated into β,γ-unsaturated esters in excellent yields at 
low temperature.  The newly formed double bonds slightly favored E-geometry, whereas 
,β-unsaturated esters bearing poor leaving groups afforded both deconjugated products 
and saturated products.   
Bryostatin 1, a macrocyclic lactone isolated from the bryozoan Bugula neritina, has 
attracted great attention from the scientific community since its structure was identified by 
Pettit in 1982.  Clinical development of bryostatin 1 has been ongoing since 1990.  To date, 
bryostatin 1 has been the subject for various cancers, HIV and Alzheimer’s disease in more 
than 80 human clinical trials.  All the unique bioactivities of bryostatin 1 are closely related 
to its ability to modulate protein kinase C isozymes (PKCs), which are the key players in 
cell proliferation and death.  Clarifying the structure-activity relationship (SAR) of 
bryostatin 1 promises extraordinary benefits to our understanding of the detailed 
mechanism of PKC activation and regulation. 
The work described herein focuses on the preparation of the C-27 des-methyl bryostatin 





extension of our pyran-annulation and catalytic asymmetric allylation (CAA) 
methodologies was developed and successfully delivered the target analogue.  Upon 
addition of a catalytic amount of pyridine, the pyran-annulation reaction was more effective 
and consistent in terms of its yields.  The des-methyl analogue demonstrated that the C-27 
had no effect on the binding affinity to PKCs and the biological properties of the molecule.  
This discovery may facilitate future analogue syntheses.    
In order to investigate the role of the C-9 hemiketal hydroxyl group in the biological 
profile of bryostatin 1, a synthetic route was designed to prepare an analogue with the 
hemiketal alcohol.  In this route, SmI2-mediated reductive cyclization was attempted to 
construct the hydroxypyran A-ring.  Unfortunately, a side reaction occurring on the C-ring 
of the analogue prevented the desired cyclization.  Without the cyclized A-ring, an 
unexpected analogue was finally obtained, which had an expanded macrolactone with a 
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IR   infrared 
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μ   micro 
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xii 
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Me   methyl 
MeCN  acetonitrile 
MeOH  methanol 
MHz  megahertz 
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mol  mole(s) 
mp   melting point 
MS  mass spectrometry; molecular sieves 
Ms   methylsulfonyl (mesyl)  
m/z   mass to charge ratio 
NCS  N-Chlorosuccinimide 
nM   nanomolar (nanomoles per liter) 
NMO  N-methylmorpholie-N-oxide 
NMR  nuclear magnetic resonance 
NOE  nuclear Overhauser effect 
NOESY  nuclear Overhauser effect spectroscopy 
PCC  pyridinium chlorochromate 
PDC  pyridinium dichromate 
Ph   Phenyl 
PKC  protein kinase C 
xiii 
 
PMA  phorbol-12-myristate-13-acetate 
PMB   p-Methoxybenzyl  
ppm  parts per million (in NMR) 
PPTS  Pyridinium p-toluenesulfonate 
Pr   propyl 
iPr   isopropyl 
Py   pyridine 
q   quartet (spectral) 
quant  quantitative  
quin  quintuplet (spectral) 
Rf   retention factor (in chromatography) 
ROESY  rotating frame Overhauser effect spectroscopy 
rt   Room temperature 
s   second(s); singlet (spectral) 
SET   single electron transfer 
sext  sextet (spectral) 
t   triplet (spectral) 
TBAF  tetrabutylammonium fluoride 
TBDPS  tert-butyldiphenylsilyl 
TBS  tert-Butyldimethylsilyl  
TEMPO  2,2,6,6-tetramethyl-1-piperidinyloxyl 
Tf   trifluoromethanesulfonyl (triflyl)  
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TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TLC  thin-layer chromatography 
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TOCSY  total correlation spectroscopy 
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Ts   p-toluenesulfonyl 
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UV  ultraviolet 
vol   volume 
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The β,γ-unsaturated carbonyl functionalities are widely contained in naturally 
occurring products, and most of them exhibit unique biological activities.1-3  Many of them 
and their synthetic derivatives are currently used as drugs (Figure 1.1).  For instance, 
molfarnate 1.1 is a common antiulcerogenic agent, clavulanic acid 1.2 is an antibiotic drug, 
and the steroid tibolone 1.3 is utilized worldwide.  Ivermectins 1.4 and 1.5 are among the 
world’s most successful antiparasitic drugs in human medicine.4,5 These are listed on the 
“World Health Organization’s List of Essential Medicines”, which is a directory of the 
most important medication needed in a basic human health system.6   
The β,γ-unsaturated carbonyl functionalities also serve as intermediates to prepare 
various homoallylic functional groups, butyrolactones and five-membered rings, thus 
making them among the important building blocks in organic chemistry.  Since the 
thermodynamically stable ,β-unsaturated carbonyls are readily available, deconjugation 
is the straightforward method to access their relatively unstable isomers.   
Since the seminal report of the usage of samarium diiodide (SmI2) in organic chemistry 
by Kagan,7,8 it has become an important reducing reagent in organic synthesis.9-18     SmI2 
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is a polyvalent single-electron reducing agent and readily available in laboratories.7,8,19,20   
In addition, its reduction ability can be further modified by addition of Lewis bases, proton 
sources, and Lewis acids.21-24  More importantly, SmI2-mediated reductions demonstrate 
great chemoselectivity and wide functional group compatibility.8,25-30  Despite the plethora 
of synthesis applications in reductive eliminations and fragmentations,27,31-36 very little 
precedent exists in the SmI2-mediated deconjugation of ,β-unsaturated carbonyls.  To the 
best of our knowledge, the successful examples consist of only fluorides and epoxides.37-
40   
 
Previous α,β-Unsaturated Carbonyl Deconjuation Strategies 
Generally, ,β-unsaturated carbonyls are more thermodynamically stable than their 
deconjugated isomers.  Thus, in practice, deconjugated carbonyls are frequently isomerized 
to conjugated carbonyls.  Conversely, the application of deconjugation of ,β-unsaturated 
carbonyls in organic synthesis is limited.  In some instances, however, it is necessary to 
obtain the deconjugated isomers directly from the corresponding ,β-unsaturated 
carbonyls.   
In the vast literature, the most widely used strategy is kinetic protonation or alkylation 
(Figure 1.2).  Using strong bases, such as lithium N-isopropylcyclohexylamide (LiICA), 
the conjugated carbonyl is deprotonated to provide dienolate anion 1.8 at low temperature 
without self-condensation.  This anion predominantly reacts at the alpha carbon. 41-47  That 
the alpha carbon is more reactive than the gamma carbon is well explained by molecular 
orbital theory.41,42  Therefore, when dienolate anions react with electrophiles under kinetic 
conditions, they provide deconjugated β,γ-unsaturated carbonyls.  In the presence of 
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HMPA, the sterically unfavorable Z-geometrical isomers are predominantly formed.47  
Because the strong base is utilized, the molecules with base sensitive functionalities, 
especially the advanced intermediate, are excluded from this reaction.  This reaction is 
largely limited to the initial steps of syntheses.   
Photochemical deconjugation of α,β-unsaturated carbonyls has been studied for a long 
time. 48-54  For enones, two distinct absorptions are around 210-240 nm and 300-320 nm, 
corresponding to the π-π* and n-π* transition, respectively.  Under irradiation, α,β-
unsaturated carbonyl 1.11 undergoes a rapid E/Z isomerization of the double bond to 
provide geometrical isomer 1.12, which undergoes a concerted hydrogen migration 
following the Woodward-Hoffman rules (Figure 1.3).  This hydrogen migration provides 
a photodienol intermediate 1.13 via the single-excited state.  The photodienol can finally 
revert to the starting material, or can furnish β,γ-unsaturated carbonyl 1.14 after 
tautomerization.  This reaction generally suffers a moderate yield, though it has been 
successfully applied in the synthesis of Stemona alkaloids.55   
α,β-Unsaturated acids can be converted to β,γ-unsaturated esters via conjugated ketene 
imtermediates.56,57  Treatment of acid 1.18 with DCC provides 1.19, which undergoes an 
elimination to afford α,β-unsaturated ketene 1.20 (Figure 1.4).  Esterification of the 
unsaturated ketene with alcohol furnishes deconjugated ester 1.21.  Similarly, α,β-
unsaturated acid chlorides can be converted into β,γ-unsaturated esters via the same ketene 
intermediates.58,59  However, α,β-unsaturated acids or acid chlorides are not always readily 
accessible.  Thus, this approach is not widely applicable.  
Transition metal complexes are good catalysts for olefin migrations, but a mixture of 
inseparable isomers is generally obtained in deconjugation reactions.60  Other approaches 
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are occasionally reported, but they either require very specific reaction conditions, or are 
restricted to certain precursors.  Thus, it remains a great challenge to develop an efficient 
deconjugation method with wide applicability. 
 
Results and Discussion 
In the course of our ongoing bryostatin analogue studies, an interesting observation was 
made during the total synthesis of a novel analogue.  It offered a potential solution to the 
deconjugation of α,β-unsaturated carbonyls problem.   
Previously, an annulation strategy was developed in our lab.  This protocol allowed us 
to construct a cyclic ring from allylhalide 1.22 in an intramolecular fashion (Figure 1.5).61  
A model study demonstrated that, upon treatment with SmI2, the simplified bryostatin AB 
ring system 1.23 was obtained at 0 oC in high yield.  However, upon subjection of the real 
substrate 1.24 to the reductive-cyclization conditions, no desired product was observed.  
When 1.24 was attempted at -78 oC with a limited amount of SmI2, the eliminated C-20 
side chain was identified, and the labile allyl iodide functionality was found intact using a 
crude 1H NMR analysis.  This elimination of the C-20 side chain was completed in seconds 
after an addition of SmI2 reagent, monitored by TLC.  This process presumably occurred 
via sequential single-electron transfers and an elimination sequence.  These observations 
gave credence to the notion that SmI2 would be used to selectively deconjugate γ-
substituted ,β-unsaturated carbonyls under mild conditions.  And we decided to 
investigate the scopes and limitations of this methodology. 
A variety of γ-substituted conjugated esters were prepared.  They were derived from 




Based on the previous observation of the octadienoate elimination (the C-20 side chain 
of 1.24), γ-acetate conjugated ester 1.25a was probably a good candidate to be used to 
optimize the reaction conditions for deconjugation at this time.  It was then subjected to 
5.0 equivalents of SmI2 in THF at 0 oC (Table 1.1, entry 1).  This was adopted as standard 
conditions for the model substrates.  In this instance, the starting material 1.25a was 
consumed completely in seconds after the addition of SmI2, and the product 1.26 was 
obtained, however, in a poor yield.  Numerous unidentifiable compounds were collected.  
It was also found that the persistence of characteristic deep-blue color of SmI2 solution 
could be used to judge the endpoint of reactions.  Unfortunately, lowering the load of SmI2 
did not help increase the yield.  Although improved results were obtained at low 
temperatures, the yields were still moderate.   
It was suspected that the low yields were due to the side reactions of the intermediate 
dienolate anion 1.35, which was highly reactive and should be quenched immediately.  
With this in mind, the deconjugation reaction was investigated in the presence of proton 
sources in an attempt to avoid side reactions.  Significantly improved yields were obtained 
when the reaction was performed in protic sources (Table 1.1, entry 5-7).  With 1 equivalent 
of MeOH at -78oC, an improved 76% yield was obtained.  The optimal result in terms of 
yield was obtained with more than 10 equivalents of MeOH.  The replacement of MeOH 
by t-BuOH afforded essentially the same yield.  Under any circumstances, neither simple 
deacetylation product 1.28 nor olefin-reduced product 1.27a was observed.  It was worth 
noting that the addition of alcohol would also increase the reducing ability of SmI2 because 
of the good coordination ability of alcohols to oxophilic samarium. 21-23   
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Substrates with poor leaving groups at the γ-position required elevated temperatures to 
undergo deconjugations (Table 1.1, entry 10).  γ-Methoxy conjugated ester 1.25b was inert 
to SmI2 below -30 oC.  Even at room temperature, the reaction was sluggish with slightly 
more SmI2 and needed 4 hours to consume all the starting material.  In addition, the 
saturated compound 1.27b was obtained along with the deconjugated product 1.26, but no 
1.28 was observed.   
Having identified optimized conditions for deconjugation reaction, a series of primary 
γ-substituted ,β-unsaturated esters were examined to determine the impact of γ-
functionality upon the viability of this approach to deconjugation.  These reactions were 
performed under our optimized conditions, and the results are summarized in Table 1.2.  
These results clearly demonstrated that the nature of the substituent at the γ-position largely 
determined the reaction temperature required, and the selectivity as well as the yield of the 
deconjugation.    
In the cases of excellent and moderate leaving groups, the reactions were accomplished 
almost instantaneously at -78 oC under Ar (Table 1.2, entry 1, 3-6, 11-13).  Only 
deconjugated product 1.26 was obtained, and its yield was generally higher than 90%.  For 
instance, γ-iodo conjugated ester 1.25e furnished the deconjugated product in an almost 
quantitative yield.  The frequently occurred deiodination reaction was not observed, and 
this phenomenon was consistent with what happened during our bryostatin analogue 
synthesis.    
In contrast, with substituents bearing poor leaving groups, higher temperatures and 
much longer periods of time were required (Table 1.2, entry 2, 7-10).  Along with the 
deconjugated product 1.26, the saturated product 1.27 was also obtained.  The individual 
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yields and ratio of these two products varied, depending on the nature of a substituent.  
Methoxy group, for instance, provided more deconjugated product (1.26 : 1.27b = 66% : 
18%), whereas silyloxy group favored the saturated product (1.26 : 1.27i = 24% : 72%).  
As for allyloxy group, two products were obtained in equal ratio.  Once again, no 1.28 was 
observed in these reactions.  
An interesting case was 1.25g containing a hydroxy group.  It furnished exclusively 
deconjugated product 1.26 in 94% yield with in a relatively shorter period of time, 
compared to other substrates bearing poor leaving groups.  It assumed that this 
phenomenon was probably due to the coordination between the free hydroxy group and 
SmI2.  This coordination made the hydroxy group a good leaving group, thus its elimination 
was facilitated, leading to the deconjugated product. 
As a control reaction, unsubstituted crotonate 1.25n was subjected to the optimized 
conditions at room temperature.  After 6 hours’ treatment with SmI2, only about 46% of 
starting material was consumed and reduced to the expected saturated product (Table 1.2, 
entry 14).  It revealed that unsubstituted enoates were quite inert to our conditions.  In 
addition, the reactivity of the substituted (or unsubstituted) enoate was quite consistent with 
the nature of the leaving group in the molecule.     
Introducing an alkyl group at the γ-position of 1.25 could provide two geometric 
isomers, the cis and trans forms.  In addition, the steric hindrance of the alkyl group would 
potentially alter the composition of products.  To address the impact of the additional 
substituent on the deconjugation, several secondary γ-substituted conjugated esters of 1.29 
were prepared.  They were subjected to the optimized conditions.  The results are shown 
in Table 1.3.  
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The effect of the additional substituent on the chemoselectivity significantly depended 
on the leaving group involved.  The substrates with good leaving groups were not obviously 
affected (Table 1.3, entry 1-10, 17-19).  Either the racemic or chiral substrate furnished 
only the deconjugated product 1.30 (an inseparable mixture of geometric isomers), whose 
yield was virtually the same as that of the corresponding primary γ-functionalized enoate.  
By contrast, substrates with poor leaving groups were significantly influenced to provide 
more saturated product 1.31 to an extent of 10-20% more (Table 1.3, entry 13-16).  For 
instance, the TBS protected enoate 1.29i afforded saturated 1.31 as a single product in 93% 
yield.  The free hydroxyl 1.29f was a unique exception (Table 1.3, entry 11).  Its 
deconjugation pattern closely resembled that of the substrate with a good leaving group, 
probably because of the previously mentioned coordination of the hydroxyl group.    
In all instances, the deconjugated compound 1.30 was obtained as an inseparable 
mixture of Z/E isomers.  For the substrates 1.29 with a methyl group at the γ-position, the 
E-isomer was the favored one but the product ratios were largely substituent-dependent.  
Based on the integration of 1H NMR, substrates with chloride, mesylate and methoxy 
groups provided relatively good geometric selectivity at 4 : 1 favoring the E-isomer.  The 
iodide substituent barely gave any geometric selectivity.  Thus, the reductive elimination 
presumably proceeded via kinetic control, since little equilibration was developed towards 
the thermodynamically more stable E-isomers.  
Based on the results, the mechanism of this reductive deconjugation was proposed 
(Figure 1.6).  A single-electron transfer from the SmI2 to the substrate 1.32 furnished 1.33.  
With a good leaving group, a kinetic elimination provided 1.34, which was rapidly reduced 
to afford dienolate anion 1.35.  Then, a kinetic protonation gave the deconjugated product.  
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With a poor leaving group at the γ-position, a protonation reaction competed with the 
elimination on the intermediate 1.33, leading to the saturated product.   
 
Conclusion 
A new protocol has been developed to prepare deconjugated β,γ-unsaturated esters 
from γ-functionalized ,β-unsaturated esters.  Upon treatment with SmI2 in the presence 
of alcohol, substrates bearing good leaving groups at the γ-position are exclusively 
deconjugated rapidly in excellent yields at low temperature.  Substrates with a free 
hydroxyl group at the γ-position are also efficiently converted into deconjugated enoates, 
but an elevated temperature is required.  By contrast, a substrate bearing poor leaving 
groups generally affords a great amount of saturated product along with the deconjugated 
one.  The geometric selectivity of the newly formed double bond moderately favors the E-
isomer, with the best ratio as 4:1, obtained from –Cl- and –OMs-substituted substrates.62   
Further work will investigate the scope of this deconjugation reaction with respect to 
the types of functionalities that can be employed under these conditions.  Use of this 
reaction to prepare branched esters via alkylation will also be studied.  
 
Experimental Section 
All solvents were dried and distilled according to the guidelines in Purification of 
Laboratory Chemicals, 6th Ed. (Armarego and Chai, Butterworth-Heinemann: Oxford, 
U.K., 2009).  Diisopropylamine, diisopropylethylamine, triethylamine, pyridine, 
dichloromethane and ethyl acetate were distilled from CaH2 under an atmosphere of N2.  
Ether solvents (THF and Et2O) were distilled under N2 from sodium benzophenone ketyl.  
10 
 
Benzene and toluene were distilled from molten sodium metal under N2.  Solvents and 
reagents were deoxygenated where necessary by Freeze-Pump-Thaw technique and 
refilled with nitrogen prior to use.  Titanium tetrachloride and titanium isopropoxide were 
distilled prior to use.  Deuterated solvents were purchased from Cambridge Isotope 
Laboratories (all ≥ atom% D).  Reagents were purchased from Acros, Aldrich and Alfa, 
and used as received unless stated otherwise.  Argon, oxygen, and syngas (1:1 mixture of 
H2 and CO) were acquired from Airgas and used as received.  Glassware for reactions was 
oven dried at 110 oC for 4 hours and cooled down under a dry atmosphere prior to use, or 
flame-dried under an atmosphere of N2.  All air- and moisture-sensitive manipulations were 
performed by using oven-dried glassware, standard Schlenk techniques, and a glovebox 
under an atmosphere of N2.  Analytical thin-layer chromatography was performed on 
Merck Kieselgel 60 F254 plates eluting with the solvents indicated, visualized by exposure 
to UV light (254 nm), and stained with either an ethanolic solution of 12-
molybdophosphoric acid or a solution of KMnO4/K2CO3/NaOH.  Organic solutions were 
concentrated on a rotovap at aspirator pressure at 20-30 oC.  Flash column chromatography 
was performed on SiliaFlash® F60 silica gel (230-400 mesh, 60Å), and eluted with solvents 
indicated.  Melting points were recored using open capillary tubes on a Mel-Temp 
electrochemical melting point apparatus and were uncorrected.  Nuclear magnetic 
resonance (NMR) spectra were acquired on a Variann Inova 500 spectrometer operating at 
500 MHz and 125 MHz for 1H and 13C separately.  All 1H NMR chemical shifts were 
quoted in parts per million (ppm) relative to the line of the CDCl3 residual singlet at 7.27 
ppm (or the C6D6 residual singlet at 7.16 ppm), and 13C NMR chemical shifts were relative 
to the center line of CDCl3 triplet at 77.23 ppm (or the center line of C6D6 triplet at 128.62 
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ppm).  Multiplicities in the 1H NMR spectra were described as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, ABq = AB quartet, quin = quintet, sext = sextet, m = 
multiplet, br =broad.  Coupling constants were reported in Hz.  The structural assignments 
of 1H and 13C NMR spectra were elucidated with the aid of gCOSY, gDQCOSY, TOCSY, 
DEPT, HMQC and HMBC experiments.  Stereochemical assignments were based on 
coupling constants where possible, and with the aid of NOSEY1D, ROSEY1D, NOSEY 
and ROSEY experiments.  AA’BB’ systems were reported as doublets.  Infrared (IR) 
spectra were recored from a Perkin Elmer FT-IR Paragon 1000 PC spectrometer using a 
thin film supported between NaCl plates.  Optical rotations were acquired on Perkin Elmer 
Model 343 polarimeter using Na D-line with a 10 cm path length micro cell at 20 oC from 
CHCl3 solutions.  Ozone was generated by a Welsbach model T-816 generator.  Yields 
refer to purified and spectroscopically pure compounds.    
3-(t-Butyldimethylsilyloxy)propan-1-ol (1.37): To a round-
bottomed flask was charged NaH (60% dispersion in mineral oil, 
3.26 g, 81.4 mmol, 1.1 equiv) and anhydrous THF (160 mL, 0.5 
M).  With an ice-water bath, 1,3-propanediol (6.00 mL, 81.4 mmol, 1.1 equiv) was added 
dropwise via a syringe over 5 minutes under an atmosphere of N2.  It was allowed to warm 
to room temperature and stirred for 1 hour.  It was then cooled to 0 oC, and a solution of t-
butylchlorodimethylsilane (11.4 g, 73.9 mmol, 1.0 equiv) in THF (10 mL) was added into 
this reaction dropwise via a cannula over 10 minutes.  After the addition, it was allowed to 
warm to room temperature, and stirred at room temperature for 16 hours.  It was then 
quenched with brine (200 mL), and extracted with 3 x 30 mL of EtOAc.  The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
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pressure.  The remainder was distilled under reduced pressure at 80.0-84.0 oC/2.5 mmHg 
to provide the titled compound (13.2 g, 69.3 mmol, 99% yield) as a colorless oil.  
TLC:  Rf = 0.26 (EtOAc/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3): δ 3.84 (t, J = 5.6 Hz, 2H, H-3), 3.81 (t, J = 5.6 Hz, 2H, H-1), 
2.55 (bs, 1H, -OH), 1.78 (p, J = 5.6, 2H, H-2), 0.91 (s, 9H, H-6), 0.083 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3): δ 63.2 (C-3), 62.7 (C-1), 34.4 (C-2), 26.1 (C-6), 18.4 (C-5), 
-5.3 (C-4, C-4’); 
FTIR (neat): νmax 3347 (br), 2931, 2859, 1472, 1389, 1361, 1256, 1096, 964, 837, 777, 665 
cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C9H22O2SiNa 213.1287; found 213.1293. 
(2E,4E)-3-(tert-Butyldimethylsilyloxy)propyl Hexa-
2,4-dienoate (1.38): With an ice-water bath, to a mixture 
of sorbic acid (14.9 g, 131 mmol, 1.2 equiv), 1.37 (20.8 
g, 109 mmol, 1.0 equiv) and DMAP (6.76 g, 54.8 mmol, 0.5 equiv) in CH2Cl2 (220 mL, 
0.5 M) was added a solution of DCC (27.4 g, 131 mmol, 1.2 equiv) in CH2Cl2 (65 mL, 2.0 
M) via cannula, and the clear solution turned cloudy immediately.  This reaction was 
allowed to warm to room temperature slowly, and stirred for 16 hours under an atmosphere 
of N2.  The resulting milky reaction was filtered through a pad of celite, and the filtrate was 
washed with brine containing 1 vol% HCl (300 mL).  The aqueous layer was extracted 
with Et2O (3 x 30 mL).  The combined organic layers were washed with brine (200 mL) 
and dried over anhydrous Na2SO4.  The solution was filtered and concentrated under 
reduced pressure.  The remainder was purified by flash chromatography on silica gel 
eluting with 2-8 vol% of EtOAc in hexanes to provide the titled compound (30.4 g, 107.0 
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mmol, 98% yield) as a colorless oil.   
TLC:  Rf = 0.68 (EtOAc/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3) δ 7.25 (dd, J = 15.3, 10.1 Hz, 1H, H-9), 6.26 ~ 6.06 (m, 2H, 
H-11, H-10), 5.78 (dd, J = 15.3, 0.8 Hz, 1H, H-8), 4.24 (t, J = 6.5 Hz, 2H, H-1), 3.72 (t, J 
= 6.1 Hz, 2H, H-3), 1.88 (p, J = 6.2 Hz, 2H, H-2), 1.86 (d, J = 6.0 Hz, 3H, H-12), 0.90 (s, 
9H, H-6), 0.055 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 167.5 (C-7), 145.2 (C-9), 139.5 (C-11), 130.0 (C-10), 119.2 
(C-8), 61.4 (C-1), 59.7 (C-3), 32.1 (C-2), 26.1 (C-6), 18.9 (C-5, C-12), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 2120, 1717, 1647, 1619, 1471, 1390, 1360, 1328, 1301, 
1244, 1187, 1140, 1104, 1000, 938, 837, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H28O3SiNa 307.1705; found 307.1706. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-oxobut-2-
enoate (1.39): To a solution of 1.38 (1.54 g, 5.41 mmol, 
1.0 equiv) in 200 proof ethanol (50 mL, 0.1 M) was added 
Sudan Red 7B (0.6 mg, 2 umol, 0.03% equiv) as an indicator.  Then, this solution was 
cooled down to -78 oC, and purged with O3 (3 Psi, 60 Volts) at -78 oC.  When the bright 
pink-red color faded, the O3 stream was shut down and O2 bubbled through the reaction for 
5 minutes.  Then, DMS (4.0 mL, 54 mmol, 10.0 equiv) was added into this reaction in one 
portion at this temperature.  It was allowed to warm to room temperature, and stirred 
overnight (ca. 16 hours).  The solution was concentrated in vacuo.  The remainder was 
purified by a silica gel flash column eluting with 3-9 vol% EtOAc in hexanes to provide 
the titled compound (1.13g, 4.14 mmol, 77% yield) as a yellow oil.   
TLC:  Rf = 0.33 (Et2O/Hex = 3:7, v/v); 
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500 MHz 1H NMR (CDCl3) δ 9.76 (d, J = 8.3 Hz, 1H, H-10), 6.96 (dd, J = 15.9, 7.6 Hz, 
1H, H-9), 6.72 (d, J = 16.1 Hz, 1H, H-8), 4.34 (t, J = 6.4 Hz, 2H, H-1), 3.72 (t, J = 5.9 Hz, 
2H, H-3), 1.90 (p, J = 6.1 Hz, 2H, H-2), 0.88 (s, 9H, H-6), 0.043 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 192.5 (C-10), 165.0 (C-7), 140.5 (C-9), 139.4 (C-8), 63.0 
(C-1), 59.3 (C-3), 31.8 (C-2), 26.1 (C-6), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2931, 2858, 1730, 1701, 1643, 1471, 1392, 1361, 1305, 1250, 1176, 
1104, 1008, 981, 939, 838, 778, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H24O4SiNa 295.1342; found 295.1359. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Hydroxybut-2-enoate (1.25g): To a stirred solution of 
1.39 (3.17 g, 11.6 mmol, 1.0 equiv) in MeOH (40 mL, 0.3 
M) was added CeCl3∙7H2O (8.69 g, 23.3 mmol, 2.0 equiv) in one portion at room 
temperature.  It was stirred for 10 minutes until the entire solid was dissolved, this reaction 
was cooled down to -15 oC, and NaBH4 (0.679 g, 17.6 mmol, 1.5 equiv) was added in one 
portion. After 2 hours, this reaction was diluted with EtOAc (50 mL), and poured into a 
cold H2O (100 mL).  The aqueous layer was extracted with EtOAc (4 x 15 mL).  The 
combined organic layers were washed with brine (100 mL) and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure.  The 
remainder was purified by a silica gel flash column eluting with 15-25 vol% EtOAc in 
hexanes to provide the titled compound (3.07 g, 11.2 mmol, 96% yield) as a colorless oil.   
TLC:  Rf = 0.25 (EtOA/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3) δ 7.02 (dt, J = 15.7, 4.2 Hz, 1H, H-9), 6.09 (dt, J = 15.7, 2.3 
Hz, 1H, H-8), 4.34 (ddd, J = 4.0, 2.0, 1.0 Hz, 2H, H-10), 4.24 (t, J = 6.4 Hz, 2H, H-1), 
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3.70 (t, J = 6.1 Hz, 2H, H-3), 2.15 (bs, 1H, -OH), 1.86 (p, J = 6.2 Hz, 2H, H-2), 0.89 (s, 
9H, H-6), 0.043 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.7 (C-7), 147.1 (C-9), 120.3 (C-8), 62.0 (C-10), 61.7 (C-
1), 59.7 (C-3), 32.0 (C-2), 26.1 (C-6), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 3431 (br), 2956, 2930, 2858, 1723, 1661, 1471, 1391, 1361, 1278, 1170, 
1103, 1009, 837, 778, 717, 664 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H26O4SiNa 297.1498; found 297.1502. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Acetoxybut-2-enoate (1.25a): To a solution of 1.25g 
(703 mg, 2.56 mmol, 1.0 equiv) in CH2Cl2 (25 mL, 0.1 
M) was added DMAP (0.318 g, 2.58 mmol, 1.0 equiv), N,N-diisopropylethylamine (4.50 
mL, 25.8 mmol, 10.0 equiv) and acetic anhydride (0.73 mL, 7.6 mmol, 3.0 equiv) 
subsequently, at room temperature.  It was stirred for 18 hours, and then quenched with a 
saturated NaHCO3 solution (30 mL).  The aqueous solution was extracted with Et2O (3 x 
10 mL).  The combined organic layers were washed with brine (30 mL), and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure.  
The remainder was purified by flash chromatography on silica gel eluting with 3-9 vol% 
of EtOAc in hexanes to provide the titled compound (738 mg, 2.33 mmol, 91% yield) as a 
colorless oil. 
TLC:  Rf = 0.55 (EtOA/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3) δ 6.92 (ddd, J = 15.7, 4.9, 4.4 Hz, 1H, H-9), 6.01 (dt, J = 15.7, 
2.0 Hz, 1H, H-8), 4.73 (dd, J = 4.4, 2.0 Hz, 2H, H-10), 4.24 (t, J = 6.4 Hz, 2H, H-1), 3.70 
(t, J = 6.1 Hz, 2H, H-3), 2.11 (s, 3H, H-12), 1.86 (p, J = 6.2 Hz, 2H, H-2), 0.88 (s, 9H, H-
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6), 0.037 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 170.4 (C-11), 165.9 (C-7), 141.3 (C-9), 122.5 (C-8), 62.7 
(C-10), 61.9 (C-1), 59.6 (C-3), 32.0 (C-2), 26.1 (C-6), 20.8 (C-12), 18.5 (C-5), -5.2 (C-4, 
C-4’); 
FTIR (neat): νmax 2956, 2931, 2858, 1750, 1726, 1667, 1471, 1385, 1363, 1307, 1228, 1177, 
1104, 1026, 971, 838, 778, 717, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H28O5SiNa 339.1604; found 339.1614. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Methoxybut-2-enoate (1.25b): To a stirred solution of 
1.25g (134 mg, 0.489 mmol, 1.0 equiv) in DMF (12 mL, 
0.1 M) was added NaH (60% dispersion in mineral oil, 40 mg, 1.0 mmol, 2.0 equiv) at 0 
oC.  This reaction was stirred for 10 minutes under an atmosphere of N2 and treated with 
MeI (125 uL, 1.99 mmol, 4.0 equiv).  After 1.5 hours, it was quenched with a saturated 
solution of NH4Cl (30 mL).  The aqueous layer was extracted by Et2O (3 x 10 mL).  The 
combined organic layers were washed with brine (30 mL), and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure to provide a 
yellowish oil.  The crude product was purified by flash chromatography on silica gel eluting 
with 1-6 vol% of ethyl acetate in hexanes to provide the titled compound (45.2 mg, 0.157 
mmol, 32% yield) as a colorless oil.   
TLC:  Rf = 0.52 (EtOA/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3) δ 6.94 (dt, J = 15.7, 4.4 Hz, 1H, H-9), 6.07 (dt, J = 15.7, 2.0 
Hz, 1H, H-8), 4.25 (t, J = 6.6 Hz, 2H, H-1), 4.09 (dd, J = 4.4, 2.0 Hz, 2H, H-10), 3.71 (t, 
J = 6.1 Hz, 2H, H-3), 3.40 (s, 3H, H-11), 1.87 (pent, J = 6.2 Hz, 2H, H-2), 0.90 (s, 9H, H-
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6), 0.053 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.5 (C-7), 144.3 (C-9), 121.5 (C-8), 71.4 (C-10), 61.7 (C-
1), 59.7 (C-3), 58.9 (C-11), 32.1 (C-2), 26.1 (C-6), 18.5 (C-5), -5.2 (C-4, C-4’);   
FTIR (neat): νmax 2956, 2930, 2858, 1725, 1664, 1471, 1389, 1302, 1258, 1169, 1105, 1039, 
838, 777, 664 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H28O4SiNa 311.1655, found 311.1658. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-Chlorobut-
2-enoate (1.25c): To a stirred solution of 1.25g (250 mg, 
0.910 mmol, 1.0 equiv) in anhydrous CH2Cl2 (9.0 mL, 0.1 
M) was added PPh3 (362 mg, 1.37 mmol, 1.5 equiv).  Then a solution of NCS (186 mg, 
1.37 mmol, 1.5 equiv) in CH2Cl2 (3.4 mL, 0.4 M) was added via cannula at -30 oC.  This 
reaction was stirred at for 2 hours at 0 oC under an atmosphere of N2.  Then, it was poured 
into a mixture of saturated NaHCO3 solution (20 mL) and saturated Na2S2O3 solution (20 
mL).  The aqueous layer was extracted by Et2O (3 x 10 mL).  The combined organic layers 
were washed with brine (20 mL) and dried over anhydrous Na2SO4.  The solution was 
filtered and concentrated under reduced pressure.  The remainder was dissolved in 50 mL 
of Et2O/hexanes (40:60) mixture, and the precipitate was filtered.  The solution was 
concentrated and purified by flash chromatography on silica gel eluting with 2-10 vol% of 
Et2O in hexane to provide the titled compound (186 mg, 0.637 mmol, 70% yield) as a 
colorless oil.   
TLC:  Rf = 0.61 (EtOA/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3) δ 6.97 (dt, J = 15.2, 6.1 Hz, 1H, H-9), 6.11 (dt, J = 15.2, 1.5 
Hz, 1H, H-8), 4.27 (t, J = 6.4 Hz, 2H, H-1), 4.17 (dd, J = 6.1, 1.7 Hz, 2H, H-10), 3.71 (t, 
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J = 6.1 Hz, 2H, H-3), 1.88 (p, J = 6.2 Hz, 2H, H-2), 0.90 (s, 9H, H-6), 0.054 (s, 6H, H-4, 
H-4’); 
125 MHz 13C NMR (CDCl3) δ 165.8 (C-7), 141.9 (C-9), 124.3 (C-8), 62.0 (C-1), 59.6 (C-
3), 42.7 (C-10), 32.0 (C-2), 26.1 (C-6), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1726, 1662, 1471, 1391, 1361, 1315, 1271, 1197, 1172, 
1151, 1105, 1008, 977, 939, 838, 777, 745, 664 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H25O3ClSiNa 315.1159; found 315.1156. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-Bromobut-
2-enoate (1.25d): To a stirred solution of 1.25g (275 mg, 
1.00 mmol, 1.0 equiv) in anhydrous CH2Cl2 (10 mL, 0.1 
M) was added CBr4 (509 mg, 1.52 mmol, 1.5 equiv) and imidazole (103 mg, 1.50 mmol, 
1.5 equiv).  Then, a solution of PPh3 (370 mg, 1.40 mmol, 1.4 equiv) in CH2Cl2 (3.5 mL, 
0.4 M) was added dropwise via addition funnel over a period of 30 minutes at 0 oC under 
an atmosphere of N2.  After addition, this reaction was stirred for 1 hour, and poured into 
a saturated NaHCO3 solution (30 mL).  The aqueous layer was extracted by Et2O (3 x 10 
mL), and the combined organic layers were washed with brine (30 mL), and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure to 
provide a yellowish oil.  The crude product was purified by flash chromatography on silica 
gel eluting with 2-10 vol% of ethyl ether in hexanes to provide the titled compound (255 
mg, 0.755 mmol, 75% yield) as a colorless oil.   
TLC:  Rf = 0.59 (EtOA/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3) δ 6.99 (dt, J = 15.2, 7.3 Hz, 1H, H-9), 6.02 (dt, J = 15.2, 1.0 
Hz, 1H, H-8), 4.25 (t, J = 6.4 Hz, 2H, H-1), 4.00 (dd, J = 7.3, 1.0 Hz, 2H, H-10), 3.70 (t, 
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J = 6.1 Hz, 2H, H-3), 1.87 (p, J = 6.3 Hz, 2H, H-2), 0.89 (s, 9H, H-6), 0.043 (s, 6H, H-4, 
H-4’); 
125 MHz 13C NMR (CDCl3) δ 165.6 (C-7), 141.9 (C-9), 124.8 (C-8), 62.0 (C-1), 59.6 (C-
3), 31.9 (C-2), 29.2 (C-10), 26.1 (C-6), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2857, 1725, 1657, 1471, 1391, 1360, 1315, 1257, 1191, 1105, 
1008, 976, 939, 837, 777, 721, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H25O3BrSiNa 359.0654; found 359.0659.  
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-Iodobut-2-
enoate (1.25e): To a stirred mixture of imidazole (296 mg, 
4.30 mmol, 5.0 equiv) and PPh3 (460 mg, 1.74 mmol, 2.0 
equiv) in freshly distilled CH2Cl2 (9.0 mL) was added I2 (335 mg, 1.31 mmol, 1.5 equiv) 
at room temperature.  It was stirred for 20 minutes under an atmosphere of N2.  Then the 
resulting yellowish solution was ready to use. 
To another stirred solution of 1.25g (238 mg, 0.867 mmol, 1.0 equiv) in anhydrous 
CH2Cl2 (9.0 mL, 0.1 M) was added the abovementioned solution dropwise via cannula at 
room temperature under an atmosphere of N2.  After 1 hour, the reaction was diluted with 
a solution of 15 vol% of Et2O in hexanes (50 mL).  The precipitate was filtered by a pack 
of Celite®.  The solution was concentrated under reduced pressure.  The remainder was 
purified by flash chromatography on silica gel eluting with 1-6 vol% of ethyl acetate in 
hexanes to provide the titled compound (204 mg, 0.524 mmol, 61% yield) as a yellow oil.   
TLC:  Rf = 0.61 (EtOA/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3) δ 7.04 (dt, J = 15.2, 8.3 Hz, 1H, H-9), 5.93 (dt, J = 15.3, 1.2 
Hz, 1H, H-8), 4.24 (t, J = 6.6 Hz, 2H, H-1), 3.93 (dd, J = 8.3, 1.0 Hz, 2H, H-10), 3.70 (t, 
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J = 6.1 Hz, 2H, H-3), 1.87 (p, J = 6.2 Hz, 2H, H-2), 0.89 (s, 9H, H-6), 0.048 (s, 6H, H-4, 
H-4’); 
125 MHz 13C NMR (CDCl3) δ 165.7 (C-7), 143.7 (C-9), 123.4 (C-8), 61.9 (C-1), 59.6 (C-
3), 32.0 (C-2), 26.1 (C-6), 18.5 (C-5), 0.9 (C-10), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2955, 2929, 2857, 1721, 1648, 1471, 1391, 1360, 1313, 1257, 1194, 1151, 
1104, 1008, 973, 837, 777, 718, 663 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H25O3ISiNa 407.0515; found 407.0522. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Methylsulfonyloxybut-2-enoate (1.25f): To a stirred 
solution of 1.25g (269 mg, 0.979 mmol, 1.0 equiv) in 
anhydrous Et2O (20 mL, 0.05 M) and CH3CN (10 mL, 0.1 M) was added AgNO3 (333 mg, 
1.96 mmol, 2.0 equiv) in one portion at room temperature.  Until the salt was completely 
dissolved, DIPEA (680 uL, 3.90 mmol, 4.0 equiv) was added, followed by addition of 
MsCl (155 uL, 1.98 mmol, 2.0 equiv) dropwise at 0 oC.  This reaction was allowed to warm 
to room temperature and stirred for 1 hour under an atmosphere of N2.  Then, it was filtered 
through a pad of Celite®.  The solution was poured into a saturated solution of NaHCO3 
(30 mL).  The aqueous layer was extracted by Et2O (3 x 10 mL).  The combined organic 
layers were washed with brine (40 mL), and dried over anhydrous Na2SO4.  The solution 
was filtered and concentrated under reduced pressure to provide a yellowish oil.  The crude 
product was purified by flash chromatography on silica gel eluting with 15-25 vol% of 
ethyl acetate in hexanes to provide the titled compound (324 mg, 0.920 mmol, 94% yield) 
as a yellowish oil.   
TLC:  Rf = 0.58 (EtOA/CH2Cl2 = 1:9, v/v); 
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500 MHz 1H NMR (CDCl3) δ 6.92 (dt, J = 15.7, 4.9 Hz, 1H, H-9), 6.15 (dt, J = 15.7, 2.0 
Hz, 1H, H-8), 4.87 (dd, J = 4.7, 1.7 Hz, 2H, H-10), 4.27 (t, J = 6.4 Hz, 2H, H-1), 3.71 (t, 
J = 5.9 Hz, 2H, H-3), 3.07 (s, 3H, H-11), 1.88 (p, J = 6.2 Hz, 2H, H-2), 0.89 (s, 9H, H-6), 
0.050 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 165.5 (C-7), 138.8 (C-9), 124.2 (C-8), 67.2 (C-10), 62.2 (C-
1), 59.5 (C-3), 38.2 (C-11), 31.9 (C-2), 26.1 (C-6), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 1725, 1668, 1471, 1361, 1308, 1256, 1175, 1104, 976, 
838, 778, 722, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H28O6SSiNa 375.1274; found 375.1282. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-Allyloxybut-
2-enoate (1.25h): With an ice-water bath, to a stirred 
mixture of 1.25g (218 mg, 0.794 mmol, 1.0 equiv) and allyl 
bromide (280 uL, 3.20 mmol, 4.0 equiv) in anhydrous DMF (8.0 mL, 0.1 M) was added 
NaH (60% dispersion in mineral oil, 42 mg, 1.1 mmol, 1.3 equiv) at 0 oC.  It was stirred 
under an atmosphere of N2 for 1 hour, and then poured into a saturated NH4Cl solution (30 
mL).  The aqueous layer was extracted by Et2O (3 x 10 mL).  The combined organic layers 
were washed with brine (30 mL), and dried over anhydrous Na2SO4.  The solution was 
filtered and concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 5-10 vol% of ethyl ether in hexanes to provide 
the titled compound (52.8 mg, 0.168 mmol, 21% yield) as a yellowish oil.  
TLC:  Rf = 0.58 (EtOA/CH2Cl2 = 1:9, v/v); 
500 MHz 1H NMR (CDCl3) δ 6.95 (dt, J = 15.8, 4.2 Hz, 1H, H-9), 6.08 (dt, J = 15.7, 2.0 
Hz, 1H, H-8), 5.96 ~ 5.86 (m, 1H, H-12), 5.27 (br. d, J =17.1 Hz, 1H, H-13a), 5.21 (br. d, 
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J = 10.6 Hz, 1H, H-13b), 4.24 (t, J = 6.4 Hz, 2H, H-1), 4.14 (dd, J = 3.9, 2.0 Hz, 2H, H-
10), 4.02 (ddd, J = 5.4, 2.4, 1.5 Hz, 2H, H-11), 3.71 (t, J = 6.1 Hz, 2H, H-3), 1.86 (p, J = 
6.2 Hz, 2H, H-2), 0.89 (s, 9H, H-6), 0.044 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.5 (C-7), 144.5 (C-9), 134.4 (C-12), 121.5 (C-8), 117.5 
(C-13), 71.9 (C-11), 68.8 (C-10), 61.6 (C-1), 59.7 (C-3), 32.0 (C-2), 26.1 (C-6), 18.5 (C-
5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2857, 1724, 1664, 1471, 1390, 1360, 1301, 1258, 1172, 1106, 
926, 837, 777, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C16H30O4SiNa 337.1811; found 337.1817. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-(tert-
Butyldimethylsilyloxy)but-2-enoate (1.25i): To a 
stirred solution of 1.25g (279 mg, 1.02 mmol, 1.0 
equiv) in DMF (10 mL, 0.1 M) was added imidazole 
(233 mg, 3.38 mmol, 3.0 equiv) and TBSCl (238 mg, 1.53 mmol, 1.5 equiv) at room 
temperature, subsequently.  This reaction was stirred under an atmosphere of N2 for 24 
hours.  Then, it was diluted with Et2O (10 mL), and the reaction was poured into a saturated 
solution of NaHCO3 (30 mL).  The aqueous layer was extracted by Et2O (3 x 10 mL).  The 
combined organic layers were washed with brine (40 mL), and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure to provide a 
colorless oil.  The crude product was purified by flash chromatography on silica gel eluting 
with 2-8 vol% of ethyl acetate in hexanes to provide the titled compound (381 mg, 0.981 
mmol, 97% yield) as a colorless oil.  
TLC:  Rf = 0.61 (EtOA/Hex = 3:7, v/v);  
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500 MHz 1H NMR (CDCl3) δ 6.98 (dt, J = 15.6, 3.4 Hz, 1H, H-9), 6.09 (dt, J = 15.6, 2.3 
Hz, 1H, H-8), 4.33 (dd, J = 3.4, 2.0 Hz, 2H, H-10), 4.24 (t, J = 6.4 Hz, 2H, H-1), 3.71 (t, 
J = 6.1 Hz, 2H, H-3), 1.87 (p, J = 6.2 Hz, 2H, H-2), 0.92 (s, 9H, H-13), 0.89 (s, 9H, H-6), 
0.082 (s, 6H, H-11, H-11’), 0.046 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.8 (C-7), 147.5 (C-9), 119.9 (C-8), 62.4 (C-10), 61.5 (C-
1), 59.7 (C-3), 32.1 (C-2), 26.1 (C-13), 26.1 (C-6), 18.6 (C-12), 18.5 (C-5), -5.2 (C-4, C-
4’, C-11, C-11’); 
FTIR (neat): νmax 2956, 2930, 2858, 1725, 1663, 1471, 1390, 1362, 1295, 1256, 1165, 1137, 
1021, 965, 837, 777, 722, 664 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C19H40O4Si2Na 411.2363; found 411.2364. 
(E)-3-((tert-Butyldimethylsilyl)oxy)propyl 4-
(Ethylthio)but-2-enoate (1.25j): To a stirred solution of 
1.25d (237 mg, 0.702 mmol, 1.0 equiv) in anhydrous acetone 
(14 mL, 0.05 M) was added ethanethiol (160 uL, 2.10 mmol, 3.0 equiv) and anhydrous 
K2CO3 (196 mg, 1.41 mmol, 2.0 equiv).  It was stirred under an atmosphere of N2 for 3 
days and filtrated before being concentrated under reduced pressure.  The remainder was 
purified by flash chromatography on silica gel eluting with 0-10 vol% of ethyl ether in 
hexanes to provide the titled compound (211 mg, 0.661 mmol, 94% yield) as a colorless 
oil.   
TLC:  Rf = 0.58 (EtOA/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.88 (dt, J = 15.2, 7.4 Hz, 1H, H-9), 5.86 (dt, J = 15.2, 1.3 
Hz, 1H, H-8), 4.24 (t, J = 6.4 Hz, 2H, H-1), 3.72 (t, J = 5.9 Hz, 2H, H-3), 3.24 (dd, J = 7.3, 
1.5 Hz, 2H, H-10), 2.48 (q, J = 7.3 Hz, 2H, H-11), 1.88 (pent, J = 6.2 Hz, 2H, H-2), 1.24 
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(t, J = 7.3 Hz, 3H, H-12), 0.90 (s, 9H, H-6), 0.052 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.3 (C-7), 144.0 (C-9), 122.8 (C-8), 61.7 (C-1), 59.6 (C-
3), 32.5 (C-10), 32.0 (C-2), 26.1 (C-6), 25.2 (C-11), 18.5 (C-5), 14.6 (C-12), -5.2 (C-4, C-
4’); 
FTIR (neat): νmax 2958, 2930, 2858, 1725, 1662, 1471, 1391, 1360, 1170, 1105, 1016, 978, 
838, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H30O3SSiNa 341.1583; found 341.1591. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
(Ethylsulfinyl)but-2-enoate (1.25k): To a stirred mixture 
of 1.25j (40 mg, 0.12 mmol, 1.0 equiv) in anhydrous 
MeOH (6.0 mL, 0.02 M) and D.I. H2O (4.0 mL, 0.03 M) was added NaIO4 (27 mg, 0.13 
mmol, 1.1 equiv) in one portion at 0 oC.  This reaction was stirred at this temperature for 
10 minutes, and slowly warmed up to room temperature over a period of time of 2 hours.  
Then this reaction was poured into a saturated NaHCO3 solution (30 mL), and the aqueous 
layer was extracted by EtOAc (4 x 10 mL).  The combined organic layers were washed 
with brine (30 mL), and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure to provide yellowish oil.  The crude product was 
purified by flash chromatography on silica gel eluting with 15-30 vol% of ethyl acetone in 
hexanes to provide the titled compound (41 mg, 0.12 mmol, 96% yield) as a colorless oil.   
TLC:  Rf = 0.17 (Aetone/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.93 (dt, J = 15.7, 7.8 Hz, 1H, H-9), 6.10 (dt, J = 15.7, 1.2 
Hz, 1H, H-8), 4.26 (t, J = 6.4 Hz, 2H, H-1), 3.70 (t, J = 6.1 Hz, 2H, H-3), 3.60 (ddd, J = 
13.2, 7.8, 1.5 Hz, 1H, H-10a), 3.53 (ddd, J = 12.9, 7.8, 1.5 Hz, 1H, H-10b), 2.77 (dq, J = 
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13.2, 7.5 Hz, 1H, H-11a), 2.74 (dq, J = 13.2, 7.5 Hz, 1H, H-11b), 1.87 (pent, J = 6.1 Hz, 
2H, H-2), 1.35 (t, J = 7.6 Hz, 3H, H-12), 0.89 (s, 9H, H-6), 0.043 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 165.3 (C-7), 134.9 (C-9), 128.6 (C-8), 62.1 (C-1), 59.5 (C-
3), 53.6 (C-10), 45.2 (C-11), 31.9 (C-2), 26.1 (C-6), 18.5 (C-5), 6.9 (C-12), -5.2 (C-4, C-
4’); 
FTIR (neat): νmax 2957, 2928, 2858, 1721, 1653, 1461, 1320, 1260, 1197, 1055, 838, 778 
cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H30O4SSiNa 357.1532; found 357.1538. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
(Ethylsulfonyl)but-2-enoate (1.25l): To a stirred solution 
of 1.25j (84 mg, 0.26 mmol, 1.0 equiv) in anhydrous 
CH2Cl2 (13 mL, 0.02 M) was added mCPBA (116 mg, 0.672 mmol, 2.5 equiv) in one 
portion at room temperature.  This reaction was stirred overnight and poured into a 
saturated NaHCO3 solution (30 mL).  The aqueous layer was extracted by Et2O (3 x 10 
mL), and the combined organic layers were washed with brine (30 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure.  
The crude product was purified by flash chromatography on silica gel eluting with 15-30 
vol% of acetone in hexanes to provide the titled compound (81.2 mg, 0.232 mmol, 81% 
yield) as a colorless oil.   
TLC:  Rf = 0.29 (Aetone/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.91 (dt, J = 15.6, 7.8 Hz, 1H, H-9), 5.98 (dt, J = 15.7, 1.3 
Hz, 1H, H-8), 4.26 (t, J = 6.4 Hz, 2H, H-1), 3.83 (dd, J = 7.8, 1.2 Hz, 2H, H-10), 3.69 (t, 
J = 6.0 Hz, 2H, H-3), 3.00 (q, J = 7.5 Hz, 2H, H-11), 1.86 (pent, J = 6.2 Hz, 2H, H-2), 1.39 
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(t, J = 7.5 Hz, 3H, H-12), 0.87 (s, 9H, H-6), 0.024 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 164.9 (C-7), 133.2 (C-9), 129.6 (C-8), 62.3 (C-1), 59.5 (C-
3), 55.3 (C-10), 47.0 (C-11), 31.8 (C-2), 26.1 (C-6), 18.5 (C-5), 6.7 (C-12), -5.2 (C-4, C-
4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1724, 1657, 1463, 1391, 1361, 1321, 1280, 1200, 1117, 
983, 939, 838, 778, 700, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H30O5SSiNa 373.1481; found 373.1485. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
(Diethylamino)but-2-enoate (1.25m): To a stirred 
solution of 1.25d (154 mg, 0.456 mmol, 1.0 equiv) in 
freshly distilled THF (20 mL, 0.02 M) was added diethylamine (2.0 mL, 19 mmol, 40 equiv) 
and K2CO3 (126 mg, 0.903 mmol, 2.0 equiv) at room temperature.  It was stirred under an 
atmosphere of N2 for 2 days and filtrated before being concentrated under reduced pressure.  
The remainder was purified by flash chromatography on silica gel eluting with 20-40 vol% 
of EtOAc in hexanes to provide the titled compound (145 mg, 0.441 mmol, 97% yield) as 
a colorless oil.   
TLC:  Rf = 0.17 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.98 (dt, J = 15.8, 6.1 Hz, 1H, H-9), 5.98 (dt, J = 15.7, 1.7 
Hz, 1H, H-8), 4.23 (t, J = 6.4 Hz, 2H, H-1), 3.71 (t, J = 6.1 Hz, 2H, H-3), 3.24 (dd, J = 6.1, 
1.7 Hz, 2H, H-10), 2.54 (q, J = 7.2 Hz, 4H, H-11, H-11’), 1.87 (pent, J = 6.2 Hz, 2H, H-
2), 1.04 (t, J = 7.3 Hz, 6H, H-12, H-12’), 0.89 (s, 9H, H-6), 0.046 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.5 (C-7), 146.6 (C-9), 123.0 (C-8), 61.5 (C-1), 59.7 (C-
3), 54.3 (C-10), 47.4 (C-11, C-11’), 32.0 (C-2), 26.1 (C-6), 18.5 (C-5), 12.1 (C-12, C-12’), 
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-5.2 (C-4, C-4’); 
FTIR (neat): νmax 2959, 2931, 2858, 2804, 1724, 1658, 1471, 1387, 1360, 1258, 1162, 1104, 
837, 777, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C17H35NO3SiNa 352.2284; found 352.2287. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl But-2-enoate 
(1.25n): To a stirred mixture of crotonic acid (80.1 mg, 
0.912 mmol, 1.0 equiv), 1.37 (173 mg, 0.908 mmol, 1.0 
equiv), and DMAP (113 mg, 0.913 mmol, 1.0 equiv) in toluene (10 mL, 0.1 M) was added 
freshly distilled NEt3 (640 uL, 4.59 mmol, 5.0 equiv).  This reaction was then cooled down 
to 0 oC, and 2,4,6-trichlorobenzoylchloride (160 uL, 1.00 mmol, 1.1 equiv) was then added 
in dropwise via syringe.  The reaction turned cloudy and precipitated immediately.  It was 
stirred under an atmosphere of N2, and allowed to warm to room temperature slowly, and 
stirred for 3 hours.  Then, the resulting yellow solution was concentrated and purified by 
flash chromatography on silica gel eluting with 2-6 vol% of ethyl acetate in hexane to 
provide the titled compound (202 mg, 0.781 mmol, 86% yield) as a colorless oil. 
TLC:  Rf = 0.68 (EtOAc/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3) δ 6.97 (dq, J = 15.7, 6.8 Hz, 1H, H-9), 5.84 (dq, J = 15.7, 1.8 
Hz, 1H, H-8), 4.22 (t, J = 6.4 Hz, 2H, H-1), 3.71 (t, J = 6.1 Hz, 2H, H-3), 1.88 (dd, J = 6.8, 
2.0 Hz, 3H, H-10), 1.86 (p, J = 6.3 Hz, 2H, H-2), 0.89 (s, 9H, H-6), 0.050 (s, 6H, H-4, H-
4’); 
125 MHz 13C NMR (CDCl3) δ 166.8 (C-7), 144.6 (C-9), 123.0 (C-8), 61.4 (C-1), 59.7 (C-
3), 32.1 (C-2), 26.1 (C-6), 18.5 (C-5), 18.1 (C-10), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1724, 1661, 1472, 1445, 1390, 1361, 1311, 1258, 1183, 
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1102, 1024, 971, 940, 838, 777, 720, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H26O3SiNa 281.1549; found 281.1551.  
(E)-3-((tert-butyldimethylsilyl)oxy)propyl 4-
hydroxypent-2-enoate (1.29f): With a -78 oC bath, to a 
solution of 1.39 (3.33 g, 12.2 mmol, 1.0 equiv) in freshly 
distilled THF (30 mL, 0.4 M) was added MeMgBr (3.0 M in Et2O, 4.9 mL, 15 mmol, 1.2 
equiv) via syringe pump at the rate of 7 mL/h under an atmosphere of N2.  The reaction 
mixture was stirred for further 1 hour after addition.  Then, it was quenched at this 
temperature with a saturated NH4Cl solution (30 mL), and the aqueous layer was extracted 
with Et2O (3 x 10 mL).  The combined organic layers were washed with brine (50 mL) and 
dried over anhydrous Na2SO4.  The solution was filtered and concentrated under reduced 
pressure.  The remainder was purified by flash chromatography on silica gel eluting with 
10-20 vol% of EtOAc in hexanes to provide the titled compound (2.35 g, 8.14 mmol, 67% 
yield) as a pale yellow oil.  
TLC:  Rf = 0.26 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.96 (dd, J = 15.7, 4.4 Hz, 1H, H-9), 6.03 (dd, J = 15.7, 1.5 
Hz, 1H, H-8), 4.56 ~ 4.44 (m, 1H, H-10), 4.25 (t, J = 6.5 Hz, 2H, H-1), 3.72 (t, J = 6.1 Hz, 
2H, H-3), 1.88 (pent, J = 6.2 Hz, 2H, H-2), 1.74 (br. s, 1H, -OH), 1.35 (d, J = 6.4 Hz, 3H, 
H-11), 0.90 (s, 9H, H-6), 0.053 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.8 (C-7), 151.1 (C-9), 119.8 (C-8), 67.4 (C-10), 61.7 (C-
1), 59.6 (C-3), 32.0 (C-2), 26.1 (C-6), 23.0 (C-11), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 3438 (br), 2957, 2930, 2858, 1723, 1658, 1471, 1391, 1361, 1257, 1175, 
1104, 1008, 979, 940, 837, 777, 719, 665 cm-1; 
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HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H28O4SiNa 311.1655; found 311.1653. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Chloropent-2-enoate (1.29a): To a stirred solution of 
1.29f (130 mg, 0.450 mmol, 1.0 equiv) in anhydrous 
CH2Cl2 (9.0 mL, 0.05 M) was added PPh3 (179 mg, 0.674 mmol, 1.5 equiv).  Then a 
solution of NCS (92 mg, 0.67 mmol, 1.5 equiv) in CH2Cl2 (2.5 mL, 0.3 M) was added via 
cannula at -30 oC.  This reaction was stirred at for 2 hours at 0 oC under an atmosphere of 
N2.  Then, it was poured into a mixture of saturated NaHCO3 solution (15 mL) and saturated 
Na2S2O3 solution (15 mL).  The aqueous layer was extracted by Et2O (3 x 10 mL).  The 
combined organic layers were washed with brine (20 mL) and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure.  The 
remainder was purified by flash chromatography on silica gel eluting with 2-10 vol% of 
Et2O in hexanes to provide the titled compound (63.4 mg, 0.203 mmol, 45% yield) as a 
colorless oil.   
TLC:  Rf = 0.69 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.94 (dd, J = 15.5, 7.1 Hz, 1H, H-9), 6.01 (dd, J = 15.7, 1.5 
Hz, 1H, H-8), 4.62 (dqd, J = 7.1, 6.9, 1.5 Hz, 1H, H-10), 4.26 (t, J = 6.4 Hz, 2H, H-1), 
3.72 (t, J = 6.1 Hz, 2H, H-3), 1.88 (pent, J = 6.2 Hz, 2H, H-2), 1.65 (d, J = 6.9 Hz, 3H, H-
11), 0.90 (s, 9H, H-6), 0.055 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.1 (C-7), 147.3 (C-9), 121.8 (C-8), 62.0 (C-1), 59.6 (C-
3), 55.0 (C-10), 31.9 (C-2), 26.1 (C-6), 24.5 (C-11), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1725, 1661, 1471, 1390, 1360, 1341, 1272, 1178, 1106, 
1017, 975, 838, 777, 727, 665 cm-1; 
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HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H27ClO3SiNa 329.1316; found 329.1326. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Bromopent-2-enoate (1.29b): To a stirred solution of 
1.29f (137 mg, 0.475 mmol, 1.0 equiv) in anhydrous 
CH2Cl2 (9.0 mL, 0.05 M) was added CBr4 (239 mg, 0.714 mmol, 1.5 equiv) and imidazole 
(48 mg, 0.70 mmol, 1.5 equiv).  Then, a solution of PPh3 (176 mg, 0.664 mmol, 1.4 equiv) 
in CH2Cl2 (3.5 mL, 0.2 M) was added dropwise via addition funnel over a period of time 
of 5 minutes at 0 oC under an atmosphere of N2.  After addition, this reaction was stirred 
for 1 hour and poured into a saturated NaHCO3 solution (30 mL).  The aqueous layer was 
extracted by Et2O (3 x 10 mL), and the combined organic layers were washed with brine 
(30 mL) and dried over anhydrous Na2SO4.  The solution was filtered and concentrated 
under reduced pressure to provide a yellowish oil.  The crude product was purified by flash 
chromatography on silica gel eluting with 0-10 vol% of ethyl ether in hexanes to provide 
the titled compound (133 mg, 0.378 mmol, 80% yield) as a colorless oil.   
TLC:  Rf = 0.65 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 7.01 (dd, J = 15.7, 8.3 Hz, 1H, H-9), 5.93 (dd, J = 15.5, 1.0 
Hz, 1H, H-8), 4.69 (dqd, J = 8.3, 6.6, 1.0 Hz, 1H, H-10), 4.25 (t, J = 6.4 Hz, 2H, H-1), 
3.70 (t, J = 6.1 Hz, 2H, H-3), 1.87 (pent, J = 6.2 Hz, 2H, H-2), 1.82 (d, J = 6.4 Hz, 3H, H-
11), 0.88 (s, 9H, H-6), 0.042 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.0 (C-7), 147.7 (C-9), 121.2 (C-8), 62.0 (C-1), 59.6 (C-
3), 45.0 (C-10), 31.9 (C-2), 26.1 (C-6), 24.9 (C-11), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 1723, 1655, 1471, 1390, 1360, 1341, 1266, 1203, 1170, 
1104, 1010, 975, 939, 837, 777, 722, 663 cm-1; 
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HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H27BrO3SiNa 373.0811; found 373.0815. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Iodopent-2-enoate (1.29c): To a stirred mixture of 
imidazole (152 mg, 2.22 mmol, 5.0 equiv) and PPh3 (235 
mg, 0.886 mmol, 2.0 equiv) in freshly distilled CH2Cl2 (9.0 mL) was added I2 (170 mg, 
0.662 mmol, 1.5 equiv) at room temperature.  It was stirred for 20 minutes under an 
atmosphere of N2.  Then the resulting yellowish solution was ready to use. 
To other stirred solution of 1.29f (128 mg, 0.442 mmol, 1.0 equiv) in anhydrous CH2Cl2 
(4.5 mL, 0.1 M) was added the abovementioned solution dropwise via cannula at room 
temperature under an atmosphere of N2.  After 1 hour, the reaction was diluted with a 
solution of 15 vol% of Et2O in hexanes (50 mL).  The precipitate was filtered by a pack of 
Celite®.  The solution was concentrated under reduced pressure.  The remainder was 
purified by flash chromatography on silica gel eluting with 1-6 vol% of EtOAc in hexanes 
to provide the titled compound (85 mg, 0.21 mmol, 48% yield) as a colorless oil.   
TLC:  Rf = 0.65 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 7.15 (dt, J = 15.4, 8.6 Hz, 1H, H-9), 5.84 (dt, J = 15.4, 1.2 
Hz, 1H, H-8), 4.90 (dqd, J = 8.6, 6.8, 1.2 Hz, 1H, H-10), 4.24 (t, J = 6.4 Hz, 2H, H-1), 
3.71 (t, J = 6.1 Hz, 2H, H-3), 2.00 (d, J = 6.8 Hz, 3H, H-11), 1.87 (pent, J = 6.2 Hz, 2H, 
H-2), 0.89 (s, 9H, H-6), 0.050 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.1 (C-7), 150.2 (C-9), 119.0 (C-8), 62.0 (C-1), 59.6 (C-
3), 31.9 (C-2), 26.6 (C-11), 26.1 (C-6), 21.1 (C-10), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2857, 1720, 1645, 1471, 1390, 1360, 1340, 1260, 1191, 1106, 
1007, 976, 939, 837, 777, 721, 665 cm-1; 
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HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H27IO3SiNa 421.0672; found 421.0681. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Acetoxypent-2-enoate (1.29d): To a solution of 1.29f 
(109 mg, 0.378 mmol, 1.0 equiv) in CH2Cl2 (10 mL, 
0.04 M) was added DMAP (46 mg, 0.38 mmol, 1.0 equiv), N,N-diisopropylethylamine 
(660 uL, 3.79 mmol, 10 equiv) and acetic anhydride (110 uL, 1.15 mmol, 3.0 equiv) 
subsequently, at room temperature.  It was stirred for 18 hours, and then quenched with a 
saturated NaHCO3 solution (20 mL).  The aqueous solution was extracted with Et2O (3 x 
10 mL).  The combined organic layers were washed with brine (30 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure.  
The remainder was purified by flash chromatography on silica gel eluting with 3-9 vol% 
of EtOAc in hexanes to provide the titled compound (100 mg, 0.304 mmol, 81% yield) as 
a colorless oil.   
TLC:  Rf = 0.55 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.86 (dd, J = 15.8, 5.1 Hz, 1H, H-9), 5.95 (dd, J = 15.7, 2.0 
Hz, 1H, H-8), 5.48 (qdd, J = 6.8, 4.9, 1.8 Hz, 1H, H-10), 4.24 (t, J = 6.4 Hz, 2H, H-1), 
3.70 (t, J = 5.9 Hz, 2H, H-3), 2.08 (s, 3H, H-13), 1.86 (pent, J = 6.2 Hz, 2H, H-2), 1.36 (d, 
J = 6.9 Hz, 3H, H-11), 0.88 (s, 9H, H-6), 0.041 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 170.2 (C-12), 166.3 (C-7), 146.5 (C-9), 121.1 (C-8), 69.0 
(C-10), 61.9 (C-1), 59.6 (C-3), 31.9 (C-2), 26.1 (C-6), 21.3 (C-13), 19.8 (C-11), 18.5 (C-
5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2931, 2858, 1746, 1725, 1664, 1472, 1373, 1305, 1236, 1176, 1103, 
1048, 977, 837, 777, 665 cm-1; 
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HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C16H30O5SiNa 353.1760; found 353.1756. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Methylsulfonyloxypent-2-enoate (1.29e): To a stirred 
solution of 1.29f (106 mg, 0.366 mmol, 1.0 equiv) in 
anhydrous CH2Cl2 (7.0 mL, 0.05 M) was added DIPEA (260 uL, 1.49 mmol, 4.0 equiv), 
followed by addition of MsCl (56 uL, 0.72 mmol, 2.0 equiv) dropwise at 0 oC.  This 
reaction was stirred for 1 hour under an atmosphere of N2.  Then, it was poured into a 
saturated solution of NaHCO3 (30 mL).  The aqueous layer was extracted by Et2O (3 x 10 
mL).  The combined organic layers were washed with brine (30 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure to 
provide a yellowish oil.  The crude product was purified by flash chromatography on silica 
gel eluting with 10-20 vol% of ethyl acetate in hexanes to provide the titled compound (72 
mg, 0.20 mmol, 53% yield) as a yellowish oil. 
TLC:  Rf = 0.58 (EtOAc/CH2Cl2 = 1:9, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.88 (dd, J = 15.7, 5.4 Hz, 1H, H-9), 6.09 (dd, J = 15.7, 1.5 
Hz, 1H, H-8), 4.87 (qdd, J = 6.8, 5.4, 1.5 Hz, 1H, H-10), 4.27 (t, J = 6.6 Hz, 2H, H-1), 
3.71 (t, J = 6.1 Hz, 2H, H-3), 3.03 (s, 3H, H-12), 1.88 (pent, J = 6.2 Hz, 2H, H-2), 1.55 (d, 
J = 6.9 Hz, 3H, H-11), 0.89 (s, 9H, H-6), 0.051 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 165.7 (C-7), 144.2 (C-9), 123.0 (C-8), 76.6 (C-10), 62.2 (C-
1), 59.5 (C-3), 39.2 (C-12), 31.9 (C-2), 26.1 (C-6), 21.4 (C-11), 18.5 (C-5), -5.2 (C-4, C-
4’); 
FTIR (neat): νmax 2956, 2932, 2858, 1724, 1665, 1471, 1362, 1306, 1259, 1178, 1102, 1035, 
975, 896, 838, 814, 778 cm-1; 
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HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H30O6SSiNa 389.1430; found 389.1433. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Methoxybut-2-enoate (1.29g): To a stirred solution of 
1.29f (169 mg, 0.585 mmol, 1.0 equiv) in DMF (12 mL, 
0.05 M) was added NaH (60% dispersion in mineral oil, 48 mg, 1.2 mmol, 2.0 equiv) at 0 
oC.  This reaction was stirred for 10 minutes under an atmosphere of N2, and treated with 
MeI (150 uL, 2.39 mmol, 4.0 equiv).  After 1.5 hours, it was quenched with a saturated 
solution of NH4Cl (30 mL).  The aqueous layer was extracted by Et2O (3 x 10 mL).  The 
combined organic layers were washed with brine (30 mL) and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure to provide a 
yellowish oil.  The crude product was purified by flash chromatography on silica gel eluting 
with 1-6 vol% of ethyl acetate in hexanes to provide the titled compound (78 mg, 0.26 
mmol, 44% yield) as a colorless oil.   
TLC:  Rf = 0.56 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.81 (dd, J = 15.9, 6.1 Hz, 1H, H-9), 5.97 (dd, J = 15.9, 1.2 
Hz, 1H, H-8), 4.24 (t, J = 6.6 Hz, 2H, H-1), 3.90 (qdd, J = 6.4, 6.4, 1.2 Hz, 1H, H-10), 
3.71 (t, J = 5.9 Hz, 2H, H-3), 3.30 (s, 3H, H-12), 1.87 (p, J = 6.1 Hz, 2H, H-2), 1.27 (d, J 
= 6.4 Hz, 3H, H-11), 0.88 (s, 9H, H-6), 0.038 (s, 6H, H-4, H-4’);  
125 MHz 13C NMR (CDCl3) δ 166.5 (C-7), 149.2 (C-9), 121.4 (C-8), 76.4 (C-10), 61.7 (C-
1), 59.6 (C-3), 56.9 (C-12), 31.9 (C-2), 26.1 (C-6), 20.6 (C-11), 18.5 (C-5), -5.2 (C-4, C-
4’); 
FTIR (neat): νmax 2956, 2931, 2858, 1724, 1660, 1471, 1360, 1298, 1258, 1174, 1112, 1008, 
981, 838, 777 cm-1; 
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HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H30O4SiNa 325.1811; found 325.1814. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Allyloxypent-2-enoate (1.29h): With an ice-water bath, 
to a stirred mixture of 1.29f (123 mg, 0.427 mmol, 1.0 
equiv) in anhydrous DMF (9.0 mL, 0.05 M) was added 
NaH (60% dispersion in mineral oil, 35 mg, 0.89 mmol, 2.0 equiv) at 0 oC.  It was stirred 
for 10 minutes under an atmosphere of N2.  Then, allyl bromide (150 uL, 1.72 mmol, 4.0 
equiv) was added into this mixture in one portion.  This reaction was stirred for further one 
hour and diluted with Et2O (15 mL).  This mixture was poured into a saturated NH4Cl 
solution (30 mL).  The aqueous layer was extracted by Et2O (3 x 10 mL).  The combined 
organic layers were washed with brine (30 mL) and dried over anhydrous Na2SO4.  The 
solution was filtered and concentrated under reduced pressure.  The remainder was purified 
by flash chromatography on silica gel eluting with 0-5 vol% of ethyl acetate in hexanes to 
provide the titled compound (60 mg, 0.18 mmol, 43% yield) as a colorless oil.    
TLC:  Rf = 0.66 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.84 (dd, J = 15.9, 6.1 Hz, 1H, H-9), 5.98 (dd, J = 15.7, 1.5 
Hz, 1H, H-8), 5.90 (dddd, J = 17.1, 10.8, 5.9, 5.4 Hz, 1H, H-13), 5.27 (dq, J =17.4, 1.5 Hz, 
1H, H-14a), 5.18 (dq, J = 10.8, 1.5 Hz, 1H, H-14b), 4.24 (t, J = 6.4 Hz, 2H, H-1), 4.07 
(qdd, J = 6.7, 6.4, 1.5 Hz, 1H, H-10), 4.01 (ddt, J = 12.7, 5.4, 1.5 Hz, 1H, H-12a), 3.91 
(ddt, J = 12.7, 5.9, 1.5 Hz, 1H, H-12a), 3.71 (t, J = 6.1 Hz, 2H, H-3), 1.87 (pent, J = 6.2 
Hz, 2H, H-2), 1.29 (d, J = 6.8 Hz, 3H, H-11), 0.89 (s, 9H, H-6), 0.044 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.5 (C-7), 149.5 (C-9), 134.8 (C-13), 121.3 (C-8), 117.2 
(C-14), 74.1 (C-10), 70.0 (C-12), 61.7 (C-1), 59.6 (C-3), 31.9 (C-2), 26.1 (C-6), 20.8 (C-
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11), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1723, 1659, 1471, 1361, 1297, 1258, 1175, 1105, 982, 
924, 837, 777, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C17H32O4SiNa 351.1968; found 351.1965. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-(tert-
Butyldimethylsilyloxy)pent-2-enoate (1.29i): To a 
stirred solution of 1.29f (94 mg, 0.33 mmol, 1.0 equiv) 
in DMF (6.5 mL, 0.05 M) was added imidazole (67 mg, 0.97 mmol, 3.0 equiv) and TBSCl 
(73 mg, 0.47 mmol, 1.5 equiv) at room temperature, subsequently.  This reaction was 
stirred under an atmosphere of N2 for 18 hours.  Then, it was diluted with Et2O (10 mL), 
and the reaction was poured into a saturated solution of NaHCO3 (20 mL).  The aqueous 
layer was extracted by Et2O (3 x 10 mL).  The combined organic layers were washed with 
brine (30 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure to provide a colorless oil.  The crude product was 
purified by flash chromatography on silica gel eluting with 2-8 vol% of ethyl acetate in 
hexanes to provide the titled compound (96 mg, 0.24 mmol, 73% yield) as a colorless oil.   
TLC:  Rf = 0.68 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.92 (dd, J = 15.2, 3.9 Hz, 1H, H-9), 6.09 (dd, J = 15.3, 1.7 
Hz, 1H, H-8), 4.46 (qdd, J = 6.4, 3.9, 1.7 Hz, 1H, H-10), 4.25 (dt, J = 10.8, 6.4 Hz, 1H, H-
1a), 4.22 (dt, J = 10.8, 6.4 Hz, 1H, H-1b), 3.72 (t, J = 6.1 Hz, 2H, H-3), 1.88 (pent, J = 6.2 
Hz, 2H, H-2), 1.26 (d, J = 6.8 Hz, 3H, H-11), 0.91 (s, 9H, H-14), 0.89 (s, 9H, H-6), 0.082 
(s, 6H, H-11), 0.072 (s, 3H, H-12); 0.064 (s, 3H, H-12’); 0.048 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 167.1 (C-7), 152.2 (C-9), 119.1 (C-8), 67.9 (C-10), 61.5 (C-
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1), 59.7 (C-3), 32.0 (C-2), 26.1 (C-14), 26.0 (C-6), 23.7 (C-11), 18.5 (C-13), 18.4 (C-5), -
4.7 (C-12), -4.7 (C-12’), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1725, 1661, 1472, 1390, 1361, 1294, 1257, 1164, 1099, 
1007, 979, 837, 777, 717, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C20H42O4Si2Na 425.2519; found 425.2524. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
(Ethylthio)pent-2-enoate (1.29j): To a stirred solution of 
1.29b (106 mg, 0.301 mmol, 1.0 equiv) in anhydrous 
acetone (15 mL, 0.02 M) was added ethanethiol (70 uL, 0.92 mmol, 3.0 equiv) and 
anhydrous K2CO3 (85 mg, 0.61 mmol, 2.0 equiv).  It was stirred under an atmosphere of 
N2 for 3 days and filtrated before being concentrated under reduced pressure.  The 
remainder was purified by flash chromatography on silica gel eluting with 0-10 vol% of 
ethyl ether in hexanes to provide the titled compound (100 mg, 0.301 mmol, 100% yield) 
as a colorless oil.   
TLC:  Rf = 0.58 (EtOA/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.75 (dd, J = 15.3, 9.1 Hz, 1H, H-9), 5.74 (dd, J = 15.5, 0.9 
Hz, 1H, H-8), 4.24 (t, J = 6.4 Hz, 1H, H-1a), 4.23 (t, J = 6.4 Hz, 1H, H-1b), 3.71 (t, J = 
6.0 Hz, 2H, H-3), 3.43 (dqd, J = 9.2, 6.9, 0.8 Hz, 1H, H-10), 2.43 (q, J = 7.4 Hz, 2H, H-
12), 1.87 (pent, J = 6.2 Hz, 2H, H-2), 1.36 (d, J = 6.8 Hz, 3H, H-11), 1.22 (t, J = 7.4 Hz, 
3H, H-13), 0.89 (s, 9H, H-6), 0.043 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.5 (C-7), 149.4 (C-9), 120.0 (C-8), 61.7 (C-1), 59.6 (C-
3), 40.7 (C-10), 31.9 (C-2), 26.1 (C-6), 24.9 (C-12), 19.7 (C-11), 18.5 (C-5), 14.7 (C-13), 
-5.2 (C-4, C-4’); 
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FTIR (neat): νmax 2958, 2930, 2858, 1721, 1649, 1471, 1390, 1360, 1335, 1260, 1212, 1170, 
1105, 1016, 978, 838, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C16H32O3SSiNa 355.1739; found 355.1747. 
(E)-3-((tert-Butyldimethylsilyl)oxy)propyl 4-
(Ethylsulfinyl)pent-2-enoate (1.29k): To a stirred 
mixture of 1.29j (49 mg, 0.15 mmol, 1.0 equiv) in 
anhydrous MeOH (7.5 mL, 0.02 M) and D.I. H2O (5 mL, 0.03 M) was added NaIO4 (32 
mg, 0.15 mmol, 1.0 equiv) in one portion at 0 oC.  This reaction was stirred at this 
temperature for 10 minutes, and slowly warmed up to room temperature over a period of 2 
hours.  Then this reaction was poured into a saturated NaHCO3 solution (30 mL), and the 
aqueous layer was extracted by EtOAc (4 x 10 mL).  The combined organic layers were 
washed with brine (30 mL) and dried over anhydrous Na2SO4.  The solution was filtered 
and concentrated under reduced pressure to provide yellowish oil.  The crude product was 
purified by flash chromatography on silica gel eluting with 15-30 vol% of acetone in 
hexanes to provide the titled compound (about 1:2 diastereomeric mixture denoted here as 
compound A and B, 50 mg, 0.14 mmol, 96% yield) as a colorless oil.   
TLC:  Rf = 0.16 (Aetone/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3): 
A: δ 6.91 (dd, J = 15.7, 8.6 Hz, 1H, HA-9), 6.01 (dd, J = 15.7, 0.9 Hz, 1H, HA-8), 4.24 (t, 
J = 6.4 Hz, 2H, HA-1), 3.69 (t, J = 6.0 Hz, 2H, HA-3), 3.43 (dqd, J = 8.6, 6.8, 0.9 Hz, 1H, 
HA-10), 2.67 (dq, J = 13.2, 7.3 Hz, 1H, HA-12a), 2.55 (dq, J = 13.2, 7.5 Hz, 1H, HB-12b), 
1.86 (pent, J = 6.2 Hz, 2H, HA-2), 1.50 (d, J = 6.8 Hz, 3H, HA-11), 1.32 (t, J = 7.6 Hz, 3H, 
HA-13), 0.87 (s, 9H, HA-6), 0.030 (s, 6H, HA-4, HA-4’); 
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B: δ 6.84 (dd, J = 15.7, 8.7 Hz, 1H, HB-9), 6.03 (dd, J = 15.7, 0.9 Hz, 1H, HB-8), 4.24 (t, J 
= 6.4 Hz, 2H, HB-1), 3.69 (t, J = 6.0 Hz, 2H, HB-3), 3.51 (dqd, J = 8.7, 6.8, 0.9 Hz, 1H, 
HB-10), 2.72 (dq, J = 13.2, 7.6 Hz, 1H, HB-12a), 2.60 (dq, J = 13.2, 7.5 Hz, 1H, HB-12b), 
1.86 (pent, J = 6.2 Hz, 2H, HB-2), 1.48 (d, J = 6.8 Hz, 3H, HB-11), 1.35 (t, J = 7.6 Hz, 3H, 
HB-13), 0.87 (s, 9H, HA-6), 0.030 (s, 6H, HA-4, HA-4’); 
125 MHz 13C NMR (CDCl3): 
A: 165.4 (CA-7), 141.0 (CA-9), 126.1 (CA-8), 62.0 (CA-1), 59.5 (CA-3), 56.2 (CA-10), 42.7 
(CB-12), 31.9 (CA-2), 26.1 (CA-6), 18.5 (CA-5), 13.3 (CA-11), 7.5 (CA-13), -5.2 (CA-4, C-
4’);   
B: 165.5 (CB-7), 141.6 (CB-9), 125.8 (CB-8), 62.1 (CB-1), 59.5 (CB-3), 58.4 (CB-10), 42.8 
(CB-12), 31.9 (CB-2), 26.1 (CB-6), 18.4 (CB-5), 13.5 (CB-11), 7.1 (CB-13), -5.2 (CB-4, C-
4’);   
FTIR (neat): νmax 2957, 2930, 2857, 1721, 1650, 1461, 1389, 1360, 1333, 1258, 1178, 1104, 
1060, 838, 778, 727, 666 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C16H32O4SSiNa 371.1688; found 371.1695. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
(Ethylsulfonyl)pent-2-enoate (1.29l): To a stirred 
solution of 1.29j (42 mg, 0.13 mmol, 1.0 equiv) in 
anhydrous CH2Cl2 (6.5 mL, 0.02 M) was added mCPBA (49 mg, 0.28 mmol, 2.2 equiv) in 
one portion at -10 oC.  After 20 minutes, the cooling bath was removed, and the reaction 
was stirred at room temperature for 6 hours under an atmosphere of N2 for 6.  Then, it was 
poured into a saturated NaHCO3 solution (20 mL).  The aqueous layer was extracted by 
Et2O (3 x 10 mL) and the combined organic layers were washed with brine (30 mL) and 
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dried over anhydrous Na2SO4.  The solution was filtered and concentrated under reduced 
pressure to provide a yellowish oil.  The crude product was purified by flash 
chromatography on silica gel eluting with 10-30 vol% of acetone in hexanes to provide the 
titled compound (45 mg, 0.12 mmol, 96% yield) as a colorless oil.   
TLC:  Rf = 0.16 (Aetone/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3): δ 6.92 (dd, J = 15.7, 8.8 Hz, 1H, H-9), 6.10 (dd, J = 15.7, 1.0 
Hz, 1H, H-8), 4.26 (t, J = 6.4 Hz, 2H, H-1), 3.81 (dqd, J = 9.2, 6.9, 1.0 Hz, 1H, H-10), 
3.70 (t, J = 6.1 Hz, 2H, H-3), 2.97 (q, J = 7.3 Hz, 2H, H-12), 1.87 (pent, J = 6.1 Hz, 2H, 
H-2), 1.57 (d, J = 7.3 Hz, 3H, H-11), 1.39 (t, J = 7.3 Hz, 3H, H-13), 0.88 (s, 9H, H-6), 
0.040 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 165.1 (C-7), 140.3 (C-9), 127.0 (C-8), 62.3 (C-1), 59.8 (C-
10), 59.5 (C-3), 44.9 (C-12), 31.8 (C-2), 26.1 (C-6), 18.5 (C-5), 12.4 (C-11), 6.2 (C-13), -
5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2857, 1723, 1656, 1461, 1390, 1361, 1312, 1183, 1109, 982, 
838, 779, 715, 663 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C16H32O5SSiNa 387.1637; found 387.1642. 
(E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
(Ethylthio)pent-2-enoate (1.29m): To a stirred solution 
of 1.29b (83 mg, 0.24 mmol, 1.0 equiv) in freshly 
distilled THF (12 mL, 0.02 M) was added diethylamine (1.3 mL, 12 mmol, 50 equiv) at 
room temperature.  It was stirred under an atmosphere of N2 for 2 days and filtrated before 
being concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 20-40 vol% of EtOAc in hexanes to provide the 
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titled compound (58 mg, 0.17 mmol, 72% yield) as a colorless oil.   
TLC:  Rf = 0.16 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 6.96 (dd, J = 15.7, 6.8 Hz, 1H, H-9), 5.87 (dd, J = 15.7, 1.5 
Hz, 1H, H-8), 4.23 (t, J = 6.6 Hz, 2H, H-1), 3.71 (t, J = 6.1 Hz, 2H, H-3), 3.47 (dqd, J = 
6.8, 6.7, 1.5 Hz, 1H, H-10), 2.56 (dq, J = 13.2, 7.2 Hz, 2H, H-12a, H-12a’), 2.49 (dq, J = 
13.2, 7.2 Hz, 2H, H-12b, H-12b’), 1.87 (pent, J = 6.2 Hz, 2H, H-2), 1.17 (d, J = 6.8 Hz, 
3H, H-11), 1.03 (t, J = 7.1 Hz, 6H, H-13, H-13’), 0.89 (s, 9H, H-6), 0.047 (s, 6H, H-4, H-
4’); 
125 MHz 13C NMR (CDCl3) δ 166.8 (C-7), 151.6 (C-9), 121.4 (C-8), 61.5 (C-1), 59.7 (C-
3), 56.4 (C-10), 43.8 (C-12, C-12’), 32.0 (C-2), 26.1 (C-6), 18.5 (C-5), 16.2 (C-11), 13.6 
(C-13, C-13’), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2959, 2930, 2858, 1723, 1652, 1471, 1387, 1258, 1170, 1105, 1008, 983, 
837, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C18H38O3NSi 344.2621; found 344.2620. 
3-(tert-Butyldimethylsilyloxy)propyl 2-Bromoacetate 
(1.40): To a stirred mixture of bromoacetic acid (7.31 g, 51.5 
mmol, 1.2 equiv), 1.37 (7.99 g, 42.0 mmol, 1.0 equiv) and 
DMAP (2.53 g, 20.5 mmol, 0.5 equiv) in CH2Cl2 (100 mL, 0.5 M) was added DCC (10.76 
g, 51.65 mmol, 1.2 equiv) in one portion at 0 oC.  The clear solution turned cloudy 
immediately.  This reaction was allowed to warm to room temperature slowly, and stirred 
for 16 hours under an atmosphere of N2.  The resulting milky reaction was filtered through 
a pad of celite, and the filtrate was washed with brine containing 1 vol% HCl (100 mL).  
The aqueous layer was extracted CH2Cl2 (3 x 30 mL).  The combined organic layers were 
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washed with brine (100 mL) and dried over anhydrous Na2SO4.  The solution was filtered 
and concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 1-5 vol% of EtOAc in hexanes to provide the 
titled compound (6.87 g, 22.1 mmol, 53% yield) as a colorless oil.   
TLC:  Rf = 0.64 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.29 (t, J = 6.4 Hz, 2H, H-1), 3.83 (s, 2H, H-8), 3.71 (t, J = 
6.0 Hz, 2H, H-3), 1.87 (pent, J = 6.2 Hz, 2H, H-2), 0.89 (s, 9H, H-6), 0.055 (s, 6H, H-4, 
H-4’); 
125 MHz 13C NMR (CDCl3) δ 167.4 (C-7), 63.5 (C-1), 59.3 (C-3), 31.7 (C-2), 26.1 (C-6, 
C-8), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 1741, 1471, 1409, 1361, 1281, 1257, 1165, 1106, 1008, 
971, 837, 777, 716, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C11H23O3BrSiNa 333.0498; found 333.0500. 
3-(tert-Butyldimethylsilyloxy)propyl 2-
(Diethoxyphosphoryl)acetate (1.41): To a stirred solution 
of 1.40 (4.11 g, 13.2 mmol, 1.0 equiv) was added triethyl 
phosphate (2.8 mL, 16 mmol, 1.2 equiv) in benzene (25 mL, 0.5 M) at room temperature.  
This reaction was then reluxed for 30 hours under an atmosphere of N2.  It was concentrated 
in reduced pressure, and the remainder was purified by a flash column on silica gel eluting 
with 5-20 vol% acetone in hexanes to provide the titled compound (4.78 g, 13.0 mmol, 98% 
yield) as a colorless oil.   
TLC:  Rf = 0.35 (Acetone/Hex = 5:5, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.22 (t, J = 6.4 Hz, 2H, H-1), 4.15 (dq, J = 8.2, 7.0 Hz, 4H, 
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H-9), 3.67 (t, J = 6.0 Hz, 2H, H-3), 2.94 (d, J = 21.6 Hz, 2H, H-8), 1.83 (pent, J = 6.2 Hz, 
2H, H-2), 1.32 (td, J = 7.0, 0.5 Hz, 6H, H-10), 0.86 (s, 9H, H-6), 0.021 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.0 (d, Jc,p = 6.1 Hz, C-7), 62.8 (C-1), 62.8 (d, Jc,p = 6.1 
Hz, C-9), 59.4 (C-3), 34.5 (C-8), 31.9 (C-2), 26.0 (C-6), 18.4 (C-5), 16.5 (d, Jc,p = 6.1 Hz, 
C-10), -5.3 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2931, 2858, 1740, 1472, 1392, 1273, 1164, 1102, 1027, 971, 838, 
778, 663 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H33O6PSiNa 391.1682; found 391.1688. 
(S)-Ethyl 2-(4-methoxybenzyloxy)propanoate (1.42):  
4-Methoxybenzyltrichloroacetimidate (PMBTCA): To a 
stirred suspension of NaH (60% dispersion in mineral 
oil, 0.631 g, 15.8 mmol) in Et2O (80 mL) was added a solution of 4-methoxybenzyl alcohol 
(10.0 mL, 78.9 mmol) in Et2O (8 mL) dropwise at 0 oC.  The resulting cloudy orange 
mixture was stirred for 30 minutes at room temperature then cooled to 0 oC, and 
trichloroaetonitrile (8.50 mL, 83.1 mmol) was added dropwise.  This reaction was allowed 
to warm to room temperature and stirred for 5 hours.  The reaction mixture was then 
concentrated under reduced pressure.  The resulting residue was diluted with hexane (80 
mL, 1.0 M) and filtered with Celite.  The filtrate was concentrated under reduced pressure 
to give the crude product (22.9 g, 80.9 mmol, 100% yield) as a yellow-orange oil.  It was 
used in the next step without any further purification.  500 MHz 1H NMR (CDCl3) δ 8.37 
(bs, 1H, NH), 7.38 (d, J = 8.7 Hz, 2H, Ar-H), 6.92 (d, J = 8.7 Hz, 2H, Ar-H), 5.29 (s, 2H, 
-OCH2Ar), 3.83 (s, 3H, -OCH3); 125 MHz 13C NMR (CDCl3) δ 162.84 (-C=NH), 159.93 
(Ar-C-OCH3), 129.92 (2xAr-C), 127.73(Ar-C-CH2O-), 114.13 (2xAr-C), 91.71(-CCl3), 
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70.90(-OCH2Ar), 55.48(-OCH3);  
With an ice-water bath, to a stirred solution of (S)-(-)-ethyl lactate (6.00 mL, 51.9 mmol, 
1.0 equiv) in anhydrous toluene (100 mL, 0.5 M) was added Sc(OTf)3 (261 mg, 0.524 
mmol, 0.01 equiv) in one portion.  Then, a solution of abovementioned PMBTCA (22.7 g, 
80.2 mmol, 1.5 equiv) in toluene (40 mL, 2.0 M) was added via cannula to this mixture.  
This mixture was allowed to warm to room temperature over 6 hours under an atmosphere 
of N2.  It was then concentrated in vacuo.  The remainder was diluted with a cold mixture 
of Et2O/Hex (1:9, v/v) solution (50 mL) and filtered with Celite.  The pad of Celite was 
washed with cold mixute Et2O/Hex (1:9, v/v) solution (4 x 10 mL).  The combined filtrate 
was concentrated under vacuum.  The crude product was purified by flash chromatography 
on silica gel eluting with 5-12 vol% of EtOAc in hexanes to provide the titled compound 
(11.9 g, 50.0 mmol, 96% yield) as a colorless oil. 
TLC:  Rf = 0.51 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -76.4 (c 1.94, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.30 (d, J = 8.8 Hz, 2H, H-8, H-8’), 6.88 (d, J = 8.6 Hz, 2H, 
H-9, H-9’), 4.63 (d, J = 11.2 Hz, 1H, H-6a), 4.39 (d, J = 11.2 Hz, 1H, H-6b), 4.24 (dq, J 
= 10.8, 7.1 Hz, 1H, H-1a), 4.21 (dq, J = 10.7, 7.1 Hz, 1H, H-1b), 4.03 (q, J = 6.8 Hz, 1H, 
H-4), 3.88 (s, 3H, H-11), 1.42 (d, J = 6.8 Hz, 3H, H-5), 1.30 (t, J = 7.1 Hz, 3H, H-2);  
125 MHz 13C NMR (CDCl3) δ 173.6 (C-3), 159.6 (C-10), 129.9 (C-7, C-8, C-8’), 114.0 
(C-9, C-9’), 73.9 (C-4), 71.8 (C-6), 61.0 (C-1), 55.5 (C-11), 18.9 (C-5), 14.4 (C-2); 
FTIR (neat): νmax 2985, 2938, 2838, 1745, 1613, 1587, 1514, 1464, 1372, 1302, 1250, 1199, 
1143, 1065, 1034, 916, 823, 757, 666 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H18O4Na 261.1103; found 261.1095. 
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(S)-2-(4-Methoxybenzyloxy)propanal (1.43): To a 
solution of 1.42 (11.9 g, 50.0 mmol, 1.0 equiv) in CH2Cl2 
(250 mL, 0.2 M) was introduced DIBAL solution (1.0 M in 
CH2Cl2, 60 mL, 60 mmol, 1.0 equiv) by a syringe pump at 15 mL/h at -78 oC under an 
atmosphere of N2.  When the reaction was completed (monitored by TLC), methanol (10 
mL) was added into this reaction via a syringe pump at 15 mL/h.  The cold bath was then 
removed.  A saturated Rochelle’s salt solution (200 mL) was added and vigorously stirred 
overnight (ca. 8 hours).  The separated aqueous layer was extracted by Et2O (3 x 30 mL).  
The combined organic layers were washed by brine (200 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated in a vacuum.  The crude colorless oil was purified by 
flash chromatography on silica gel eluting with 5-15 vol% of ethyl acetate in hexanes to 
provide the titled compound (9.22 g, 47.5 mmol, 95% yield) as a colorless oil.   
TLC:  Rf = 0.33 (EtOAc/Hex = 3:7, v/v); 
[α]20 D  -50.1 (c 1.10, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 9.64 (d, J = 1.8 Hz, 1H, H-1), 7.30 (d, J = 8.8 Hz, 2H, H-6, 
H-6’), 6.90 (d, J = 8.8 Hz, 2H, H-7, H-7’), 4.57 (ABq, J = 11.4 Hz, Δν = 12.4 Hz, 2H, H-
4), 3.88 (qd, J = 6.9, 1.8 Hz, 1H, H-2), 3.82 (s, 3H, H-9), 1.32 (d, J =7.0 Hz, 3H, H-3);  
125 MHz 13C NMR (CDCl3): δ 203.8 (C-1), 159.7 (C-8), 129.8 (C-6, C-6’), 129.5 (C-5), 
114.1 (C-7, C-7), 79.3 (C-2), 71.9 (C-4), 55.5 (C-9), 15.5 (C-3); 
FTIR (neat): νmax 2957, 2935, 2857, 1734, 1613, 1586, 1514, 1464, 1374, 1303, 1249, 1175, 
1095, 1035, 822, 757 cm-1; 





With an ice-water bath, to a stirred mixture of 
NaH (60% dispersion in mineral oil, 1.48 g, 36.9 mmol, 1.05 equiv) and anhydrous THF 
(90 mL, 0.4 M) was added a solution of 1.41 (12.94 g, 35.11 mmol, 1.0 equiv) in THF (70 
mL, 0.5 M) dropwise via cannula over a period of 15 minutes.  This reaction was then 
stirred under an atmosphere of N2 for 10 minutes, whereupon a solution of 1.43 (6.819 g, 
35.11 mmol, 1.0 equiv) in THF (90 mL, 0.4 M) was added via a cannula over a period of 
15 minutes.  It was kept stirring in this condition for 2 hours.  Then, a saturated NaHCO3 
solution (200 mL) was added.  The separated aqueous layer was extracted by ether (3 x 50 
mL).  The combined organic layers were washed with brine (300 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure to 
provide a yellowish oil.  The crude product was purified by flash chromatography on silica 
gel eluting with 5-15 vol% of ethyl acetate in hexanes to afford the titled compound (13.35 
g, 32.67 mmol, 93% yield) as a yellowish oil. 
TLC:  Rf = 0.62 (Acetone/Hex = 5:5, v/v); 
[α]20 D  -30.9  (c 1.29, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.26 (d, J = 8.8 Hz, 2H, H-14, H-14’), 6.89 (dd, J = 8.8 Hz, 
2H, H-15, H-15’), 6.89 (dd, J = 15.7, 6.4 Hz, 1H, H-9), 6.02 (dd, J = 15.7, 1.5 Hz, 1H, H-
8), 4.51 (d, J = 11.3 Hz, 1H, H-12a), 4.37 (d, J = 11.3 Hz, 1H, H-12b), 4.26 (t, J = 6.6 Hz, 
2H, H-1), 4.11 (qdd, J = 6.4, 6.4, 1.5 Hz, 1H, H-10), 3.82 (s, 3H, H-17), 3.73 (t, J = 6.1 
Hz, 2H, H-3), 1.89 (pent, J = 6.2 Hz, 2H, H-2), 1.31 (d, J = 6.4 Hz, 3H, H-11), 0.90 (s, 9H, 
H-6), 0.062 (s, 6H, H-4, H-4’); 
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125 MHz 13C NMR (CDCl3) δ 166.6 (C-7), 159.4 (C-16), 149.6 (C-9), 130.4 (C-13), 129.5 
(C-14, C-14’), 121.4 (C-8), 114.0 (C-15, C-15’), 73.7 (C-10), 70.6 (C-12), 61.7 (C-1), 59.6 
(C-3), 55.5 (C-17), 32.0 (C-2), 26.1 (C-6), 20.9 (C-11), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2931, 2858, 1722, 1658, 1614, 1514, 1467, 1390, 1300, 1251, 1174, 
1104, 1037, 981, 837, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C22H36O5SiNa 431.2230; found 431.2209. 
(S,E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Hydroxypent-2-enoate (1.29f-(S)): To a stirred solution 
of 1.44 (13.04 g, 31.91 mmol, 1.0 equiv) in CH2Cl2 (160 
mL, 0.2 M) was added H2O (30 mL, 1.0 M) and DDQ (8.223 g, 35.50 mmol, 1.1 equiv) in 
one portion at room temperature.  This reaction was then stirred for 1 hour and quenched 
by a saturated NaHCO3 solution (200 mL).  The aqueous layer was extracted by EtOAc (3 
x 50 mL).  The combined organic layers were washed with brine (200 mL) and dried over 
anhydrous Na2SO4.  The solution was filtrated and concentrated in vacuo to provide 
brownish oil.  The crude product was purified by flash chromatography on silica gel eluting 
with 10-20 vol% of ethyl acetate in hexanes to provide the titled compound (8.594 g, 29.79 
mmol, 93% yield) as a pale yellow oil. 
TLC:  Rf = 0.26 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +13.1  (c 1.52, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 6.96 (dd, J = 15.7, 4.7 Hz, 1H, H-9), 6.03 (dd, J = 15.7, 1.7 
Hz, 1H, H-8), 4.50 (qdd, J = 6.5, 4.6, 1.7 Hz, 1H, H-10), 4.25 (t, J = 6.4 Hz, 2H, H-1), 
3.72 (t, J = 6.1 Hz, 2H, H-3), 1.88 (pent, J = 6.2 Hz, 2H, H-2), 1.71 (br. s, 1H, -OH), 1.35 
(d, J = 6.6 Hz, 3H, H-11), 0.90 (s, 9H, H-6), 0.053 (s, 6H, H-4, H-4’); 
48 
 
125 MHz 13C NMR (CDCl3) δ 166.8 (C-7), 151.1 (C-9), 119.8 (C-8), 67.4 (C-10), 61.7 (C-
1), 59.6 (C-3), 32.0 (C-2), 26.1 (C-6), 23.0 (C-11), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 3438 (br), 2957, 2930, 2858, 1723, 1658, 1471, 1391, 1361, 1257, 1175, 
1104, 1008, 979, 940, 837, 777, 719, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H28O4SiNa 311.1655; found 311.1631. 
(R,E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Chloropent-2-enoate (1.29a-(R)): With an ice-water 
bath, to a stirred solution of 1.29f-(S) (127 mg, 0.441 
mmol, 1.0 equiv) in anhydrous CH2Cl2 (9.0 mL, 0.05 M) was added PPh3 (178 mg, 0.672 
mmol, 1.5 equiv) and NCS (90 mg, 0.66 mmol, 1.5 equiv) subsequently.  This reaction was 
then stirred at for 1 hour under an atmosphere of N2.  It was then poured into a mixture of 
saturated NaHCO3 solution (15 mL) and saturated Na2S2O3 solution (15 mL).  The aqueous 
layer was extracted by Et2O (3 x 10 mL).  The combined organic layers were washed with 
brine (20 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 2-10 vol% of Et2O in hexanes to provide the 
titled compound (96.9 mg, 0.316 mmol, 72% yield) as a colorless oil.   
TLC:  Rf = 0.69 (EtOAc/Hex = 3:7, v/v); 
[α]20 D -3.3 (c 1.08, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 6.94 (dd, J = 15.5, 7.1 Hz, 1H, H-9), 6.01 (dd, J = 15.7, 1.5 
Hz, 1H, H-8), 4.62 (dqd, J = 7.1, 6.9, 1.5 Hz, 1H, H-10), 4.26 (t, J = 6.4 Hz, 2H, H-1), 
3.72 (t, J = 6.1 Hz, 2H, H-3), 1.88 (pent, J = 6.2 Hz, 2H, H-2), 1.65 (d, J = 6.9 Hz, 3H, H-
11), 0.90 (s, 9H, H-6), 0.055 (s, 6H, H-4, H-4’); 
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125 MHz 13C NMR (CDCl3) δ 166.1 (C-7), 147.3 (C-9), 121.8 (C-8), 62.0 (C-1), 59.6 (C-
3), 55.0 (C-10), 31.9 (C-2), 26.1 (C-6), 24.5 (C-11), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1725, 1661, 1471, 1390, 1360, 1341, 1272, 1178, 1106, 
1017, 975, 838, 777, 727, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H27ClO3SiNa 329.1316; found 329.1319. 
(R,E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Bromopent-2-enoate (1.19b-(R)): To a stirred solution 
of 1.29f-(S) (535 mg, 1.856 mmol, 1.0 equiv) in 
anhydrous CH2Cl2 (25 mL, 0.08 M) was added CBr4 (940 mg, 2.81 mmol, 1.5 equiv) and 
imidazole (194 mg, 2.82 mmol, 1.5 equiv).  Then, PPh3 (691 mg, 2.61 mmol, 1.4 equiv) 
was added in one portion at 0 oC.  This reaction was stirred under an atmosphere of N2 for 
1 hour and poured into a saturated NaHCO3 solution (50 mL).  The aqueous layer was 
extracted by Et2O (3 x 10 mL), and the combined organic layers were washed with brine 
(50 mL) and dried over anhydrous Na2SO4.  The solution was filtered and concentrated 
under reduced pressure to provide a yellowish oil.  The crude product was purified by flash 
chromatography on silica gel eluting with 0-10 vol% of Et2O in hexanes to provide the 
titled compound (475 mg, 1.35 mmol, 73% yield) as a colorless oil.  
TLC:  Rf = 0.65 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +4.2 (c 1.28, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.01 (dd, J = 15.7, 8.3 Hz, 1H, H-9), 5.93 (dd, J = 15.5, 1.0 
Hz, 1H, H-8), 4.69 (dqd, J = 8.3, 6.6, 1.0 Hz, 1H, H-10), 4.25 (t, J = 6.4 Hz, 2H, H-1), 
3.70 (t, J = 6.1 Hz, 2H, H-3), 1.87 (pent, J = 6.2 Hz, 2H, H-2), 1.82 (d, J = 6.4 Hz, 3H, H-
11), 0.88 (s, 9H, H-6), 0.042 (s, 6H, H-4, H-4’); 
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125 MHz 13C NMR (CDCl3) δ 166.0 (C-7), 147.7 (C-9), 121.2 (C-8), 62.0 (C-1), 59.6 (C-
3), 45.0 (C-10), 31.9 (C-2), 26.1 (C-6), 24.9 (C-11), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 1723, 1655, 1471, 1390, 1360, 1341, 1266, 1203, 1170, 
1104, 1010, 975, 939, 837, 777, 722, 663 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H27BrO3SiNa 373.0811; found 373.0817. 
(R,E)-3-(tert-Butyldimethylsilyloxy)propyl 4-Iodopent-
2-enoate (1.29c-(R)): To a stirred solution of 1.29f-(S) 
(170 mg, 0.588 mmol, 1.0 equiv) in anhydrous CH2Cl2 (6.0 
mL, 0.1 M) was added imidazole (207 mg, 3.00 mmol, 5.0 equiv), PPh3 (314 mg, 1.19 
mmol, 2.0 equiv) and I2 (277 mg, 1.08 mmol, 1.8 equiv) at room temperature.  This reaction 
was stirred for 1 hour under an atmosphere of N2.  Then, it was diluted with a solution of 
15 vol% of Et2O in hexanes (50 mL).  The precipitate was filtered by a pack of Celite®.  
The solution was concentrated under reduced pressure.  The remainder was purified by 
flash chromatography on silica gel eluting with 1-6 vol% of EtOAc in hexanes to provide 
the titled compound (124 mg, 0.310 mmol, 53% yield) as a yellow oil. 
TLC:  Rf = 0.65 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -0.7 (c 1.10, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.15 (dt, J = 15.4, 8.6 Hz, 1H, H-9), 5.84 (dt, J = 15.4, 1.2 
Hz, 1H, H-8), 4.90 (dqd, J = 8.6, 6.8, 1.2 Hz, 1H, H-10), 4.24 (t, J = 6.4 Hz, 2H, H-1), 
3.71 (t, J = 6.1 Hz, 2H, H-3), 2.00 (d, J = 6.8 Hz, 3H, H-11), 1.87 (pent, J = 6.2 Hz, 2H, 
H-2), 0.89 (s, 9H, H-6), 0.050 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 166.0 (C-7), 150.2 (C-9), 119.0 (C-8), 62.0 (C-1), 59.6 (C-
3), 31.9 (C-2), 26.6 (C-11), 26.1 (C-6), 21.1 (C-10), 18.5 (C-5), -5.2 (C-4, C-4’); 
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FTIR (neat): νmax 2956, 2930, 2857, 1720, 1645, 1471, 1390, 1360, 1340, 1260, 1191, 1106, 
1007, 976, 939, 837, 777, 721, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H27IO3SiNa 421.0672; found 421.0671. 
(S,E)-3-(tert-Butyldimethylsilyloxy)propyl 
4-Acetoxypent-2-enoate (1.29d-(S)): To a solution of 
1.29f-(S) (133 mg, 0.460 mmol, 1.0 equiv) in CH2Cl2 
(9.0 mL, 0.05 M) was added DMAP (57 mg, 0.46 mmol, 1.0 equiv), N,N-
diisopropylethylamine (800 uL, 4.59 mmol, 10.0 equiv) and acetic anhydride (130 uL, 1.36 
mmol, 3.0 equiv) subsequently, at room temperature.  It was stirred for 18 hours, and then 
quenched with a saturated NaHCO3 solution (20 mL).  The aqueous solution was extracted 
with Et2O (3 x 10 mL).  The combined organic layers were washed with brine (30 mL) and 
dried over anhydrous Na2SO4.  The solution was filtered and concentrated under reduced 
pressure.  The remainder was purified by flash chromatography on silica gel eluting with 
3-9 vol% of EtOAc in hexanes to provide the titled compound (138 mg, 0.417 mmol, 91% 
yield) as a colorless oil.   
TLC:  Rf = 0.55 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -21.3 (c 1.38, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 6.86 (dd, J = 15.8, 5.1 Hz, 1H, H-9), 5.95 (dd, J = 15.7, 2.0 
Hz, 1H, H-8), 5.48 (qdd, J = 6.8, 4.9, 1.8 Hz, 1H, H-10), 4.24 (t, J = 6.4 Hz, 2H, H-1), 
3.70 (t, J = 5.9 Hz, 2H, H-3), 2.08 (s, 3H, H-13), 1.86 (pent, J = 6.2 Hz, 2H, H-2), 1.36 (d, 
J = 6.9 Hz, 3H, H-11), 0.88 (s, 9H, H-6), 0.041 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 170.2 (C-12), 166.3 (C-7), 146.5 (C-9), 121.1 (C-8), 69.0 
(C-10), 61.9 (C-1), 59.6 (C-3), 31.9 (C-2), 26.1 (C-6), 21.3 (C-13), 19.8 (C-11), 18.5 (C-
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5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2931, 2858, 1746, 1725, 1664, 1472, 1373, 1305, 1236, 1176, 1103, 
1048, 977, 837, 777, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C16H30O5SiNa 353.1760; found 353.1765. 
(S,E)-3-(tert-Butyldimethylsilyloxy)propyl 4-
Methylsulfonyloxypent-2-enoate (1.29e-(S)): To a 
stirred solution of 1.29f-(S) (147 mg, 0.509 mmol, 1.0 
equiv) in anhydrous CH2Cl2 (10.0 mL, 0.05 M) was added DIPEA (360 uL, 2.07 mmol, 
4.0 equiv), followed by addition of MsCl (80 uL, 1.0 mmol, 2.0 equiv) dropwise at 0 oC.  
This reaction was stirred for 1 hour under an atmosphere of N2.  Then, it was poured into 
a saturated solution of NaHCO3 (30 mL).  The aqueous layer was extracted by Et2O (3 x 
10 mL).  The combined organic layers were washed with brine (30 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure to 
provide a yellowish oil.  The crude product was purified by flash chromatography on silica 
gel eluting with 10-20 vol% of ethyl acetate in hexane to provide the titled compound (149 
mg, 0.406 mmol, 80% yield) as a yellowish oil.   
TLC:  Rf = 0.58 (EtOAc/CH2Cl2 = 1:9, v/v);  
[α]20 D -23.2 (c 1.33, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 6.88 (dd, J = 15.7, 5.4 Hz, 1H, H-9), 6.09 (dd, J = 15.7, 1.5 
Hz, 1H, H-8), 4.87 (qdd, J = 6.8, 5.4, 1.5 Hz, 1H, H-10), 4.27 (t, J = 6.6 Hz, 2H, H-1), 
3.71 (t, J = 6.1 Hz, 2H, H-3), 3.03 (s, 3H, H-12), 1.88 (pent, J = 6.2 Hz, 2H, H-2), 1.55 (d, 
J = 6.9 Hz, 3H, H-11), 0.89 (s, 9H, H-6), 0.051 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 165.7 (C-7), 144.2 (C-9), 123.0 (C-8), 76.6 (C-10), 62.2 (C-
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1), 59.5 (C-3), 39.2 (C-12), 31.9 (C-2), 26.1 (C-6), 21.4 (C-11), 18.5 (C-5), -5.2 (C-4, C-
4’); 
FTIR (neat): νmax 2956, 2932, 2858, 1724, 1665, 1471, 1362, 1306, 1259, 1178, 1102, 1035, 
975, 896, 838, 814, 778 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H30O6SSiNa 389.1430; found 389.1438. 
General procedure of preparing 0.1 M SmI2 solution: To an oven dried flask, equipped 
with a stirring bar, was added Sm chips (301 mg, 2.0 mmol, 2.0 equiv), and stirred 
vigorously overnight.  Then, freshly distilled THF (10.0 mL, 0.1 M) was added into this 
flask, followed by CH2I2 (81.5 uL, 1.00 mmol, 1.0 equiv) at room temperature under an 
atmosphere of N2.  After 5 hours, a deep blue/purple SmI2 solution was ready to use. 
General procedure of SmI2 mediated reductive deconjugation reaction:  
3-(tert-Butyldimethylsilyloxy)propyl But-3-enoate (1.26): 
Under an atmosphere of Ar, to a mixture of 1.25a (34.7 mg 
0.110 mmol, 1.0 equiv), MeOH (90 uL, 2.2 mmol, 20 equiv) 
and freshly distilled THF (5.5 mL, 0.02 M) was added SmI2 (0.1M solution, 2.2 mL, 2.2 
equiv) via syringe pumb over a period of 5 minutes at -78 oC.  The reaction completed in 
seconds judged by the disappearance of characteristic deep blue-purple color of SmI2 
solution.  Then, the reaction was diluted with Et2O (10 mL) and poured into a saturated 
Rochelle’s salt solution (20 mL).  The aqueous solution was extracted with Et2O (3 x 5 
mL).  The combined organic layers were washed with brine (20 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure.  
The remainder was purified by flash chromatography on silica gel eluting with 0-6 vol% 
of Et2O in hexanes to provide the titled compound (26.7 mg, 0.103 mmol, 94% yield) as a 
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colorless oil.  
TLC:  Rf = 0.20 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3) δ 5.93 (ddt, J = 17.1, 10.0, 7.3 Hz, 1H, H-9), 5.22 ~ 5.12 (m, 
2H, H-10), 4.20 (t, J = 6.4 Hz, 2H, H-1), 3.70 (t, J = 6.3 Hz, 2H, H-3), 3.09 (dt, J = 6.9, 
1.5 Hz, 2H, H-8), 1.85 (p, J = 6.3 Hz, 2H, H-2), 0.90 (s, 9H, H-6), 0.055 (s, 6H, H-4, H-
4’); 
125 MHz 13C NMR (CDCl3) δ 171.8 (C-7), 130.6 (C-9), 118.7 (C-10), 61.9 (C-1), 59.6 (C-
3), 39.4 (C-8), 31.9 (C-2), 26.1 (C-6), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1742, 1644, 1471, 1391, 1361, 1328, 1257, 1174, 1104, 
1010, 974, 921, 837, 777, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H26O3SiNa 281.1549; found 281.1546. 
3-(tert-Butyldimethylsilyloxy)propyl 4-
Methoxybutanoate (1.27b): The tilted compound (5.6 mg, 
0.019 mmol, 18% yield) as a colorless oil and compound 
1.26 (18.3 mg, 0.0708 mmol, 66% yield) were obtained from 1.25b (30.8 mg, 0.107 mmol, 
1.0 equiv) with SmI2 (0.1 M solution, 3.2 mL, 0.32 mmol, 3.0 equiv) as the general 
procedure described above but at room temperature for 4 hours.  The titled compound was 
purified by flash chromatography on silica gel eluting with 6-10 vol% of Et2O in hexanes.  
TLC:  Rf = 0.15 (Et2O/Hex = 1:9, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.18 (t, J = 6.4 Hz, 2H, H-1), 3.70 (t, J = 6.1 Hz, 2H, H-3), 
3.41 (t, J = 6.1 Hz, 2H, H-10), 3.33 (s, 3H, H-11), 2.39 (t, J = 7.6 Hz, 2H, H-8), 1.90 (tt, J 




125 MHz 13C NMR (CDCl3) δ 173.7 (C-7), 71.8 (C-10), 61.6 (C-1), 59.7 (C-3), 58.8 (C-
11), 32.0 (C-2), 31.2 (C-8), 26.1 (C-6), 25.2 (C-9), 18.5 (C-5), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 1738, 1471, 1362, 1256, 1168, 1119, 837, 777, 665 
cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H30O4SiNa 313.1811; found 313.1811. 
3-(tert-Butyldimethylsilyloxy)propyl 4-
(Allyloxy)butanoate (1.27h): The titled compound (16.5 
mg, 0.0521 mmol, 46% yield) as a colorless oil and 
compound 1.26 (13.1 mg, 0.0507 mmol, 45% yield) were obtained from 1.25h (35.3 mg, 
0.112 mmol, 1.0 equiv) with SmI2 (0.1 M solution, 3.3 mL, 0.33 mmol, 3.0 equiv) as the 
general procedure described above but at room temperature for 4 hours.  The titled 
compound was purified by flash chromatography on silica gel eluting with 3-10 vol% of 
Et2O in hexanes.  
TLC:  Rf = 0.16 (Et2O/Hex = 1:9, v/v);  
500 MHz 1H NMR (CDCl3) δ 5.90 (ddt, J = 17.1, 10.3, 5.9 Hz, 1H, H-12), 5.27 (ddt, J 
=17.1, 2.0, 1.5 Hz, 1H, H-13a), 5.17 (ddt, J = 10.5, 2.0, 1.5 Hz, 1H, H-13b), 4.17 (t, J = 
6.4 Hz, 2H, H-1), 3.96 (ddd, J = 5.4, 1.5, 1.5 Hz, 2H, H-11), 3.70 (t, J = 6.1 Hz, 2H, H-3), 
3.47 (t, J = 6.1 Hz, 2H, H-10), 2.41 (t, J = 7.3 Hz, 2H, H-8), 1.91 (tt, J = 7.3, 6.1 Hz, 2H, 
H-9), 1.84 (p, J = 6.2 Hz, 2H, H-2), 0.90 (s, 9H, H-6), 0.053 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 173.7 (C-7), 135.1 (C-12), 117.0 (C-13), 72.0 (C-11), 69.4 
(C-10), 61.6 (C-1), 59.7 (C-3), 32.0 (C-2), 31.3 (C-8), 26.1 (C-6), 25.3 (C-9), 18.5 (C-5), -
5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 1738, 1472, 1391, 1361, 1256, 1174, 1106, 923, 837, 
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777, 664 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C16H32O4SiNa 339.1968; found 339.1971. 
3-(tert-Butyldimethylsilyloxy)propyl 4-(tert-
Butyldimethylsilyloxy)butanoate (1.27i): The titled 
compound (35.7 mg, 0.0914 mmol, 72% yield) as a 
colorless oil and compound 1.26 (7.8 mg, 0.0302 mmol, 24% yield) were obtained from 
1.25i (49.1 mg, 0.126 mmol, 1.0 equiv) with SmI2 (0.1 M solution, 3.8 mL, 0.38 mmol, 3.0 
equiv) as the general procedure described above but at room temperature for 4 hours.  The 
tiltled compound was purified by flash chromatography on silica gel eluting with 3-10 vol% 
of Et2O in hexanes.  
TLC:  Rf = 0.29 (Et2O/Hex = 1:9, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.17 (t, J = 6.4 Hz, 2H, H-1), 3.70 (t, J = 6.1 Hz, 2H, H-3), 
3.64 (t, J = 6.1 Hz, 2H, H-10), 2.39 (t, J = 7.3 Hz, 2H, H-8), 1.88 ~ 1.80 (m, 4H, H-2, H-
9), 0.90 (s, 18H, H-6, H-13), 0.053 (s, 6H, H-4, H-4’),  0.047(s, 6H, H-11, H-11’); 
125 MHz 13C NMR (CDCl3) δ 173.9 (C-7), 62.2 (C-10), 61.5 (C-1), 59.7 (C-3), 32.1 (C-
2), 30.9 (C-8), 28.2 (C-9), 26.1 (C-6, C-13), 18.5 (C-5, C-12), -5.2 (C-11, C-11’), -5.2 (C-
4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 1739, 1472, 1390, 1362, 1256, 1171, 1106, 1007, 967, 
837, 777, 720, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C19H42O4Si2Na 413.2519; found 413.2525. 
3-(tert-Butyldimethylsilyloxy)propyl 4-
(Allylthio)butanoate (1.27j): The titled compound (18.3 
mg, 0.0571 mmol, 43% yield) as a colorless oil and 
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compound 1.26 (15.2 mg, 0.0588 mmol, 45% yield) were obtained from 1.25j (42.1 mg, 
0.132 mmol, 1.0 equiv) with SmI2 (0.1 M solution, 4.0 mL, 0.40 mmol, 3.0 equiv) as the 
general procedure described above but at room temperature for 4 hours.  The tilteld 
compound was purified by flash chromatography on silica gel eluting with 3-10 vol% of 
Et2O in hexanes.   
TLC:  Rf = 0.38 (Et2O/Hex = 2:8, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.18 (t, J = 6.4 Hz, 2H, H-1), 3.70 (t, J = 6.1 Hz, 2H, H-3), 
2.57 (t, J = 7.2 Hz, 2H, H-10), 2.55 (q, J = 7.6 Hz, 2H, H-11), 2.44 (t, J = 7.3 Hz, 2H, H-
8), 1.92 (p, J = 7.2 Hz, 2H, H-9), 1.84 (p, J = 6.2 Hz, 2H, H-2), 1.26 (t, J = 7.3 Hz, 3H, H-
12), 0.90 (s, 9H, H-6), 0.057 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 173.4 (C-7), 61.7 (C-1), 59.7 (C-3), 33.3 (C-8), 32.0 (C-2), 
31.1 (C-10), 26.1 (C-6), 26.0 (C-11), 25.0 (C-9), 18.5 (C-5), 15.0 (C-12), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1738, 1471, 1367, 1260, 1170, 1115, 838, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H32O3SSiNa 343.1739; found 343.1736. 
3-(tert-Butyldimethylsilyloxy)propyl butyrate (1.27n): 
Following the general procedure, 1.25n (30.9 mg, 0.120 mmol, 
1.0 equiv) was treated with SmI2 (0.1 M solution, 3.6 mL, 0.36 
mmol, 3.0 equiv) at room temperature for 6 hours to funish the titled compound (11.5 mg, 
0.0442 mmol, 37% yield) as a colorless oil, along with the recovered starting material 
1.25n (16.7 mg, 0.0646 mmol, 54% yield).  The tilteld compound was purified by flash 
chromatography on silica gel eluting with 2-10 vol% of Et2O in hexanes.   
TLC:  Rf = 0.48 (Et2O/Hex = 2:8, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.17 (t, J = 6.4 Hz, 2H, H-1), 3.70 (t, J = 6.1 Hz, 2H, H-3), 
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2.28 (t, J = 7.6 Hz, 2H, H-8), 1.84 (p, J = 6.2 Hz, 2H, H-2), 1.66 (sext, J = 7.4 Hz, 2H, H-
9), 0.96 (t, J = 7.3 Hz, 3H, H-10), 0.90 (s, 9H, H-6), 0.054 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 173.9 (C-7), 61.4 (C-1), 59.7 (C-3), 36.5 (C-8), 32.1 (C-2), 
26.1 (C-6), 18.7 (C-9), 18.5 (C-5), 13.9 (C-10), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2956, 2930, 2858, 1739, 1470, 1362, 1257, 1112, 835, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H28O3SiNa 283.1705; found 283.1707. 
3-((tert-Butyldimethylsilyl)oxy)propyl pent-3-
enoate (1.30): To a solution of 1.29b (38.2 mg, 0.109 
mmol, 1.0 equiv) in THF was added SmI2 solution SmI2 
(0.1 M solution, 2.4 mL, 0.24 mmol, 2.2 equiv) as the general procedure described above.  
The reaction was purified by flash chromatography on silica gel eluting with 0-6 vol% of 
Et2O in hexanes to provide the titled compound (29.5 mg, 0.108 mmol, 99% yield) as a 
colorless oil, which was an inseparable mixture of Z/E isomers (Z:E = 1:3 based on 1HNMR 
intergration).    
TLC:  Rf = 0.61 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3): 
E-isomer: δ 5.63 ~ 5.49 (m, 2H, H-9, H-10), 4.17 (t, J = 6.4 Hz, 2H, H-1), 3.69 (t, J = 6.1 
Hz, 2H, H-3), 3.07 ~ 2.93 (m, 2H, H-8a, H-8b), 1.84 (pent, J = 6.2 Hz, 2H, H-2), 1.73 ~ 
1.66 (m, 3H, H-11), 0.89 (s, 9H, H-6), 0.047 (s, 6H, H-4, H-4’);  
Z-isomer: δ 5.65 (dqt, J = 12.0, 6.6, 1.6 Hz, 1H, H-10), 5.57 (dtq, J = 12.0, 6.9, 1.5 Hz, 
1H, H-9), 4.18 (t, J = 6.4 Hz, 2H, H-1), 3.69 (t, J = 6.1 Hz, 2H, H-3), 3.12 ~ 3.06 (m, 2H, 
H-8a, H-8b), 1.84 (pent, J = 6.2 Hz, 2H, H-2), 1.67 ~ 1.61 (m, 3H, H-11), 0.89 (s, 9H, H-
6), 0.045 (s, 6H, H-4, H-4’);  
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125 MHz 13C NMR (CDCl3): 
E-isomer: δ 172.4 (C-7), 129.5 (C-10), 123.0 (C-9), 61.7 (C-1), 59.6 (C-3), 38.3 (C-8), 
31.9 (C-2), 26.1 (C-6), 18.5 (C-5), 18.1 (C-11), -5.2 (C-4, C-4’);  
Z-isomer: δ 172.2 (C-7), 127.6 (C-10), 122.1 (C-9), 61.8 (C-1), 59.6 (C-3), 32.9 (C-8), 
32.0 (C-2), 26.1 (C-6), 18.5 (C-5), 13.1 (C-11), -5.2 (C-4, C-4’);  
FTIR (neat): νmax 2957, 2930, 2858, 1741, 1472, 1390, 1361, 1256, 1164, 1103, 1008, 967, 
837, 777, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C14H28O3SiNa 295.1705; found 295.1713. 
3-(tert-Butyldimethylsilyloxy)propyl 4-
Methoxypentanoate (1.31g): The titled compound (13.8 
mg, 0.0453 mmol, 38% yield) as a colorless oil and 
compound 1.30 (18.2 mg, 0.0668 mmol, 56% yield) were obtained from 1.29g (35.9 mg, 
0.119 mmol, 1.0 equiv) with SmI2 (0.1 M solution, 3.6 mL, 0.36 mmol, 3.0 equiv) as the 
general procedure described above but at room temperature for 6 hours.  The tilteld 
compound was purified by flash chromatography on silica gel eluting with 3-10 vol% of 
Et2O in hexanes.   
TLC:  Rf = 0.19 (EtOAc/Hex = 1:9, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.17 (t, J = 6.6 Hz, 2H, H-1), 3.70 (t, J = 6.1 Hz, 2H, H-3), 
3.33 (sxet, J = 6.0 Hz, 1H, H-10), 3.31 (s, 3H, H-12), 2.41 (ddd, J = 16.1, 7.8, 7.3, 1H, H-
8a), 2.37 (ddd, J = 16.1, 7.8, 7.3, 1H, H-8b), 1.84 (pent, J = 6.2 Hz, 2H, H-2), 1.82 ~ 1.75 
(m, 2H, H-9a, H-9b), 1.15 (d, J = 6.4 Hz, 3H, H-11), 0.90 (s, 9H, H-6), 0.053 (s, 6H, H-4, 
H-4’);  
125 MHz 13C NMR (CDCl3) δ 174.0 (C-7), 76.0 (C-10), 61.5 (C-1), 59.7 (C-3), 56.3 (C-
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12), 32.0 (C-2), 31.6 (C-9), 30.5 (C-8), 26.1 (C-6), 19.1 (C-11), 18.5 (C-5), -5.2 (C-4, C-
4’);  
FTIR (neat): νmax 2956, 2930, 2858, 1738, 1464, 1257, 1170, 1100, 837, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C15H32O4SiNa 327.1968; found 327.1969. 
3-(tert-Butyldimethylsilyloxy)propyl 4-
(Allyloxy)pentanoate (1.31h): The titled compound (25.3 
mg, 0.765 mmol, 71% yield) as a colorless oil and 
compound 1.30 (7.7 mg, 0.283 mmol, 26% yield) were obtained from 1.29h (35.6 mg, 
0.108 mmol, 1.0 equiv) with SmI2 (0.1 M solution, 3.3 mL, 0.33 mmol, 3.0 equiv) as the 
general procedure described above but at room temperature for 6 hours.  The tilteld 
compound was purified by flash chromatography on silica gel eluting with 3-10 vol% of 
Et2O in hexanes.   
TLC:  Rf = 0.29 (EtOAc/Hex = 1:9, v/v);  
500 MHz 1H NMR (CDCl3) δ 5.90 (ddt, J = 17.1, 10.3, 5.9 Hz, 1H, H-13), 5.26 (ddt, J = 
17.1, 2.0, 1.5 Hz, 1H, H-14a), 5.15 (ddt, J = 10.3, 2.0, 1.5 Hz, 1H, H-14b), 4.16 (t, J = 6.4 
Hz, 2H, H-1), 4.03 (ddt, J = 12.7, 5.9, 1.5 Hz, 1H, H-12a), 3.90 (ddt, J = 12.7, 5.9, 1.5 Hz, 
1H, H-12b), 3.69 (t, J = 6.1 Hz, 2H, H-3), 3.49 (sext, J = 6.1 Hz, 1H, H-10), 2.43 (ddd, J 
= 16.1, 7.8, 7.3 Hz, 1H, H-8a), 2.38 (ddd, J = 16.1, 7.8, 7.3 Hz, 1H, H-8b), 1.83 (pent, J = 
6.1 Hz, 1H, H-2), 1.80 (td, J = 7.6, 6.0 Hz, 2H, H-9a, 9b), 1.16 (d, J = 5.9 Hz, 3H, H-11), 
0.89 (s, 9H, H-6), 0.049 (s, 6H, H-4, H-4’); 
125 MHz 13C NMR (CDCl3) δ 174.0 (C-7), 135.5 (C-13), 116.7 (C-14), 74.0 (C-10), 69.7 
(C-12), 61.5 (C-1), 59.7 (C-3), 32.0 (C-2), 31.8 (C-9), 30.5 (C-8), 26.1 (C-6), 19.7 (C-11), 
18.5 (C-5), -5.2 (C-4, C-4’); 
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FTIR (neat): νmax 2957, 2930, 2858, 1738, 1464, 1376, 1339, 1257, 1175, 1101, 1007, 922, 
837, 777, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C17H34O4SiNa 353.2124; found 353.2124. 
3-(tert-Butyldimethylsilyloxy)propyl 4-((tert-
Butyldimethyl)-silyloxy)pentanoate (1.31i): The 
titled compound (39.5 mg, 0.0976 mmol, 93% yield) 
as a colorless oil was obtained from 1.29i (42.3 mg, 0.105 mmol, 1.0 equiv) with SmI2 (0.1 
M solution, 3.3 mL, 0.33 mmol, 3.0 equiv) as the general procedure described above but 
at room temperature for 6 hours.  The tilteld compound was purified by flash 
chromatography on silica gel eluting with 3-5 vol% of Et2O in hexanes.   
TLC:  Rf = 0.31 (Et2O/Hex = 1:9, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.17 (t, J = 6.4 Hz, 2H, H-1), 3.85 (sxet, J = 6.0 Hz, 1H, H-
10), 3.70 (t, J = 6.1 Hz, 2H, H-3), 2.40 (ddd, J = 16.1, 9.2, 6.4, 1H, H-8a), 2.34 (ddd, J = 
16.1, 8.8, 6.8, 1H, H-8b), 1.84 (pent, J = 6.2 Hz, 2H, H-2), 1.80 ~ 1.70 (m, 2H, H-9a, H-
9b), 1.14 (d, J = 6.4 Hz, 3H, H-11), 0.90 (s, 9H, H-6), 0.89 (s, 9H, H-14), 0.053 (s, 9H, H-
4, H-4’, H-12), 0.043 (s, 3H, H-12’);  
125 MHz 13C NMR (CDCl3) δ 174.1 (C-7), 67.7 (C-10), 61.5 (C-1), 59.7 (C-3), 34.6 (C-
9), 32.0 (C-2), 30.6 (C-8), 26.1 (C-6), 26.1 (C-14), 23.9 (C-11), 18.5 (C-5), 18.3 (C-13), -
4.2 (C-12), -4.6 (C-12’), -5.2 (C-4, C-4’); 
FTIR (neat): νmax 2957, 2930, 2858, 1740, 1471, 1361, 1256, 1171, 1095, 1006, 837, 776, 
665 cm-1; 




(Ethylthio)pentanoate (1.31j): The titled compound (19.1 
mg, 0.0571 mmol, 43% yield) as a colorless oil and 
compound 1.30 (16.3 mg, 0.0598 mmol, 45% yield) were obtained from 1.29j (44.3 mg, 
0.133 mmol, 1.0 equiv) with SmI2 (0.1 M solution, 4.0 mL, 0.40 mmol, 3.0 equiv) as the 
general procedure described above but at room temperature for 6 hours.  The tilteld 
compound was purified by flash chromatography on silica gel eluting with 3-10 vol% of 
Et2O in hexanes.   
TLC:  Rf = 0.35 (Et2O/Hex = 2:8, v/v);  
500 MHz 1H NMR (CDCl3) δ 4.18 (t, J = 6.4 Hz, 2H, H-1), 3.70 (t, J = 6.1 Hz, 2H, H-3), 
2.80 (sxet, J = 6.7 Hz, 1H, H-10), 2.55 (q, J = 7.5 Hz, 2H, H-12), 2.50 ~ 2.43 (m, 2H, H-
8a, H-8b), 1.97 ~ 1.75 (m, 4H, H-2, H-9a, H-9b), 1.29 (d, J = 6.8 Hz, 3H, H-11), 1.25 (t, 
J = 7.3 Hz, 3H, H-13), 0.90 (s, 9H, H-6), 0.053 (s, 6H, H-4, H-4’);  
125 MHz 13C NMR (CDCl3) δ 173.7 (C-7), 61.6 (C-1), 59.6 (C-3), 39.3 (C-10), 32.0 (C-
2), 31.9 (C-9), 31.8 (C-8), 26.1 (C-6), 24.3 (C-12), 21.6 (C-11), 18.5 (C-5), 15.1 (C-13), -
5.2 (C-4, C-4’); 
FTIR (neat): νmax 2958, 2929, 2858, 1738, 1462, 1378, 1361, 1257, 1167, 1104, 1008, 969, 
837, 777 cm-1; 



































































































(L = -OAc) 
5.0 -- 0 ~ 5 min 23 -- -- 
2 1.25a 
(L = -OAc) 
2.2 -- 0 ~ 5 min 25 -- -- 
3 1.25a 
(L = -OAc) 
2.2 -- -41 ~ 5 min 33 -- -- 
4 1.25a 
(L = -OAc) 
2.2 -- -78 ~ 5 min 41 -- -- 
5 1.25a 
(L = -OAc) 
2.2 
MeOH 
1.0 eq  
-78 ~ 5 min 76 -- -- 
6 1.25a 
(L = -OAc) 
2.2 
MeOH 
> 10 eq  
-78 ~ 5 min 94 -- -- 
7 1.25a 
(L = -OAc) 
2.2 
t-BuOH 
> 10 eq 
-78 ~ 5 min 89 -- -- 
8 1.25b 
(L = -OMe) 
3.0 
MeOH 
> 10 eq 
-78 4 h no   reaction 
9 1.25b 
(L = -OMe) 
3.0 
MeOH 
> 10 eq 
-31 4 h no   reaction 
10 1.25b 
(L = -OMe) 
3.0 
MeOH 
> 10 eq 
rt 4 h 66 18 -- 
a To a solution of about 0.1 mmol of the starting material in 5 mL of THF was added SmI2 solution under Ar. 
b The time started since SmI2 solution was added into the reaction via syringe pumb over a period of 5  min.. 



















1 1.25a (L = -OAc) -78 ~ 5 min 94 -- -- 
2 1.25b (L = -OMe) rt 4 h 66 18 -- 
3 1.25c (L = -Cl) -78 ~ 5 min 97 -- -- 
4 1.25d (L = -Br) -78 ~ 5 min 99 -- -- 
5 1.25e (L = -I) -78 ~ 5 min 99 -- -- 
6 1.25f (L = -OMs) -78 ~ 5 min 96 -- -- 
7 1.25g (L = -OH) rt 3 h 94 -- -- 
8 1.25h (L = -OAllyl) rt 4 h 45 46 -- 
9 1.25i (L = -OTBS) rt 4 h 24 72 -- 
10 1.25j (L = -SEt) rt 4 h 45 43 -- 
11 1.25k (L = -SOEt) -78 5 min 73 -- -- 
12 1.25l (L = -SO2Et) -78 5 min 93 -- -- 
13 1.25m (L = -NEt2) -78 5 min 95 -- -- 
14 1.25n (L = -H) rt 6 h  37e -- 
 a To a mixture of about 0.1 mmol of the starting material and 20 equiv of MeOH in 5 mL of THF was 
added SmI2 solution under Ar. 
b Reactions at -78 oC were added 2.2 equiv of SmI2, and reactions at rt were added 3.0 equiv of SmI2. 
c The time started since SmI2 solution was added into the reaction via syringe pumb over a period of 5 
minutes. 
d Isolated yields. 

















1 1.29a (L = -Cl) racemic -78; 5 min 95 18/82 -- 
2 1.29a-(R) (L = -Cl) R -78; 5 min 95 19/81  
3 1.29b (L = -Br) racemic -78; 5min 99 25/75 -- 
4 1.29b-(R) (L = -Br) R -78; 5 min 98 25/75  
5 1.29c (L = -I) racemic -78; 5 min 97 43/57 -- 
6 1.29c-(R) (L = -I) R -78; 5 min 96 43/57  
7 1.29d (L = -OAc) racemic -78; 5 min 97 37/63 -- 
8 1.29d-(S) (L = -OAc) S -78; 5 min 94 36/64  
9 1.29e (L = -OMs) racemic -78; 5 min 92 23/77 -- 
10 1.29e-(S) (L = -OMs) S -78; 5 min 96 20/80  
11 1.29f (L = -OH) racemic rt; 4 h 92 30/70 -- 
12 1.29f-(S) (L = -OH) S rt; 4 h 90 33/67  
13 1.29g (L = -OMe) racemic rt; 6 h 56 19/81 38 
14 1.29h (L = -OAllyl) racemic rt; 6 h 26 26/74 71 
15 1.29i (L = -OTBS) racemic rt; 6 h 0  93 
16 1.29j (L = -SEt) racemic rt; 6 h 45 33/67 43 
17 1.29k (L = -SOEt) racemic -78; 5 min 86 25/75 -- 
18 1.29l (L = -SO2Et) racemic -78; 5 min 85 33/67 -- 
19 1.29m (L = -NEt2) racemic -78; 5 min 85 25/75 -- 
a To a mixture of about 0.1 mmol of the starting material and 20 equiv of MeOH in 5 mL of THF was added 
SmI2 solution under Ar. 
b Reactions at -78 oC were added 2.2 equiv of SmI2, and reactions at rt were added 3.0 equiv of SmI2. The 
time started since SmI2 solution was added into the reaction via syringe pumb over a period of 5 minutes. 
c Isolated yields 
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THE DEVELOPMENT, SYNTHESIS AND BIOLOGICAL EVALUATION  
OF C-27 DES-METHYL NORTHERN HEMISPHERE  
SIMPLIFIED BRYOSTATIN ANALOGUE 
 
Introduction 
The planet we share is called Earth, and it is the only planet in our solar system whose 
name is not derived from Greek or Roman mythology.1  The name “Earth” originates from 
the Old English word “eor(th)e” or “ertha”, which can be traced back to an Anglo-Saxon 
word “erda” and its Germanic equivalent ‘Erde’, meaning ground or soil.  Ironically, our 
planet “Earth” is something of an “ocean planet”.  The oceans cover about 71% of the 
surface of our planet and over 90% of the volume of its crust.2  Actually, all the exposed 
planetary land has a mean elevation of about 840 meters, and can be completely hidden in 
the oceans, which have an average depth of 3795 meters.  The total volume of the oceans 
is estimated at about 1.37 x 109 km.  Considering that a typical milliliter (cm3) of seawater 
contains approximately 103 fungi, 106 bacteria and 107 viruses,3 gigantic amounts of 
microorganisms exist in the oceans.  To adapt to and survive in diverse marine 
environments, from the frigidity of the Antarctic Ocean to overheated hydrothermal vents, 
from photic continental shelves to dark benthic zones, from highly salty areas to extremely 
toxic and acidic regions, marine life, especially the microorganisms, have enormous 
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biodiversity, and many of them have no terrestrial equivalents.  For example, with more 
than 30 recognized phyla, all Animalia are represented in the oceans except the phylum 
Onychophora.4     
Thanks to a complex system of biochemical reactions, marine organisms produce some 
organic molecules which are called metabolites.  They are further divided into primary 
metabolites and second metabolites.  The primary metabolites are used by cells for their 
own function and reproduction in favor of a single origin of life, which is a common 
phenomenon to all living organisms from bacteria to human beings.  On the other hand, 
the secondary metabolites are not necessary to maintain the producers’ essential growth, 
but represent diversity and specificity to help them adapt to the unique environments to get 
better chances of survival and development.  The primary metabolites thus reflect the unity 
of the living world, while the secondary metabolites represent its diversity.5  Many of these 
marine metabolites demonstrate antiviral, anti-inflammatory, antitumor, cytotoxic, 
neurotoxic and other strong biological activities, which are of considerable biochemical 
interest.  They are still the major source of drug models, drug leads and promising 
pharmaceutical agents today.   
However, intense study of the oceans, especially for the purpose of pharmaceutics, 
began very late in the history of human beings.  In all recorded human history, the earliest 
documented medicine may date back to a time as early as 3,000-4,000 years ago in ancient 
Egypt, India, and China.6  Until the 19th century terrestrial plants and animals were still 
utilized as the main source of medicinal agents.  Historically, humans had the 
misconception that the massive ocean was only a huge reservoir of terrestrial streams and 
a place for fishing.  This situation was changed when modern chemical and biological 
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sciences developed.  The discoveries of penicillin by Fleming in 19287 and sulfonamides 
by Gerhard Domagk in the 1930s8 opened the gate to the “Golden Age of Antibiotics”. At 
that time, terrestrial microorganisms became the focal point for one of the most prolific 
drug discovery methods ever.  The intensity of these investigations to discoveries of new 
microorganisms reached virtually all accessible terrestrial environments, from frigid arctic 
areas to tropical regions.  Although the massive ocean was less probed, pioneering work 
by Claude Zobell,9 Giuseppe Brotz10 and Werner Bergmann11 revealed a new, incredibly 
diverse world to us. In the middle of the 1970s, the systematic investigations of marine 
environments as new sources of novel pharmaceutical agents began intensely.  Bacteria, 
fungi, certain groups of algae, sponges (phylum Porifera), bryozoans, cnidarians (formerly 
coelenterate), and mollusca were the most studied marine organisms among the phyla 
found in the oceans.   
 
Discovery of Bryostatins 
Bryostatins and Their Origin  
In the context of raising interest in marine organisms, George R. Pettit and his 
collaborators found some extracts exhibiting extraordinary antineoplastic activity, which 
were from certain marine animals including bryozoans (the name means “moss animals”, 
phylum Bryozoa) and other invertebrates and vertebrates from a broad geographic area.12  
These compounds were further isolated and identified from 500 kg of bryozoan Bugula 
neritina (Figure 2.1) collected from the Gulfs of Mexico, California, and Sagami off Japan.  
Because of their origin and biological activity, these compounds were named bryostatins.  
The structure of bryostatin 1 was elucidated by crystallographic and spectroscopic 
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techniques,13 and was further confirmed by X-ray diffraction analysis of a heavy atom 
dispersion of 7-p-bromobenzoate derived from bryostatin 2.14  Currently, a total of 21 
bryostatins have been isolated and well documented, mainly as a result of the work of Pettit 
and colleagues.13-27.   
Figure 2.2 summarizes the structures of all 21 members of the bryostatin family.  All 
of them are featured with a unique 26-membered macrolactone skeleton, in which a smaller 
20-membered ring was embedded, and some constant structures.  The larger macrolactone 
ring contains three highly functionalized pyran rings (referred to as A-, B-, and C-rings 
anticlockwise from the right northern side to the southern part of the molecule sequentially) 
that are successively linked by a methylene bridge, an E-geometrical olefin, and an ester 
tether; all the bryostatins have germinal dimethyl at C-8; and all the family members have 
free hydroxyl groups at C-3, C-9 and C-26.  Most bryostatins have an exocyclic methyl 
enoate in both their B-ring (C-13) and C-ring (C-21), except bryostatin 3, 19, and 20, which 
have a fused butenolide instead of the aforementioned methyl enoate. Virtually, each 
bryostatin has a free hydroxyl group at C-19 as a part of cyclized hemiketal moiety, but 
bryostatin 16 and 17 have this hydroxyl eliminated and possess a glycal moiety.  In most 
cases, the vast variation occurs at C-7 on the A-ring and C-19 on the C-ring.  Bryostatin 
21, the latest member, is surprisingly different from others, which has only one methyl 
group at C-18 instead of germinal dimethyl, and demonstrates increased cytotoxicity.27   
Most bryostatins are isolated from bryozoan Bugula neritina from diverse geographical 
origins, but are also found in another bryozoan species, Amathia convoluta.28  Bryozoans 
mainly living on bacteria and phytoplankton are fouling organisms, and usually colonize 
on the surface of other substrates, such as algae, shells, rocks and boat hulls.  Because they 
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are specifically preyed upon by sea slugs and fish, as a strategy for their survival, secondary 
metabolites, which are often toxic, are secreted to defend against external attacks.  Thus 
the bryozoans were recognized as the ultimate origin of bryostatins.  However, this notion 
was challenged by several facts.  The low abundance of bryostatin collected from B. 
neritina (Table 2.1); bryostatin ratios varied between different sites and depths where the 
bryozoans were harvested (average abundance 10-6-10-5 wt%28 except at the Gulf of 
Aomori in Japan29); and all the other marine organisms containing bryostatins were found 
within the biomass of bryozoans.   
By using a small subunit (SSU) of ribosomal RNA gene sequence, Haygood and 
Davidson discovered a noncultured symbiotic bacterium which was a new species of γ-
proteobacteria, and named it “Candidatus Endobugula sertula”.  They also suggested that 
this symbiont was the actual producer of the bryostatin.30  Evidence collected by molecular 
techniques supported this hypothesis.  After an antibiotic-treatment of B. neritina larvae, 
the content of bryostatins was reduced concomitant with the reduction of Candidatus 
Endobugula sertula which could not be eliminated, whereas the bryozoan hosts were not 
affected by this treatment. 31,32  Moreover, the different strains found in the Candidatus 
Endobugula sertula were always coincident with the diversity of bryostatins.33,34  
Additional evidence came from the role of Candidatus Endobugula sertula in the 
biosynthesis of bryostatins.  Expression of mRNA from the bry gene cluster (a bacterial 
gene cluster containing a sequence of gene codes from several modular polyketides 
synthases) was detected by in situ hybridization in Candidatus Endobugula sertula cells, 
not in the host B.neritina cells.  And the biosynthetic compound ‘bryostatin 0’, which was 
the precursor of bryostatins, was produced by the symbiont Candidatus Endobugula 
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sertula.32  Later, the Haygood group tried to express this bry cluster in another host to 
produce the bryostatin or its precursor, and tried to regulate the process of bryostatin 
biosynthesis.35   
 
Attractive Biological Activities of Bryostatins 
As the initial aim of Pettit’s group was to find antineoplastic agents from marine 
organisms, bryostatins exhibited extraordinary antitumor activities at the very beginning 
of their discovery.  In the first report, a 168-200% life extension against murine P388 
lymphocytic leukemia cell lines (PS system) was observed in several doses.12   Later, this 
group documented in detail ED50 (effective dose to reduce the cytopathic effect of a given 
virus by 50% in vitro tests) values of most bryostatin members known by that time against 




𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑢𝑟𝑣𝑖𝑎𝑙 𝑜𝑓 𝑡ℎ𝑒 𝑡𝑒𝑠𝑡𝑒𝑑 𝑔𝑟𝑜𝑢𝑝
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝
 x 100%) value was reported as high as 170-
200% of bryostatin 1.13-24,28  Generally, the ED50 reflects the antiviral activity of tested 
compounds, and it is considered very active when the value is less than 1 g/mL.  And a 
pure product is regarded as interesting when its T/C ratio is larger than 125%.  Most 
bryostatins demonstrate the ED50 results at the scale of 10-3 ug/mL (Table 2.1)!  Therefore, 
great attention was attracted on these compounds, and they were quickly in clinical 
investigations.  Soon, a wide range of biological activities of bryostatins were discovered, 
which included growth inhibition, immune stimulation, cell differentiation, nervous system 
activation, and so forth.  These activities were recognized to associate with protein kinase 
C isozymes (PKCs), according to the initial experiments by Blumberg’s group at the US 
National Cancer Institute (NCI).36,37  
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Biology of Bryostatins - PKC Activators 
Protein Kinase C (PKC) 
A kinase, in biochemistry, is a type of enzyme that catalyzes the transfer of phosphate 
groups from phosphate donor molecules to specific substrates in living organisms.  A 
protein kinase, directly from its name, is a kinase enzyme that transfers the phosphate to 
proteins, specific substrates, to regulate their functions.  In the human body, a total 518 
protein kinases, constituting about 1.7% of all human genes, regulate an estimated 30% of 
all human proteins!38  
 
Classification of PKCs 
Protein Kinase C (PKC) is a family of protein kinase enzymes that control the proteins 
containing serine or threonine amino acids particularly, and play an important role in the 
cellular signal transduction associated with proliferation, differentiation, apoptosis, 
transformation, cognition, and so forth.  It was discovered by Yasutomi Nishizuka at Kobe 
University in 1977.  The enzyme which was first identified needed a calcium (in PKC, C 
is for calcium) ion to fully activate itself.39  Nowadays, the PKC family is composed of 10 
isoforms (isozymes) at least (the former PKC-μ and PKC-υ are now classified in PKD40), 
which can be further classified into three groups, namely classical PKC (cPKC), novel 
PKC (nPKC) and atypical PKC (aPKC), based on their protein structure and the necessity 
of a secondary messenger (a second activator or cofactor).  All the PKCs share the same 
structure in common, consisting of a regulatory domain and a kinase domain (or catalytic 
domain).  Typically, the regulatory domain contains C1 and C2 (or C2-like), two highly 
conserved functional modules, except those of aPKCs which do not have the C2 modules.  
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The kinase domain has C3 and C4 functional modules (Figure 2.3).  
 
Structure of PKCs 
The regulatory domain is at the N-terminal of PKCs.  The C1 module is a cysteine-
rich motif duplicated in most isozymes (except in aPKCs), called C1A and C1B.  These 
two siblings are the binding sites for the endogenous ligand diacylglycerol (DAG) as well 
as for the exogenous ligands such as phorbol esters, but they do not have equal chances to 
bind to the ligands.41  In aPKCs, the C1 module is not duplicated, and its single ligand-
binding pocket cannot bind to any activator such as DAG because it is impaired.  Towards 
the NH2-terminal, the C1 module is attached to a pseudosubstrate (PS) region, which is a 
small sequence of amino acids without serine or threonine phosphoacceptor residues.  For 
this reason, the PS keeps the enzyme inactive when it is mimicking a substrate binding to 
the kinase domain, thus preventing the activation of the enzyme by inappropriate stimuli 
and conditions. 
The C2 module contains the recognition site for acidic lipids.  The three PKC subtypes 
have a huge difference in this module.  In cPKCs, the C2 module contains a Ca2+ binding 
site, and binds to anionic phospholipids in a Ca2+-dependent manner.  In nPKCs, the real 
C2 module is replaced by a structurally similar C2-like module which does not have any 
functional group to modulate Ca2+ binding.  In aPKCs, no C2 residue exists.  Instead, a 
protein-protein interaction module PB1 (Phox and Bem 1) is contained, which regulates 
interactions with other proteins containing PB1. 
The C-terminal kinase domain is responsible for the phosphotransfer activity, and 
hosts the C3 and C4 modules which bind respectively to ATP and the substrate to be 
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transphosphorylated.  Besides these two modules, the kinase domain also contains some 
phosphorylation sites, which are essential to activate the enzymes.  The cPKCs and nPKCs 
have three phosphorylation sites, namely activation loop, turn motif (TM), and 
hydrophobic motif (HM).  The aPKCs only have the first two sites for phosphorylation, 
whereas the subsititution of a glutamic acid for a serine in the third region makes the 
phosphorylation impossible in this site due to the same electronic charge of the 
phosphorylation donor and the receiver.   
The regulatory domain and kinase domain are connected by a hinge.  When the 
enzyme is bound to a membrane, this hinge is proteolyzed and the two domains are 
separated, and a proteolytically generated kinase domain (protein kinase M) is then 
released. 
 
Activation of PKCs 
Based on the structural differences, these PKC isozymes exhibit varying co-factor 
regulation and activity.  To active the cPKC (, I, II and γ) isozymes, which are initially 
identified by Nishizuka, a diacylglycerol (DAG) for the C1 module, a Ca2+ ion for the C2 
module, and a phosphatidylserine for the phosphorylation sites in the kinase domain are 
necessary.  The activation of nPKCs (δ, ε, η and θ) is similar to that of the cPKCs, expect 
the former is in a Ca2+-independent manner.  The aPKCs (ζ, ι/λ) are significantly different 
from the other two PKC subtypes with respect to the C1 module, the C2 module, and the 
phosphorylation sites, and no DAG and Ca2+ are required for the activation.  Since the 
aPKCs do not bind to DAG, they do not bind to any DAG-competing ligands, such as 
tumor-promoting phorbol esters, either.42  
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When PKCs are inactive, the pseudosubstrate motif in the regulatory domain mimics 
a substrate and is bound to the substrate-binding pocket in the C4 module, thereby 
suppressing kinase activity.   
The first step of activation is a rate-limiting phosphorylation step at the activation loop 
of the kinase domain by an upstream kinase 3-phosphoinositide-dependent kinase-1 (PDK-
1).43,44  This phosphorylation is mediated by another lipid molecule phosphoinositide 3-
kinase (PI3K) and in a PI3K-dependent manner.  The PI3K pathway produces an inositol 
phospholipid containing an additional phosphate at its third position, which subsequently 
activates the PKD-1 and then the PKC.45  In the case of cPKCs, the phosphorylation of the 
activation loop promotes the autophosphorylation of the turn motif (TM), followed by the 
autophosphorylation of the hydrophobic motif (HM), which is the major determinant of 
PKC’s stability.  In the case of nPKCs, additional kinases are required for the third 
phosphorylation, i.e., the phosphorylation of the hydrophobic motif (HM).46  After all the 
three residues are phosphorylated, the cPKCs and nPKC are converted into thermally active 
conformations and are ready to receive the signals from secondary messengers.43,44,46-48  In 
the case of aPKCs, the PDK-1 phosphorylation of the turn motif (TM) is catalyzed by a 
rapamycin complex 2 (mTORC2),49 and an acidic phosphomimetic (e.g. aspartic or 
glutamic acid) in the hydrophobic motif (HM) enhances the binding to PKD-1.  
At this stage, PKCs are “mature”, but are not activated yet.  To become catalytically 
active, PKCs need to bind to cofactors.  These cofactors (secondary messengers) are 
produced by an enzyme phospholipase C (PLC) that facilitates the hydrolysis of 
phosphoinositides.  Promoted by agonists (external signals), PLCs catalyze the hydrolysis 
of 4,5-bisphosphate (PIP2) to generate DAG, whose prominent intracellular targets are the 
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PKC family and inositol trisphosphate (IP3) which mobilizes intracellular calcium (Ca2+).50  
The Ca2+ binds to the C2 module of cPKCs, and increases the affinity of cPKCs for 
membranes (negatively charged lipids) by electrostatic interaction in a coordinated manner.  
However, this affinity is relatively low, and cPKCs still diffuse within the plane of the lipid 
bilayer. After Ca2+ signaling, the binding of the membrane-restricted DAG to the C1 
module enhances the affinity for membrane lipids, and changes the conformation of the 
cPKC.  The pseudosubstrate motif is then expelled from the substrate-binding pocket, 
resulting in the activation of the cPKC (Figure 2.4).51,52  Due to the lack of Ca2+ binding 
sites, the nPKCs are an order slower than the cPKCs to translocate to membranes.  Since 
the aPKCs do not bind to DAG and Ca2+, they are translocated to membranes by the 
interaction of the PB1 module with lipid components, such as arachidonic acid, ceramide 
and phosphatidylinositol-3,4,5-trisphosphate.  Generally, the translocation of PKC 
isozymes from the cytosol to membranes is the sign of activation.  However, this is only a 
simple model that is not sufficient to explain all the complex reality.  
 
Distribution of PKCs and Signal Transduction 
Some proteins act as anchoring proteins (intracellular receptors) for PKCs, and they 
are divided into receptors for inactive C-kinase (RICKs) and receptors for activated C-
kinase isozymes (RACKs).53  The PKCs interact with RACKs through their regulatory 
domains,54 while release of PKCs from RICKs is promoted by PKC activators.   
These anchoring proteins play an important role in the distribution of PKCs.  By 
changing receptors, inactive PKCs are translocated from cytosols to membrane lipids as 
activated ones.  Moreover, each PKC isozyme has its unique and specific function,44,54,55 
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and the isozyme-specific binding relationship of PKCs to RACKs/RICKs is responsible 
for the heterogeneity, not only in the unique subcellular localization of different PKC 
isozymes but also in the different intracellular distribution of the same isoform respective 
to tissues, cell types, and organisms.55  For instance, some isozymes, such as PKC-, PKC-
δ and PKC-ζ, are expressed widely and are recognized in all tissues;55,56 while other 
isozymes are found only in a specific tissue or several tissues, such as PKC-Is in the 
spleen, PKC-IIs in the spleen and brain, PKC-η in keratinocytes, PKC-θ in skeletal 
muscle, T cells and epidermis, and PKC-ι/λ in the testis and insulin-secreting cells.55-57  In 
addition, the distribution of PKCs in subcellular compartments varies depending on the 
organism, tissue, and stimulation.  Different diets can also affect the expression and 
localization of PKC isozymes.55-57  Peptides that mimic either the PKC-binding site on 
RACKs or the RACK-binding site on PKCs are isozyme-specific translocation inhibitors 
of PKCs.   
After the translocation on various membranes including plasma, nuclear membranes, 
and cytoskeleton via their anchoring proteins, PKCs initiate signal transduction via 
phosphorylation of various proteins and enzymes downstream, therefore regulating their 
properties and activities.  For instance, PKCs activate Akt signaling and regulate cell 
migration-related molecules, including focal adhesion kinase, paxillin, and vinculin.  
Because of their important role in signal transduction cascades and specific functions, 
PKCs, as well as their activators and receptors, have gained extensive attention as 





Bryostatins and Disease Therapies 
Generally, with few exceptions, the biological activities of all bryostatin family 
members are essentially the same. The differences are only the extent of potencies in a 
given system.  
 
Bryostatin and Cancer 
In cancer cells, PKC isozymes participate in cell proliferation, apoptosis, migration, 
angiogenesis, invasion, and anticancer drug resistance as in the same way of the signal 
transduction in normal cells.  Figure 2.5 illustrates the regulation and signal transduction 
pathways of PKCs in cancer cells.  These cascades shown in black arrows indicate that the 
PKCs play an active role in the process directly or indirectly, while the red arrows indicate 
they act in an inhibitory role.  For example, the PKCs increase the proliferation and survival 
of cancer cells via their association with the stimulation of the Ras-Raf-MEK-ERK 
pathway, one of the most important signaling pathways in cancer.  Mediated by PKCs, the 
pathway is initiated by the binding of a signal ligand to a growth factor receptor tyrosine 
kinase on the cell surface, and this signal is transferred to the cell nucleus subsequently via 
Ras, Raf, mitogen-activated protein kinase (MEK) and finally extracellular signal-
regulated kinase (ERK), which regulates gene expression in cell division, growth, 
differentiation, and migration.  Meanwhile, the expression of apoptotic signals or pathways, 
such as the caspase cascade or Bax subfamily, which are related to the suppression of 
cancer, are inhibited.  It is worth noting that PKC isozymes may exhibit similar expression 
patterns and functions in several types of cancer, but in some cases they demonstrate 
specific patterns and functions largely engaged in the specific type of cancer concerned.  
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For instance, cPKC- demonstrates a proliferative effect in several types of cancers, but 
has an antiproliferative function in colon cancers.58,59 
As good competitive binding ligands for the C1 module of PKC isozymes, bryostatins 
are able to bind to various individual PKCs.  The abovementioned isozyme-specific 
binding relationship between PKCs and their receptors distributes the specific PKC-
bryostatin complexes to the different compartments of cells, and subsequently modulates 
PKC’s functions and expression patterns within the cells.53   
Some tumors are caused by that overexpression or up-regulation of some PKC 
isozymes stimulates the Ras-Raf-MEK-ERK pathway of cancers.  For example, elevated 
nPKC-ε levels in rat NIH3T3 cells and fibroblasts made them both malignant and 
tumorigenic,60,61 also high cPKC- levels were related to human A549 lung cancer.62  For 
those overexpressed PKC isozymes, bryostatins were able to selectively down-regulate 
them through an induced conformational change via binding, thus favoring plasma 
membrane insertion and degradation.  In the high cPKC- level case, treatment with 
bryostatin 1, the growth of A549 lung cancer cells was inhibited by down-regulation of 
bryostatin 1 activated cPKC-.62  The detailed mechanism was demonstrated by using the 
32P labeled cPKC- in renal epithelial cells along with cPKC- and nPKC-ε in human 
fibroblasts.63-65  After activation and transfer to the plasma membrane, these activated PKC 
complexes were dephosphorylated by membrane-bound alkaline phosphatases, resulting in 
catalytically inactive complexes which were ready for ubiquitination, referred to as the 
“kiss of death” for proteins.  The ubiquitin-attached PKCs were then proteolyzed and 
degraded.   
The development of cancer is also due to the apoptotic pathways of cancer cells being 
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suppressed.  nPKC-δ isozymes are responsible for the proliferation and apoptosis of cells.  
Overexpression of nPKC-δ in mouse keratinocytes inhibited tumors successfully via the 
apoptosis of cancer cells.66  Blumberg and coworkers found that the tumor-promoting 
phorbol ester PMA translocated nPKC-δ to the plasma membrane primarily, where these 
isozymes suffered down-regulation seriously.67,68  Bryostatins could protect some tumor-
suppressors including nPKC-δ isozymes from undergoing down-regulation in certain 
cells.67,69,70  With the isozyme-specific binding relationship, bryostatin 1 translocated them 
mainly to the nuclear membrane, and therefore prevented them from being proteolyzed.68  
One additional example was that nPKC-δ isozymes, which were involved in the contact-
dependent inhibition of growth in human FH109 and murine NIH3T3 fibroblasts, were 
prevented from being down-regulated by co-application of bryostatin 1 and PMA.70 
   
Bryostatin and Immune System Disorders 
Among the key players of the immune system, nPKC-θ isozyme has an unique role in 
immune responses.71  This family member of PKCs modulates several important molecules, 
including nuclear factor kappa-light-chain-enhacecer of activated B cell (NF-κB), activator 
protein 1 (AP-1), mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase 
(JNK).  Those molecules are critical in regulating the immune response to bacterial and 
viral infections, in directing cell proliferation and apoptosis, and in controlling the 
transcription of DNA and cytokine production.  nPKC-θ also interacts with downstream 
effectors to regulate the activation, differentiation, and migration of T cells, which are a 
type of white blood cell that plays a central role in cell-mediated immunity.  Disorders of 
nPKC-θ lead to several diseases, such as inflammation, autoimmunity, muscular dystrophy, 
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and cancer.    
Besides the direct antineoplastic properties, numerous studies have shown bryostatins 
have strong immunostimulatory activities.  Medicated by PKCs, bryostatin 1 was able to 
activate human resting T and B cells, and then promoted their proliferation.72,73  Bryostatin 
1 also stimulated the tumor antigen-specific cytotoxic T lymphocytes (CTLs) to produce a 
variety of cytokines, including tumor necrosis factor- (TNF-), TNF-γ and certain 
interleukins (IL),74-77 which were normally produced after immunostimulation by the body.  
Synergized by IFN-γ, bryostatin 1 significantly elevated both levels of nitic oxide (NO) 
measured as accumulated nitrite (NO2-) in culture supernatant and inducible nitric oxide 
synthase (i-NOS) gene expression in the murine macrophage cell line ANA-1.78  The i-
NOS gene was known to catalyze the production of NO, which also induced apoptosis in 
tumor cells, from an amino acid L-arginine.  Nagarkatti’s group demonstrated that 
bryostatin 1 could activate bone marrow-derived dendritic cells, which were antigen-
presenting cells and played a critical role in the regulation of the adaptive immune response 
as a toll-like receptor 4 (TLR4) ligand.79  In vivo treatment, the dendritic cells promoted a 
TLR4-dependent activation of NF-κB, and induced a variety of cytokines, including 
interleukins (IL-5, IL-6 and IL-10) and chemokines (RANTES and MIP1-).  In vivo 
administration of bryostatin 1 induced a TLR4-dependent T helper cell 2 (Th2) cytokine 
response, and increased a subset of myeloid dendritic cells.79  All the studies suggested that 
the antitumor activities of bryostatins could be partially ascribed to their 
immunostimulatory properties.   
It is worth noting that the immunostimulatory activities of bryostatins are associated 
with their C-20 side chains.  The class of C20-deoxy bryostatins such as bryostatin 13 does 
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not exhibit this activity.  In the stimulation experiment of normal human hematopoietic 
cells, bryostatin 1, 3, 8, and 9, all of which had C-20 carboxylic side chains, could directly 
stimulate bone marrow progenitor cells to form colonies in vitro and could functionally 
activate neutrophils; whereas bryostatin 13 without C-20 side chain fail to do so 
completely.74  Similarly, bryostatin 1 but not bryostatin 13 was able to induce human 
polymorphonuclear neutrophil (PMN) and monocyte release of reactive oxygen radicals.80   
AIDS is still an incurable disease which is caused by the virus HIV.  HIV attacks the 
CD4+ T cells, which are a type of white blood cell helping the immune system fight off 
infections, thus weakening and destroying the body’s immune system.  Current HIV/AIDS 
therapies can only turn this “death sentence” into a chronic illness, since they have no effect 
on latent HIV-infected cells.  When a small fraction of the HIV-infected CD4+ T cells stays 
in a quiescent state, the HIV genomes inside are latent until the cells are activated.  Thus, 
HIV can hide itself for as long as the drugs are taken.  When antiretroviral therapy is 
interrupted, the HIV-infected cells become active eventually, and trigger the replication 
and spread of the HIV quickly.  Clinical studies of bryostatins as promising agents to 
eradicate the latent HIV are under way.  Bryostatin 1 reactivated the latent HIV-1 through 
a classical PKC-dependent pathway in Jurkat-LAT-GFP cells, a tractable model of HIV-1 
latency.81  Through MAPKs and NF-κB pathways, bryostatin 1 synergized with several 
histone deacetylase (HDAC) inhibitors which were used in current medical practice to 
antagonize HIV-1 latency.  Bryostatin 1 also prevented de novo HIV-1 infection in 
susceptible cells by downregulating the expression of the HIV-1 co-receptors CD4 and 
CXCR4.  Bryostatin 5 inhibited chemotaxis induced by a chemokine stromal cell-derived 
factor 1 (SDF-1) in Jurkat cells, due to induced receptor desensitization and 
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downregulation of cell surface CXCR4.82    
 
Bryostatins and Neurological Disorders 
PKC is present in nervous systems in high concentrations.  Actually, the brains of many 
animal species are the most abundant source of PKCs in terms of both quantity and species.  
Therefore, PKCs are involved in a variety of neuronal functions.  By regulating 
proliferation and apoptosis the same way as in other cells, PKCs influence the process of 
neurite outgrowth or necrosis.  For instance, PKC plays an important role in neuronal 
differentiation and synaptogenesis via HuD-mediated mRNA stability in the hippocampal 
neurons.83,84  nPKC isozymes are associated with plasmalemmal repair (sealing), which is 
vital for the survival of damaged neurons.85  For victims of neurotrauma, loss of nerve cells 
leads to loss of functional behaviors and even paralysis.  PKC is also the key player of 
synaptic plasticity, which is the ability of synapses to change the connection strength 
between neurons and is the foundation for the models of learning and memory.  The most 
widely studied form of synaptic plasticity in mammals is long-term potentiation (LTP), a 
mechanism for the establishment of stable memories.  Evidence demonstrates that 
activation of PKCs, particularly cPKC-, nPKC-ε and PKMζ (the independent catalytic 
domain of aPKC-ζ), is critical in developing LTP.86-89  It is believed PKMζ is synthesized 
de novo as an active kinase which is involved in the molecular mechanism of lasting 
memory.90,91  Memory task learning is also associated with cPKC-γ immunoreactivity in 
the principal hippocampal neurons and cholinergic receptors.92,93   
Intensive studies demonstrated that bryostatins greatly repaired and improved memory 
and learning by activation of the PKCs which were involved in synaptogenesis, presynaptic 
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ultrastructural specialization, and protein synthesis.94  In the Morris spatial water maze task, 
improved performance of rats was observed upon the intracerebral ventricular 
administration of bryostatin 1.95  After 15 days’ treatment of bryostatin 1 and training, the 
densities of mushroom spine synapses and memories of the aged rats that had lower levels 
were restored to the levels of young rats, thus reversing the decline in aging.96  Stimulated 
by bryostatin 1, PKC activation induced the synthesis of proteins necessary and sufficient 
for subsequent long-term memory consolidation in Hermissenda, a sea slug and valuable 
animal model for studying the mechanisms of learning and memory.87,94,97  Further study 
proved that bryostatin could activate cPKC- and nPKC-ε, and therefore facilitated LTP 
induction in the Schaffer-collateral fibers of the hippocampus.87   
Alzheimer’s disease (AD) is closely associated with the plaques which are clumps of 
the protein pieces referred to as β-amyloids.  These amyloid plaques are involved in the 
destruction of brain cells, though the ultimate causes of brain-cell death in AD are not fully 
understood.  When amyloid precursor protein (APP) is cleaved by β-secretase and γ-
secretase, the “sticky” β-amyloids are produced and gradually build up to form plaques, 
resulting in inflammation and cell-to-cell signaling obstruction.  -Secretase enzyme 
preferentially stimulates APP processing toward the nontoxic soluble -amyloid precursor 
protein (sAPP-) and precludes β-amyloid formation, thereby suppressing inflammation 
and angiogenic processes.98,99  Thus, an increase in -secretase cleavage is considered a 
therapeutic approach for AD.  It is known that PKC isozymes can activate -secretase.  As 
a nontumor activator of PKCs, bryostatins significantly improved cognitive performance 
in AD mouse models, and reduced extracellular senile plague formation.99  In AD double-
transgenic mice, bryostatin 1, at the concentration of 0.1 nM or 0.01 nM, dramatically 
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enhanced the secretion of the -secretase and produced soluble sAPP- in fibroblasts from 
AD patients.  Furthermore, the accumulations of both β-amyloid-40 and β-amyloid-42 
were reduced efficiently.100    
 
Bryostatins and Cancer Multidrug Resistance (MDR) 
Many chemotherapy drugs suffer failure in cancer therapies due to multidrug resistance 
(MDR) developed by cancer cells.  Among various mechanisms, the drug efflux pump 
MDR is predominant.  In this mechanism, the ATP-binding cassette transporter membrane 
proteins, such as P-glycoprotein (P-gp), referred to as the multidrug efflux pump, are 
responsible for the expulsion of drug out of the cell.  After exposure to chemotherapy drugs, 
cancer cells overexpress the P-gp protein, which is broadly distributed in cancers and is 
encoded by the multidrug resistance 1 (MDR1) gene.  By an ATP-dependent efflux of the 
drugs and decreasing their intracellular concentration, the cellular functions of cancer cells 
are not impeded.  Since PKCs, particularly cPKC- and nPKC-ε, promote the P-gp- 
mediated MDR, inhibition of the corresponding PKCs is a therapeutic approach to remove 
MDR, therefore enhancing the apoptosis of cancer cells.101    
In the course of bryostatin antitumor studies, it was found that bryostatin 1 was able to 
modulate the P-gp-mediated MDR.  Bryostatin 1 could reverse the resistance to 
chemotherapy drugs vinblastine and colchicine in two cell lines overexpressing a mutant 
MDR1-encoded P-gp, namely KB-C1 and HeLa cells transfected with an MDR1-V185 
construct (HeLa-MDR1-V185) in which glycine at position 185 (G185) was substituted 
for valine (V185).102  It also was reported that bryostatin 1 decreased MDR1 RNA 
expression after 24 hours in a diffusing large cell lymphoma (DLCL) model after sequential 
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administration of anticancer drug vincristine and bryostatin 1.103 
 
Bryostatins and Synergistic Interactions 
Much attention is also focused on synergistic interactions between bryostatins and other 
cytotoxic agents.  When bryostatin 1 is used in combination with other chemotherapy drugs, 
the antitumor effect is greater than the sum of its individual effects.  Therefore, lower 
dosages of cytotoxic agents can be used to obtain better therapeutic effects with fewer side 
effects and less potential MDR.  This is achieved by downregulating antiapoptotic protein 
B-cell lymphoma 2 (Bcl-2), which prevents programmed cell death (PCD), and by 
upregulating cytotoxic drug-mediated caspases, which control cell apoptosis.104  For 
instance, the leukemia patients who had failed in high-dose cytosine arabinoside (Ara-C) 
therapy exhibited highly positive responses with the administration of a combination of 
high levels of Ara-C and low levels of bryostatin 1, including 5 complete responses out of 
23 patients.104  Some early cases of synergistic interaction between bryostatin 1 and other 
drugs, which trigger further evaluations in clinical trials, are summarized in Table 2.2.105  
However, it is worth mentioning that these synergistic effects largely exhibit both schedule- 
and dose-dependence.   
 
Bryostatins in Clinical Trials 
To date, bryostatin 1 has been in more than 80 clinical trials, including more than 20 
trials completed at both phase I and phase II levels.  Although several other members of 
this family have been used in animal tests and preclinical trials, only bryostatin 1 has been 
evaluated in human clinical trials so far.  The main reason is that the isolation required to 
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meet the current good manufacturing practice (cGMP) regulations for clinical trials is 
prevented by the abundances of bryostatins in natural sources (Table 2.1).  Most of the 
bryostatin 1 used in clinical trials was collected from the Bay of California under the NCI’s 
auspices.   
The study undertaken in mice demonstrated that bryostatin 1 was widely distributed in 
many organs but accumulated in the lung, liver, gastrointestinal tract, and fatty tissue.106  
The major side effect of bryostatin 1 in humans was dose-limiting myalgia whose 
maximum toxicity was of WHO grade 3.107  Other minor adverse reactions were 
photophobia, eye pain, headache, and flu-like symptoms, which were occasionally reported 
in several clinic trials.   
Initially, bryostatin 1 was investigated in a variety of monotherapies of solid or blood 
tumors, including melanomas, epithelial ovarian, pancreatic carcinoma, breast, esophageal, 
gastric, renal, myeloid and varied leukemia cancers, as a promising antitumor agent.  
Unfortunately, phase II trials exhibited minimal activity of bryostatin 1, though the results 
of phase I trials were encouraging.  Moreover, relapses arose in many cases soon after the 
treatment was interrupted.  Therefore, bryostatin 1 was not effective enough to enter phase 
III trials as a single chemotherapeutic agent.  
Soon, the discovery of its synergistic effect with other cytotoxic drugs and the ability 
to decrease MDR led bryostatin 1 into a new direction of cancer therapy.  Recently, 
bryostatin 1 was investigated in combination with paclitaxel, cisplatin, fludarabine, 
vincristine and other cytotoxins in several cancer therapy phase I and phase II trials.  It was 
reported that a combination of bryostatin 1 and vincristine or fludarabine succeeded in the 
treatment of Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia 
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(CLL).108  The efficacy of this combination was achieved in a phase II study too.109  The 
overall response rate was 31%, with two complete-response cases. 
Currently, bryostatin 1 is involved in a phase I trial against HIV infection (identifier 
number: NCT02269605), and two phase II trials against Alzheimer’s disease 
(NCT00606164 and NCT02431468).  These trials have not been completed yet, and they 
may broaden the application of bryostatins in PKC-target therapies. 
 
Bryostatin Supply 
Due to extensive studies by the medical community, the annual demand of bryostatin 
1 is estimated to be in the range of about 100–200 g.  To date, almost all of the supply still 
depends on the collection of natural source material.   
 
Natural Sources (Wild Collection) 
The low abundance of bryostatin 1 in its natural source makes its isolation 
exceptionally difficult and costly.  This is exemplified by a typical isolation conducted 
under the NCI’s auspices.110  After the demonstration of its antitumor activity in the initial 
preclinical trial, gram quantities of bryostatin 1 of the current Good Manufacturing Practice 
(cGMP, regulations enforced by FDA for the design, monitoring and control of 
pharmaceutical manufacturing processes and facilities) grade were required for phase I and 
phase II studies.  Collected off the coast of California, approximately 12.7 tons (12,7000 
Kg) of wet bryozoans B. neritina, corresponding to a volume of about 40,000 L in 
isopropanol, shipped to the lab in Colorado.  The bryostatins were then concentrated to 78 
L via a four-stage extraction-concentration process, which was further divided into 15 
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aliquots each of 5.2 L.  Each aliquot was subjected to chromatography on a column 
approximately 1 m in length and 50 cm in diameter, containing 53 Kg of silica gel.  After 
15 purifications of a multistep procedure, a total of 18 g of 99% pure bryostatin 1 was 
isolated after 10 months of work!  Later, technique improvements, especially the 
substitution of supercritical fluid extraction (technique of the American company Aphios) 
for conventional liquid-liquid extraction, reduced the processing time to under a month and 
provided the bryostatin 1 with a similar purity in higher yield.  The market price of 
bryostatin 1, however, is still about 150 US$ for 10 ug.   
Besides the cost, ecological considerations also necessitate a new source of bryostatins.  
In a long term view, it is not possible to harvest bryostatin largely from its natural sources.  
Therefore, considerable effort has been devoted to the obtention of alternative sources.   
 
Aquaculture and Biosynthesis 
The limitations of wild collections were recognized at the very beginning of the 
isolation “direct from the sea”.  In the early 1990s, the NCI funded a now-defunct company 
CalBioMarine via the Small Business Innovation Research program (SBIR) to 
investigation aquaculture of B. neritina for the acquirement of bryostatins.  Subsequently, 
the contract (phase I) was extended to phase II, and the project was successful.  It was 
claimed by the former president of the company that bryozoans were capable of growing 
under controlled-system conditions both on land and in sea, with the lowest environmental 
impact when compared with open-sea systems, which were all subject to the unpredictable 
vagaries of nature.  The isolation of bryostatins from aquacultured animals was in adequate 
quantities and proved cost-effective, though significant optimization of feeding, recovery 
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and other protocols was needed.111  However, the aquaculture supply was never 
implemented in market.  Soon after that report was published, CalBioMarine closed its 
business due to a funding deficit.   
During the course of the collaboration with CalBioMarine in aquaculturing bryostatins, 
the Haygood group found that a bacterial flora was associated with the production of 
bryostatins.  This noncultured symbiont bacterium, referred to as Candidatus Endobugula 
sertula,32 was suggested to be the actual producer of bryostatins.30  Later, this group 
identified and cloned the putative biosynthetic gene cluster of this bacterium successfully.  
By using this cluster, a macrolidic structure called bryostatin 0 was produced, which might 
be further elaborated by tailoring enzymes to achieve the real bryostatin molecules.  Further 
identification of different symbionts from other Bugula species producing bryostatins led 
to the discovery of the putative bryA gene cluster.112  Recently, the complete putative 
genomic sequence of bryA was elucidated.  Unfortunately, neither the Candidatus 
Endobugula sertula cluster nor bryA cluster has been successfully expressed in a 
heterologous host.  Moreover, to date, the tailoring enzymes aforementioned converting 
bryostatin 0 into real bryostatins have not been elucidated yet. 
 
Chemical Synthesis 
Chemical synthesis was another potential option for bryostatin supply.  The first total 
synthesis was that of bryostatin 7 by Masamune and co-workers in 1990.113  Seven years 
later, Evans’ group reported a remarkable symmetric total synthesis of bryostatin 2 in 
1998.114  In 2000, bryostatin 3, one of the most complex types containing a fused butenolide, 
was synthesized by Nishiyama and Yamamura.115  A relatively short and elegant synthesis 
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of bryostatin 16, involving metal-catalyzed reactions, was reported by Trost’s group in 
2008.116  Up to that time, bryostatin 1 was never formally synthesized, though Pettit’s group 
demonstrated bryostatin 1 could be converted from bryostatin 2 or 12.117  In 2011, the Keck 
group published an impressive asymmetric de novo total synthesis of bryostatin 1.118  
Almost at the same time, bryostatin 9 was synthesized by Wender et al.,119 a pioneer in 
early bryostatin analogue design and synthesis.  Further, two additional total syntheses of 
bryostatin 7 were also reported by Hale et al. in 2006 and Krische in 2011,120,121 along with 
the synthetic efforts of several other research groups. 
While great achievements have been made in the total synthesis of bryostatin 1 and its 
analogues, none of them can be used to supply sufficient amounts of bryostatins in practice.  
All these synthetic approaches are either too long or complex.  For instance, the shortest 
route still requires more than 36 steps. 
More importantly, bryostatins are produced by bryozoans for their own sake, but not 
for human beings as therapeutic drugs.  Therefore, bryostatins demonstrate unsatisfactory 
clinical performances as a monotherapeutic reagent for tumors, and several undesired side 
effects.  Thus, the structural modification of bryostatins is necessary to improve their 
biological activities and to remove off-target effects.  These modified bryostatins 
(analogues) are also useful probes for us to explore PKC’s profile.  Consequently, the 
analogues of bryostatins are a more feasible solution and an active area of current research.  
 
Bryostatin Analogues 
A multitude of naturally occurring compounds are PKC activators (Figure 2.6), and 
therefore modulate various biological events, such as cell proliferation, differentiation, 
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apoptosis and so on.  Many of these compounds, including phorbol esters and teleocidins 
serving as drug leads, are investigated in clinical trials against some diseases.  Actually, 
most exogenous PKC ligands are associated with a range of tumor-promoting activity.  For 
instance, the indolactam teleocidins exhibit relatively weak tumor-promoting properties, 
while the phorbol ester PMA is one of the most potent tumor promotors.  Bryostatins are 
unique in that they are little known for their tumor-promoting properties122 and even 
suppress the tumor-promoting effects of PMA when co-administrated.123  
As good competitors with the endogenous ligand DAG in binding to the C1 module of 
PKC isozymes, bryostatin 1 and PMA share highly similar binding affinity (Ki).  On the 
other hand, they differ from each other in downstream effects.  In primary mouse 
keratinocytes, bryostatin 1 at low concentrations downregulated nPKC-δ to a similar extent 
to PMA, but at high concentration bryostatin 1 antagonized PMA and protected nPKC-δ 
from downregulation.69  Their distinguished biological activities were probably ascribed to 
their lipophilicity and their distribution via isozyme-specific function.67,68,70  The more 
hydrophilic ligand bryostatin 1 translocated nPKC-δ mainly to the nuclear membrane, 
whereas the more hydrophobic ligand PMA translocated it to the plasma membrane in 
CHO-K1 cells.  In addition, bryostatin 1 but not PMA exhibited a transient response 
followed by loss of responsiveness in primary mouse epidermal cells.124  Bryostatin 1 could 
cause more rapid downregulation of some PKCs as compared to PMA.  The mechanisms 
of the behaviors of different PKC ligands are not fully understood.  Analogues of 
bryostatins are excellent models to clarify the mechanism of cellular signaling pathways 




Wender’s Analogue Study 
Wender’s Initial Analogue Design 
The collaboration of the Wender, Blumberg, and Pettit groups resulted in a 
pharmacophoric model of bryostatin, based upon various structure-activity studies of 
several PKC activators.125  By comparing the binding affinities of bryostatins and their 
semisynthetic derivatives to PKC, it was soon recognized that the C-26 hydroxyl group 
was involved in binding, since either esterification or epimerization of this functional group 
caused significant loss of binding affinity (Figure 2.7, entries 1-3, 5-6).  Because PKC 
activators bound to the C1 module of PKCs in a competitive manner, it was reasonable to 
postulate that DAG, PMA, and bryostatins shared a common chemical structure as a 
pharmacophore which interacted with the proteins.  Using the C-26 hydroxy group as a 
reference, computational studying revealed additional binding elements involving the C-1 
carbonyl and C-19 hydroxyl groups.  These three oxygen heteroatoms composed a triad, 
which could be superimposed on the corresponding triads in the structural rigid PMA and 
endogenous DAG (Figure 2.8).  Significantly, these triads were in the lowest energy 
conformation, which was critical in fitting the lipid domains in spatial array.  Later 
evidence derived from an X-ray crystal structure strongly supported this hypothesis.126  The 
complex of phorbol 13-acetate bound to the C1B motif of murine nPKC-δ demonstrated 
the 3D model of the triads in the reality (Figure 2.8). 
In contrast, minor modification of only bryostatin’s northern hemisphere did not affect 
binding affinity considerably.  Neither epoxidation of the C13-C30 exocyclic olefin of 
bryostatin 4 nor hydrogenation of that of bryostatin 2 changed the binding affinities 
significantly (Figure 2.7, entry 4, 8).125,127  However, when the hydrogenation product 
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aforementioned was further hydrogenated on the C21-C34 olefin of C-ring, the binding 
affinity varied dramatically (Figure 2.7, entry 9).  It was concluded that the essential 
property of bryostatin’s northern hemisphere was a lipophilic element referred to as spacer 
domain.  It did not interact with or bind to PKCs directly, but served to properly align the 
conformation of molecules for binding. 
It is very clear that this hypothesis focuses on binding affinity.  It cannot explain the 
difference between tumor-promoters and nonpromoters.  Nevertheless, it is still a good 
starting point for the exploration of bryostatins and their analogues. 
 
Wender’s Analogues 
Under the guidance of this hypothesis, Wender’s group synthesized a great number of 
bryostatin analogues.  Their strategy was to divide the molecule into two pieces, northern 
and southern pieces, for maximum convergent benefit.  The southern hemisphere retained 
the pharmacophoric C-ring for binding to PKCs, and the northern fragment was allowed 
for modification and simplification.  With a few exceptions, the macrolactone scaffold was 
maintained in order to mimic the conformation of bryostatin 1.  The coupling of two 
fragments was accomplished by Yamaguchi esterification and acetalization cyclization.  
An alternative macrocyclization approach was the construction of the C16-17 double 
bound, but it was proved to be a formidable obstacle in many contemporaneous total 
synthesis efforts due to the adjacent gem-dimethyl group.  The acetalization was achieved 
in a mild condition, and could be applied to the reactions in the presence of various 
sensitive functional groups.  Therefore, the naturally occurring tetrahydropyran B-ring was 
largely replaced by 1,3-dioxane in Wender’s analogues.     
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Several representative bryostatin analogues of Wender’s are shown in Figure 2.9.  
Analogue 2.1, with a simplified spacer domain, exhibited a comparable PKC binding 
affinity (Ki =3.4 nM) with bryostatin 1 (Ki = 1.35 nM) when treated with mixed rat brain 
PKCs.128  Esterification of the C-26 hydroxyl group led to compound 2.2, which lost its 
binding affinity drastically, over 3 orders of magnitude.  Once again, it was confirmed that 
the C-26 alcohol was an important binding site for PKCs.   
In the cases of analogues 2.5-2.9, the A-ring was depleted, but the C-5 and C-9 were 
retained as an ether linkage to maintain the preferred macrocyclic conformation.  Their 
binding affinities were essentially the same as that of analogue 2.1, indicating that the A-
ring was not necessary for keeping PKC potency.129-131  Further removal of the ether 
linkage (the compound not shown in Figure 2.9) resulted in the lack of 20-membered 
macrocyclic backbone, and therefore lost the binding affinity entirely. 
Analogues 2.10-2.14 varying at C-20 ester proved that this position was not crucial in 
binding, but was more amenable to the adjustment of the lipophilicity and solubility.132-134  
A simple acyl group 2.10 diminished the binding affinity, while hydrophobic phenyl 
groups 2.12 and 2.14 or saturated long hydrocarbon chains 2.11 and 2.13 maintained high 
binding affinities.  Thus, the C-20 ester could be applied to optimize physical properties, 
including those related to the pharmaceutical criteria ADME (absorption, distribution, 
metabolism, and excretion), and could be used to attach a fluorescent tag in mechanism 
studies.   
Although the early study demonstrated that the A-ring had little contribution to the 
binding affinity, substituents at the C-7 could be used to modulate molecule’s activity.  The 
magnitude of alteration in binding affinity depended on both the type of functionalities 
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(2.15 - 2.17) and the stereochemistry of the carbon center (2.18, 2.19).135  This hotspot for 
PKC affinity discovered in these analogues was not observed in natural bryostatins.  It was 
recommended by the author that the C-7 functionalities could potentially be used for the 
selective regulation of PKC isozymes. 
According to Wender’s binding hypothesis, the C-3 hydroxyl group made a nominal 
contribution to the binding affinity.  However, both the inversion 2.3 and the removal 2.4 
of the C-3 hydroxyl resulted in the loss of 2 orders of magnitude.  This result coincided 
with the early observation of Kamano’s group.  By using solution NMR techniques, 
Kamano et al. found a temperature-dependent variation in chemical shift for the C-3 
hydroxyl and C-19 hemiketal hydroxyl groups, and proposed an intramolecular hydrogen-
bonding network.136  In this network, the H-bonding connected the C-3 hydroxyl, C-19 
hemiketal hydroxyl, and the two oxygens in the tetrahydropyran A- and B-rings together.  
Thus, this H-bonding was critical for the molecule to maintain the lowest energy 
conformation.  The lack of a proper H-bonding network in epi-2.3 and deoxy-2.4 led to a 
distorted conformation, therefore decreasing the binding affinity drastically.   
Finally, the removal of the C-27 terminal methyl group eliminated the adjacent 
stereocenter, while still retaining high PKC potency, demonstrated by analogues 2.15-2.19.  
It can be used to simplify future analogue syntheses. 
 
Keck’s Analogues Study 
Markó-Keck Annulation Strategy 
The Keck group has committed to the development of new synthetic methodology and 
the total synthesis of natural products for a long time.  During the course of bryostatin 
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analogue program as well as the total synthesis of bryostatin 1, the Markó-Keck annulation 
and the SmI2-mediated esterification-reductive cyclization strategies were developed. 137  
Initially, Markó reported a Sakurai-Prins cyclization strategy which he called an 
“intramolecular silyl-modified Sakurai (ISMS) reaction”.138,139  Envisioning its great 
convergent value in total synthesis, soon the Keck group further developed this 
methodology in an asymmetric manner, as well as the reaction condition.  Then, they first 
applied this reaction in a total synthesis, and successfully set up the absolute 
stereochemistry at the C-2 and C-6 positions of the resulted tetrahydropyran, with an 
excellent yield.140   
Shown in Scheme 2.1, this two-step strategy commences with a CAA (catalytic 
asymmetric allylation) reaction, establishing the stereocenter of alcohol 2.22.  Promoted 
by a slight excess of TMSOTf, combination of the β-hydroxylallylsilane 2.22 with 
aldehyde 2.23 provides tetrahydropyran 2.25 at -78 oC.  Anhydrous diethyl ether turns out 
to be the ideal solvent for this coupling, since it provides the best stereoselectivity and 
yield.140  This reaction is via a six-membered chair transition state 2.24, by which the 
substituent R1 at the pre-established stereocenter directs the substituent R2 in the syn-
position, and therefore the absolute stereochemistry of the newly formed chiral center.  This 
methodology allows us to quickly install the simplified A- and B-ring scaffolds in our 
bryostatin analogues. 
 
A- and B-Ring Simplified Analogues  
Several A- and B-ring simplified analogues of the Keck group are shown in Figure 
2.10.141-144  These bryostatin analogues are identified via Merle numbers in honor of the 
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great musician, singer and instrumentalist Merle Haggard.  The Keck group collaborates 
with Dr. Peter Blumberg, who is a leading expert on protein kinases at the National Cancer 
Institute (NCI), in accomplishing Merle analogue’s biological studies.  Their aim is to 
clarify the structure-activity relationships (SARs) of bryostatin 1 and the PKC-mediated 
mechanism of its antitumor activity, therefore helping develop a highly effective antitumor 
drug with the fewest necessary structures.   
Keck’s first bryostatin analogue, 2.26, which was synthesized by Dr. Truong, was 
significantly simplified and served as a springboard for their future work.  This analogue 
was designed to validate the application of Markó-Keck annulation in the synthesis of a 
complex molecule and to probe the roles of C-20 ester and C-21 exo-enoate.  Eventually, 
the accomplishment of 2.26 provided a synthetically accessible route to a series of 
analogues.   
The synthetic plan is outlined in Figure 2.11.  The backbone of the target molecule was 
achieved from the combination of enal 2.32, allylsilane 2.33 and 2.34 via sequential ring-
annulations as the key reactions, followed by a Yamaguchi macrolactonization.  The 
truncated C-ring enal 2.32 was prepared from an advanced acyclic thioester, which was 
further derived from the commercially available 2.35 though a serials of carbon-chain 
elongation reactions, including allylations, prenylation and Horner-Emmons olefination.  
Both allylsilane 2.33 and 2.34 were obtained from the common source diol 2.36 though the 
well-established CAA reation,141 but with different enantioselectivity. 
Segment 2.34 was obtained via 6 sequential steps as shown in Scheme 2.2.  The 
synthesis began with the monoprotection of diol 2.36 with a silyl group and then a Swern 
oxidation to afford aldehyde 2.37.  A Keck’s asymmetric allylation installed the 
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stereocenter in alcohol 2.38, with both excellent yield and enantioselectivity.  The resulting 
alcohol was strategically protected as the PMB ether 2.38, which would participate in 1,3-
chelation controlled allylation.  After an oxidative cleavage, the resulting aldehyde 2.39 
was converted into β-hydroxyallylsilane 2.34 as a single diastereomer.  The TMS-
allylstannane, which was used in the last step, was also used to react with aldehyde 2.37 to 
produce compound 2.33 by Keck’s asymmetric allylation.   
The longest linear sequence in this synthesis was the preparation of enal 2.32 (Scheme 
2.3).  The chiral lactate 2.35 was protected as a BOM ether, which would be engaged to 
achieve 1,3- chelation, and then the resulting intermediate was reduced to aldehyde 2.40.  
Chelation-controlled allylation by reaction with allylstannane in the presence of MgBr2 
etherate provided a homoallylic alcohol, which was protected by PMB, leading to 
compound 2.41.  After ozonolysis, the resulting aldehyde 2.42 was subjected to a second 
chelation-controlled allylation, followed by silyl ether protection to provide olefin 2.43.  
Hydroformylation was accomplished under the Buchwald conditions catalyzed by bulky 
ligand BIPHEPHOS, which enriched the desired terminal aldehyde 2.44.  Indium-mediated 
prenylation followed by a chromium-based oxidation afforded ketone 2.45.  The alkene 
unit in this ketone was oxidatively cleaved, and the resulting aldehyde was elongated by 
Horner-Emmons reaction to provide ,β-unsaturated thiol ester 2.46.  The introduction of 
thiol ester instead of oxyl ester into the conjugated molecule was due to its ability amenable 
to half reduction.  This acyclic thiol ester 2.46 was deprotected by fluoride reagent, and the 
resulting intermediate was converted into glycal 2.47 catalyzed by CSA in benzene.   
Finally, DIBAL half-reduction of the thiol ester provided enal 2.32 in high yield. 
The first pyran annulation was the coupling of enal 2.32 and allylsilane 2.33 to 
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construct the simplified B-ring (Scheme 2.4).  The resulting molecule 2.48 was then 
converted into aldehyde 2.49 after the removal of the TBDPS-protecting group and the 
exposure to oxidation.  Subsequently, a second pyran annulation combined allylsilane 2.34 
with 2.49 smoothly, and installed the truncated A-ring in compound 2.50.  At this time, the 
C-ring was functionalized by several transformations including epoxidation, methanolysis 
and TPAP oxidation.  Then, trivial manipulations of protecting groups afforded a seco-acid 
ready for Yamaguchi macrolactonization.  With macrolactone 2.51 in hand, Keck’s first 
bryostatin analogue 2.26 was achieved after global deprotection by LiBF4.   
The analogue containing a fully functionalized C-ring was synthesized by Dr. Sanchez 
from the highly advanced intermediate 2.51 (Scheme 2.5).142  The free hydroxyl was 
protected as silyl ether 2.52, which in turn was subjected to an aldol reaction to provide a 
diastereomeric mixture.  The exo-enoate 2.53 was obtained by an elimination reaction 
under Burgess’ protocol. Luche reduction and a benzoic anhydride esterification installed 
the C-20 ester side chain.  A global deprotection provided the analogue 2.27 referred to as 
Carina 1, which was later renamed as Merle 21.  Using a similar strategy but a different 
order of construction A- and B-rings, Dr. Li and Dr. Kraft synthesized Merle 22 and 23, 
varying in the size of C-20 side chain.   
Analogue 2.26 has a binding affinity at Ki = 546 nM, which is over 2 orders of 
magnitude smaller than that of bryostatin 1 (Ki = 0.48 nM).  Similarly, Merle 24 and 25 as 
shown in Figure 2.10, both lacking exo-enoate at the C-21, suffer drastic losses in binding 
affinity (37.7 nM and 47.1 nM respectively).  In contrast, Merle 21, which has the C-21 
carbomethoxyenoate group, maintains the binding affinity (Ki = 0.70 nM) almost the same 
as that of bryostatin 1.  Previously, Pettit et al. reported a semisynthesis study on bryostatin 
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2.127  Simultaneous hydrogenation of the C-13 exo-enoate, C-20 octadienoate side chain 
and the C-21enoate led to a 100-fold decrease in binding affinity, whereas only 
hydrogenation the first two positions introduced little impact on the affinity and the 
resulting analogue was as potent as the original compound (Figure 2.7).  All the evidence 
strongly indicates that the C-21enoate plays a crucial role in maintaining the binding 
affinity.  This functional group probably keeps the C-ring in the optimized conformation 
for the molecule to bind to PKCs.    
Merle 21, 22 and 23, containing the simplified northern hemisphere of bryostatin 1, 
retain the C-ring’s essential skeleton of bryostatin 1, including the C-21 enoate.  The subtle 
difference between them is the size of the C-20 side chain.  Their PKC- potencies (0.70 
nM, 1.05 nM and 0.70 nM, respectively) are quite similar to that of bryostatin 1 (0.40 nM).  
Our results are in accord with the Wender’s findings that a modification only in the C-20 
side chain will not alter the binding affinity drastically.   
As noted earlier, the tumor-promoting PMA and antineoplastic bryostatin 1 as PKC 
activators obtain comparable potency to PKC isozymes, but demonstrate different 
biological activities.  The U937 human leukemia cell lines and the LNCaP human prostate 
cell lines are good candidates for their identification, because PMA and bryostatin 1 behave 
distinctively in both cell line assays.   
In the U937 cell lines, phorbol ester PMA inhibited proliferation and induced 
attachment in a dose-dependent manner, whereas bryostatin 1 had less impact on either.  
Instead, bryostatin 1 would suppress the effect of PMA when co-administered.  Figure 2.12 
shows the results of U937 proliferation and attachment experiments with Merle 23,143  
Merle 21 and 22 exhibit almost identical results, and therefore their results and diagrams 
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are not displayed here.  In these experiments, the U937 cells were treated with PMA (0.1-
100 nM), bryostatin 1(0.1-1000 nM), and Merle 23 (1-1000 nM) for 72 hours.  When PMA 
was co-administered with other compounds, its concentration was 10 nM.  The numbers of 
attached cells were counted, and the attached cells were graphed as percent of total cells.  
The bars and error bars represented the average percentage and the standard error, 
respectively.  In the cases of mono-administration, Merle 23, along with Merle 21 and 22, 
resembled tumor-promoting phorbol ester PMA in a dose-dependent manner, and 
displayed different behavior from bryostatin 1.  When Merle-23 was co-administered with 
PMA, no antagonistic effect against PMA was observed, which was shown by bryostatin 
1.  In the K-562 human erythroleukemia cell line assays, Merle 23 also exhibited a behavior 
pattern similar to PMA for inhibiting cell growth.144,145  That bryostatin analogue Merle 23 
resembled the biological response of PMA and not bryostatin 1 in U937 cells strongly 
suggested that the A- and B-rings of bryostatin 1 play a key role in discriminating 
bryostatin itself from tumor-promoting PMA.   
In order to gain further insight into the relationship between the structural features of 
bryostatin analogues and their biology, the LNCaP human prostate cell line assays were 
utilized for the evaluation.145  In this second system, phorbol ester PMA inhibited 
proliferation and induced apoptosis, whereas bryostatin 1 failed to do so.  The inhibition 
effect of an indicated compound on cell growth was represented by the difference in 
confluency of the cells before treatment and 72 hours later,  and the apoptosis effect was 
detected after 48 h treatment.  Merle 23 resembled bryostatin 1 and not PMA, neither 
inhibiting cell growth nor inducing apoptosis (Figure 2.13).  When Merle 23 was co-
administered with PMA, the latter agent was antagonized in a pattern similar to that of the 
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combination of bryostatin 1 and PMA.  In addition, Merle 23 also demonstrated bryostatin-
like effects on tumor necrosis factor alpha (TNF-) secretion and cell cycle analysis.  The 
cell cycle is the series of events leading to a cell’s division and duplication of its DNA, and 
TNF- is a key player in the regulation of immune cells.  They are both closely associated 
with a cell’s proliferation and apoptosis.    
However, the pattern of behavior of Merle 23 relative to bryostatin 1 and PMA was 
largely determined by the specific conditions.145  Proteasome inhibitors, such as the well-
characterized lactacystin and MG-132, shifted the response pattern of the LNCaP cells to 
Merle 23 from bryostatin-like to PMA-like, including inhibition of cell growth, apoptosis, 
and TNF- secretion.  For example, TNF- secretion induced by Merle 23 was increased 
in the presence of proteasome inhibitors and the effects of Merle 23 and PMA became 
similar, whereas the level of TNF- induced by bryostatin 1 remained very low.   
Merle 23 was further compared with bryostatin 1 and PMA in PKC signaling pathways, 
namely MAPK pathways, using Nano-Pro technology to detect the phosphorylation of the 
known PKC substrates MARCKS and PKD1.145  In a number of these downstream 
responses in LNCaP cell assays, Merle 23 showed a duration of response intermediate 
between those of bryostatin and PMA.  Distinct patterns of down-regulation of the PKC 
isoforms were also shown for these three compounds.  PMA had equal potency for down-
regulation of all PKC isoforms and of PKD1.  Bryostatin 1 down-regulated PKC-δ 
biphasically, as described previously,69 and it was the most potent and efficient in down-
regulating PKC-.  It was the least potent in down-regulating PKC-ε and PKD1.  Merle 23 
was unique in being the most efficient for down-regulating PKC-δ, but the least efficient 
for PKC-.  It was PMA-like for down-regulating PKC-ε and PKD1.  Furthermore, Merle 
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23, bryostatin 1 and PMA translocated PKCs from cytoplasm to different membrane 
structures, including plasma membrane, nuclear membrane and mitochondria in distinct 
patterns.  In the translocation study with endogenous PKC-δ, PMA mainly induced the 
translocation of PKC-δ to plasma membrane, while bryostatin 1 translocated most of it to 
cytoplasm and internal membranes.  Merle 23 was unique, and demonstrated a different 
translocation pattern from those of PMA and bryostatin 1.  PKC-δ localized to both plasma 
membrane and cytoplasm after the treatment with Merle 23.  These findings clearly proved 
that Merle 23 could not be simply characterized as bryostatin-like or PMA-like.   
Overall, Merle 23 displayed a highly complex pattern of activity, depending on the 
specific conditions and mechanistic changes.  It could be bryostatin-like, PMA-like, 
intermediate in its behavior, or more effective than either.  Byrostatin properties could not 
be simply understood at the level of binding affinity for PKC isozymes, and there was not 
a single pharmacophore conferring a bryostatin-like as distinct from a PMA-like pattern of 
response.  Dr. Blumberg also suggested that Merle 23 would be considered a novel 
bryostatin derivative with its own effects, which provided powerful tools to dissect subsets 
of bryostatin mechanism and response.   
 
Total Synthesis of Novel Analogue Merle 41 
Analogue Design and Retrosynthetic Plan 
To further evaluate bryostatin structure and activity relationships, a novel bryostatin 
analogue, 2.54, is designed.  It is based on Merle 23, since analogue Merle 21, 22, and 23, 
especially Merle 23, demonstrate a complex pattern of activity.  To maintain the high 
binding affinity to PKCs, the binding triad involved in Wender’s hypothesis and the C-21 
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enoate vital for keeping the optimized conformation are retained in the new molecule 
design.  The modification is the removal of the C-27 terminal methyl.  This functional 
group does not interact with PKCs directly, and both PMA and DAG contain a terminal 
alcohol in the same position.  It is of interest to know the function of this methyl group in 
bryostatin biological responses.   
The necessity of the C-26 stereocenter is another matter of great concern.  The removal 
of the C-27 methyl group results in the elimination of the C-26 stereocenter.  It would 
benefit future analogue synthesis, but could also alter potency.  The epimerization of this 
chiral center in bryostatin 4 decreased the binding affinity significantly (Figure 2.7, entry 
2).125  In contrast, Wender synthesized his most potent analogue “picolog” with the absence 
of the C-27 methyl group, which was more potent than bryostatin 1.133  However, his 
picolog contained a 1,3-dioxane B-ring rather than the naturally occurring tetrahydropyran.  
This variation would induce a conformational distortion, especially in the presence of 
hydrogen-bond.  In addition, not all the Wender’s des-methyl analogues maintained high 
binding affinity. 
The successful syntheses of Keck’s first analogue and Carina 1 (Merle 21) provided us 
a feasible and convergent route for accessing a series of bryostatin analogues.  Actually, 
the major disconnections of Keck’s first analogue were found in the majority of the Merle 
analogues.  Again, the proposed analogue 2.54 would follow the same synthetic strategy, 
which is outlined in Figure 2.14.  The late stage macrolactonization was expected to be 
cyclized by Yamaguchi’s protocol.  Both truncated A- and B-rings were constructed by our 
pyran-annulation strategy as the key steps.  Thus, the analogue 2.54 was disconnected into 
three pieces.  The C-ring aldehyde 2.55 was prepared from allyl alcohol 2.56 via several 
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carbon-chain elongation reactions which were utilized in the synthesis of Keck’s first 
analogue.  Since there was no chirality in this commercially available compound, an 
asymmetric allylation reaction was applied to set the first desired chiralcenter.  The 
segment 2.33 and 2.34 were both derived from diol 2.36.   
 
Results and Discussion  
Synthesis of the C-Ring Aldehyde 2.55  
The synthesis of aldehyde 2.55 began with the protection of the commercially available 
allyl alcohol 2.56.  The BOMCl was freshly prepared by the combination of 
paraformaldehyde and benzyl alcohol in TMSCl at room temperature.146  Long-term 
storage degraded the quality of BOMCl.  The crude product 2.57 was subjected to 
ozonolysis, providing aldehyde 2.58 in 84.2% yield over 2 steps.  Alternatively, aldehyde 
2.58 could be obtained from 1,4-butendiol in the same way, but dimerization of BOMCl 
was up to 30% in the first step.  Keck’s catalytic asymmetric allylation (CAA) reaction 
with (R)-BITIP afforded homoallylic alcohol 2.60 with the desired stereocenter in 93% 
yield and 99% ee.  It was planned that this chiral center at C-25 would later be used to 
establish another stereocenter at C-23 through 1,3-chelation control.  For this reason, 
alcohol 2.60 was strategically protected as PMB ether 2.61.  Oxidative cleavage of the 
olefin with ozone provided aldehyde 2.62 (Scheme 2.6). 
With the aldehyde 2.62 in hand, the next reaction was allylation via 1,3-asymmetric 
induction.  A chelation-controlled allylation with stannane 2.59 was initially applied 
according to the plan.  However, a large variety of common chelating Lewis acids, 
including MgBr2·OEt2, Ti(OPri)2Cl2, AlMe2Cl, TiCl4 and SnCl4, resulted in moderate 
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diastereomeric selectivity or side reactions.  The best diastereomeric ratio was 4:1, favoring 
the desired stereocenter.  Generally, for a 1,3-asymmetric induction reaction, either 
internal-chelated transition state or open-chain nonchelated transition state preferred the 
same diastereomeric selectivity.  Therefore, the reaction was also investigated in 
nonchelated conditions.  Unfortunately, the results were far from satisfactory.  Using 
nonchelating Lewis acid, such as BF3 and TMSOTf, or replacement of PMB protecting 
group by nonchelating silyl group did not improve the selectivity.  Finally, a second CAA 
reaction with (S)-BITIP was applied to install this stereocenter in 2.63 with 89% yield and 
99% dr on a 20 g scale.   
Alcohol 2.63 was protected with TBS group, and the resulting olefin 2.64 was subjected 
to the hydroformylation conditions developed by Buchwald et al.147  The results were not 
consistent with our early experience.  The major side reaction was the double bond 
migration, which led to an unwanted branched aldehyde.  Later, it was found that using 
degassed THF as a solvent was able to solve this problem.  By slightly increasing the 
pressure of syngas, the desired aldehyde 2.65 was obtained with approximate 90% yield 
consistently.   
In our initial experiments, relatively expensive indium metal was utilized for 
prenylation.  Application of zinc dust in aqueous conditions lowered the cost of this 
reaction, and made manipulations easier.148  More importantly, this reaction demonstrated 
exclusive regioselectivity.  Crude product 2.67 was obtained as a single regioisomer with 
quantitative yield.  In addition, no purification was necessary at this time.  After normal 
workup, the purity was larger than 95% based on 1H NMR integration (Scheme 2.7).   
Oxidized under Swern-modified Moffatt’s conditions, the racemic alcohol 2.67 was 
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converted into ketone 2.68 smoothly.  After ozonolysis and sequential Horner-Wadsworth-
Emmons reaction with phosphonate 2.70, the exclusive E-olefin 2.71 was produced in one 
pot with 86% yield.  The TBS protecting group was successfully removed by buffered 
hydrofluoric acid.  Using a Dean-Stark apparatus, the resulting free alcohol 2.72 was 
cyclized and dehydrated in the refluxing toluene with a catalytic amount of CSA.  Half 
reduction of thio-ester 2.73 with DIBAL at low temperature provided enal 2.55 with the 
essential skeleton of the natural C-ring.  
 
Pyran-Annulation Modification and Synthesis of the Truncated B-ring  
The pyran-annulation between aldehyde 2.55 and β-hydroxyallylsilane 2.33 installed 
the truncated B-ring.  However, the yield obtained under the standard conditions was 
capricious and relatively low.140  A trace of TfOH acid was suspected to be the perpetrator, 
which induced the decomposition of the acid sensitive moieties, especially the glycal and 
allylsilane.  Actually, the desired compound 2.74 was observed when the polar byproduct 
was resubmitted to the previous dehydration condition.   
Thus, pyridine and other amines were examined to evacuate the trace amount of acid 
(Table 2.3).  It was found that sterically hindered amines, such as triethyl amine and N,N-
diisopropylethylamine, did not prevent the decomposition.  They merely acted as bases, 
and facilitated the protection of the β-hydroxy group of the compound 2.33 by TMSOTf.  
In contrast, addition of a limited amount of pyridine (less than 0.2 equiv respect to aldehyde) 
largely suppressed decompositions, and the alcohol protection was negligible.  When the 
amount of pyridine was increased to 0.4 equiv, the protection reaction became noticeable, 
but the resulting TMS ether of 2.33 was still reactive in the pyran-annulation reaction.  
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Consequently, a much longer period of time was required to complete the reaction.  When 
the amount of pyridine was more than 0.5 equiv, this reaction turned out to be an alcohol 
protection reaction.  Overall, the best results were achieved when 0.2-0.3 equiv of pyridine 
was added; more pyridine led to an incomplete reaction.  To our delight, with this 
modification, the reaction yield was improved by 20-30%, and the final yield was up to 90% 
(Scheme 2.8).   
To avoid the interference of the labile glycal in the remaining synthetic steps, we 
decided to oxidize the glycal moiety and fully functionalize the C-ring at this moment.  
Thus, compound 2.74 was treated with mCPBA in methanol.  It was chemoselectively 
epoxidized and subsequently opened with methanol in situ.  The resulting ketal was 
subjected to a catalytic amount of PPTS, which shifted the equilibrium of the epimeric 
mixture further towards the thermodynamically more stable isomer 2.75.  The methoxy 
group at C-19 occupied the axial position, favored by the anomeric effect.  These 
transformations were conducted after the first pyran-annulation because of the “gem-
dimethyl” effect or Thorpe-Ingold effect.  If the abovementioned transformations were 
accomplished on enal 2.55 or ,β-unsaturated thioester 2.73, an undesired Michael addition 
between the C-20 alcohol and ,β-unsaturated carbonyl was inevitable.  The additional 
quaternary center adjacent to the C-18 gem-dimethyl group further significantly increased 
the propensity of cyclization, which was called “double Thorpe-Ingold effect” by Hale in 
his review.149  Similar instances were documented by the Keck group144 and several other 
groups.149,150     
The relatively unstable 2.75 was immediately oxidized to ketone 2.76 with Dess-Martin 
periodinane in high yield.  The addition of tert-butyl alcohol was to accelerate the reaction.  
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Mediated by K2CO3, the exocyclic methyl enoate was efficiently furnished by aldol 
condensation with freshly distilled methyl glyoxylate.  It was obtained as a single isomer, 
whose geometry was predicted by A1,3 strain.  The Luche reduction of 2.77 proceeded 
satisfactorily to afford the relatively unstable alcohol 2.78 as a single diastereomer.  A 
subsequent esterification with 2.79 under standard Yamaguchi conditions provided 2.80, 
and completed the functionalization of the C-ring (Scheme 2.8). 
The absolute configuration of the C-23 stereocenter was assigned by Mosher ester 
analysis of 2.63.  It was, in turn, used to determine the stereochemical and conformational 
relationships of the substituents on the C-ring with NOESY1D, ROSEY1D and 2D-
NOESY experiments.  The strong NOE effects observed among the concerned atoms or 
groups solidly supported our assignment of the stereochemistry.  In a similar way, the 
stereogenic information of the B-ring was also revealed (Figure 2.15).   
The geometry of the C-ring exocyclic enoate was confirmed by both NOESY1D 
experiment and chemical shift variation.  The obvious NOE effect between the C-20 proton 
and C-34 proton indicated they were close in space.  Another convincing piece of evidence 
came from the observation that Luche reduction significantly changed the chemical shift 
of the C-34 proton.  It moved from 6.57 ppm to 5.91 ppm upfield after the ketone reduction.  
It was well documented that the reduction of ketone 2.83 had little effect on the chemical 
shift of the remote enoate proton (Figure 2.15).151,152  In contrast, the removal of the 
carbonyl group of 2.81 made the chemical shift of the nearby enoate proton move upfield 
drastically.151, 153  This was due to the removal of the strong magnetic anisotropic effect of 
the vicinal carbonyl group.  
The following steps were taken to prepare for the second Markó-Keck annulation.  The 
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TBDPS group removed by NH4F in methanol at reflux, and the resulting alcohol 2.85 was 
oxidized with DMP providing aldehyde 2.86 in excellent yield (Scheme 2.9).  Since there 
was no way to distinguish the two PMB ethers at C-3 and C-25 after the second annulation, 
the protecting group replacement was taken at this point.  Thus, alcohol 2.87 was liberated 
after DDQ-mediated PMB cleavage.  An attempt was made to protect this alcohol as TBS 
ether by using conventional agent TBSCl.  However, only a trace amount of the desired 
compound was obtained, even when employing a large excess of TBSCl.  The failure of 
this reaction could be attributed to steric hindrance.  Therefore, the more reactive TBSOTf 
was used, and the protection was completed in 1 h.  The desired 2.88 was obtained in 90% 
yield, and ready for the annulations.  
 
Modified Scaled Synthesis of Allylsilane 2.34 
The synthesis of A-ring allylsilane 2.34 employed the approaches previously described.  
Since several synthetic steps were largely scaled up, the procedures were modified and 
optimized to circumvent the tedious purifications and cumbersome manipulations.    
The synthesis was initiated with the monoprotection of 1,3-propanediol 2.36 with 
TBDPSCl.  By using NaH instead of high-boiling-point amine, most side products could 
be washed out.  After a normal workup, silyl ether 2.89 was used directly in the next step 
without any further purification (Scheme 2.10).  It was subsequently oxidized to aldehyde 
2.37 under Swern conditions.  The catalytic asymmetric allylation reaction of aldehyde 
2.37 with 2.57 and (R)-BIITS furnished chiral alcohol 2.90 in 98% yield and 98% ee.  This 
reaction set the desired stereocenter at C-5, which was confirmed by Mosher ester analysis.  
As previously described, a PMB ether was preferred at this site because the protected 
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alcohol could retain the ability to participate in a chelation-controlled reaction later.  
However, the purification was particularly troublesome when 2.90 was protected with 
PMB-acetimidate and traditional catalyst CSA.  Fortunately, using catalytic scandium 
triflate instead of CSA in toluene,154 only one chromatography was needed to achieve 
satisfactory separation.  Inspired by this result, we briefly investigated the application of 
other Lewis acids in PMB ether formation.  We found that Sc(OTf)3, Sn(OTf)2, Cu(OTf)2, 
Yb(OTf)3, Bi(OTf)3, BF3·Et2O were more effective than CSA, or at least similarly effective.  
Generally, the purifications of Lewis-acid-catalyzed reactions were much easier than those 
of CSA- or TsOH-treated reactions.  However, Lewis acid CeCl3, MgBr2·OEt2, CuBr2 were 
not as good as CSA in terms of yield.  It was worth noting that a significant silyl group 
(TBDPS) migration was observed in the alcohol 2.90 under basic conditions.   
Next, 2.38 was oxidatively cleaved with ozone, followed by a 1,3-chelation controlled 
allylation with TMS-allylstannane 2.91 to provide β-hydroxylallylsilane 2.34 in 85% yield 
and with excellent diastereomeric selectivity.  β-Hydroxylallylstannane was also obtained 
in approximately 10% yield, because the allylsilane moiety and allylstannane moiety of 
2.91 competed with each other in the allylation reaction.  Again, the desired chiral center 
2.34 was proved by Mosher ester analysis.   
 
Completion of the Synthesis of Des-Methyl Analogue  
With the aldehyde 2.88 and β-hydroxyallylsilane 2.34 in hand, we were able to install 
the A-ring to achieve the tricyclic core of analogue 2.54.  Based on our previous experience, 
under the standard pyran-annulation conditions, the second annulations generally gave a 
moderate yield which was quite lower than that of the first annulations.  To our delight, 
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2.92 was obtained in excellent yield (90% !) under our modified conditions.  It proved our 
modified conditions of the annulation were effective and reliable.   
With the carbon backbone in hand, we were several steps away from the completion of 
the des-methyl analogue.  Using ammonium fluoride in methanol at reflux, the TBDPS 
silyl ether at C-1 was selectively deprotected in the presence of secondary TBS silyl ether.  
Subsequently, a Dess-Martin oxidation reaction afforded aldehyde 2.93 in 57% yield over 
2 steps.  The aldehyde was oxidized into its corresponding carboxylic acid 2.94 under mild 
conditions which were developed by Lindgren155 and Kraus156 (also called Pinnick 
oxidation).  Next, the removal of the C-25 TBS group furnished a seco-acid which was 
ready for macrocyclization.  Yamaguchi macrolactoniztion with high dilution techniques 
provided macrolactone 2.95.  Removal of PMB with DDQ and subsequent global 
deprotection with LiBF4 afforded the C-27 des-methyl analogue 2.54 or Merle 41.157  
Finally, 1H NMR, 13C NMR, DEPT, gCOSY, gDQCOSY, gHMQC, gHMBC, NOESY1D, 
2D-NOESY, 2D-ROESY and 2D-TOCSY experiments were performed on this analogue 
to obtain its complete structural and stereochemical information. 
 
Biological Evaluation of Merle 41158 
Binding Affinity 
As we know, the isozyme-specific binding relationship causes different ligands or 
activators to have different binding affinities to different PKC isozymes.  To compare 
Merle 41 with Merle 23, PKC-, which was used in Merle 23 evaluation, was bound to 
Merle 41.  The binding affinity of Merle 41 was Ki = 0.73  0.05 nM, and closely matched 
those of Merle 23 and bryostatin 1 (0.70  0.06 and 0.48 nM, respectively).143  In contrast 
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to Wender’s “piclog” analogue,133 removal the C-27 methyl did not increase the binding 
affinity.  On the other hand, that it did not interfere in binding supported the binding model.  
  
Growth Inhibition and Attachment Studies 
The biological profile of Merle 41 in U937 leukemia cell assays was evaluated.  As 
previously described, U937 cells responded to PMA with growth inhibition, whereas 
bryostatin 1 caused little growth inhibition.  Generally, Merle 23 closely resembled PMA 
in its effect in U937 cells, but demonstrated a somewhat biphasic dose response.  The 
behavioral pattern of Merle 41 was identical to that of Merle 23 (Figure 2.16).  When PMA 
was co-administered with Merle 23 or Merle 41, U937 response was similar to that of being 
treated with Merle 23 or Merle 41 alone.   
In response to PMA, U937 cells release TNF-, which contributes to the growth 
inhibition.  Bryostatin 1 induces a negligible secretion of TNF-.  Merle 23 and 41 caused 
a measurable TNF- secretion, but the amounts were less than that of PMA (Figure 2.17).  
The dose response curves of these two analogues for TNF- secretion were identical, with 
absolute maximal levels of release of 66.6  2.6% and 65.2  2.6%, respectively.  In 
combination with PMA, Merle 23 and 41 both predominated over PMA, and reduced the 
level of TNF- secretion.   
Unlike U937 leukemia cell lines, the Toledo cell line is one of the most sensitive cell 
lines for growth inhibition by both PMA and bryostatin 1 (Figure 2.16).  Similarly, Merle 
23 and Merle 41 inhibited Toledo cell growth too.  All the compounds demonstrated similar 
inhibition patterns.  And again, Merle 41 closely resembled Merle 23 both in potency and 
in the level of inhibition. 
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In U937 cell assays, PMA induced attachment while bryostatin 1 almost had no effect.  
Merle 23 and 41 could motivate the attachment to the same level as PMA did, but they 
displayed biphasic responses and had fewer attachments compared with PMA at 
concentration 300 nM or above (Figure 2.17).  In the combination of PMA and Merle 23 
or Merle 41, both analogues partially suppressed the effect of PMA at high concentration.  
Once again, the patterns of the two analogues were identical.   
 
Down-Regulation of PKC Isozymes and PKD1 
As previously observed, the down-regulation patterns of PKCs for PMA and bryostatin 
1 were quite distinct in the LNCaP human prostate cancer cell lines.145  PKC- was down-
regulated by both PMA and bryostatin 1, while the latter induced more down-regulation.  
Merle 41 acted as Merle 23, less effective than either PMA or bryostatin 1 (Figure 2.18).  
At low dose instances, two analogues even moderately increased PKC-.  For PKC-δ, the 
biphasic curve of bryostatin 1 was observed in a dose-dependent manner.  PMA caused 
more down-regulation than bryostatin 1, but did not exhibit the biphasic pattern.  Both 
Merle 23 and 41 caused more extensive down-regulation than PMA, and closely resembled 
each other.  In the case of PKC-ε, PMA, bryostatin 1, and Merle 23 and 41 demonstrated 
modest down-regulation patterns, while both analogues resembled PMA and had relatively 
stronger effects than bryostatin 1.  Finally, PKD1 was greatly down-regulated by PMA.  
Again, Merle 23 and 41 acted similarly to each other, and were bryostatin-like to cause 





Translocation of PKC Isozymes 
Merle 41, like Merle 23, translocated PKC-δ in a unique pattern quite different from 
PMA and bryostatin 1.  PMA initially translocated PKC-δ mainly on plasma membrane, 
while bryostatin 1 caused more PKC-δ accumulation on nuclear and internal membranes.  
Merle 23 and 41 behaved in the intermediate between PMA and bryostatin 1, slightly 
favoring the bryostatin pattern.   
PKC-ε isozyme was translocated to the plasma membrane by PMA.  Both analogues 
were relatively less effective at doing so,  and bryostatin 1 had even weaker response to 
PKC-ε compared with Merle 23 as well as Merle 41.  Once again, Merle 41 resembled 
Merle 23.  Because the extents of differences were so small, the comparison of 
translocations was not able to determine the minor differences in behavior of these 
compounds.  
 
Dose Dependence of the Induced Gene Expression 
To reveal the subtle differences in the response to Merle 23 and 41, the time and dose 
dependence of the induction of gene expression approach was employed in the evaluations 
of the responses caused by the analogues in both the U937 cell lines and the LNCaP cell 
assays.  After the treatment for 2 hours, PMA, bryostatin 1, Merle 23 and 43 caused 
responses similar to each other in LNCaP cells (Figure 2.19).  By 6 hours, the responses to 
bryostatin 1 decreased to variable extents, depending on the type of individual genes, 
compared with those caused by PMA,  and the curves representing the responses to Merle 
23 and Merle 41 began to separate from that of PMA.  By 24 hours, the curves of Merle 23 
and Merle 41 further separated from that of PMA, and were closer to that of bryostatin 1.  
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In each case, the curve of Merle 41 almost overlapped with that of Merle 23, indicating 
that the responses to Merle 41 were identical to those to Merle 23 in essence.   
The more complex approach, namely the complete dose response curves, was used to 
examine the response of the individual gene in a dose- and time-dependent manner.  Out 
of the 15 genes examined in the LNCaP cells and the 12 genes examined in the U937 cells, 
a modest, statistically significant difference in the responses to Merle 23 and Merle 41 was 
observed in only one case.  These results further confirmed that Merle 41 behaved similarly 
to Merle 23 under virtually all assay conditions.   
 
Conclusion 
As part of the extensive synthetic effort to understand the structure and activity 
relationship of bryostatin 1, a novel bryostatin analogue, Merle 41, was prepared in a 
convergent manner.  The pyran-annulation strategy developed by our group played a vital 
role in the construction of the simplified A- and B-rings.  Using a catalytic amount of 
pyridine made this reaction more applicable and reliable.  This synthesis route was also 
optimized for scaled synthesis, and the focus was placed on the easiness of manipulation 
and purification, as well as the efficiency of time and cost.   
Merle 41 and Merle 23 are structurally identical except for the C-27 methyl group.  
Although absent the naturally occurring terminal methyl group, Merle 41 retains the 
binding affinity identical to Merle 23.  It indicates that the C-27 methyl group does not 
interfere with the adjacent C-26 alcohol in binding, at least in our work.  Furthermore, 
Merle 41 resembles Merle 23 in all the biological responses, including growth inhibition, 
TNF- secretion, attachment, PKC isozyme translocation and down-regulation, and 
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induced gene-expression.  All the convincing evidence makes us assume that the effect of 
C-27 methyl group on the biological activities is negligible.  The elimination of the C-26 
stereocenter will facilitate the synthesis of more efficient analogues, therefore having great 
significance for the future analogue and drug designs.   
Merle 23 differs from bryostatin 1 at only four positions in the northern hemisphere.  
Extensive studies demonstrated Merle 23 and Merle 41 displayed a highly complex pattern 
of activity, largely depending on the specific biological response and conditions.  They 
could be bryostatin-like, PMA-like, or intermediate between them.  Merle 23 and Merle 41 
further sustain our understanding that the major pharmacophoric elements are in the 
southern hemisphere.  In addition, several functional groups in the C-ring, including the C-
19 hemiketal and the C-21 exo-enoate, are pivotal in preserving high binding affinity.  The 
northern hemisphere is not a mere spacer domain.  The substitution patterns on the A- and 
B-rings, as well as the cellular pattern involved, determine the behavior of the analogue in 
biological responses.  To better understand the complex relationships behind the structure, 
the roles of the substituents on the top half of the bryostatin 1 are systematically studied, 
which will be discussed in the next chapter.   
 
Experimental Section 
All solvents were dried and distilled according to the guidelines in Purification of 
Laboratory Chemicals, 6th Ed. (Armarego and Chai, Butterworth-Heinemann: Oxford, 
U.K., 2009).  Diisopropylamine, diisopropylethylamine, triethylamine, pyridine, 
dichloromethane and ethyl acetate were distilled from CaH2 under an atmosphere of N2.  
Ether solvents (THF and Et2O) were distilled under N2 from sodium benzophenone ketyl.  
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Benzene and toluene were distilled from molten sodium metal under N2.  Solvents and 
reagents were deoxygenated where necessary by Freeze-Pump-Thaw technique and 
refilled with nitrogen prior to uses.  Titanium tetrachloride and titanium isopropoxide were 
distilled prior to use.  Deuterated solvents were purchased from Cambridge Isotope 
Laboratories (all ≥ atom% D).  Reagents were purchased from Acros, Aldrich and Alfa, 
and used as received unless stated otherwise.  Argon, oxygen, and syngas (1:1 mixture of 
H2 and CO) were acquired from Airgas and used as received.  Glassware for reactions was 
oven dried at 110 oC for 4 hours and cooled down under a dry atmosphere prior to use, or 
flame-dried under an atmosphere of N2.  All air- and moisture-sensitive manipulations were 
performed by using oven-dried glassware, standard Schlenk techniques, and a glovebox 
under an atmosphere of N2.  Analytical thin-layer chromatography was performed on 
Merck Kieselgel 60 F254 plates eluting with the solvents indicated, and visualized by 
exposure to UV light (254 nm), and stained with either an ethanolic solution of 12-
molybdophosphoric acid or a solution of KMnO4/K2CO3/NaOH.  Organic solutions were 
concentrated on a rotovap at aspirator pressure at 20-30 oC.  Flash column chromatography 
was performed on SiliaFlash® F60 silica gel (230-400 mesh, 60Å), and eluted with solvents 
indicated.  Melting points were recored using open capillary tubes on a Mel-Temp 
electrochemical melting point apparatus and were uncorrected.  Nuclear magnetic 
resonance (NMR) spectra were acquired on a Variann Inova 500 spectrometer operating at 
500 MHz and 125 MHz for 1H and 13C separately.  All 1H NMR chemical shifts were 
quoted in parts per million (ppm) relative to the line of the CDCl3 residual singlet at 7.27 
ppm (or the C6D6 residual singlet at 7.16 ppm), and 13C NMR chemical shifts were relative 
to the center line of CDCl3 triplet at 77.23 ppm (or the center line of C6D6 triplet at 128.62 
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ppm).  Multiplicities in the 1H NMR spectra were described as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, ABq = AB quartet, quin = quintet, sext = sextet, m = 
multiplet, br =broad.  Coupling constants were reported in Hz.  The structural assignments 
of 1H and 13C NMR spectra were elucidated with the aid of gCOSY, gDQCOSY, TOCSY, 
DEPT, HMQC, and HMBC experiments.  Stereochemical assignments were based on 
coupling constants where possible, and with the aid of NOSEY1D, ROSEY1D, NOSEY, 
and ROSEY experiments.  AA’BB’ systems were reported as doublets.  Infrared (IR) 
spectra were recored from a Perkin Elmer FT-IR Paragon 1000 PC spectrometer using a 
thin film supported between NaCl plates.  Optical rotations were acquired on Perkin Elmer 
Model 343 polarimeter using Na D-line with a 10 cm path length micro cell at 20 oC from 
CHCl3 solutions.  Ozone was generated by a Welsbach model T-816 generator.  Yields 
refer to purified and spetroscopically pure compounds.    
Allyloxymethyl Benzyl Ether (2.57):  
Preparation of BOMCl: To a mixture of paraformaldehyde 
(3.02 g, 95.7 mmol, 1.0 equiv) and trimethylchlorosilane 
(50.0 mL, 383 mmol, 4.0 equiv) was added a solution of benzyl alcohol (10.0 mL, 95.7 
mmol, 1.0 equiv) dropwise via syringe at room temperature.  After 3 hours, solid 
paraformaldehyde was consumed, and the reaction was concentrated under reduced 
pressure to provide a colorless oil.  The crude product was used directly in the next step 
without further purification.    
With an ice-water bath, to 60% suspension of NaH (7.56 g, 189 mmol, 2.0 equiv) in 
THF (40 mL) was added allyl alcohol 2.56 (13.0 mL, 189 mmol, 2.0 equiv) dropwise via 
syringe under an atmosphere of N2.  After 30 minutes, a solution of the aforementioned 
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crude BOMCl (theoretically 95.67 mmol, 1.0 equiv) in THF (100 mL, 1.0 M) was added 
dropwise over 1.5 hours via additional funnel.  This reaction was allowed to warm to room 
temperature slowly, and stirred under an atmosphere of N2 overnight.  It was then quenched 
with an ice cube carefully, followed by the addition of cold 1N HCl solution (100 mL).  
The aqueous layer was extracted with Et2O (3 x 20 mL).  The combined organic layers 
were washed with 100 mL of brine and dried over anhydrous K2CO3.  The solution was 
filtrated, and concentrated in vacuo.  The yellow crude product was used directly in next 
step without any purification.  The analytical sample could be obtained via vacuum 
distillation collected at 92-94 oC/3 mmHg.  It was a colorless oil.  
TLC:  Rf = 0.57 (Et2O/Hex = 4:6, v/v); 
500 MHz 1H NMR (CDCl3): δ 7.39-7.33 (m, 8H, H-7a, H-7a’, H-7b, H-7b’, H-6a, H-6a’, 
H-6b, H-6b’), 7.33-7.28 (m, 2H, H-8a, H-8b), 5.82-5.74 (m, 2H, H-1a, H-1b), 4.78 (s, 4H, 
H-3a, H-3a’, H-3b, H-3b’), 4.62 (s, 4H, H-4a, H-4a’, H-4b, H-4b’), 4.26-4.19 (m, 4H, H-
2a, H-2a’, H-2b, H-2b’); 
125 MHz 13C NMR (CDCl3): δ 138.0 (C-5a, C-5b), 129.4 (C-1a, C-1b), 128.6 (C-7a, C-
7a’, C-7b, C-7b’), 128.1 (C-6a, C-6a’, C-6b, C-6b’), 127.9 (C-8a, C-8b), 94.1 (C-3a, C-
3b), 69.6 (C-4a, C-4b), 63.3 (C-2a, C-2b);  
FTIR (neat): νmax 3032, 2883, 1648, 1497, 1455, 1381, 1172, 1107, 1050, 929, 737, 698, 
666 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C11H14O2Na 201.0891; found 201.0895. 
2-(Benzyloxymethoxy)acetaldehyde (2.58): To a solution 
of crude 2.57 (theoretically 95.67 mmol, 1.0 equiv) in CH2Cl2 
(350 mL, 0.3 M) was purged with O3 (3 Psi, 90 Volts) at -78 
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oC.   When the colorless reaction became pinkish, O3 was turned off, and O2 flushed 
through the reaction until it turned colorless again.  DMS (30 mL, 400 mmol, 3.0 equiv) 
was then added into this reaction in one portion.  It was allowed to warm to room 
temperature, then stirred for 6 hours.  The solution was concentrated in vacuo.  The residue 
was distilled, and collected at 93-96 o C /3 mmHg to provide the titled compound (14.52 g, 
80.55 mmol, 84.2% yield over 2 steps) as a colorless oil.   
TLC:  Rf = 0.24 (EtOAc/Hex = 3:7, v/v); 
500 MHz 1H NMR (CDCl3): δ 9.72 (d, J = 0.9 Hz, 1H, H-2), 7.40-7.29 (m, 5H, H-6, H-6’, 
H-7, H-7’, H-8), 4.85 (s, 2H, H-3), 4.67 (s, 2H, H-4), 4.22 (d, J = 0.9 Hz, 1H, H-1);  
125 MHz 13C NMR (CDCl3): δ 199.9 (C-2), 137.4 (C-5), 128.7 (C-7, C-7’), 128.1 (C-8), 
128.1 (C-6, C-6’), 95.2 (C-3), 73.4 (C-1), 70.2 (C-4);  
FTIR (neat): νmax 3423, 3064, 3032, 2889, 1960, 1737, 1497, 1455, 1382, 1209, 1170, 1116, 
745, 700 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C10H12O3Na 203.0684; found 203.0687. 
Allyltributylstannane (2.59):  A 1000-mL 3-necked round-
bottomed flask equipped with a magnetic stirring bar, a reflux 
condenser, an additional funnel, and a gas inlet was flame dried.  Then, magnesium chip 
(20.7 g, 0.850 mol, 1.5 equiv), anhydrous THF (500 mL) and a small amount of I2 crystal 
(half match-head, catalytic amount) was added into this apparatus.  This mixture was 
refluxed with stirring under an atmosphere of N2.  When the red-brown reaction turned 
yellow, the mixture of Bu3SnCl (160 mL, 0.566 mol, 1.0 equiv) and allyl bromide (58 mL, 
0.65 mol, 1.1 equiv) in THF (70.0 mL) was added dropwise via additional-funnel.  It was 
refluxed for 20 hours, and an ice-water bath was used to precipitate the salt.  Then, it was 
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filtered through a pad of Celit and wash with hexanes.  The filtrate was washed with a 
saturated NaHCO3 solution (100 mL) and brine (100 mL), dried over anhydrous Na2SO4, 
and concentrated in vacuo.  The crude product was subjected to vacuum distillation to give 
a colorless oil (186.4 g, 0.563 mol, 99.5% yield) at 84-86 oC/0.2 mmHg. 
TLC:  Rf = 0.63 (EtOAc/Hex = 1:9, v/v); 
500 MHz 1H NMR (CDCl3): δ 5.94 (ddt, J = 16.9, 9.9, 8.7 Hz, 1H, H-2), 4.80 (ddt, J = 
16.9, 2.1, 1.3 Hz, 1H, H-3a), 4.65 (ddt, J = 9.9, 2.1, 0.8 Hz, 1H, H-3b), 1.78 (ddd, J = 8.7, 
1.3, 0.8 Hz, 2H, H-1), 1.50 (tt, J = 8.1, 7.6 Hz, 6H, H-5, H-5’, H-5’’), 1.31 (tq, J = 7.6, 7.3 
Hz, 6H, H-6, H-6’, H-6’’), 0.90 (t, J = 7.3 Hz, 9H, H-7, H-7’, H-7’’), 0.88 (t, J = 8.1 Hz, 
6H, H-4, H-4’, H-4’’); 
125 MHz 13C NMR (CDCl3): δ 138.4 (C-2), 109.3 (C-3), 29.3 (C-5, C-5’, C-5’’), 27.6 (C-
6, C-6’, C-6’’), 16.4 (C-1), 13.9 (C-7, C-7’, C-7’’), 9.3 (C-4, C-4’, C-4’’). 
(R)-1-(Benzyloxymethoxy)pent-4-en-2-ol (2.60): To 
an oven-dried round-bottomed flask was charged (R)-
BINOL (1.909 g, 6.601 mmol, 0.2 equiv), 4Ǻ MS (13.24 
g, 400 mg/mmol) and freshly distilled CH2Cl2 (110 mL, 0.3 M).  Under an atmosphere of 
N2, Ti(Oi-Pr)4 (0.980 mL, 3.31 mmol, 0.1 equiv) was introduced into this reaction dropwise 
via syringe with stirring, followed by addition of TFA (12.5 ul, 0.167 mmol, 0.005 equiv) 
at room temperature.  The resulting dark brown mixture was heated at reflux for a period 
of 1 h, and then allowed to cool to room temperature.  At this point, a solution of aldehyde 
2.58 (5.873 g, 32.59 mmol, 1.0 equiv) in dry CH2Cl2 (5 mL) was added via cannula, and 
additional CH2Cl2 (2 x 3 mL) rinse was transferred into the reaction flask via cannula.  This 
reaction was stirred for 30 minutes at room temperature, and then cooled to -78 oC.  
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Allyltributylstannane 2.59 (15.5 mL, 46.8 mmol, 1.4 equiv) was then added dropwise via 
syringe over 10 minutes.  This reaction was stirred for further 30 minutes in this condition, 
and transferred to a -35 oC freezer.  After 7 days, this reaction was diluted with CH2Cl2 
(100 mL), and filtrated over a pad of Celite.  The filtrate was washed with a saturated 
NaHCO3 solution (100 mL).  The aqueous solution was extracted with ethyl ether (3 x 30 
mL).  The combined organic layers were washed with brine (150 mL) and dried over 
anhydrous Na2SO4.   The solution was filtered and concentrated under reduced pressure to 
provide a brown oil.  The remainder was purified by flash chromatography on silica gel 
eluting with 3-8 vol% of acetone in hexanes, to provide the titled compound (6.736 g, 30.30 
mmol, 93.0% yield, 98.9% ee) as a colorless oil.  
TLC:  Rf = 0.44 (Acetone/Hex = 3:7, v/v); 
[α]20 D -0.9 (c 1.68, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.40-7.34 (m, 4H, H-9, H-9’, H-10, H-10’), 7.34-7.29 (m, 
1H, H-11), 5.86 (dddd, J = 17.1, 10.3, 7.3, 6.9 Hz, 1H, H-4), 5.17 (dq, J = 17.1, 1.6 Hz, 
1H, H-5a), 5.15-5.10 (m, 1H, H-5b), 4.81 (ABq, J = 6.9 Hz, Δν = 5.5 Hz, 2H, H-6), 4.64 
(ABq, J = 12.0 Hz, Δν = 4.9 Hz, 2H, H-7), 3.87 (qd, J = 6.6, 3.0 Hz, 1H, H-2), 3.69 (dd, J 
=10.3, 2.9 Hz, 1H, H-1a), 3.51 (dd, J =10.3, 7.1 Hz, 1H, H-1b), 2.52 (br. s, 1H, -OH), 2.29 
(ddt, J = 7.3, 6.1, 1.5 Hz, 2H, H-3);  
125 MHz 13C NMR (CDCl3): δ 137.7 (C-8), 134.3 (C-4), 128.7 (C-10, C-10’), 128.1 (C-9, 
C-9’), 128.0 (C-11), 118.0 (C-5), 95.3 (C-6), 72.6 (C-1), 70.0 (C-2), 69.9 (C-7), 38.1 (C-
3);  
FTIR (neat): νmax 3448(br), 3070, 3032, 2931, 1642, 1497, 1454, 1381, 1209, 1169, 1116, 
1044, 963, 917, 741, 699, 665 cm-1; 
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HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C13H18O3Na 245.1154; found 245.1153. 
Determination of Absolute Configuration of the New Stereocenter of Compound (R)-
1-(Benzyloxymethoxy)pent-4-en-2-ol (2.60) via Mosher Ester Method:  
(R)-1-(Benzyloxymethoxy)pent-4-en-2-yl (S)-α-
Methoxy-α-(trifluoromethyl)phenylacetate (2.60-
S-MTPA): To a screw-capped vial equipped with a 
stirring bar was added 2.60 (36.3 mg, 0.163 mmol, 
1.0 equiv), (S)-(-)-MTPA-OH acid (42.9 mg, 0.180 
mmol, 1.1 equiv), DMAP (19.9 mg, 0.161 mmol, 1.0 equiv) and toluene (3.5 mL, 0.05 M), 
subsequently, at room temperature.  Freshly distilled NEt3 (115 uL, 0.826 mmol, 5.0 equiv) 
was then added to this mixture.  This reaction was cooled down to 0 oC, and 2,4,6-
trichlorobenzoylchloride (28.6 uL, 0.179 mmol, 1.1 equiv) was added dropwise via syringe.  
The reaction turned cloudy and precipitated immediately.  The vial was tightly capped.  
The reaction was allowed to warm to room temperature slowly, and stirred for 6 hours.  
Then, the resulting yellow mixture was concentrated and purified by flash chromatography 
on silica gel eluting with 4-8 vol% of ethyl ether in hexanes to provide the titled compound 
(65.7 mg, 0.150 mmol, 91.8% yield) as a colorless oil. 
TLC:  Rf = 0.56 (EtOAc/Hex = 3:7, v/v); 
[α]20 D -36.8 (c 2.37, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.62-7.55 (m, 2H, Ph-2, Ph-2’), 7.44-7.28 (m, 8H, H-9, H-
9’, H-10, H-10’, H-11, Ph-3, Ph-3’, Ph-4), 5.79 (ddt, J = 17.1, 10.3, 7.3 Hz, 1H, H-4), 
5.39 (qd, J = 6.9, 3.9 Hz, 1H, H-2), 5.20-5.12 (m, 2H, H-5), 4.65 (ABq, J = 6.9 Hz, Δν = 
16.2 Hz, 2H, H-6), 4.50 (s, 2H, H-7), 3.68 (dd, J = 11.3, 3.9 Hz, 1H, H-1a), 3.64 (dd, J = 
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10.8, 6.8 Hz, 1H, H-1b), 3.58 (s, 3H, -OMe), 2.55-2.43 (m, 2H, H-3);  
125 MHz 13C NMR (CDCl3): δ 166.3 (C=O), 137.9 (C-8), 132.7 (C-4), 132.5 (Ph-1), 129.7 
(Ph-4), 128.6 (C-10, C-10’), 128.5 (Ph-3, Ph-3’), 128.1 (C-9, C-9’), 128.0 (C-11), 127.8 
(Ph-2, Ph-2’), 123.5 (q, JC-F = 288.6 Hz, -CF3), 119.1 (C-5), 94.9 (C-6), 84.9 (q, JC-F = 
27.6 Hz, -CC=O), 74.8 (C-2), 69.6 (C-7), 68.4 (C-1), 55.7 (-OMe), 35.5 (C-3); 
FTIR (neat): νmax 3068, 3033, 2949, 1749, 1644, 1497, 1453, 1381, 1265, 1171, 1120, 1025, 
924, 836, 719, 699 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C23H25O5F3Na 461.1552; found 461.1557. 
(R)-1-(Benzyloxymethoxy)pent-4-en-2-yl (R)-α-
Methoxy-α-(trifluoromethyl)phenylacetate (2.60-R-
MTPA): To a screw-capped vial equipped with a 
stirring bar was added compound 2.60 (38.5 mg, 
0.173 mmol, 1.0 equiv), (R)-(+)-MTPA-OH acid (45.0 mg, 0.190 mmol, 1.1 equiv), DMAP 
(21.4 mg, 0.173 mmol, 1.0 equiv) and  toluene (3.5 mL, 0.05 M), subsequently, at room 
temperature.  Freshly distilled NEt3 (125 uL, 0.897 mmol, 5.0 equiv) was then added to 
this mixture.  This reaction was cooled down to 0 oC. 2,4,6-Trichlorobenzoylchloride (30.5 
uL, 0.191 mmol, 1.1 equiv) was then added dropwise via syringe.  The reaction turned 
cloudy and precipitated immediately.  The vial was tightly capped.  The reaction was 
allowed to warm to room temperature slowly, and stirred for 6 hours.  Then, the resulting 
yellow mixture was concentrated and purified by flash chromatography on silica gel eluting 
with 4-8 vol% of ethyl acetate in hexanes to provide the titled compound (69.7 mg, 0.159 
mmol, 91.9% yield) as a colorless oil. 
TLC:  Rf = 0.57 (EtOAc/Hex = 3:7, v/v);  
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[α]20 D  +19.3 (c 2.43, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.66-7.57 (m, 2H, Ph-2, Ph-2’), 7.45-7.29 (m, 8H, H-9, H-
9’, H-10, H-10’, H-11, Ph-3, Ph-3’, Ph-4), 5.69 (ddt, J = 16.6, 10.8, 7.3 Hz, 1H, H-4), 
5.38 (qd, J = 7.1, 3.7 Hz, 1H, H-2), 5.11-5.04 (m, 2H, H-5), 4.78 (ABq, J = 6.6 Hz, Δν = 
15.5 Hz, 2H, H-6), 4.60 (s, 2H, H-7), 3.76 (dd, J = 11.0, 3.7 Hz, 1H, H-1a), 3.71 (dd, J = 
11.0, 7.1 Hz, 1H, H-1b), 3.60 (s, 3H, -OMe), 2.48-2.34 (m, 2H, H-3); 
125 MHz 13C NMR (CDCl3): δ 166.4 (C=O), 137.8 (C-8), 132.7 (Ph-1), 132.3 (C-4), 129.7 
(Ph-4), 128.7 (C-10, C-10’), 128.5 (Ph-3, Ph-3’), 128.1 (C-9, C-9’), 128.0 (C-11), 127.7 
(Ph-2, Ph-2’), 123.6 (q, JC-F = 288.6 Hz, -CF3), 119.026 (C-5), 94.9 (C-6), 84.9 (q, JC-F = 
27.8 Hz, -CC=O), 74.7 (C-2), 69.8 (C-7), 68.4 (C-1), 55.6 (-OMe), 35.4 (C-3); 
FTIR (neat): νmax 3068, 3033, 2949, 1749, 1645, 1497, 1454, 1381, 1269, 1171, 1121, 1025, 
923, 834, 765, 736, 720, 698, 665, 591 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C23H25O5F3Na 461.1552; found 461.1557. 
The chemical shift differences (in ppm) between the (S)- and (R)-MTPA Mosher esters of 
the (R)-1-(benzyloxymethoxy)pent-4-en-2-ol are consistent for a (R)-configuration of the 




methoxybenzyloxy)pent-1-ene (2.61): To a 1L rb flask 
was charged KH (dispersion in mineral oil ~35%, 5.06 g, 
44.2 mmol, 1.5 equiv) and freshly distilled THF (90 mL, 
0.5 M).  With an ice-water bath, a solution of alcohol 2.60 
(6.546 g, 29.45 mmol, 1.0 equiv) in dry THF (150 mL, 0.2 M) was added into the reaction 
flask dropwise via cannula over 30 minutes.  After addition, it was then stirred under an 
atmosphere of N2 for 10 minutes.  A solution of PMB-Br (9.182 g, 45.67 mmol, 1.5 equiv) 
in anhydrous THF (90 mL, 0.5 M) was added into this reaction via cannula over 30 minutes.  
This reaction was stirred in this condition for 1 hour, and all the alcohol was consumed.  
Then diethyl amine (20 mL, 193 mmol) was added, and stirred for a further 1 hour.  This 
reaction was quenched with ice cubes carefully, and poured into a saturated NaHCO3 
solution (200 mL).  The aqueous layer was extracted by ether (3 x 30 mL).  The combined 
organic layers were washed with brine (200 mL), and dried over anhydrous Na2SO4.  The 
solution was filtrated and concentrated by rotary evaporation.  The residue was purified by 
flash chromatography on silica gel eluting with 3-10 vol% of ethyl acetate in hexanes to 
provide the titled compound (9.710 g, 28.35 mmol, 96.3% yield) as a coloress oil. 
TLC:  Rf = 0.48 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +3.5 (c 2.94, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.39-7.33 (m, 4H, H-9, H-9’, H-10, H-10’), 7.33-7.29 (m, 
1H, H-11), 7.27 (d, J = 8.7 Hz, 2H, H-14, H-14’), 6.87 (d, J = 8.7 Hz, 2H, H-15, H-15’), 
5.85 (ddt, J = 17.1, 10.2, 7.1 Hz, 1H, H-4), 5.12 (ddt, J = 17.0, 2.0, 1.5 Hz, 1H, H-5a), 5.08 
(ddt, J = 10.2, 2.1, 1.1 Hz, 1H, H-5b), 4.79 (ABq, J = 6.7 Hz, Δν = 3.5 Hz, 2H, H-6), 4.62 
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(s, 2H, H-7), 4.58 (ABq, J = 11.4 Hz, Δν = 18.2 Hz, 2H, H-12), 3.81 (s, 3H, H-17), 3.69-
3.60 (m, 3H, H-1a, H-1b, H-2), 2.37 (dddd, J = 7.0, 5.8, 1.4, 1.2 Hz, 2H, H-3);  
125 MHz 13C NMR (CDCl3): δ 159.3 (C-16), 138.1 (C-8), 134.8 (C-4), 131.0 (C-13), 129.5 
(C-14, C-14’), 128.6 (C-10, C-10’), 128.1 (C-9, C-9’), 127.9 (C-11), 117.4 (C-5), 113.9 
(C-15, C-15’), 95.1 (C-6), 77.5 (C-2), 71.6 (C-12), 69.7 (C-1), 69.6 (C-7), 55.5 (C-17), 
36.4 (C-3);  
FTIR (neat): νmax 3069, 3032, 2934, 1883, 1641, 1613, 1586, 1513, 1458, 1380, 1348, 1301, 
1248, 1173, 1043, 917, 822, 741, 699, 666, 589 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C21H26O4Na 365.1729; found 365.1734. 
(R)-4-Benzyloxymethoxy-3-(4-
methoxybenzyloxy)butanal (2.62): A solution of olefin 
2.61 (9.278 g, 27.09 mmol, 1.0 equiv) in CH2Cl2 (140 mL, 
0.2 M) was purged with O3 (3 Psi, 60 Volts) at -78 oC.   
When the colorless reaction became pinkish, O3 was turned 
off, and O2 flushed through the reaction until it turned colorless again.  Triphenylphospine 
(10.87 g, 41.02 mmol, 1.5 equiv) was then was added into this reaction.  It was allowed to 
warm to room temperature and stirred for 6 hours.  The solution was concentrated in vacuo.  
The residue was purified by flash chromatography on silica gel eluting with 10-25 vol% of 
ethyl acetate in hexanes to provide the titled compound (7.702 g, 22.36 mmol, 82.6% yield) 
as a colorless oil. 
TLC:  Rf = 0.29 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +13.9 (c 1.73, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.77 (t, J = 2.0 Hz, 1H, H-4), 7.40-7.33 (m, 4H, H-8, H-8’, 
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H-9, H-9’, H-10), 7.33-7.28 (m, 1H, H-11), 7.25 (d, J = 8.8 Hz, 2H, H-13, H-13’), 6.88 
(d, J = 8.8 Hz, 2H, H-14, H-14’), 4.79 (s, 2H, H-5), 4.61 (s, 2H, H-6), 4.57 (ABq, J = 11.2 
Hz, Δν = 39.5 Hz, 2H, H-11), 4.11 (dddd, J = 7.3, 4.9, 4.9, 4.9 Hz, 1H, H-2), 3.81 (s, 3H, 
H-16), 3.71 (dd, J = 10.6, 4.9 Hz, 1H, H-1a), 3.69 (dd, J = 10.5, 5.1 Hz, 1H, H-1b), 2.72 
(ddd, J = 16.9, 7.3, 2.2 Hz, 1H, H-3a), 2.64 (ddd, J = 16.8, 4.9, 2.0 Hz, 1H, H-3b);  
125 MHz 13C NMR (CDCl3) δ 201.0 (C-4), 159.6 (C-15), 137.9 (C-7), 130.2 (C-12), 129.7 
(C-13, C-13’), 128.7 (C-9, C-9’), 128.1 (C-8, C-8’), 128.0 (C-10), 114.1 (C-14, C-14’), 
95.1 (C-5), 72.9 (C-2), 71.9 (C-11), 69.9 (C-6), 69.1 (C-1), 55.5 (C-16), 46.5 (C-3); 
FTIR (neat): νmax 3032, 3003, 2879, 2731, 1886, 1725, 1613, 1586, 1514, 1459, 1382, 1301, 
1248, 1173, 1043, 823, 743, 700, 666 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C20H24O5Na 367.1521; found 367.1529. 
(4S,6R)-7-(Benzyloxymethoxy)-6-(4-
methoxybenzyloxy)hept-1-en-4-ol (2.63): To an oven-
dried round-bottomed flask was charged (S)-BINOL 
(5.508 g, 19.04 mmol, 0.2 equiv), 4Ǻ MS (41.47 g, 400 
mg/mmol) and freshly distilled CH2Cl2 (320 mL, 0.3 M).  
Under an atmosphere of N2, Ti(Oi-Pr)4 (2.80 mL, 9.46 mmol, 0.1 equiv) was introduced 
into this reaction dropwise via syringe with stirring, followed by addition of TFA (35 ul, 
0.47 mmol, 0.005 equiv) at room temperature.  The resulting dark brown mixture was 
heated at reflux for a period of 1 h, and then allowed to cooled to room temperature.  
Whereupon, a solution of of aldehyde 2.62 (32.63 g, 94.73 mmol, 1.0 equiv) in dry CH2Cl2 
(9.5 mL, 10 M) was added via cannula, and additional CH2Cl2 (2 x 5 mL) rinse was 
transferred into the reaction flask via cannula.  This reaction was stirred for 30 minutes at 
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room temperature, and then cooled to -78 oC.  Then, allyltributylstannane 2.59 (42 mL, 135 
mmol, 1.4 equiv) was added dropwise via syringe over 10 minutes.  This reaction was 
stirred for further 30 minutes in this condition, and transferred to a -35 oC freezer.  After 7 
days, this reaction was filtrated over a pad of Celite.  The filtrate was washed with a mixture 
of saturated NaHCO3 solution (200 mL) and saturated KF solution (300 mL).  The aqueous 
solution was extracted with ethyl ether (3 x 100 mL).  The combined organic layers were 
washed with brine (300 mL) and dried over anhydrous Na2SO4.   The solution was filtered 
and concentrated under reduced pressure to provide a brown oil.  The remainder was 
purified by flash chromatography on silica gel eluting with 3-10 vol% of acetone in 
hexanes, to provide the titled compound (32.74 g, 84.70 mmol, 89.4% yield, single 
diastereomer) as a yellow oil.  
TLC:  Rf = 0.29 (Et2O/Hex = 5:5, v/v);  
[α]20 D +28.1 (c 1.45, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.41-7.35 (m, 4H, H-11, H-11’, H-12, H-12’), 7.35-7.29 
(m, 1H, H-13), 7.29 (d, J = 8.8 Hz, 2H, H-16, H-16’), 6.89 (d, J = 8.8 Hz, 2H, H-17, H-
17’), 5.84 (dddd, J = 17.3, 9.9, 7.2, 7.2 Hz, 1H, H-6), 5.17-5.12 (m, 1H, H-7a), 5.12-5.08 
(m, 1H, H-7b), 4.81 (ABq, J = 6.8 Hz, Δν = 4.8 Hz, 2H, H-8), 4.64 (s, 2H, H-9), 4.61 (ABq, 
J = 11.3 Hz, Δν = 66.0 Hz, 2H, H-14), 3.97-3.84 (m, 1H, H-4), 3.86-3.80 (m, 1H, H-2), 
3.81 (s, 3H, H-19), 3.72 (d, J = 5.2 Hz, 2H, H-1), 2.39 (br. s, 1H, -OH), 2.30-2.17 (m, 2H, 
H-5), 1.78 (ddd, J = 14.6, 8.2, 2.5 Hz, 1H, H-3a), 1.65 (ddd, J = 14.6, 9.6, 3.6 Hz, 1H, H-
3b);  
125 MHz 13C NMR (CDCl3): δ 159.5 (C-18), 138.0 (C-10), 135.0 (C-6), 130.6 (C-15), 
129.8 (C-16, C-16’), 128.6 (C-12, C-12’), 128.1 (C-11, C-11’), 127.9 (C-13), 117.9 (C-7), 
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114.0 (C-17, C-17’), 95.1 (C-8), 75.2 (C-2), 72.1 (C-14), 70.1 (C-1), 69.7 (C-9), 67.7 (C-
4), 55.5 (C-19), 42.4 (C-5), 38.7 (C-3); 
FTIR (neat): νmax 3457 (br.), 3069, 2934, 1641, 1613, 1514, 1457, 1380, 1302, 1249, 1172, 
1040, 917, 821, 742, 699, 665, 591, 536 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C23H30O5Na 409.1991; found 409.1992. 
Determination of Absolute Configuration of the New Stereocenter of Compound 
(4S,6R)-7-(Benzyloxymethoxy)-6-(4-methoxybenzyloxy)hept-1-en-4-ol (2.63) via 




To a screw-capped vial equipped with a stirring bar 
was added 2.63 (42.6 mg, 110 umol, 1.0 equiv), (S)-(-)-MTPA-OH acid (29.0 mg, 121 
umol, 1.1 equiv), DMAP (13.6 mg, 110 umol, 1.0 equiv) and toluene (2.2 mL, 0.05 M), 
subsequently, at room temperature.  Freshly distilled NEt3 (77.0 uL, 552 umol, 5.0 equiv) 
was then added to this mixture.  This reaction was cooled down to 0 oC, 2,4,6-
trichlorobenzoylchloride (17.5 uL, 108 umol, 1.1 equiv) was then added dropwise via 
syringe.  The reaction turned cloudy and precipitated immediately.  The vial was tightly 
capped.  The reaction was allowed to warm to room temperature slowly and stirred 
overnight (ca. 10 hours).  Then, the resulting white mixture was concentrated and purified 
by flash chromatography on silica gel eluting with 8-15 vol% of ethyl ether in hexanes to 
provide the titled compound (61.8 mg, 103 umol, 93.0% yield) as a colorless oil. 
TLC:  Rf = 0.41 (EtOAc/Hex = 3:7, v/v);  
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[α]20 D +9.9 (c 2.33, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.61-7.52 (m, 2H, Ph-2, Ph-2’), 7.44-7.30 (m, 8H, H-11, 
H-11’, H-12, H-12’, H-13, Ph-3, Ph-3’, Ph-4), 7.28 (d, J = 8.5 Hz, 2H, H-16, H-16’), 6.88 
(d, J = 8.8 Hz, 2H, H-17, H-17’), 5.66 (dddd, J = 15.9, 11.0, 7.1, 7.1 Hz, 1H, H-6), 5.48 
(dq, J = 7.3, 5.6 Hz, 1H, H-4), 5.08-4.99 (m, 2H, H-7), 4.77 (ABq, J = 6.9 Hz, Δν = 4.7 
Hz, 2H, H-8), 4.61 (s, 2H, H-9), 4.59 (d, J = 10.8 Hz, 1H, H-14a), 4.39 (d, J = 11.2 Hz, 
1H, H-14b), 3.80 (s, 3H, H-19), 3.65 (dd, J = 10.5, 4.6 Hz, 1H, H-1a), 3.61 (dd, J = 10.1, 
4.4 Hz, 1H, H-1b), 3.59-3.53 (m, 1H, H-2), 3.51 (s, 3H, -OMe), 2.51-2.32 (m, 2H, H-5), 
1.86 (dd, J = 7.3, 5.4 Hz, 2H, H-3);   
125 MHz 13C NMR (CDCl3): δ 166.3 (-C=O), 159.5 (C-18), 138.0 (C-10), 132.8 (C-6), 
132.4 (Ph-1), 130.6 (C-15), 129.8 (C-16, C-16’), 129.8 (Ph-4), 128.7 (C-12, C-12’), 128.6 
(C-11, C-11’), 128.0 (Ph-3, Ph-3’), 128.0 (C-13), 127.8 (Ph-2, Ph-2’), 123.6 (q, JC-F = 
288.6 Hz, -CF3), 118.8 (C-7), 114.1 (C-17, C-17’), 95.1 (C-8), 84.9 (q, JC-F = 27.6 Hz, -
CC=O), 74.3 (C-2), 73.7 (C-4), 72.1 (C-14), 69.7 (C-9), 69.7 (C-1), 55.6 (Ar-OMe), 55.5 
(C-19), 39.1 (C-5), 37.0 (C-3); 
FTIR (neat): νmax 3068, 3032, 2934, 1744, 1642, 1612, 1587, 1514, 1454, 1380, 1251, 1171, 
1117, 1081, 1041, 962, 924, 820, 737, 720, 699, 644, 591, 536 cm-1; 




MTPA):To a screw-capped vial equipped with a 
stirring bar was added 2.63 (35.4 mg, 91.6 umol, 1.0 equiv), (R)-(+)-MTPA-OH acid (25.1 
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mg, 106 umol, 1.16 equiv), DMAP (11.9 mg, 96.4 umol, 1.0 equiv) and toluene (2.0 mL, 
0.05 M), subsequently, at room temperature.  Freshly distilled NEt3 (65.0 uL, 466 umol, 
5.0 equiv) was then added to this mixture.  This reaction was cooled down to 0 oC, 2,4,6-
trichlorobenzoylchloride (17.0 uL, 107 umol, 1.16 equiv) was then added dropwise via 
syringe.  The reaction turned cloudy and precipitated immediately.  The vial was tightly 
capped.  The reaction was allowed to warm to room temperature slowly and stirred for 10 
hours.  Then, the resulting yellow solution was concentrated and purified by flash 
chromatography on silica gel eluting with 8-15 vol% of ethyl ether in hexanes to provide 
the titled compound (48.2 mg, 80.0 umol, 87.3% yield) as a colorless oil. 
TLC:  Rf = 0.49 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +47.1 (c 1.81, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.65-7.51 (m, 2H, Ph-2, Ph-2’), 7.46-7.28 (m, 8H, H-11, 
H-11’, H-12, H-12’, H-13, Ph-3, Ph-3’, Ph-4), 7.30 (d, J = 8.8 Hz, 2H, H-16, H-16’), 6.90 
(d, J = 8.8 Hz, 2H, H-17, H-17’), 5.78 (dddd, J = 17.1, 9.8, 7.3, 7.3 Hz, 1H, H-6), 5.51 
(dddd, J = 9.1, 5.9, 5.9, 3.2 Hz, 1H, H-4), 5.20-5.05 (m, 2H, H-7), 4.73 (ABq, J = 6.6 Hz, 
Δν = 4.6 Hz, 2H, H-8), 4.59 (s, 2H, H-9), 4.56 (d, J = 10.8 Hz, 1H, H-14a), 4.34 (d, J = 
10.8 Hz, 1H, H-14b), 3.81 (s, 3H, H-19), 3.60 (dd, J = 10.7, 4.4 Hz, 1H, H-1a), 3.58 (s, 
3H, -OMe), 3.54 (dd, J = 10.7, 4.4 Hz, 1H, H-1b), 3.44 (dddd, J = 9.5, 4.4, 4.4, 3.2 Hz, 1H, 
H-2), 2.55-2.44 (m, 2H, H-5), 1.86 (ddd, J = 14.7, 9.8, 3.4 Hz, 1H, H-3a), 1.80 (ddd, J = 
15.1, 9.7, 2.9 Hz, 1H, H-3b);   
125 MHz 13C NMR (CDCl3): δ 166.4 (-C=O), 159.5 (C-18), 138.0 (C-10), 133.0 (C-6), 
132.5 (Ph-1), 130.7 (C-15), 129.8 (Ph-4), 129.7 (C-16, C-16’), 128.6 (C-12, C-12’), 128.6 
(C-11, C-11’), 128.0 (Ph-3, Ph-3’), 127.9 (C-13), 127.6 (Ph-2, Ph-2’), 123.7 (q, JC-F = 
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288.8 Hz, -CF3), 118.9 (C-7), 114.1 (C-17, C-17’), 94.9 (C-8), 84.6 (q, JC-F = 27.4 Hz, -
CC=O), 74.4 (C-2), 73.8 (C-4), 72.2 (C-14), 69.6 (C-9), 69.6 (C-1), 55.7 (Ar-OMe), 55.5 
(C-19), 39.4 (C-5), 37.0 (C-3); 
FTIR (neat): νmax 3068, 3032, 2946, 1745, 1643, 1612, 1587, 1514, 1454, 1380, 1347, 1251, 
1171, 1114, 1082, 1040, 962, 925, 820, 766, 736, 720, 699, 665, 591, 536 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C33H37F3O7Na 625.2389; found 625.2394. 
The chemical shift differences (in ppm) between the (S)- and (R)-MTPA Mosher esters of 
the (4S,6R)-7-(benzyloxymethoxy)-6-(4-methoxybenzyloxy)hept-1-en-4-ol (2.61) are 
consistent for a (S)-configuration of the new formed stereocenter.  
(4S,6R)-7-(Benzyloxymethoxy)-4-(tert-
butyldimethylsilyloxy)-6-(4-
methoxybenzyloxy)hept-1-ene (2.64): To a stirred 
solution of alcohol 2.63 (9.383 g, 24.28 mmol, 1.0 equiv) 
in DMF (120 mL, 0.2 M) was added imidazole (6.726 g, 97.80 mmol, 4.0 equiv) and TBSCl 
(7.549 g, 48.58 mmol, 2.0 equiv) at room temperature, subsequently.  This reaction was 
stirred under an atmosphere of N2 for 20 hours.  Then, it was diluted with Et2O (100 mL), 
and the reaction was poured into a saturated solution of NaHCO3 (200 mL).  The aqueous 
layer was extracted by Et2O (3 x 30 mL).  The combined organic layers were washed with 
brine (100 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
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concentrated under reduced pressure to provide a yellowish oil.  The crude product was 
purified by flash chromatography on silica gel eluting with 2-6 vol% of ethyl acetate in 
hexanes to provide the titled compound (12.07 g, 24.11 mmol, 99.3% yield) as a colorless 
oil.   
TLC:  Rf = 0.62 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +23.5 (c 1.81, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.41-7.35 (m, 4H, H-11, H-11’, H-12, H-12’), 7.35-7.30 (m, 
1H, H-13), 7.30 (d, J = 8.8 Hz, 2H, H-16, H-16’), 6.90 (d, J = 8.8 Hz, 2H, H-17, H-17’), 
5.86 (dddd, J = 20.0, 9.5, 7.1, 7.1 Hz, 1H, H-6), 5.12-5.04 (m, 2H, H-7a, H-7b), 4.82 (ABq, 
J = 6.6 Hz, Δν = 5.5 Hz, 2H, H-8), 4.69 (d, J = 11.0 Hz, 1H, H-14a), 4.65 (s, 2H, H-9), 
4.51 (d, J = 11.0 Hz, 1H, H-14b), 4.03 (dddd, J = 8.8, 4.4, 4.4, 3.9 Hz, 1H, H-4), 3.82 (s, 
3H, H-19), 3.83-3.78 (m, 1H, H-2), 3.75 (dd, J = 10.3, 3.9 Hz, 1H, H-2a), 3.68 (dd, J = 
10.3, 5.4 Hz, 1H, H-2b), 2.37-2.23 (m, 2H, H-5), 1.81 (ddd, J = 14.2, 8.8, 3.4 Hz, 1H, H-
3a), 1.63 (ddd, J = 14.2, 8.8, 3.4 Hz, 1H, H-3b), 0.94 (s, 9H, H-22), 0.12 (s, 3H, H-20a), 
0.11 (s, 3H, H-20b);  
125 MHz 13C NMR (CDCl3) δ 159.3 (C-18), 138.1 (C-10), 134.8 (C-6), 131.3 (C-15), 
129.2 (C-16, C-16’), 128.6 (C-12, C-12’), 128.0 (C-11, C-11’), 127.8 (C-13), 117.3 (C-7), 
113.9 (C-17, C-17’), 95.0 (C-8), 75.4 (C-2), 71.4 (C-14), 70.5 (C-1), 69.6 (C-9), 69.0 (C-
4), 55.4 (C-19), 42.9 (C-5), 40.1 (C-3), 26.1 (C-22), 18.3 (C-21), -3.8 (C-20a), -4.3 (C-
20b); 
FTIR (neat): νmax 3070, 3032, 2931, 2858, 1641, 1613, 1587, 1514, 1464, 1380, 1301, 1250, 
1172, 1045, 915, 834, 775, 739, 698, 666, 591 cm-1; 





methoxybenzyloxy)octanal (2.65): To an oven-
dried flask equipped with a stirring bar was added 
dicarbonylacetylacetonatorhodium (I) (17.9 mg, 0.0687 mmol, 0.5 mol%), BIPHEPHOS 
(217 mg, 0.276 mmol, 2.0 mol%) and freshly distilled degassed THF (70 mL).  This flask 
was evacuated and refilled with N2 by 3 times.  It was then stirred at room temperature 
under an atmosphere of N2 for 10 minutes, whereupon the mixture was dissolved.  The 
solution of olefin 2.64 (6.906 g, 13.79 mmol, 1.0 equiv) in degassed THF (7 mL, 2.0 M) 
was added into this flask via cannula.  This flask was unsealed and put into a Parr autoclave 
quickly.  Then the Parr pressure vessel was sealed tightly.  The atmosphere of this reaction 
vessel was exchanged with 100 psi of CO/H2 (1:1 mixture) three times by being evacuated 
with an oil pump and refilled with syngas.  Then, the reaction vessel was pressurized with 
CO/H2 (1:1 mixture) at 100 psi., and stirred at 57 oC for 36 hours.  After cooling to room 
temperature, the reaction was depressurized and concentrated by rotary vacuum.  The 
remainder was purified by flash chromatography on silica gel eluting with 7-16 vol% of 
ethyl acetate in hexanes to provide the titled compound (6.399 g, 12.06 mmol, 87.4% yield) 
as a yellowish oil. 
TLC:  Rf = 0.43 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +17.8 (c 1.87, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.75 (t, J = 1.5 Hz, 1H, H-8), 7.40-7.33 (m, 4H, H-12, H-
12’, H-13, H-13’), 7.33-7.28 (m, 1H, H-14), 7.27 (d, J = 8.6 Hz, 2H, H-17, H-17’), 6.88 
(d, J = 8.8 Hz, 2H, H-18, H-18’), 4.80 (ABq, J = 6.6 Hz, Δν = 5.5 Hz, 2H, H-9), 4.67 (d, J 
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= 11.3 Hz, 1H, H-15a), 4.63 (s, 2H, H-10), 4.47 (d, J = 11.3 Hz, 1H, H-15b), 3.94 (dddd, 
J = 8.8, 5.4, 5.4, 4.4 Hz, 1H, H-4), 3.81 (s, 3H, H-20), 3.74 (dddd, J = 8.5, 4.9, 4.5, 3.9 Hz, 
1H, H-2), 3.72 (dd, J = 10.3, 3.9 Hz, 1H, H-1a), 3.65 (dd, J = 10.3, 4.9 Hz, 1H, H-1b), 
2.34 (td, J = 7.3, 1.5 Hz, 2H, H-7), 1.75 (ddd, J = 13.5, 8.6, 3.9 Hz, 1H, H-3a), 1.72-1.60 
(m, 3H, H-3b, H-6a, H-6b), 1.59-1.44 (m, 2H, H-5a, H-5b), 0.91 (s, 9H, H-23), 0.068 (s, 
3H, H-21a), 0.066 (s, 3H, H-21b); 
125 MHz 13C NMR (CDCl3) δ 202.6 (C-8), 159.3 (C-19), 138.1 (C-11), 131.1 (C-16), 
129.3 (C-17, C-17’), 128.6 (C-13, C-13’), 128.0 (C-12, C-12’), 127.9 (C-14), 114.0 (C-18, 
C-18’), 95.0 (C-9), 75.4 (C-2), 71.5 (C-15), 70.3 (C-1), 69.6 (C-10), 69.1 (C-4), 55.5 (C-
20), 44.2 (C-7), 40.1 (C-3), 37.5 (C-5), 26.1 (C-23), 18.3 (C-22), 17.4 (C-6), -3.9 (C-21a), 
-4.2 (C-21b);  
FTIR (neat): νmax 3032, 2932, 2717, 2062, 1726, 1613, 1587, 1514, 1463, 1382, 1301, 1250, 
1173, 1047, 835, 776, 740, 699, 665 cm-1; 




ol (2.67): To a stirred mixture of aldehyde 2.65 
(3.976 g, 7.491 mmol, 1.0 equiv) and 1-bromo-3-methylbut-2-ene 2.66 (1.40 mL, 11.6 
mmol, 1.5 equiv) in THF (15 mL, 0.5 M) and saturate aqueous NH4Cl solution (75 mL, 0.1 
M) was added Zn dust (0.776 g, 11.6 mmol, 1.5 equiv) in one portion at room temperature.  
It was stirred overnight (ca. 12 hours), then Et2O (50 mL) was poured into this reaction.  
The aqueous layer was extracted with Et2O (3 x 20 mL).  The combined organic layers 
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were washed with brine (50 mL) and dried over anhydrous Na2SO4.  Filtered, it was then 
concentrated by rotary vacuum to give a yellow oil (4.591 g, 7.640 mmol, 100% yield), 
which was used in the next step without further purification.    




one (2.68): With a –78 oC bath, to a stirred solution 
of oxalyl chloride (1.00 mL, 11.4 mmol, 1.5 equiv) 
in dry CH2Cl2 (60 mL, 0.2 M) was added a solution of DMSO (1.60 mL, 22.5 mmol, 3.0 
equiv) in dry CH2Cl2 (40 mL, 0.5 M) dropwise via cannula under an atmosphere of N2.  
After 30 minutes, the solution of crude alcohol 2.67 (4.573 g, theoretically 7.607 mmol, 
1.0 equiv) in dry CH2Cl2 (80 mL, 0.1 M) was added dropwise via cannula.  This reaction 
was stirred for 1 hour in this condition.  Then, NEt3 (5.4 mL, 39 mmol, 5.0 equiv) was 
introduced dropwise via syringe.  After 5 minutes, the cooling bath was removed, and the 
reaction was stirred at room temperature for 1.5 hours.  The solution was poured into a 
saturated solution of NH4Cl (150 mL).  The aqueous layer was extracted with Et2O (3 x 30 
mL).  The combined organic layers were washed with brine (200 mL) and dried over 
anhydrous Na2SO4.  Filtered, it was then concentrated by rotary vacuum.  The remainder 
was purified by flash chromatography on silica gel eluting with 5-12 vol% of ethyl acetate 
in hexanes to provide the titled compound (4.152 g, 6.932 mmol, 91.1% yield in two steps) 
as a yellow oil.    
TLC:  Rf = 0.65 (EtOAc/Hex = 3:7, v/v);  
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[α]20 D +15.7 (c 2.17, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.41-7.33 (m, 4H, H-16, H-16’, H-17, H-17’), 7.33-7.28 (m, 
1H, H-18), 7.28 (d, J = 8.6 Hz, 2H, H-21, H-21’), 6.87 (d, J = 8.3 Hz, 2H, H-22, H-22’), 
5.91 (dd, J = 17.6, 10.8 Hz, 1H, H-10), 5.14 (d, J = 16.6 Hz, 1H, H-11a), 5.14 (d, J = 11.2 
Hz, 1H, H-11b), 4.79 (ABq, J = 6.6 Hz, Δν = 4.6 Hz, 2H, H-13), 4.66 (d, J = 11.2 Hz, 1H, 
H-19a), 4.63 (s, 2H, H-14), 4.48 (d, J = 11.2 Hz, 1H, H-19b), 3.92 (dddd, J = 9.0, 5.4, 5.4, 
3.9 Hz, 1H, H-4), 3.80 (s, 3H, H-24), 3.76 (dddd, J = 8.6, 5.4, 3.9, 3.9 Hz, 1H, H-2), 3.71 
(dd, J = 10.3, 3.9 Hz, 1H, H-1a), 3.64 (dd, J = 10.3, 5.4 Hz, 1H, H-1b), 2.46 (dt, J = 17.1, 
7.2 Hz, 1H, H-7a), 2.41 (dt, J = 17.1, 7.2 Hz, 1H, H-7b), 1.75 (ddd, J = 14.2, 8.8, 3.9 Hz, 
1H, H-3a), 1.62 (ddd, J = 14.2, 8.3, 3.9 Hz, 1H, H-3b), 1.61-1.53 (m, 2H, H-6a, H-6b), 
1.48-1.40 (m, 2H, H-5a, H-5b), 1.23 (s, 6H, H-12a, H-12b), 0.91 (s, 9H, H-27), 0.066 (s, 
3H, H-25a), 0.061 (s, 3H, H-25b);  
125 MHz 13C NMR (CDCl3) δ 212.9 (C-8), 159.3 (C-23), 142.8 (C-10), 138.1 (C-15), 
131.3 (C-20), 129.2 (C-21, C-21’), 128.6 (C-17, C-17’), 128.1 (C-16, C-16’), 127.8 (C-18), 
114.3 (C-11), 114.0 (C-22, C-22’), 95.1 (C-13), 75.5 (C-2), 71.4 (C-19), 70.6 (C-1), 69.6 
(C-14), 69.4 (C-4), 55.5 (C-24), 50.9 (C-9), 40.1 (C-3), 37.7 (C-7), 37.7 (C-5), 26.2 (C-27), 
23.7 (C-12a, C-12b), 19.5 (C-6), 18.3 (C-26), -3.8 (C-25a), -4.2 (C-25b); 
FTIR (neat): νmax 2932, 2858, 1710, 1613, 1514, 1464, 1379, 1302, 1250, 1172, 1107, 1044, 
921, 835, 775, 738, 698, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C35H54O6SiNa 621.3587; found 621.3592. 
(7S,9R)-10-(Benzyloxymethoxy)-7-(tert-
butyldimethylsilyloxy)-9-(4-methoxybenzyloxy)-2,2-
dimethyl-3-oxodecanal (2.69): With an acetone/dry ice bath 
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(–78 oC), a steam of O3 (3.0 psi, 60 Volts) purged through a solution of olefin 2.68 (5.644 
g, 9.423 mmol, 1.0 equiv) in CH2Cl2 (100 mL, 0.1 M) until the colorless solution turned 
pinkish.  Whereupon, the O3 was turned off, and a stream of N2 flushed the solution until 
the color faded.  Then, triphenylphosphine (3.716 g, 14.02 mmol, 1.5 equiv) was added at 
one portion.  The reaction was stirred at room temperature for 6 hours.  The resulting yellow 
solution was concentrated under reduced pressure.  Then, an ice-cold solution of 30% (v/v) 
Et2O in pentane (100 mL, 0.1 M) was added into the remainder.  It was stirred at 0 oC for 
30 minutes.  The white precipitate was filtrated, and washed with an ice-cold solution of 
10% (v/v) Et2O in pentane (3 x 10 mL).  The solution was concentrated by rotary 
evaporation to give a yellow oil which was used directly in the next step without any further 
purification.  




oxododec-2-enethioate (2.71): To a round-
bottomed flask was charged NaH (60% dispersion in mineral oil, 0.574 g, 14.4 mmol, 1.5 
equiv) and anhydrous THF (35 mL, 0.4 M).  With an ice-water bath, a solution of diethyl 
ethylthiocarbonylmethylphosphonate 2.70 (3.00 mL, 14.3 mmol, 1.5 equiv) in THF (30 
mL, 0.5 M) was added dropwise via cannula.  This reaction was then stirred under an 
atmosphere of N2 for 10 minutes, whereupon a solution of aldehyde 2.69 (theoretically 
9.423 mmol, 1.0 equiv) in THF (25 mL, 0.4 M) was added via a cannula.  It was kept 
stirring in this condition for 2 hours.  Then, a saturated NaHCO3 solution (100 mL) was 
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added.  The separated aqueous layer was extracted by ether (3 x 20 mL).  The combined 
organic layers were washed with brine (100 mL), and dried over anhydrous Na2SO4.  The 
solution was filtered and concentrated under reduced pressure to provide a yellowish oil.  
The crude product was purified by flash chromatography on silica gel eluting with 4-10 
vol% of ethyl acetate in hexanes to afford the titled compound (5.550 g, 8.078 mmol, 85.7% 
yield over two steps) a yellowish oil. 
TLC:  Rf = 0.60 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +13.7 (c 1.79, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.39-7.33 (m, 4H, H-19, H-19’, H-20, H-20’), 7.33-7.28 (m, 
1H, H-21), 7.27 (d, J = 8.8 Hz, 2H, H-24, H-24’), 6.96 (d, J = 16.1 Hz, 1H, H-10), 6.87 
(d, J = 8.8 Hz, 2H, H-25, H-25’), 6.14 (d, J = 15.8 Hz, 1H, H-11), 4.79 (ABq, J = 6.6 Hz, 
Δν = 4.6 Hz, 2H, H-16), 4.66 (d, J = 11.2 Hz, 1H, H-22a), 4.62 (s, 2H, H-17), 4.47 (d, J = 
10.8 Hz, 1H, H-22b), 3.91 (dddd, J = 9.0, 5.6, 5.4, 3.9 Hz, 1H, H-4), 3.80 (s, 3H, H-27), 
3.74 (dddd, J = 8.8, 5.0, 3.9, 3.9 Hz, 1H, H-2), 3.70 (dd, J = 10.8, 3.9 Hz, 1H, H-1a), 3.64 
(dd, J = 10.8, 5.1 Hz, 1H, H-1b), 2.97 (q, J = 7.3 Hz, 2H, H-13), 2.44 (ddd, J = 17.6, 7.3, 
7.3 Hz, 1H, H-7a), 2.41 (ddd, J = 17.6, 7.3, 6.9 Hz, 1H, H-7b), 1.74 (ddd, J = 14.2, 8.6, 
3.7 Hz, 1H, H-3a), 1.62 (ddd, J = 14.2, 8.3, 3.4 Hz, 1H, H-3b), 1.61-1.53 (m, 2H, H-6a, 
H-6b), 1.48-1.38 (m, 2H, H-5a, H-5b), 1.30 (t, J = 7.3 Hz, 3H, H-14), 1.28 (s, 6H, H-15a, 
H-15b), 0.90 (s, 9H, H-30), 0.056 (s, 3H, H-28a), 0.053 (s, 3H, H-28b);  
125 MHz 13C NMR (CDCl3) δ 210.5 (C-8), 190.0 (C-12), 159.3 (C-26), 147.3 (C-10), 
138.1 (C-18), 131.2 (C-23), 129.2 (C-24, C-24’), 128.6 (C-20, C-20’), 128.0 (C-19, C-19’), 
127.8 (C-21), 127.7 (C-11), 113.9 (C-25, C-25’), 95.0 (C-16), 75.5 (C-2), 71.4 (C-22), 70.5 
(C-1), 69.6 (C-17), 69.3 (C-4), 55.4 (C-27), 50.6 (C-9), 40.1 (C-3), 38.5 (C-7), 37.6 (C-5), 
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26.1 (C-30), 23.7 (C-15a, C-15b), 23.5 (C-13), 19.2 (C-6), 18.3 (C-29), 14.9 (C-14), -3.8 
(C-28a), -4.3 (C-28b); 
FTIR (neat): νmax 2932, 2885, 2859, 1713, 1671, 1622, 1587, 1514, 1463, 1408, 1380, 1299, 
1250, 1172, 1109, 1049, 835, 775, 740, 699, 665 cm-1; 




oxododec-2-enethioate (2.72): To an ice-
cold solution of protected alcohol 2.71 (4.031 g, 5.867 mmol, 1.0 equiv) in MeCN (60 mL, 
0.1 M) was added pyridine (60 mL, 0.1 M) and DI H2O (3.0 mL, 2.0 M).  Then, aqueous 
HF solution (48 wt%, 9.0 mL, 0.25 mol, 40 equiv) was added dropwise.  This reaction was 
allowed to warm to room temperature for 3 hours, and other portion of HF solution (48 
wt%, 9.0 mL, 0.25 mol, 40 equiv) was added dropwise.  Then, HF solution (48 wt%, 9.0 
mL, 0.25 mol, 40 equiv) was added dropwise every 6 hours until 45 mL of HF solution 
(200 equiv) was added.  This reaction was stirred for 36 hours, whereupon solid NaHCO3 
(40.8 g, 0.482 mol, 80 equiv) was carefully added into this reaction in several portions over 
3 hours.  Then, it was carefully poured into a mixture of saturated NaHCO3 solution (200 
mL) and 100 mL EtOAc.  The aqueous phase was further extracted with EtOAc (3 x 50 
mL).  The combined organic solutions were washed with brine (200 mL), a saturated 
solution of Cu2SO4 (200 mL), and subsequently brine (200 mL).  The organic solution was 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to provide 
a yellow oil (crude 3.380 g, 5.902 mmol, 100% yield), which was used directly in the next 
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step without further purification. 





(2.73): To a solution of crude 2.72 (3.380 g, 
theoretically 5.867 mmol, 1.0 equiv) in toluene (120 mL, 0.05 M) was added CSA (41 mg, 
0.17 mmol, 0.03 equiv) in  one portion at room temperature.  This reaction was refluxed 
with dean-stark apparatus for an hour under an atmosphere of N2.  Then, freshly distilled 
pyridine (1.0 mL, 12 mmol) was added into this reaction.  It was cooled down to room 
temperature under an atmosphere of N2, and poured into a saturated NaHCO3 solution (150 
mL).  The aqueous layer was extracted by ethyl ether (3 x 30 mL).  The combined organic 
layers were washed with brine (150 mL) and dried over anhydrous Na2SO4.  The solution 
was filtered and concentrated under reduced pressure to provide a yellow oil.  The crude 
product was purified by flash chromatography on silica gel eluting with 10-25 vol% of 
ethyl ether in hexanes to afford the titled compound (2.555 g, 4.606 mmol, 78.5% yield in 
2 steps) a yellowish oil. 
TLC:  Rf = 0.52 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +45.2 (c 1.18, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.41-7.33 (m, 4H, H-19, H-19’, H-20, H-20’), 7.33-7.28 (m, 
1H, H-21), 7.26 (d, J = 9.0 Hz, 2H, H-24, H-24’), 6.97 (d, J = 15.7 Hz, 1H, H-10), 6.86 
(d, J = 8.8 Hz, 2H, H-25, H-25’), 6.09 (d, J = 15.7 Hz, 1H, H-11), 4.80 (ABq, J = 6.6 Hz, 
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Δν = 4.6 Hz, 2H, H-16), 4.65 (d, J = 10.8 Hz, 1H, H-22a), 4.63 (s, 2H, H-17), 4.60 (dd, J 
= 5.2, 2.7 Hz, 1H, H-7), 4.50 (d, J = 10.8 Hz, 1H, H-22b), 4.00 (dddd, J = 9.8, 9.3, 3.4, 2.5 
Hz, 1H, H-4), 3.90 (dddd, J = 9.0, 4,4, 4.4, 4.4 Hz, 1H, H-2), 3.80 (s, 3H, H-27), 3.71 (dd, 
J = 10.5, 4.2 Hz, 1H, H-1a), 3.64 (dd, J = 10.5, 5.1 Hz, 1H, H-1b), 2.90 (q, J = 7.3 Hz, 2H, 
H-13), 2.09 (dddd, J = 16.6, 9.3, 6.4, 2.7 Hz, 1H, H-6eq), 1.99 (dddd, J = 17.1, 6.1, 4.9, 3.4 
Hz, 1H, H-6ax), 1.77 (app. ddt, J = 13.2, 5.8, 2.9 Hz, 1H, H-5eq), 1.75 (ddd, J = 14.2, 9.3, 
3.9 Hz, 1H, H-3a), 1.71 (ddd, J = 14.2, 9.3, 3.4 Hz, 1H, H-3b), 1.50 (dddd, J = 13.5, 9.8, 
9.8, 6.1 Hz, 1H, H-5ax), 1.24 (t, J = 7.3 Hz, 3H, H-14), 1.23 (s, 3H, H-15a), 1.22 (s, 3H, 
H-15b);  
125 MHz 13C NMR (CDCl3) δ 190.6 (C-12), 159.4 (C-26), 157.2 (C-8), 152.0 (C-10), 
138.2 (C-18), 131.2 (C-23), 129.6 (C-24, C-24’), 128.6 (C-20, C-20’), 128.1 (C-19, C-19’), 
127.9 (C-21), 125.8 (C-11), 114.0 (C-25, C-25’), 95.1 (C-16), 94.6 (C-7), 74.9 (C-2), 72.8 
(C-22), 72.0 (C-4), 70.6 (C-1), 69.6 (C-17), 55.5 (C-27), 41.4 (C-9), 38.5 (C-3), 28.1 (C-
5), 25.3 (C-15a), 25.2 (C-15b), 23.3 (C-13), 20.5 (C-6), 14.9 (C-14); 
FTIR (neat): νmax 3032, 2929, 2877, 1711, 1667, 1625, 1587, 1513, 1456, 1380, 1289, 1248, 
1171, 1094, 1044, 940, 824, 782, 740, 698 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C32H42O6SNa 577.2600; found 577.2607. 
(E)-4-((S)-2-((R)-3-(Benzyloxymethoxy)-2-(4-
methoxybenzyloxy)propyl)-3,4-dihydro-2H-
pyran-6-yl)-4-methylpent-2-enal (2.55): With a 
–78 oC bath, to a stirred solution of thio ester 2.73 
(2.555 g, 4.606 mmol, 1.0 equiv) in fresh distilled CH2Cl2 (50 mL, 0.1 M) was added a 
DIBAL solution (1.0 M solution in CH2Cl2, 6.90 mL, 6.90 mmol, 1.5 equiv) at the rate of 
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10 mL/h via syringe pump under an atmosphere of N2.  After addition, it was stirred for 30 
minutes, and EtOAc (5 mL) was then added into the reaction at the same rate above.  Then, 
a saturated Rochelle’s salt solution (100 mL) was added, and the mixture was stirred 
vigorously for 3 hours, whereupon two clear phases appeared.  The aqueous layer was 
extracted by Et2O (3 x 20 mL).  The combined organic layers were washed with brine (100 
mL) and dried over anhydrous Na2SO4.  The solution was filtered and concentrated under 
reduced pressure.  The crude product was purified by flash chromatography on silica gel 
eluting with 5-15 vol% of ethyl acetate in hexanes to provide the titled compound (1.825 
g, 3.690 mmol, 80.1% yield) as a colorless oil.   
TLC:  Rf = 0.40 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +35.2 (c 1.90, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.49 (d, J = 7.8 Hz, 1H, H-12), 7.41-7.33 (m, 4H, H-17, H-
17’, H-18, H-18’), 7.33-7.28 (m, 1H, H-19), 7.25 (d, J = 8.8 Hz, 2H, H-22, H-22’), 6.87 
(d, J = 9.2 Hz, 2H, H-23, H-23’), 6.86 (d, J = 15.7 Hz, 1H, H-10), 6.11 (dd, J = 15.9, 7.6 
Hz, 1H, H-11), 4.80 (ABq, J = 6.4 Hz, Δν = 6.1 Hz, 2H, H-14), 4.66 (d, J = 11.2 Hz, 1H, 
H-20a), 4.63 (s, 2H, H-15), 4.63 (dd, J = 5.8, 2.8 Hz, 1H, H-7), 4.47 (d, J = 10.8 Hz, 1H, 
H-20b), 4.06 (dddd, J = 9.8, 9.3, 3.7, 2.4 Hz, 1H, H-4), 3.87 (dddd, J = 8.8, 4.9, 4.4, 3.9 
Hz, 1H, H-2), 3.80 (s, 3H, H-25), 3.70 (dd, J = 10.3, 4.4 Hz, 1H, H-1a), 3.64 (dd, J = 10.3, 
5.1 Hz, 1H, H-1b), 2.11 (dddd, J= 16.9, 9.8, 6.3, 2.9 Hz, 1H, H-6eq), 2.00 (dddd, J = 17.1, 
5.9, 4.9, 3.4 Hz, 1H, H-6ax), 1.79 (dddd, J = 13.2, 6.4, 3.4, 2.9 Hz, 1H, H-5eq), 1.77 (ddd, 
J = 14.2, 9.3, 3.9 Hz, 1H, H-3a), 1.72 (ddd, J = 14.2, 9.3, 3.4 Hz, 1H, H-3b), 1.51 (dddd, 
J = 13.2, 9.8, 9.8, 5.9 Hz, 1H, H-5ax), 1.26 (s, 3H, H-13a), 1.25 (s, 3H, H-13b);  
125 MHz 13C NMR (CDCl3) δ 194.7 (C-12), 165.6 (C-10), 159.4 (C-24), 156.9 (C-8), 
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138.1 (C-16), 131.0 (C-21), 129.8 (C-11), 129.5 (C-22, C-22’), 128.6 (C-18, C-18’), 128.0 
(C-17, C-17’), 127.9 (C-19), 114.0 (C-23, C-23’), 95.2 (C-14), 94.9 (C-7), 74.8 (C-2), 72.6 
(C-20), 72.1 (C-4), 70.6 (C-1), 69.7 (C-15), 55.5 (C-25), 42.1 (C-9), 38.5 (C-3), 28.1 (C-
5), 25.3 (C-13a), 25.2 (C-13b), 20.5 (C-6);   
FTIR (neat): νmax 2928, 2879, 1690, 1613, 1587, 1513, 1459, 1381, 1349, 1298, 1248, 1171, 
1096, 1043, 940, 822, 741, 699, 665 cm-1; 







With a –78 oC bath, to a stirred mixtue of aldehyde 2.55 (608 mg, 1.23 mmol, 1.0 equiv) 
and compound β-hydroxyallylsilane 2.33 (812 mg, 1.84 mmol, 1.5 equiv) in fresh distilled 
Et2O (25 mL, 0.05 M) was added pyridine (30.0 uL, 0.371 mmol, 0.3 equiv) via syringe 
under an atmosphere of N2.  Then, a solution of 1.0 M TMSOTf in Et2O (1.5 mL, 1.5 mmol, 
1.2 equiv) was introduced into this reaction dropwise via syringe.  It was stirred for 30 
minutes, and quenched with DIPEA (2.2 mL, 13 mmol, 10 equiv) at this temperature.  After 
another 30 minutes, it was poured into a saturated NaHCO3 solution (50 mL).  The aqueous 
layer was extracted by Et2O (3 x 10 mL).  The combined organic layers were washed with 
brine (50 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure to provide a colorless oil.  The crude product was 
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purified by flash chromatography on silica gel eluting with 5-20 vol% of Et2O in hexanes 
to provide the titled compound (967 mg, 1.14 mmol, 93.2% yield) as a colorless oil.   
TLC:  Rf = 0.38 (Et2O:Hex = 3:7, v/v);  
[α]20 D +21.3 (c 1.07, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.74-7.64 (m, 4H, H-36, H-36’, H-40, H-40’), 7.48-7.33 (m, 
10H, H-24, H-24’, H-25, H-25’, H-37, H-37’, H-38, H-41, H-41’, H-42), 7.33-7.28 (m, 
1H, H-26), 7.28 (d, J = 8.8 Hz, 2H, H-29, H-29’), 6.86 (d, J = 8.8 Hz, 2H, H-30, H-30’), 
5.79 (dd, J = 16.1, 1.0 Hz, 1H, H-10), 5.52 (dd, J = 16.1, 6.1 Hz, 1H, H-11), 4.81 (ABq, J 
= 6.8 Hz, Δν = 4.7 Hz, 2H, H-21), 4.73 (d, J = 2.0 Hz, 1H, H-20a), 4.72 (d, J = 2.0 Hz, 1H, 
H-20b), 4.68 (d, J = 10.8 Hz, 1H, H-27a),  4.64 (s, 2H, H-22), 4.55 (t, J = 3.9 Hz, 1H, H-
7), 4.54 (d, J = 10.8 Hz, 1H, H-27b), 4.06 (dddd, J = 9.8, 9.3, 2.9, 2.4 Hz, 1H, H-4), 3.96 
(dddd, J = 9.3, 9.3, 5.1, 4.1 Hz, 1H, H-2), 3.87 (ddd, J = 10.3, 7.8, 5.4 Hz, 1H, H-18a), 
3.79 (s, 3H, H-32), 3.82-3.74 (m, 2H, H-12, H-18b), 3.72 (dd, J = 10.5, 4.1 Hz, 1H, H-1a), 
3.75 (dd, J = 10.5, 5.1 Hz, 1H, H-1b), 3.55 (dddd, J = 12.5, 7.6, 5.1, 2.4 Hz, 1H, H-16), 
2.30-2.23 (m, 1H, H-13eq), 2.26-2.20 (m, 1H, H-15eq), 2.15-2.02 (m, 2H, H-6eq, H-13ax), 
2.02-1.82 (m, 3H, H-6ax, H-15ax, H-17a), 1.82-1.66 (m, 4H, H-17b, H-5eq, H-3a, H-3b), 
1.50 (dddd, J = 13.4, 9.8, 9.8, 6.1 Hz, 1H, H-5ax), 1.19 (s, 6H, H-19a, H-19b), 1.06 (s, 9H, 
H-34);  
125 MHz 13C NMR (CDCl3) δ 159.4 (C-31), 159.2 (C-8), 145.0 (C-14), 139.1 (C-10), 
138.1 (C-23), 135.8 (C-36, C-36’, C-40, C-40’), 134.3 (C-35), 134.2 (C-39), 131.2 (C-28), 
129.7 (C-38), 129.7 (C-42), 129.6 (C-29, C-29’), 128.6 (C-25, C-25’), 128.1 (C-24), (C-
24’), 127.8 (C-26, C-37, C-37’, C-41, C-41’), 127.6 (C-11), 114.0 (C-30, C-30’), 108.6 (C-
20), 95.1 (C-21), 93.4 (C-7), 79.2 (C-12), 75.4 (C-16), 75.1 (C-2), 72.8 (C-27), 71.7 (C-4), 
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70.8 (C-1), 69.6 (C-22), 60.6 (C-18), 55.5 (C-32), 41.4 (C-13), 40.9 (C-15), 40.7 (C-9), 
39.3 (C-17), 38.6 (C-3), 28.2 (C-5), 27.1 (C-34), 26.1 (C-19a), 25.9 (C-19b), 20.5 (C-6), 
19.5 (C-33); 
FTIR (neat): νmax 3070, 2931, 2856, 1660, 1613, 1513, 1471, 1428, 1380, 1358, 1292, 1247, 
1172, 1088, 1039, 972, 939, 891, 822, 737, 700 cm-1; 







2H-pyran-3-ol (2.75): With a –10 oC bath, to a stirred solution of glycol 2.74 (391 mg, 
0.463 mmol, 1.0 equiv) in fresh distilled CH2Cl2 (23 mL, 0.02 M) and MeOH (12 mL, 0.04 
M) was added a solution of mCPBA(120 mg, 0.695 mmmol, 1.5 equiv) in CH2Cl2 (7.0 mL, 
0.1 M) via cannula.  This reaction was stirred at this temperature under an atmosphere of 
N2 for 2 hours.  Then, a saturated solution Na2S2O3 (20 mL) was added.  It was stirred at 
room temperature for 30 minutes.  It was then poured into H2O (20 mL).  The aqueous 
layer was extracted by EtOAc (3 x 10 mL).  The combined organic layers were washed 
with brine (50 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure to provide a colorless oil.   
To the solution of the crude product above in MeOH (46 mL, 0.01 M) was added PPTS 
(11.6 mg, 0.0462  mmol, 0.1 equiv) in one portion at room temperature.  It was stirred 
161 
 
under an atmosphere of N2 for 2 hours.  It was then poured into a saturated solution of 
NaHCO3 (100 mL).  The aqueous layer was extracted with 1:1 (v/v) mixture of EtOAc/Hex 
(3 x 20 mL).  The combined organic layers were washed with brine (50 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated by rotary evaporation.  The 
remainder (397 mg, 0.445 mmol, 96.2% yield, crude) was used directly in next step without 
any further purification.  







pyran-3(4H)-one (2.76): To a stirred solution of alcohol 2.75 (397 mg, theoretically 0.445 
mmol, 1.0 equiv) in dry CH2Cl2 (45 mL, 0.01 M) was added t-BuOH (56 uL, 0.59 mmol, 
1.3 equiv) and freshly distilled pyridine (110 uL, 1.36 mmol, 3.0 equiv).  Then, this reaction 
was cooled down to 0 oC, and Dess-Martin periodinane (291 mg, 0.664 mmol, 1.5 equiv) 
was added in one portion.  The cooling bath was removed, and the reaction was stirred at 
room temperature for 1 hour under an atmosphere of N2.  At this point, the reaction was 
diluted with Et2O (20 mL), and a saturated NaHCO3 solution (30 mL) was added, followed 
by a saturated Na2S2O3 solution (30 mL).  This mixture was stirred for 10 minutes at room 
temperature.  The aqueous layer was extracted by Et2O (3 x 15 mL).  The combined organic 
layers were washed with brine (50 mL) and dried over anhydrous Na2SO4.  The solution 
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was filtered and concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 10-20 vol% of EtOAc in hexanes to provide the 
titled compound (368 mg, 0.413 mmol, 89.3% yield in 2 steps) as a yellow oil.   
TLC:  Rf = 0.48 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +8.1 (c 3.54, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.73-7.64 (m, 4H, H-36, H-36’, H-40, H-40’), 7.48-7.34 (m, 
10H, H-24, H-24’, H-25, H-25’, H-37, H-37’, H-38, H-41, H-41’, H-42), δ 7.34-7.28 (m, 
1H, H-26), 7.25 (d, J = 8.6 Hz, 2H, H-29, H-29’), 6.87 (d, J = 8.6 Hz, 2H, H-30, H-30’), 
6.02 (d, J = 16.1 Hz, 1H, H-10), 5.51 (dd, J = 16.1, 6.0 Hz, 1H, H-11), 4.82 (ABq, J = 6.6 
Hz, Δν = 6.4 Hz, 2H, H-21), 4.76 (br. s, 2H, H-20a, H-20b), 4.72 (d, J = 10.9 Hz, 1H, H-
27a), 4.65 (s, 2H, H-22), 4.48 (d, J = 10.9 Hz, 1H, H-27b), 4.18 (dddd, J = 9.1, 8.8, 3.4, 
3.1 Hz, 1H, H-4), 3.97 (dq, J = 8.3, 4.4 Hz, 1H, H-2), 3.85 (ddd, J = 10.1, 7.8, 5.3 Hz, 1H, 
H-18a), 3.79 (s, 3H, H-32), 3.82-3.74 (m, 3H, H-18b, H-12, H-1a), 3.69 (dd, J = 10.6, 4.8 
Hz, 1H, H-1b), 3.56 (dddd, J = 11.9, 7.3, 4.9, 2.1 Hz, 1H, H-16), 3.26 (s, 3H, H-43), 2.45 
(ddd, J = 17.7, 9.9, 7.8 Hz, 1H, H-6eq), 2.39 (ddd, J = 17.7, 7.5, 3.9 Hz, 1H, H-6ax), 2.29-
2.20 (m, 2H, H-13eq, H-15eq), 2.03 (dd, J = 12.9, 11.4 Hz, 1H, H-13ax), 1.98-1.66 (m, 7H, 
H-15ax, H-3a, H-5eq, H-17a, H-3b, H-5ax, H-17b), 1.18 (s, 3H, H-19a), 1.12 (s, 3H, H-
19b), 1.06 (s, 9H, H-34);  
125 MHz 13C NMR (CDCl3) δ 207.2 (C-7), 159.4 (C-31), 144.7 (C-14), 138.1 (C-23), 
136.8 (C-10), 135.7 (C-36, C-36’, C-40, C-40’), 134.2 (C-35), 134.1 (C-39), 130.9 (C-28), 
129.7 (C-25, C-25’), 129.4 (C-11), 129.4 (C-29, C-29’), 128.6 (C-38, C-42), 128.0 (C-24, 
C-24’), 127.9 (C-26), 127.8 (C-37, C-37’, C-41, C-41’), 114.0 (C-30, C-30’), 108.8 (C-20), 
104.1 (C-8), 95.2 (C-21), 79.0 (C-12), 75.5 (C-16), 74.9 (C-2), 71.7 (C-27), 70.2 (C-1), 
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69.7 (C-22), 69.6 (C-4), 60.6 (C-18), 55.4 (C-32), 52.3 (C-43), 44.3 (C-9), 41.3 (C-13), 
40.9 (C-15), 39.4 (C-17), 39.4 (C-3), 37.6 (C-6), 30.3 (C-5), 27.1 (C-34), 22.9 (C-19a), 
22.3 (C-19b), 19.4 (C-33); 
FTIR (neat): νmax 2933, 1737, 1613, 1514, 1463, 1428, 1372, 1302, 1244, 1172, 1109, 1041, 
892, 821, 735, 700 cm-1; 









Preparation of Methyl Glyoxylate: With an acetone/dry ice bath (–78 oC), a steam of O3 
(3.0 psi, 90 Volts) purged through a solution of dimethyl maleate (5.00 mL, 38.3 mmol, 
1.0 equiv) in CH2Cl2 (75 mL, 0.5 M) for 1.5 hours.  At this point, the O3 was turned off, 
and a stream of O2 flushed the dark purple solution until the color faded.  Then, DMS (3.4 
mL, 46 mmol, 1.2 equiv) was added dropwise at this temperature.  This reaction was then 
stirred at room temperature for 6 hours.  The solvent was removed by rotary evaporation.  
The remainder was distilled under a vacuum to provide a pale yellow oil (aobut 5 mL) at 
45-55 oC/aspirator.  
To a stirred solution of keone 2.76 (748 mg, 0.840 mmol, 1.0 equiv) in dry MeOH (8.5 mL, 
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0.1 M) was added K2CO3 solid (333 mg, 2.39 mmol, 5.0 equiv).  Then a solution of above 
freshly distilled methyl glyoxylate (about 4 mL, 45 mmol, 50 equiv) in dry THF (5.0 M, 
8.0 mL) was added into this reaction via syringe in one portion at room temperature.  It 
was stirred under an atmosphere of N2 for 2.5 hours, whereupon, the reaction was diluted 
with Et2O (20 mL).  It was poured into a saturated NaHCO3 solution (50 mL).  The aqueous 
layer was extracted by Et2O (3 x 10 mL).  The combined organic layers were washed with 
brine (30 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 20-30 vol% of Et2O in hexanes to provide the 
titled compound (617 mg, 0.642 mmol, 76.4% yield, E:Z > 95:5) as a yellow oil.   
TLC:  Rf = 0.36 (Et2O/Hex = 5:5, v/v);  
[α]20 D -43.9 (c 1.56, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.68 (ddd, J = 7.9, 3.4, 1.5 Hz, 4H, H-36, H-36’, H-40, H-
40’), 7.47-7.34 (m, 10H, H-24, H-24’, H-25, H-25’, H-37, H-37’, H-38, H-41, H-41’, H-
42), 7.31 (tt, J = 8.3, 3.9 Hz, 1H, H-26), 7.22 (d, J = 8.8 Hz, 2H, H-29, H-29’), 6.84 (d, J 
= 8.8 Hz, 2H, H-30, H-30’), 6.57 (dd, J = 3.4, 2.0 Hz, 1H, H-44), 5.82 (dd, J = 15.9, 1.2 
Hz, 1H, H-10), 5.41 (dd, J = 16.1, 5.9 Hz, 1H, H-11), 4.82 (ABq, J = 6.8 Hz, Δν = 7.0 Hz, 
2H, H-21), 4.73 (d, J = 1.5 Hz, 1H, H-20a), 4.71 (d, J = 1.5 Hz, 1H, H-20b), 4.71 (d, J = 
11.3 Hz, 1H, H-27a), 4.65 (s, 2H, H-22), 4.46 (d, J = 10.8 Hz, 1H, H-27b), 4.21 (dddd, J 
= 12.2, 9.3, 2.4, 1.9 Hz, 1H, H-4), 3.99 (dtd, J = 7.8, 4.5, 3.4 Hz, 1H, H-2), 3.84 (ddd, J = 
10.3, 7.6, 5.6 Hz, 1H, H-18a), 3.79 (s, 3H, H-32), 3.81-3.74 (m, 2H, H-18b, H-1a), 3.74 
(s, 3H, H-46), 3.75-3.67 (m, 2H, H-1a, H-12), 3.55-3..47 (m, 1H, H-16), 3.29 (dt, J = 18.6, 
2.0, 1H, H-5eq), 3.25 (s, 3H, H-43), 2.85 (ddd, J = 18.8, 12.5, 3.4, 1H, H-5ax), 2.23 (br. d, 
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J = 12.7 Hz, 1H, H-15eq), 2.11 (br. d, J = 13.2 Hz, 1H, H-13eq), 1.99-1.89 (m, 3H, H-13ax, 
H-3a, H-15ax), 1.89-1.80 (m, 2H, H-3b, H-17a), 1.74 (dddd, J = 13.4, 7.6, 5.9, 5.9 1H, H-
17b), 1.15 (s, 3H, H-19a), 1.07 (s, 9H, H-34), 1.06 (s, 3H, H-19b);  
125 MHz 13C NMR (CDCl3) δ 197.6 (C-7), 166.2 (C-45), 159.4 (C-31), 148.2 (C-6), 144.6 
(C-14), 138.0 (C-23), 135.7 (C-10, C-36, C-36’, C-40, C-40’), 134.2 (C-35), 134.1 (C-39), 
130.7 (C-28), 130.3 (C-11), 129.7 (C-38), 129.7 (C-42), 129.2 (C-29, C-29’), 128.6 (C-25, 
C-25’), 128.0 (C-24, C-24’), 127.9 (C-26), 127.8 (C-37, C-37’, C-41, C-41’), 123.1 (C-44), 
114.0 (C-30, C-30’), 108.8 (C-20), 104.7 (C-8), 95.2 (C-21), 79.0 (C-12), 75.5 (C-16), 74.5 
(C-2), 71.4 (C-27), 70.0 (C-1), 69.8 (C-22), 69.3 (C-4), 60.6 (C-18), 55.4 (C-32), 52.3 (C-
43), 51.9 (C-46), 44.9 (C-9), 40.8 (C-15), 40.7 (C-13), 39.3 (C-3), 39.2 (C-17), 36.2 (C-5), 
27.1 (C-34), 22.6 (C-19a), 21.7 (C-19b), 19.4 (C-33); 
FTIR (neat): νmax 3071, 2937, 1706, 1651, 1613, 1588, 1514, 1463, 1429, 1383, 1361, 1303, 
1249, 1207, 1178, 1113, 894, 823 cm-1; 








methoxydihydro-2H-pyran-4(3H)-ylidene)acetate (2.78): To a stirred solution of keone 
2.77 (564 mg, 0.587 mmol, 1.0 equiv) in the mixture of toluene (0.6 mL, 1.0 M) and MeOH 
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(60 mL, 0.01 M) was added CeCl3∙7H2O (2.19 g, 5.88 mmol, 10.0 equiv) in one portion at 
room temperature.  It was stirred for 10 minutes until the entire solid was dissolved, this 
reaction was cooled down to -78 oC, and NaBH4 (160 mg, 4.14 mmol, 7.0 equiv) was added 
in one portion.  It was stirred for 2 hours at -78 oC, and then stirred further 15 minutes at 0 
oC.  The reaction was diluted with EtOAc (30 mL), and poured into a cold H2O (100 mL).  
The aqueous layer was extracted with EtOAc (4 x 15 mL).  The combined organic layers 
were washed with brine (50 mL), and dried over anhydrous Na2SO4.  The solution was 
filtered and concentrated under reduced pressure.  The remainder was used in the next step 
without any further purification.   








methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl Octa-2,4-dienoate (2.80): To a 
stirred solution of (2E,4E)-octa-2,4-dienoic acid 2.79 (246 mg, 1.76 mmol, 3.0 equiv) in 
dry toluene (35 mL, 0.05 M) was added freshly distilled NEt3 (820 uL, 5.88 mmol, 10.0 
equiv), followed by 2,4,6-trichlorobenzoylchloride (280 uL, 1.76 mmol, 3.0 eq) at 0 oC.  
After 10 minutes, the cooling bath was removed, and the reaction was stirred at room 
temperature under an atmosphere of N2 for 2 hours.  Then this reaction was transferred to 
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a solution of crude alcohol 2.78 (crude 564 mg, theoretically 0.587 mmol, 1.0 equiv) in 
toluene (6.0 mL, 0.1 M) via cannula at 0 oC.  Then, a solution of DMAP (108 mg, 0.873 
mmol, 1.5 equiv) in toluene (9.0 mL, 0.1 M) was added into this mixture via cannula.  After 
10 minutes, the cooling bath was removed, and this reaction was stirred at room 
temperature for 3 hours.  Then, methanol (1.0 mL, 25 mmol) was added at room 
temperature.  This reaction was stirred further 2 hours.  It was diluted with ether (10 mL) 
and poured into a saturated NaHCO3 solution (30 mL).  The aqueous layer was extracted 
with ether (3 x 10 mL).  The combined organic layers were washed with brine (30 mL).  
The organic layer was dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure.  The reminder was purified by flash chromatography 
on silica gel eluting with 10-15 vol% of EtOAc in hexanes to provide a single diastereomer 
(592 mg, 0.546 mmol, 93.0% yield, dr > 95:5) as a yellow oil. 
TLC:  Rf = 0.50 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -10.8 (c 0.93, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.71-7.63 (m, 4H, H-36, H-36’, H-40, H-40’), 7.47-7.32 (m, 
10H, H-37, H-37’, H-38, H-41, H-41’, H-42, H-24, H-24’, H-25, H-25’), 7.32-7.25 (m, 
2H, H-26, H-49), 7.23 (d, J = 8.6 Hz, 2H, H-29, H-29’), 6.84 (d, J = 8.8 Hz, 2H, H-30, H-
30’), 6.20-6.10 (m, 2H, H-50, H-51), 6.02 (dd, J = 16.1, 1.3 Hz, 1H, H-10), 5.91 (dd, J = 
1.0, 0.8 Hz, 1H, H-44), 5.78 (d, J = 15.3 Hz, 1H, H-48), 5.57 (s, 1H, H-7), 5.40 (dd, J = 
16.1, 5.7 Hz, 1H, H-11), 4.80 (ABq, J = 6.6 Hz, Δν = 5.6 Hz, 2H, H-21), 4.72 (d, J = 1.8 
Hz, 1H, H-20a), 4.69 (d, J = 11.1 Hz, 1H, H-27a), 4.69 (d, J = 1.6 Hz, 1H, H-20b), 4.63 
(s, 2H, H-22), 4.46 (d, J = 10.9 Hz, 1H, H-27b), 4.13 (dddd, J = 11.9, 9.4, 2.9, 2.8 Hz, 1H, 
H-4), 3.98 (dddd, J = 9.3, 4.5, 4.2, 3.9 Hz, 1H, H-2), 3.85 (ddd, J = 10.1, 7.5, 5.5 Hz, 1H, 
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H-18a), 3.78 (s, 3H, H-32), 3.78-3.72 (m, 2H, H-1a, H-18b), 3.72-3.66 (m, 2H, H-12, H-
1b), 3.68 (s, 3H, H-46), 3.56-3.48 (m, 1H, H-16), 3.51-3.43 (m, 1H, H-5eq), 3.24 (s, 3H, 
H-43), 2.35 (ddd, J = 16.0, 11.5, 2.1 Hz, 1H, H-5ax), 2.32 (ddd, J = 14.0, 1.8, 1.7 Hz, 1H, 
H-15eq), 2.20 (ddd, J = 13.4, 1.8, 1.6 Hz, 1H, H-13eq), 2.14 (td, J = 7.1, 5.3 Hz, 2H, H-52), 
2.00 (dd, J = 13.0, 11.7 Hz, 1H, H-13ax), 1.95-1.68 (m, 5H, H-15ax, H-3a, H-17a, H-3b, 
H-17b), 1.45 (sext, J = 7.4 Hz, 2H, H-53), 1.15 (s, 6H, H-19a, H-19b), 1.05 (s, 9H, H-34), 
0.92 (t, J = 7.4 Hz, 3H, H-54);  
125 MHz 13C NMR (CDCl3) δ 166.6 (C-45), 165.5 (C-47), 159.3 (C-31), 152.8 (C-6), 
146.6 (C-49), 145.7 (C-51), 144.8 (C-14), 138.5 (C-10), 138.0 (C-23), 135.7 (C-36, C-36’, 
C-40, C-40’), 134.2 (C-35), 134.1 (C-39), 130.8 (C-28), 129.7 (C-38, C-42), 129.4 (C-29, 
C-29’), 128.6 (C-25, C-25’, C-50), 128.0 (C-24, C-24’), 127.8 (C-27), 127.8 (C-37, C-37’, 
C-41, C-41’), 126.8 (C-11), 118.7 (C-48), 117.2 (C-44), 114.0 (C-30, C-30’), 108.6 (C-20), 
102.9 (C-8), 95.1 (C-21), 79.0 (C-12), 75.5 (C-16), 74.7 (C-2), 71.9 (C-7), 71.7 (C-27), 
70.2 (C-1), 69.7 (C-22), 68.2 (C-4), 60.6 (C-18), 55.4 (C-32), 51.5 (C-43), 51.2 (C-46), 
46.1 (C-9), 40.9 (C-15), 40.9 (C-13), 39.5 (C-17), 39.3 (C-3), 35.2 (C-52), 33.0 (C-5), 27.1 
(C-34), 24.2 (C-19a), 24.1 (C-19b), 22.0 (C-53), 19.4 (C-33), 13.8 (C-54); 
FTIR (neat): νmax 2932, 1738, 1717, 1641, 1613, 1514, 1463, 1372, 1359, 1302, 1241, 1157, 
1132, 1104, 1042, 1000, 859, 734, 701, 634 cm-1; 









methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl Octa-2,4-dienoate (2.85): To a 
stirred solution of protected alcohol 2.80 (516 mg, 0.476 mmol, 1.0 equiv) in MeOH (25 
mL, 0.02 M) was added NH4F solid (352 mg, 9.42 mmol, 20 equiv) in one portion at room 
temperature.  This reaction was stirred at 60 oC for 20 hours, whereupon it was diluted with 
EtOAc (20 ml) and poured into H2O (30 mL).  The aqueous layer was extracted with EtOAc 
(3 x 10 mL).  The combined organic layers were washed with brine (30 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure.  
The remainder was purified by flash chromatography on silica gel eluting with 20-30 vol% 
of EtOAc in hexanes to provide the titled compound (369 mg, 0.435 mmol, 91.6% yield) 
as a yellow oil.   
TLC:  Rf = 0.21 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -21.1 (c 0.81, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.39-7.33 (m, 4H, H-36, H-36’, H-37, H-37’), 7.33-7.26 (m, 
2H, H-38, H-23), 7.23 (d, J = 8.6 Hz, 2H, H-41, H-41’), 6.84 (d, J = 8.8 Hz, 2H, H-42, H-
42’), 6.22-6.14 (m, 2H, H-24, H-25), 6.02 (dd, J = 15.8, 1.0 Hz, 1H, H-10), 5.89 (br. s, 1H, 
H-29), 5.79 (d, J = 15.3 Hz, 1H, H-22), 5.61 (br. s, 1H, H-7), 5.35 (dd, J = 16.1, 6.0 Hz, 
1H, H-11), 4.83 (ABq, J = 6.6 Hz, Δν = 5.6 Hz, 2H, H-33), 4.73 (d, J = 1.8 Hz, 1H, H-
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20a), 4.71 (d, J = 10.9 Hz, 1H, H-39a), 4.71 (d, J = 2.1 Hz, 1H, H-20b), 4.65 (s, 2H, H-
34), 4.46 (d, J = 10.9 Hz, 1H, H-39b), 4.15 (dddd, J = 12.1, 9.4, 3.1, 2.9 Hz, 1H, H-4), 4.00 
(dq, J = 8.7, 4.0 Hz, 1H, H-2), 3.81 (dd, J = 10.5, 4.0 Hz, 1H, H-1a), 3.78 (s, 3H, H-44), 
3.79-3.74 (m, 2H, H-18a, H-18b), 3.73 (dd, J = 10.6, 4.9 Hz, 1H, H-1b), 3.72-3.66 (m, 1H, 
H-12), 3.67 (s, 3H, H-31), 3.52 (dddd, J = 11.3, 8.7, 3.5, 2.5 Hz, 1H, H-16), 3.43 (dd, J = 
16.1, 2.6 Hz, 1H, H-5eq), 3.25 (s, 3H, H-32), 2.97 (br. s, 1H, -OH), 2.42 (ddd, J = 15.9, 
11.7, 1.7 Hz, 1H, H-5ax), 2.24-2.10 (m, 4H, H-26, H-13eq, H-15eq), 2.07-1.98 (m, 1H, H-
15ax), 2.03-1.94 (m, 1H, H-13ax), 1.91 (ddd, J = 14.4, 9.3, 2.9 Hz, 1H, H-3a), 1.84 (ddd, J 
= 14.4, 9.3, 3.2 Hz, 1H, H-3b), 1.83-1.64 ( m, 2H, H-18a, H-18b), 1.47 (sext, J = 7.4 Hz, 
2H, H-27), 1.14 (s, 3H, H-19a), 1.12 (s, 3H, H-19b), 0.93 (t, J = 7.4 Hz, 3H, H-28);  
125 MHz 13C NMR (CDCl3) δ 166.7 (C-30), 165.5 (C-21), 159.3 (C-43), 153.3 (C-6), 
146.6 (C-23), 145.8 (C-25), 144.1 (C-14), 139.0 (C-10), 138.0 (C-35), 130.8 (C-40), 129.4 
(C-41, C-41’), 128.6 (C-24, C-37, C-37’), 128.0 (C-36, C-36’), 127.9 (C-38), 126.4 (C-11), 
118.6 (C-22), 116.6 (C-29), 114.0 (C-42, C-42’), 109.0 (C-20), 102.8 (C-8), 95.1 (C-33), 
79.4 (C-12), 78.1 (C-16), 74.6 (C-2), 71.6 (C-39, C-7), 70.3 (C-1), 69.7 (C-34), 68.2 (C-4), 
60.9 (C-18), 55.4 (C-44), 51.2 (C-31, C-32), 46.2 (C-9), 41.0 (C-13), 40.8 (C-15), 39.4 (C-
3), 38.4 (C-17), 35.2 (C-26), 33.2 (C-5), 24.2 (C-19a), 23.9 (C-19b), 22.0 (C-27), 13.8 (C-
28);   
FTIR (neat): νmax 3527 (br.) 2931, 1717, 1642, 1614, 1514, 1456, 1435, 1381, 1348, 1248, 
1157, 1134, 1102, 1043, 1002, 889, 820, 737, 699 cm-1; 









2,4-dienoate (2.86): To a stirred solution of alcohol 2.85 (492 mg, 0.580 mmol, 1.0 equiv) 
in dry CH2Cl2 (60 mL, 0.01 M) was added t-BuOH (72 uL, 0.75 mmol, 1.3 equiv) and 
freshly distilled pyridine (140 uL, 1.73 mmol, 3.0 equiv).  Then this reaction was cooled 
down to 0 oC, and Dess-Martin periodinane (381 mg, 0.871 mmol, 1.5 equiv) was added 
in one portion.  After 10 minutes, the cooling bath was removed and the reaction was stirred 
at room temperature for 1 hour under an atmosphere of N2.  Then, a saturated NaHCO3 
solution (30 mL) was added into this reaction, followed by addition of a saturated Na2S2O3 
solution (30 mL).  This mixture was stirred for 10 minutes at ambient temperature.  The 
aqueous layer was extracted with Et2O (3 x 15 mL).  The combined organic layers were 
washed with brine (50 mL) and dried over anhydrous Na2SO4.  The solution was filtered 
and concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 12-20 vol% of EtOAc in hexanes to provide the 
titled compound (474 mg, 0.561 mmol, 96.6% yield) as a yellowish oil.   
TLC:  Rf = 0.39 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -24.3 (c 0.745, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.79 (dd, J = 2.3, 2.1, 1H, H-18), 7.41-7.33 (m, 4H, H-36, 
H-36’, H-37, H-37’), 7.33-7.25 (m, 2H, H-38, H-23), 7.23 (d, J = 8.8 Hz, 2H, H-41, H-
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41’), 6.84 (d, J = 8.8 Hz, 2H, H-42, H-42’), 6.27-6.11 (m, 2H, H-24, H-25), 6.03 (dd, J = 
15.8, 1.3 Hz, 1H, H-10), 5.89 (br. s, 1H, H-29), 5.78 (d, J = 15.1 Hz, 1H, H-22), 5.57 (br. 
s, 1H, H-7), 5.35 (dd, J = 16.1, 5.7 Hz, 1H, H-11), 4.83 (ABq, J = 6.7 Hz, Δν = 5.3 Hz, 2H, 
H-33), 4.76 (q, J = 1.8 Hz, 1H, H-20a), 4.74 (q, J = 1.8 Hz, 1H, H-20b), 4.71 (d, J = 11.1 
Hz, 1H, H-39a), 4.66 (s, 2H, H-34), 4.46 (d, J = 10.9 Hz, 1H, H-39b), 4.14 (dddd, J = 11.7, 
9.4, 3.1, 2.9 Hz, 1H, H-4), 3.99 (dq, J = 8.1, 4.4 Hz, 1H, H-2), 3.86 -3.76 (m, 1H, H-16), 
3.80 (dd, J = 10.4, 4.2 Hz, 1H, H-1a), 3.78 (s, 3H, H-44), 3.76-3.70 (m, 1H, H-12), 3.73 
(dd, J = 10.5, 5.1 Hz, 1H, H-1b), 3.67 (s, 3H, H-31), 3.46 (dd, J = 16.2, 2.9 Hz, 1H, H-5eq), 
3.25 (s, 3H, H-32), 2.66 (ddd, J = 16.4, 7.5, 2.6 Hz, 1H, H-17a), 2.51 (ddd, J = 16.4, 4.9, 
1.8 Hz, 1H, H-17b), 2.37 (ddd, J = 15.8, 11.7, 2.3 Hz, 1H, H-5ax), 2.30-2.09 (m, 4H, H-
15eq, H-13eq, H-26), 2.05-1.94 (m, 2H, H-13ax, H-15ax), 1.91 (ddd, J = 14.5, 9.6, 2.8 Hz, 
1H, H-3a), 1.82 (ddd, J = 14.5, 9.6, 3.3 Hz, 1H, H-3b), 1.47 (sex, J = 7.4 Hz, 2H, H-27), 
1.14 (s, 3H, H-19), 1.13 (s, 3H, H-19’), 0.93 (t, J = 7.4 Hz, 3H, H-28);  
125 MHz 13C NMR (CDCl3) δ 201.1 (C-18), 166.6 (C-30), 165.5 (C-21), 159.3 (C-43), 
152.9 (C-6), 146.6 (C-23), 145.9 (C-25), 143.5 (C-14), 139.1 (C-10), 138.1 (C-35), 130.8 
(C-40), 129.4 (C-41, C-41’), 128.6 (C-37, C-37’), 128.6 (C-24), 128.0 (C-36, C-36’), 127.9 
(C-38), 126.1 (C-11), 118.6 (C-22), 117.0 (C-29), 114.0 (C-42, C-42’), 109.6 (C-20), 102.8 
(C-8), 95.2 (C-33), 79.4 (C-12), 74.7 (C-2), 73.6 (C-16), 71.8 (C-7), 71.7 (C-39), 70.3 (C-
1), 69.7 (C-34), 68.2 (C-4), 55.4 (C-44), 51.4 (C-32), 51.2 (C-31), 49.9 (C-17), 46.1 (C-9), 
40.6 (C-13), 40.5 (C-15), 39.5 (C-3), 35.2 (C-26), 33.1 (C-5), 24.1 (C-19, C-19’), 22.0 (C-
27), 13.8 (C-28);  
FTIR (neat): νmax 2933, 1717, 1641, 1613, 1513, 1455, 1435, 1380, 1302, 1244, 1132, 1100, 
1039, 1001, 889, 860, 819, 735, 698 cm-1; 
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3-en-2-yl)tetrahydro-2H-pyran-3-yl Octa-2,4-dienoate (2.87): To a stirred solution of 
compound 2.86 (435 mg, 0.515 mmol, 1.0 equiv) in CH2Cl2 (10 mL, 0.05M) was added a 
0.1 M phosphate pH = 6 buffer solution (5 mL, 0.1 M).  Then, this reaction was cooled 
down to 0 oC, and DDQ (239 mg, 1.03 mmol, 2.0 equiv) was added in one portion.  It was 
stirred for 4 hours at this temperature.  Then, this reaction was diluted with EtOAc (10 mL), 
and poured into a saturated NaHCO3 solution (20 mL).  The aqueous layer was extracted 
with EtOAc (3 x 5 mL).  The combined organic layers were washed with brine (20 mL) 
and dried over anhydrous Na2SO4.  The solution was filtered and concentrated under 
reduced pressure.  The remainder was purified by flash chromatography on silica gel 
eluting with 28-38% of EtOAc in hexanes to provide the titled compound (368 mg, 0.507 
mol, 98.5% yield) as a pale yellow oil.   
TLC:  Rf = 0.20 (EtOAc/Hex = 4:6, v/v);  
[α]20 D -18.5 (c 1.31, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.81 (dd, J = 2.5, 2.2, 1H, H-18), 7.40-7.33 (m, 4H, H-36, 
H-36’, H-37, H-37’), 7.33-7.23 (m, 2H, H-38, H-23), 6.23-6.12 (m, 2H, H-24, H-25), 6.00 
(dd, J = 15.9, 1.2 Hz, 1H, H-10), 5.89 (br. s, 1H, H-29), 5.77 (d, J = 15.2 Hz, 1H, H-22), 
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5.59 (br. s, 1H, H-7), 5.34 (dd, J = 15.9, 5.9 Hz, 1H, H-11), 4.83 (ABq, J = 6.6 Hz, Δν = 
6.2 Hz, 2H, H-33), 4.76 (dt, J = 2.0, 1.8 Hz, 1H, H-20a), 4.74 (dt, J = 2.0, 1.8 Hz, 1H, H-
20b), 4.65 (ABq, J = 11.9 Hz, Δν = 4.9 Hz, 2H, H-34), 4.26-4.13 (m, 2H, H-2, H-4), 3.82 
(dddd, J = 11.4, 7.6, 5.1, 2.4 Hz, 1H, H-16), 3.73 (dd, J = 10.3, 3.4 Hz, 1H, H-1a), 3.74-
3.70 (m, 1H, H-12), 3.67 (s, 3H, H-31), 3.53 (dd, J = 10.2, 7.2 Hz, 1H, H-1b), 3.45 (dd, J 
= 15.0, 2.8 Hz, 1H, H-5eq), 3.34 (s, 3H, H-32), 2.79 (d, J = 4.2 Hz, 1H, -OH), 2.68 (ddd, J 
= 16.3, 7.6, 2.6 Hz, 1H, H-17a), 2.52 (ddd, J = 16.3, 5.0, 2.0 Hz, 1H, H-17b), 2.42 (ddd, J 
= 15.8, 12.0, 2.0 Hz, 1H, H-5ax), 2.32-2.18 (m, 2H, H-15eq, H-13eq), 2.15 (q, J = 6.7 Hz, 
2H, H-26), 2.06-1.93 (m, 2H, H-13ax, H-15ax), 1.81-1.66 (m, 2H, H-3a, H-3b), 1.47 (sex, 
J = 7.3 Hz, 2H, H-27), 1.13 (s, 3H, H-19), 1.12 (s, 3H, H-19’), 0.93 (t, J = 7.3 Hz, 3H, H-
28);  
125 MHz 13C NMR (CDCl3) δ 201.4 (C-18), 166.7 (C-30), 165.5 (C-21), 153.0 (C-6), 
146.7 (C-23), 146.0 (C-25), 143.6 (C-14), 139.2 (C-10), 137.8 (C-35), 128.7 (C-37, C-37’), 
128.6 (C-24), 128.1 (C-36, C-36’), 128.0 (C-38), 126.2 (C-11), 118.6 (C-22), 116.9 (C-29), 
109.7 (C-20), 103.0 (C-8), 95.5 (C-33), 79.4 (C-12), 73.7 (C-1), 73.6 (C-16), 71.8 (C-7), 
70.0 (C-34), 68.4 (C-4), 67.1 (C-2), 51.5 (C-32), 51.3 (C-31), 49.9 (C-17), 46.2 (C-9), 40.7 
(C-13), 40.5 (C-15), 39.4 (C-3), 35.3 (C-26), 32.9 (C-5), 24.2 (C-19), 24.0 (C-19’), 22.1 
(C-27), 13.9 (C-28); 
FTIR (neat): νmax 3447 (br), 2950, 1719, 1642, 1615, 1497, 1456, 1435, 1382, 1359, 1312, 
1245, 1165, 1133, 1105, 1046, 1004, 892, 861 cm-1; 









Octa-2,4-dienoate (2.88): With a -78 oC bath, to a stirred solution of alcohol 2.87 (603 mg, 
0.832 mmol, 1.0 equiv) in freshly distilled CH2Cl2 (17 mL, 0.05 M) was added 2,6-lutidine 
(300 uL, 2.55 mmol, 3.0 equiv) via syringe.  Then, TBSOTf (295 uL, 1.26 mmol, 1.5 eq) 
was added dropwise via syringe.  This reaction was stirred under an atmosphere of N2 for 
1 hour and poured into a saturated NaHCO3 solution (30 mL) .  The aqueous layer was then 
extracted with Et2O (3 x 10 mL).  The combined organic layers were washed with brine 
(50 mL) and dried over anhydrous Na2SO4.  The solution was filtered and concentrated 
under reduced pressure.  The remainder was purified by flash chromatography on silica gel 
eluting with 5-15 vol% of ethyl acetate in hexanes to provide the titled compound (625 mg, 
0.745 mmol, 89.6% yield) as pale yellow oil. 
TLC:  Rf = 0.64 (EtOAc/Hex = 4:6, v/v);  
[α]20 D -22.9 (c 0.52, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.80 (dd, J = 2.3, 2.1, 1H, H-18), 7.41-7.32 (m, 4H, H-36, 
H-36’, H-37, H-37’), 7.32-7.23 (m, 2H, H-38, H-23), 6.23-6.14 (m, 2H, H-24, H-25), 5.99 
(dd, J = 16.0, 1.2 Hz, 1H, H-10), 5.90 (br. s, 1H, H-29), 5.78 (d, J = 15.3 Hz, 1H, H-22), 
5.62 (br. s, 1H, H-7), 5.36 (dd, J = 16.1, 6.0 Hz, 1H, H-11), 4.79 (ABq, J = 6.6 Hz, Δν = 
5.6 Hz, 2H, H-33), 4.76 (dt, J = 2.1, 1.8 Hz, 1H, H-20a), 4.74 (dt, J = 2.0, 1.8 Hz, 1H, H-
176 
 
20b), 4.63 (s, 2H, H-34), 4.18-4.02 (m, 2H, H-2, H-4), 3.80 (dddd, J = 12.0, 7.5, 5.2, 2.3 
Hz, 1H, H-16), 3.73 (dddd, J = 11.4, 6.0, 2.6, 1.1 Hz, 1H, H-12), 3.68 (s, 3H, H-31), 3.65 
(dd, J = 10.0, 4.5 Hz, 1H, H-1a), 3.58 (dd, J = 10.1, 6.0 Hz, 1H, H-1b), 3.46 (ddd, J = 15.0, 
2.9, 1.0 Hz, 1H, H-5eq), 3.32 (s, 3H, H-32), 2.67 (ddd, J = 16.3, 7.5, 2.3 Hz, 1H, H-17a), 
2.51 (ddd, J = 16.3, 5.2, 2.1 Hz, 1H, H-17b), 2.38 (ddd, J = 16.1, 11.4, 2.1 Hz, 1H, H-5ax), 
2.29-2.20 (m, 2H, H-15eq, H-13eq), 2.15 (q, J = 6.7 Hz, 2H, H-26), 2.05-1.94 (m, 2H, H-
13ax, H-15ax), 1.94 (ddd, J = 14.3, 8.6, 4.8 Hz, 1H, H-3a), 1.73 (ddd, J = 14.3, 7.0, 3.4 Hz, 
1H, H-3b), 1.47 (sext, J = 7.4 Hz, 2H, H-27), 1.13 (s, 3H, H-19), 1.12 (s, 3H, H-19’), 0.93 
(t, J = 7.3 Hz, 3H, H-28), 0.89 (s, 9H, H-41), 0.11 (s, 3H, H-39), 0.09 (s, 3H, H-39’);  
125 MHz 13C NMR (CDCl3) δ 201.2 (C-18), 166.7 (C-30), 165.6 (C-21), 153.1 (C-6), 
146.7 (C-23), 145.9 (C-25), 143.5 (C-14), 139.0 (C-10), 138.1 (C-35), 128.6 (C-24, C-37, 
C-37’), 128.1 (C-36, C-36’), 127.9 (C-38), 126.5 (C-11), 118.6 (C-22), 116.9 (C-29), 109.7 
(C-20), 102.9 (C-8), 95.1 (C-33), 79.5 (C-12), 73.6 (C-16), 72.9 (C-1), 71.5 (C-7), 69.6 (C-
34), 69.4 (C-2), 68.7 (C-4), 51.6 (C-32), 51.3 (C-31), 49.9 (C-17), 46.1 (C-9), 42.2 (C-3), 
40.7 (C-13), 40.5 (C-15), 35.3 (C-26), 33.4 (C-5), 26.1 (C-41), 24.1 (C-19, C-19’), 22.0 
(C-27), 18.4 (C-40), 13.9 (C-28), -3.7 (C-39), -4.4 (C-39’); 
FTIR (neat): νmax 3070, 2930, 1719, 1643, 1616, 1497, 1463, 1436, 1383, 1360, 1250, 1105, 
893, 836, 811, 777 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C47H70O11SiNa 861.4585; found 861.4596. 
3-(tert-Butyldiphenylsilyloxy)propan-1-ol (2.89): To a 
round-bottomed flask was charged NaH (60% dispersion in 
mineral oil, 1.63 g, 40.8 mmol, 1.1 equiv) and anhydrous THF 
(80 mL).  With an ice-water bath, freshly distilled 1,3-
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propanediol 2.36 (3.00 mL, 40.7 mmol, 1.1 equiv) was added dropwise via a syringe over 
5 minutes under an atmosphere of N2.  It was allowed to warm to room temperature for 30 
minutes, and refluxed for 1 hour.  It was then cooled to 0 oC, and t-
butylchlorodiphenylsilane (9.80 mL, 36.9 mmol, 1.0 equiv) was added into this reaction 
dropwise via a syringe over 10 minutes.  After the addition, it was allowed to warm to room 
temperature, and refluxed with stirring for 24 hours.  It was then quenched with brine (100 
mL), and extracted with EtOAc (3 x 30 mL).  The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure.  The pale yellow 
crude product was used in next step without further purification.  
The analytic smalple could be obtained by flash column chromatography on silica gel with 
5-10 vol% ethyl acetate in hexanes to provide the titled compound (12.26 g, 38.97 mmol, 
95.8% yield) as a colorless oil.  It was crytalized as a white crystalline solid (m.p.: 38.2-
39.9 oC) after couple days on bench.  
TLC:  Rf = 0.33 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3): δ 7.74-7.66 (m, 4H, H-5, H-5’, H-9, H-9’), 7.49-7.37 (m, 6H, 
H-6, H-6’, H-7, H-10, H-10’, H-11), 3.86 (d, J = 5.7 Hz, 2H, H-1), 3.86 (td, J = 5.6, 5.3 
Hz, 2H, H-3), 2.37 (t, J = 5.3 Hz, 1H, -OH), 1.83 (tt, J = 5.7, 5.6 Hz, 2H, H-2), 1.07 (s, 
9H, H-13); 
125 MHz 13C NMR (CDCl3): δ 135.7 (C-5, C-5’, C-9, C-9’), 133.5 (C-4, C-8), 129.9 (C-
7, C-11), 127.9 (C-6, C-6’, C-10, C-10’), 63.2, (C-3), 61.8 (C-1), 34.6(C-2), 27.0 (C-13), 
19.3 (C-12);  
FTIR (neat): νmax  3282 (br), 3070, 2933, 2859, 1962, 1896, 1826, 1469, 1427, 1110, 821, 
737, 704 cm-1; 
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LRMS(ESI-TOF) m/z: [M+H+] Calcd for C19H27O2Si 315.2; found 314.9. 
3-tert-Butyldiphenylsilyloxypropanal (2.37): To a solution 
of oxalyl chloride (0.68 mL, 7.8 mmol, 1.5 equiv) in CH2Cl2 
(40 mL, 0.2 M) at –78 oC was added a solution of DMSO (1.2 
mL, 17 mmol, 3.0 equiv) in CH2Cl2 (35 mL, 0.5 M) dropwise 
via cannula under an atmosphere of N2.  After stirring for 30 minutes, the solution of 
alcohol 2.89 (1.631 g, 5.185 mmol, 1.0 equiv) in CH2Cl2 (50 mL, 0.1 M) was added 
dropwise via cannula.  After stirring further 30 minutes in this condition, triethylamine (3.6 
mL, 26 mmol, 5.0 equiv) was added dropwise via syringe.  After 5 minutes, the cooling 
bath was removed, and the reaction was allowed to warm to room temperature over one 
hour.  The solution was poured into a saturated NH4Cl solution (100 mL).  The aqueous 
layer was extracted with Et2O (3 x 20 mL).  The combined organic layers were washed 
with brine (100 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure to provide a pale yellow oil.  The crude product was 
purified by flash chromatography on silica gel eluting with 3-5 vol% of ethyl acetate in 
hexanes to provide the titled compound (1.577 g, 5.048 mmol, 97.4% yield) as a colorless 
oil.  It was crystallized as white crystalline solid (m.p.: 45.5-47.5 oC) after couple days on 
bench. 
TLC:  Rf = 0.58 (EtOAc/Hex = 3:7, v/v);  
500 MHz 1H NMR (CDCl3): δ 9.83 (t, J = 2.2 Hz, 1H, H-3), 7.70-7.64 (m, 4H, H-5, H-5’, 
H-9, H-9’), 7.48-7.37 (m, 6H, H-6, H-6’, H-7, H-10, H-10’, H-11), 4.04 (t, J = 6.0 Hz, 
2H, H-1), 2.62 (td, J = 6.0, 2.2 Hz, 2H, H-2), 1.05 (s, 9H, H-13);  
125 MHz 13C NMR (CDCl3): δ 202.1 (C-3), 135.8 (C-5, C-5’, C-9, C-9’), 133.5 (C-4, C-
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8), 130.0 (C-7, C-11), 128.0 (C-6, C-6’, C-10, C-10’), 58.5 (C-1), 46.6 (C-2), 27.0 (C-13), 
19.4 (C-12);  
FTIR (neat): νmax = 3072, 2933, 2890, 2859, 2730, 1729, 1471, 1428, 1390, 1111, 823, 741, 
704, 613 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C19H24O2SiNa 335.1443; found 335.1446. 
(R)-1-(tert-Butyldiphenylsilyloxy)hex-5-en-3-ol (2.90): 
To an oven-dried round-bottomed flask was charged (R)-
BINOL (1.618 g, 5.594 mmol, 0.2 equiv), 4Ǻ MS (11.19 g, 
0.4 g/mmol) and freshly distilled CH2Cl2 (100 mL, 0.3 M).  Under an atmosphere of N2, 
Ti(Oi-Pr)4 (0.83 mL, 2.8 mmol, 0.1 equiv) was introduced into this reaction dropwise via 
syringe with stirring, followed by addition of TFA (10.5 ul, 0.140 mmol, 0.005 equiv) at 
room temperature.  The resulting dark brown mixture was heated at reflux for a period of 
1 h, and then allowed to cooled to room temperature, whereupon a solution of aldehyde 
2.37 (8.742 g, 27.98 mmol, 1.0 equiv) in dry CH2Cl2 (5 mL) was added via cannula, and 
additional CH2Cl2 (2 x 3 mL) rinse was transferred into the reaction flask via cannula.  This 
reaction was stirred for 30 minutes at room temperature, and then cooled to -78 oC.  
Allyltributylstannane 2.57 (13 mL, 42 mmol, 1.5 equiv) was added dropwise via syringe 
over 10 minutes.  This reaction was stirred for further 30 minutes in this condition, and 
transferred to a -35 oC freezer.  After 7 days, this reaction was diluted with CH2Cl2 (100 
mL), and filtrated over a pad of Celite.  The filtrate was washed with a saturated NaHCO3 
solution (100 mL).  The aqueous solution was extracted with ethyl ether (3 x 30 mL).  The 
combined organic layers were washed with brine (100 mL) and dried over anhydrous 
Na2SO4.   The solution was filtered and concentrated under reduced pressure to provide a 
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brown oil.  The crude product was then diluted with acetonitrile (300 mL) and washed with 
hexanes (100 mL).  The acetonitrile portion was concentrated.  The remainder was purified 
by flash chromatography on silica gel eluting with 1-5 vol% of acetate in hexanes, to 
provide the titled compound (9.708 g, 27.38 mmol, 97.9% yield, 97.8% ee) as a colorless 
oil.  
TLC:  Rf = 0.49 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +4.1 (c 1.16, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.65-7.81 (m, 4H, H-8, H-8’, H-12, H-12’), 7.35-7.56 (m, 
6H, H-9, H-9’, H-10, H-13, H-13’, H-14), 5.88 (dddd, J = 7.2, 7.2, 10.1, 17.2 Hz, 1H, H-
5), 5.06-5.23 (m, 2H, H-6), 3.96-4.08 (m, 1H, H-3), 3.80-3.95 (m, 2H, H-1), 3.26 (s, 1H, -
OH), 2.23-2.37 (m, 2H, H-4), 1.63-1.83 (m, 2H, H-2), 1.08 (s, 9H, H-16);  
125 MHz 13C NMR (CDCl3): δ 135.8 (C-8, C-8’), 135.8 (C-13, C-13’), 135.2 (C-5), 133.3 
(C-7), 133.2 (C-11), 130.0 (C-10), 130.0 (C-14), 128.0 (C-9, C-9’, C-13, C-13’), 117.6 (C-
6), 71.0 (C-1), 63.5 (C-3), 42.2 (C-2), 38.1 (C-4), 27.0 (C-16), 19.3 (C-15); 
FTIR (neat): νmax 3439(br), 3072, 2933, 2859, 2361, 1641, 1471, 1428, 1390, 1110, 1083, 
823, 739, 704, 613 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C22H30O2SiNa 377.1913; found 377.1912. 
Determination of Absolute Configuration of the New Stereocenter of Compound (R)-
1-(tert-Butyldiphenylsilyloxy)hex-5-en-3-ol (2.90) via Mosher Ester Method:  
(R)-1-(tert-Butyldiphenylsilyloxy)hex-5-en-3-yl (S)-α-
Methoxy-α-(trifluoromethyl)phenylacetate (2.90-S-
MTPA): To a screw-capped vial equipped with a stirring 
bar was added 2.90 (10.0 ul, 10.4 mg, 0.0292 mmol, 1.0 equiv), (S)-(-)-MTPA-OH acid 
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(20.9 mg, 0.0875 mmol, 3..0 equiv), DMAP (10.8 mg, 0.0875 mmol, 3.0 equiv) and  DCC 
(18.3 mg, 0.0878 mmol, 3.0 equiv) subsequently.  Freshly distilled CH2Cl2 (0.50 mL, 0.05 
M) was then added to this vial.  This vial was tightly capped.  This reaction was stirred at 
room temperature for 36 hours.  It was diluted with Et2O (5 mL) and poured into brine (20 
mL).  The aqueous layer was extracted by ether (3 x 5 mL).  The combined organic layers 
were dried over anhydrous Na2SO4.  The solution was filtered and concentrated under 
reduced pressure.  The remainder was purified by flash chromatography on silica gel 
eluting with 2 vol% of ethyl acetate in hexanes.  The titled compound (16.3 mg, 0.0286 
mmol, 97.7% yield) was obtained as a colorless oil. 
TLC:  Rf = 0.62 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -38.8 (c 0.82, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.57-7.73 (m, 4H, Ar-H), 7.48-7.56 (m, 2H, Ar-H), 7.28-
7.48 (m, 9H, Ar-H), 5.77 (dddd, J = 7.2, 8.4, 8.5, 17.0 Hz, 1H, H-5), 5.45 (dddd, J = 6.2, 
6.2, 6.3, 6.3 Hz, 1H, H-3), 5.06-5.18 (m, 2H, H-6), 3.55-3.65 (m, 2H, H-1), 3.52 (s, 3H, -
OCH3), 2.37-2.55 (m, 2H, H-4), 1.73-1.89 (m, 2H, H-2), 1.06 (s, 9H, -SiPh2t-Bu);  
FTIR (neat): νmax 3072, 2933, 2858, 1747, 1471, 1390, 1266, 1171, 1110, 1019, 825, 737, 
704, 613 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C32H37O4F3SiNa 593.2311; found 593.2307. 
(R)-1-(tert-Butyldiphenylsilyloxy)hex-5-en-3-yl (R)-α-
Methoxy-α-(trifluoromethyl)phenylacetate (2.90-R-
MTPA): To a screw-capped vial equipped with a stirring 
bar was added 2.90 (10.0 ul, 10.4 mg, 0.0292 mmol, 1.0 equiv), (R)-(+)-MTPA-OH acid 
(20.9 mg, 0.0875 mmol, 3.0 equiv), DMAP (10.8 mg, 0.0875 mmol, 3.0 equiv) and  DCC 
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(18.3 mg, 0.0878 mmol, 3.0 equiv) subsequently.  Freshly distilled CH2Cl2 (0.50 mL, 0.05 
M) was then added to this vial.  This vial was tightly capped.  This reaction was stirred at 
room temperature for 36 hours.  It was diluted with Et2O (5 mL) and poured into brine (20 
mL).  The aqueous layer was extracted by ether (3 x 5 mL).  The combined organic layers 
were dried over anhydrous Na2SO4.  The solution was filtered and concentrated under 
reduced pressure.  The remainder was purified by flash chromatography on silica gel 
eluting with 2 vol% of ethyl acetate in hexanes.  The titled compound (16.7 mg, 0.0292 
mmol, 100% yield) was obtained as a colorless oil.  
TLC:  Rf = 0.63 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +0.2 (c 0.57, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.58-7.73 (m, 4H, Ar-H), 7.47-7.56 (m, 2H, Ar-H), 7.30-
7.47 (m, 9H, Ar-H), 5.63 (dddd, J = 7.2, 7.2, 10.1, 17.1 Hz, 1H, H-5), 5.42 (dddd, J = 6.2, 
6.3, 6.3, 6.3 Hz, 1H, H-3), 4.92-5.09 (m, 2H, H-6), 3.65-3.76 (m, 2H, H-1), 3.45 (s, 3H, -
OCH3), 2.29-2.47 (m, 2H, H-4), 1.80-1.93 (m, 2H, H-2), 1.06 (s, 9H, -SiPh2t-Bu);  
FTIR (neat): νmax 3072, 2933, 2858, 1747, 1471, 1390, 1266, 1171, 1110, 1019, 825, 737, 
704, 613 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C32H37O4F3SiNa 593.2311; found 593.2307. 
The chemical shift differences (in ppm) between the (S)- and (R)-MTPA Mosher esters of 
the (R)-1-(tert-butyldiphenylsilyloxy)hex-5-en-3-ol (2.81) are consistent for a (R)-




enyloxy)diphenylsilane (2.38): Prepariton of 4-
Methoxybenzyltrichloroacetimidate: To a stirred suspension 
of NaH (60% dispersion in mineral oil, 0.631 g, 15.8 mmol, 
0.2 equiv) in Et2O (80 mL, 1.0 M) was added a solution of 4-
methoxybenzyl alcohol (10.0 mL, 78.9 mmol, 1.0 equiv) in Et2O (8 mL) dropwise at 0 oC.  
The resulting cloudy orange mixture was stirred for 30 minutes at room temperature then 
cooled to 0 oC, and trichloroaetonitrile (8.5 mL, 83 mmol, 1.05 equiv) was added dropwise.  
This reaction was allowed to warm to room temperature and stirred for 5 hours.  The 
reaction mixture was then concentrated under reduced pressure.  The resulting residue was 
diluted with hexanes (80 mL, 1.0 M), and filtered with Celite.  The filtrate was concentrated 
under reduced pressure to give the crude product (22.87 g, 80.94 mmol, 100% yield) as a 
yellow-orange oil.  This crude prouct was used diretly without any further purification. 
To a stirred solution of alcohol 2.90 (3.450 g, 9.732 mmol, 1.0 equiv) in anhydrous 
toluene (100 mL, 0.1 M) was added Sc(OTf)3 (48 mg, 0.097 mmol, 0.01 equiv) at one 
portion.  A solution of above 4-methoxybenzyltrichloroacetimidate (PMBTCA) (5.524 g, 
19.55 mmol, 2.0 equiv) in toluene (10 mL, 2.0 M) was then added via cannula at 0 oC.  This 
mixture was stirred under an atmosphere of N2, and allowed to warm to room temperature 
over 6 hours.  It was then concentrated in vacuo.  The remainder was diluted with a cold 
mixture of Et2O/Hex (1:9) solution (50 mL), and filtered with Celite.  The pad of Celite 
was washed with cold Et2O/Hex (1:9) solution (4 x 10 mL).  The combined filtrate was 
concentrated under a vacuum.  The crude product was purified by flash chromatography 
on silica gel eluting with 2-5 vol% of ether in hexanes to provide the titled compound 
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(3.530 g, 7.437 mmol, 76.4% yield) as a colorless oil. 
TLC:  Rf = 0.51 (Et2O/Hex = 3:7, v/v);  
[α]20 D -11.7 (c 2.00, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.65-7.70 (m, 4H, H-8, H-8’, H-12, H-12’), 7.41-7.46 (m, 
2H, H-10, H-14), 7.36-7.41 (m, 4H, H-9, H-9’, H-13, H-13’), 7.21 (d, J = 8.5 Hz, 2H, H-
19, H-19’), 6.84 (d, J = 8.5 Hz, 2H, H-20, H-20’), 5.85 (ddt, J = 17.1, 10.2, 7.1 Hz, 1H, 
H-5), 5.04-5.13 (m, 2H, H-6), 4.45 (ABq, J = 11.1 Hz, Δν = 55.7 Hz, 2H, H-17), 3.81-3.87 
(m, 1H, H-3), 3.80 (s, 3H, H-22), 3.75 (ddd, J = 5.7, 5.7, 10.3 Hz, 1H, H-1a), 3.72 (ddd, J 
= 5.7, 5.7, 7.1 Hz, 1H, H-1b), 2.33 (ddt, J = 7.1, 5.8, 1.3 Hz, 2H, H-4), 1.72-1.83 (m, 2H, 
H-2), 1.06 (s, 9H, H-16);  
125 MHz 13C NMR (CDCl3) δ 159.2 (C-21), 135.8 (C-8, C-8’, C-12, C-12’), 135.1 (C-5), 
134.1 (C-7), 134.1 (C-11), 131.1 (C-18), 129.8 (C-10, C-14), 129.5 (C-19, C-19’), 127.8 
(C-9, C-9’), 127.8 (C-13, C-13’), 117.2 (C-6), 113.9 (C-20, C-20’), 75.3 (C-3), 71.0 (C-
17), 60.7 (C-1), 55.5 (C-22), 38.7 (C-4), 37.2 (C-2), 27.1 (C-16), 19.4 (C-15); 
FTIR (neat): νmax 3071, 2933, 2858, 2361, 1613, 1588, 1513, 1467, 1428, 1390, 1359, 1302, 
1248, 1175, 1110, 1038, 915, 822, 739, 704, 613 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C30H38O3SiNa 497.2488; found 497.2493. 
(S)-5-(tert-Butyldiphenylsilyloxy)-3-(4-
methoxybenzyloxy)pentananl (2.39): With an acetone/dry 
ice bath (–78 oC), a steam of O3 (3.0 psi, 60 Volts) purged 
through a solution of oliefin 2.38 (1.679 g, 3.537 mmol, 1.0 
equiv) in CH2Cl2 (40 mL, 0.1 M), until the colorless solution turned pinkish.  At this point, 
the O3 was turned off, and a stream of N2 flushed the solution until the color faded.  Then, 
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triphenylphosphine (1.41 g, 5.30 mmol, 1.5 equiv) was added at one portion.  The reaction 
was stirred at room temperature for 6 hours.  The resulting yellow solution was 
concentrated under reduced pressure.  The reminder was purified by flash chromatography 
on silica gel eluting with 15-20 vol% of Et2O in hexanes to provide the titled compound 
(1.558 g, 3.269 mmol, 92.4% yield) as a colorless oil. 
TLC:  Rf = 0.21 (Et2O/Hex = 3:7, v/v);  
[α]20 D +3.7 (c 2.00, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.76 (dd, J = 1.8, 2.7 Hz, 1H, H-5), 7.64-7.70 (m, 4H, H-7, 
H-7’, H-11, H-11’), 7.42-7.48 (m, 2H, H-9, H-13), 7.36-7.42 (m, 4H, H-8, H-8’, H-12, 
H-12’), 7.19 (d, J = 8.5 Hz, 2H, H-18, H-18’), 6.85 (d, J = 8.5 Hz, 2H, H-19, H-19’), 4.46 
(s, 2H, H-16), 4.15-4.23 (m, 1H, H-3), 3.79-3.88 (m, 1H, H-1a), 3.80 (s, 3H, H-21), 3.72-
3.78 (m, 1H, H-1b), 2.66 (ddd, J = 2.7, 7.2, 16.3 Hz, 2H, H-4a), 2.59 (ddd, J = 1.8, 4.9, 
16.3 Hz, 2H, H-4b), 1.85-1.98 (m, 1H, H-2a), 1.69-1.84 (m, 1H, H-2b), 1.07 (s, 9H, H-
15);  
125 MHz 13C NMR (CDCl3) δ 201.8 (C-5), 159.5 (C-20), 135.8 (C-7, C-7’, C-11, C-11’), 
133.8 (C-6), 133.8 (C-10), 130.4 (C-17), 129.9 (C-9, C-13), 129.6 (C-18, C-18’), 127.9 (C-
8, C-8’, C-12, C-12’), 114.0 (C-19, C-19’), 71.5 (C-3), 71.3 (C-16), 60.3 (C-1), 55.5 (C-
21), 48.8 (C-4), 37.3 (C-2), 27.1 (C-15), 19.4 (C-14);  
FTIR (neat): νmax 3133, 3070, 3049, 3000, 2955, 2934, 2859, 2728, 1890, 1828, 1725, 1613, 
1514, 1467, 1428, 1391, 1360, 1302, 1249, 1176, 1109, 1037, 937, 823, 740, 705 cm-1; 





en-4-ol (2.34): To a stirred solution of aldehyde 2.39 (110 
mg, 0.213 mmol, 1.0 equiv) in freshly distilled CH2Cl2 
(10.0 mL, 0.02 M) was added MgBr2∙Et2O (111 mg, 0.428 
mmol, 2.0 equiv) in one portion at –15 oC under an atmosphere of N2.  After 15 minutes, 
the mixture was then cooled down to –78 oC, and stirred for further 30 minutes.  Whereupon, 
a solution of 2-(trimethylsilylmethyl)allyltributylstannane 2.91 (134 uL, 0.321 mmol, 1.5 
eq) in CH2Cl2 (6.0 mL, 0.05 M) was introduced via cannula over 5 minutes.  It was kept in 
this condition for 4 hours, and allowed to warm to 5 oC slowly over 7 hours.  The reaction 
was diluted with Et2O (10 mL) and poured into a saturated NaHCO3 solution (30 mL).  The 
aqueous layer was extracted with Et2O (3 x 10 mL).  The combined organic layers were 
washed with brine (50 mL), and dried over anhydrous Na2SO4.  The solution was filtered 
and concentrated under reduced pressure to provide a colorless oil.  The crude product was 
purified by flash chromatography on silica gel eluting with 8-15 vol% of Et2O in hexanes 
to provide the titled compound (119 mg, 0.197 mmol, 85.1% yield, single diastereomer) as 
single diastereomer as a colorless oil. 
TLC:  Rf = 0.33 (Et2O/Hex = 3:7, v/v);  
[α]20 D +13.9 (c 1.02, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.59-7.78 (m, 4H, H-18, H-18’, H-22, H-22’), 7.42-7.49 (m, 
2H, H-20, H-24), 7.34-7.49 (m, 4H, H-19, H-19’, H-23, H-23’), 7.21 (d, J = 8.6 Hz, 2H, 
H-13, H-13’), 6.85 (d, J = 8.6 Hz, 2H, H-14, H-14’), 4.67 (s, 1H, H-9a), 4.65 (s, 1H, H-
9b), 4.48 (s, 2H, H-11), 3.93-4.06 (m, 2H, H-3, H-5), 3.78-3.86 (m, 1H, H-1a), 3.80 (s, 
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3H, H-16); 3.70-3.78 (m, 1H, H-1b), 2.68 (bs, 1H, -OH), 2.12 (dd, J = 8.1, 13.7 Hz, 1H, 
H-6a), 2.06 (dd, J = 5.1, 13.7 Hz, 1H, H-6b), 1.93 (app. ddt, J = 5.4, 14.0, 4.9 Hz, 1H, H-
2a), 1.79 (app. ddt, J = 3.8, 14.0, 6.3 Hz, 1H, H-2b), 1.68 (ddd, J = 3.6, 9.1, 14.5 Hz, 1H, 
H-4a), 1.62 (ddd, J = 2.9, 7.3, 14.5 Hz, 1H, H-4b), 1.54 (ABq, J = 11.3 Hz, Δν = 14.8 Hz, 
2H, H-8), 1.07 (s, 9H, H-26), 0.04 (s, 9H, H-10); 
125 MHz 13C NMR (CDCl3) δ 159.4 (C-15), 144.8 (C-7), 135.8 (C-18, C-22), 134.0 (C-
17), 134.0 (C-21), 130.8 (C-12), 129.8 (C-20, C-24), 129.7 (C-13), 127.9 (C-19), 127.8 (C-
23), 114.0 (C-14), 110.2 (C-9), 74.0 (C-3), 71.6 (C-11), 66.2 (C-5), 60.7 (C-1), 55.5 (C-
16), 46.9 (C-6), 40.8 (C-4), 37.2 (C-2), 27.1 (C-26), 26.9 (C-8), 19.4 (C-25), -1.2 (C-10);  
FTIR (neat): νmax 3479 (br), 3071, 2952, 2859, 1888, 1614, 1588, 1514, 1467, 1427, 1392, 
1360, 1302, 1249, 1174, 1109, 1038, 934, 850, 739, 704, 665, 613, 536 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C36H52O4Si2Na 627.3302; found 627.3306. 
Determination of Absolute Configuration of the New Stereocenter of Compound (4S, 
6S)-8-(tert-Butyldiphenylsilyloxy)-6-(4-methoxybenzyloxy)-2-




(2.34-S-MTPA): To a small via, equipped with a stirring 
bar, was added 33 (26.5 mg, 0.0438 mmol, 1.0 equiv), 
(S)-MTPA-OH (11.8 mg, 0.494 mmol, 1.1 equiv), DMAP (5.4 mg, 0.0438 mmol, 1.0 equiv) 
and toluene (2.0 mL, 0.02 M).  Then freshly distilled NEt3 (31 uL, 0.22 mmol, 5.0 equiv) 
was added into this mixture.  This reaction was cooled down to 0 oC, 2,4,6-
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trichlorobenzoylchloride (7.8 uL, 0.049 mmol, 1.1 equiv) was then added dropwise via 
syringe.  The reaction turned cloudy and white precipitate appeared during the addition.  It 
was allowed to warm to room temperature slowly, and stirred for 6 hours.  Then, it was 
concentrated and purified by flash chromatography on silica gel eluting with 3 vol% of 
ethyl acetate in hexanes to provide the titled compound (31.2 mg, 0.0380 mmol, 86.8% 
yield) as a colorless oil. 
TLC:  Rf = 0.57 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +1.9 (c 1.39, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.68 (app. dt, J = 1.5, 8.3 Hz, 4H, -Si(t-Bu)Ph2), 7.52-7.61 
(m, 2H, -Ph), 7.42-7.50 (m, 2H, -Si(t-Bu)Ph2), 7.30-7.50 (m, 7H, -Si(t-Bu)Ph2, -Ph), 7.23 
(d, J = 8.6 Hz, 2H, H-13, H-13’), 6.86 (d, J = 8.6 Hz, 2H, - H-14, H-14’), 5.57 (dddd, J 
=2.8, 6.7, 6.7, 9.5 Hz, 1H, H-5), 4.58 (s, 1H, H-9a), 4.53 (s, 1H, H-9b), 4.36 (ABq, J = 
10.6 Hz, Δν = 52.4 Hz, 2H, H-11), 3.81 (s, 3H, H-16); 3.68-3.79 (m, 2H, H-1), 3.58-3.68 
(m, 1H, H-3), 3.49 (s, 3H, -OCH3), 2.34 (dd, J = 6.7, 13.9 Hz, 1H, H-6a), 2.09 (dd, J = 6.7, 
13.9 Hz, 1H, H-6b), 1.67-1.97 (m, 4H, H-2, H-4), 1.52 (ABq, J = 13.9 Hz, Δν = 13.0 Hz, 
2H, H-8), 1.06 (s, 9H, H-26), 0.01 (s, 9H, H-10); 
125 MHz 13C NMR (CDCl3) δ 166.3 (C=O), 159.3 (C-15), 142.4 (C-7), 135.8 (C-18, C-
22), 133.9 (C-17, C-21), 132.3 (Ph-1’), 130.8 (C-12), 129.8 (C-20, C-24), 129.8 (C-13), 
129.7 (Ph-4’), 128.5 (Ph-2’), 127.9 (C-19, C-23), 127.7 (Ph-3’), 123.6 (q, JC-F = 288.9 Hz, 
-CF3), 114.0 (C-14), 111.4 (C-9), 84.8 (q, JC-F = 27.5 Hz, -CC=O), 73.0 (C-3), 72.9 (C-5), 
71.6 (C-11), 60.5 (C-1), 55.6 (-OMe), 55.5 (C-16), 43.6 (C-6), 40.0 (C-4), 37.5 (C-2), 27.1 
(C-26), 26.5 (C-8), 19.3 (C-25), -1.2 (C-10);       
FTIR (neat): νmax 3072, 2953, 2859, 2361, 1743, 1613, 1514, 1467, 1428, 1390, 1360, 1251, 
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1171, 1110, 1035, 850, 737, 704, 613, 536 cm-1; 




(2.34-R-MTPA): To a small via, equipped with a 
stirring bar, was added 33 (45.0 mg, 0.0744 mmol, 1.0 
equiv), (R)-MTPA-OH (19.5 mg, 0.0824 mmol, 1.1 equiv), DMAP (10.2 mg, 0.827 mmol, 
1.0 equiv) and toluene (2.0 mL, 0.04 M).  Then, freshly distilled NEt3 (50.0 uL, 0.359 
mmol, 5.0 equiv) was added into this mixture.  This reaction was cooled down to 0 oC, and 
2,4,6-trichlorobenzoylchloride (13.0 uL, 0.0815 mmol, 1.1 equiv) was then added 
dropwise via syringe.  The reaction turned cloudy and white precipitate appeared during 
the addition.  It was allowed to warm to room temperature slowly, and stirred for 8 hours.  
Then, it was concentrated and purified by flash chromatography on silica gel eluting with 
3% of ethyl acetate in hexanes to provide the titled compound (54.7 mg, 0.0666 mmol, 
89.5% yield) as a colorless oil. 
TLC:  Rf = 0.58 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +29.7 (c 1.94, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.63-7.74 (m, 4H, -Si(t-Bu)Ph2), 7.52-7.61 (m, 2H, -Ph), 
7.43-7.50 (m, 2H, -Si(t-Bu)Ph2), 7.37-7.42 (m, 4H, -Si(t-Bu)Ph2), 7.29-7.37 (m, 2H, -Ph), 
7.23 (d, J = 8.7 Hz, 2H, H-13, H-13’), 6.87 (d, J = 8.7 Hz, 2H, H-14, H-14’), 5.59 (dddd, 
J =2.7, 6.7, 6.9, 9.6 Hz, 1H, H-5), 4.67 (s, 1H, H-9a), 4.62 (s, 1H, H-9b), 4.32 (ABq, J = 
10.5 Hz, Δν = 54.1 Hz, 2H, H-11), 3.81 (s, 3H, H-16); 3.69 (app. t, J = 6.5 Hz, 2H, H-1), 
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3.55 (s, 3H, -OCH3), 3.46-3.53 (m, 1H, H-3), 2.44 (dd, J = 6.7, 13.9 Hz, 1H, H-6a), 2.20 
(dd, J = 6.9, 13.9 Hz, 1H, H-6b), 1.85 (ddd J = 2.8, 9.9, 15.0 Hz, 1H, H-2a), 1.67-1.81 (m, 
3H, H-2b, H-4), 1.58 (ABq, J = 14.0 Hz, Δν = 7.8 Hz, 2H, H-8), 1.06 (s, 9H, H-26), 0.03 
(s, 9H, H-10); 
125 MHz 13C NMR (CDCl3) δ 166.3 (C=O), 159.3 (C-15), 142.6 (C-7), 135.8 (C-18, C-
22), 133.9 (C-17, C-21), 132.5 (Ph-1’), 130.8 (C-12), 129.8 (C-20, C-24), 129.7 (C-13, 
Ph-4’), 128.5 (Ph-2’), 127.9 (C-19, C-23), 127.7 (Ph-3’), 123.6 (q, JC-F = 288.5 Hz, -CF3), 
114.0 (C-14), 111.4 (C-9), 84.6 (q, JC-F = 27.5 Hz, -CC=O), 73.2 (C-3), 73.0 (C-5), 71.7 
(C-11), 60.5 (C-1), 55.6 (-OMe), 55.5 (C-16), 43.8 (C-6), 40.1 (C-4), 37.5 (C-2), 27.0 (C-
26), 26.6 (C-8), 19.3 (C-25), -1.2 (C-10);  
FTIR (neat): νmax 3072, 2953, 2859, 1745, 1614, 1514, 1467, 1428, 1391, 1360, 1250, 1171, 
1110, 1034, 851, 737, 704, 614, 537 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C46H59O6F3Si2Na 843.3700; found 843.3694. 
The chemical shift differences (in ppm) between the (S)- and (R)-MTPA Mosher esters 
of the (4S, 6S)-8-(tert-butyldiphenylsilyloxy)-6-(4-methoxybenzyloxy)-2-












pyran-3-yl Octa-2,4-dienoate (2.92): With a –78 oC bath, to a stirred mixture of aldehyde 
2.88 (96.2 mg, 0.115 mmol, 1.0 equiv) and β-hydroxylallylsilane 2.34 (105.2 mg, 0.1739 
mmol, 1.5 equiv) in fresh distilled Et2O (11 mL, 0.01 M) was added pyridine (1.0 uL, 0.012 
mmol, 0.1 equiv) via syringe under an atmosphere of N2.  Then, a solution of 1.0 M 
TMSOTf in Et2O (140 uL, 0.140 mmol, 1.2 equiv) was introduced into this reaction 
dropwise via syringe.  It was stirred for 1 hour, and quenched with DIPEA (1.0 mL, 5.7 
mmol, 50 equiv) at the same temperature.  It was stirred further 30 minutes, and poured 
into a saturated NaHCO3 solution (30 mL).  The aqueous layer was extracted by Et2O (3 x 
10 mL).  The combined organic layers were washed with brine (30 mL) and dried over 
anhydrous Na2SO4.  The solution was filtered and concentrated under reduced pressure to 
provide a colorless oil.  The crude product was purified by flash chromatography on silica 
gel eluting with 5-12 vol% of EtOAc in hexanes to provide a pale yellow oil (141 mg, 
0.104 mmol, 90.3% yield).   
TLC:  Rf = 0.63 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -5.4 (c 1.15, CHCl3); 
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500 MHz 1H NMR (CDCl3) δ 7.75-7.64 (m, 4H, H-60a, H-60a’, H-60b, H-60b’), 7.49-
7.40 (m, 2H, H-62a, H-62b), 7.43-7.33 (m, 8H, H-61a, H-61a’, H-61, H-61b’, H-45, H-
45’, H-46, H-46’), 7.33-7.26 (m, 2H, H-47, H-32), 7.20 (d, J = 8.6 Hz, 2H, H-50, H-50’), 
6.86 (d, J = 8.8 Hz, 2H, H-51, H-51’), 6.27-6.10 (m, 2H, H-33, H-34), 5.98 (dd, J = 16.0, 
1.2 Hz, 1H, H-17), 5.92 (br. s, 1H, H-38), 5.80 (d, J = 15.3 Hz, 1H, H-31), 5.59 (br. s, 1H, 
H-20), 5.42 (dd, J = 15.8, 6.0 Hz, 1H, H-16), 4.79 (ABq, J = 6.5 Hz, Δν = 6.0 Hz, 2H, H-
42), 4.72 (td, J = 2.1, 1.8 Hz, 1H, H-28a), 4.70 (td, J = 2.1, 1.8 Hz, 1H, H-28b), 4.63 (s, 
2H, H-43), 4.56 (td, J = 2.1, 1.6 Hz, 1H, H-27a), 4.47 (br. s, 1H, H-27b), 4.40 (ABq, J = 
10.8 Hz, Δν = 28.8 Hz, 2H, H-48), 4.14 (dddd, J = 6.6, 6.1, 4.9, 4.7 Hz, 1H, H-25), 4.09 
(ddt, J = 11.7, 8.6, 3.2 Hz, 1H, H-23), 3.96-3.89 (m, 1H, H-3), 3.88-3.79 (m, 1H, H-1a), 
3.81 (s, 3H, H-53), 3.82-3.75 (m, 1H, H-1b), 3.77-3.70 (m, 1H, H-15), 3.69 (s, 3H, H-40), 
3.66 (dd, J = 10.2, 4.5 Hz, 1H, H-26a), 3.59 (dd, J = 10.1, 6.0 Hz, 1H, H-26b), 3.61-3.54 
(m, 1H, H-11), 3.58-3.51 (m, 1H, H-5), 3.52 (dd, J = 15.8, 2.6 Hz, 1H, H-22eq), 3.52-3.45 
(m, 1H, H-9), 3.33 (s, 3H, H-41), 2.38 (ddd, J = 15.9, 11.6, 2.1 Hz, 1H, H-22ax), 2.32-2.25 
(m, 1H, H-8eq), 2.29-2.23 (m, 1H, H-12eq), 2.23-2.10 (m, 4H, H-6eq, H-14eq, H-35), 2.06-
1.97 (m, 2H, H-8ax, H-14ax), 1.97 (ddd, J = 14.2, 8.7, 5.1 Hz, 1H, H-24a), 1.98-1.88 (m, 
2H, H-6ax, H-12ax), 1.85-1.73 (m, 2H, H-2a, H-2b), 1.75 (ddd, J = 14.3, 7.1, 3.4 Hz, 1H, 
H-24b), 1.72-1.57 (m, 4H, H-4a, H-4b, H-10a, H-10b), 1.48 (sext, J = 7.4 Hz, 2H, H-36), 
1.16 (s, 3H, H-29), 1.15 (s, 3H, H-29’), 1.09 (s, 9H, H-58), 0.94 (t, J = 7.4 Hz, 3H, H-37), 
0.92 (s, 9H, H-56), 0.13 (s, 3H, H-54), 0.12 (s, 3H, H-54’);  
125 MHz 13C NMR (CDCl3) δ 166.7 (C-39), 165.6 (C-30), 159.3 (C-52), 152.9 (C-21), 
146.7 (C-32), 145.8 (C-34), 145.0 (C-13), 144.5 (C-7), 138.6 (C-17), 138.1 (C-44), 135.8 
(C-60a, C-60a’, C-60b, C-60b’), 134.1 (C-59a), 134.0 (C-59b), 131.2 (C-49), 129.8 (C-
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62a, C-62b), 129.5 (C-50, C-50’), 128.6 (C-33, C-46, C-46’), 128.0 (C-45, C-45’), 127.8 
(C-47, C-61a, C-61a’, C-61b, C-61b), 127.1 (C-16), 118.7 (C-31), 117.3 (C-38), 114.0 (C-
51, C-51’), 108.9 (C-27), 108.6 (C-28), 102.9 (C-19), 95.1 (C-42), 79.2 (C-15), 75.1 (C-5), 
75.0 (C-11), 74.9 (C-9), 72.9 (C-26), 72.8 (C-3), 72.1 (C-48), 71.7 (C-20), 69.6 (C-43), 
69.4 (C-25), 68.7 (C-23), 60.6 (C-1), 55.4 (C-53), 51.7 (C-41), 51.2 (C-40), 46.0 (C-18), 
42.9 (C-10), 42.5 (C-4), 42.2 (C-24), 41.4 (C-6), 41.1 (C-8), 40.9 (C-14), 40.5 (C-12), 38.0 
(C-2), 35.2 (C-35), 33.2 (C-22), 27.2 (C-58), 26.1 (C-56), 24.2 (C-29), 24.1 (C-29’), 22.0 
(C-36), 19.4 (C-57), 18.4 (C-55), 13.9 (C-37), -3.8 (C-54), -4.4 (C-54’);  
FTIR (neat): νmax 3071, 2934, 2889, 2858, 1720, 1643, 1614, 1588, 1514, 146, 1429, 1383, 
1360, 1303, 1248, 1173, 1158, 1133, 1108, 1045, 1003, 890, 835, 824, 777 cm-1; 








pyran-3-yl Octa-2,4-dienoate (2.92a): To a solution of protected alcohol 2.92 (150 mg, 
0.110 mmol, 1.0 equiv) in MeOH (11 mL, 0.01 M) was added NH4F solid (82 mg, 2.1 
mmol, 20 equiv) in one portion at room temperature.  This reaction was stirred at 60 oC for 
26 hours, and quenched with a saturated solution of NaHCO3 (30 mL).  It was diluted with 
EtOAc (10 mL) and extracted with EtOAc (3 x 10 mL).  The combined organic layers were 
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washed with brine (30 mL) and dried over anhydrous Na2SO4.  The yellow crude product 
was used directly in next step without any purification. 








yl)-2-methylbut-3-en-2-yl)tetrahydro-2H-pyran-3-yl Octa-2,4-dienoate (2.93): To a 
stirred solution of crude alcohol 2.92a (132.6 mg, 0.1104 mmol, 1.0 equiv) in dry CH2Cl2 
(11.0 mL, 0.01 M) was added t-BuOH (14.0 uL, 0.146 mmol, 1.3 equiv) and freshly 
distilled pyridine (27.0 uL, 0.334 mmol, 3.0 equiv).  Then this reaction was cooled down 
to 0 oC, and Dess-Martin periodinane (72.7 mg, 0.166 mmol, 1.5 equiv) was added in one 
portion.  After 10 minutes, the cooling bath was removed and the reaction was stirred at 
room temperature for 1 hour under an atmosphere of N2.  A saturated NaHCO3 solution 
(20 mL) was then added into this reaction, followed by addition of a saturated Na2S2O3 
solution (10 mL).  This mixture was stirred for 10 minutes at ambient temperature.  The 
aqueous layer was extracted with Et2O (3 x 10 mL).  The combined organic layers were 
washed with brine (30 mL) and dried over anhydrous Na2SO4.  The solution was filtered 
and concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 10-20% of EtOAc in hexanes to provide the 
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titled compound (69.4 mg, 0.623 mmol, 56.5% yield over two steps) as a colorless oil.   
TLC:  Rf = 0.57 (EtOAc/Hex = 4:6, v/v);  
[α]20 D +0.9 (c 1.09, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.79 (t, J = 2.3, 1H, H-1), 7.40-7.32 (m, 4H, H-45, H-45’, 
H-46, H-46’), 7.32-7.25 (m, 2H, H-47, H-32), 7.23 (d, J = 8.6 Hz, 2H, H-50, H-50’), 6.88 
(d, J = 8.8 Hz, 2H, H-51, H-51’), 6.27-6.09 (m, 2H, H-33, H-34), 5.99 (dd, J = 16.0, 0.9 
Hz, 1H, H-17), 5.92 (br. s, 1H, H-38), 5.80 (d, J = 15.3 Hz, 1H, H-31), 5.59 (br. s, 1H, H-
20), 5.40 (dd, J = 16.0, 6.1 Hz, 1H, H-16), 4.79 (ABq, J = 6.7 Hz, Δν = 5.7 Hz, 2H, H-42), 
4.76-4.69 (m, 2H, H-27a, H-27b), 4.66 (td, J = 1.9, 1.6 Hz, 1H, H-28a), 4.63 (s, 2H, H-
43), 4.60 (td, J = 1.8, 1.6 Hz, 1H, H-28b), 4.48 (ABq, J = 10.8 Hz, Δν = 20.9 Hz, 2H, H-
48), 4.18 (dddd, J = 8.0, 6.0, 6.0, 4.6 Hz, 1H, H-3), 4.12 (dddd, J = 6.9, 6.3, 5.9, 4.8 Hz, 
1H, H-25), 4.07 (dddd, J = 11.5, 8.5, 3.1, 2.8 Hz, 1H, H-23), 3.80 (s, 3H, H-53), 3.72 (dddd, 
J = 11.4, 5.8, 2.4, 1.0 Hz, 1H, H-15), 3.68 (s, 3H, H-40), 3.64 (dd, J = 10.3, 4.7 Hz, 1H, 
H-26a), 3.57 (dd, J = 10.4, 6.0 Hz, 1H, H-26b), 3.55-3.46 (m, 3H, H-5, H-11, H-22eq), 
3.48-3.42 (m, 1H, H-9), 3.32 (s, 3H, H-41), 2.74-2.53 (m, 2H, H-2a, H-2b), 2.35 (ddd, J 
= 15.8, 11.5, 2.0 Hz, 1H, H-22ax), 2.28-2.21 (m, 2H, H-8eq, H-12eq), 2.21-2.11 (m, 4H, H-
14eq, H-6eq, H-35), 2.04-1.87 (m, 5H, H-14ax, H-8ax, H-24a, H-6ax, H-12ax), 1.80 (ddd, J 
= 14.3, 8.6, 2.6 Hz, 1H, H-4a), 1.73 (ddd, J = 14.3, 7.0, 3.4 Hz, 1H, H-24b), 1.67 (ddd, J 
= 14.3, 9.9, 4.4 Hz, 1H, H-4b), 1.69-1.63 (m, 1H, H-10a), 1.60 (ddd, J = 14.0, 7.0, 5.2 Hz, 
1H, H-10b), 1.47 (sext, J = 7.3 Hz, 2H, H-36), 1.13 (s, 3H, H-29), 1.13 (s, 3H, H-29’), 
0.93 (t, J = 7.3 Hz, 3H, H-37), 0.90 (s, 9H, H-56), 0.11 (s, 3H, H-54), 0.10 (s, 3H, H-54’);  
125 MHz 13C NMR (CDCl3) δ 201.6 (C-1), 166.7 (C-39), 165.7 (C-30), 159.6 (C-52), 
152.9 (C-21), 146.7 (C-32), 145.9 (C-34), 144.6 (C-13), 144.5 (C-7), 138.8 (C-17), 138.1 
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(C-44), 130.5 (C-49), 129.6 (C-50, C-50’), 128.6 (C-33, C-46, C-46’), 128.1 (C-45, C-45’), 
127.9 (C-47), 127.1 (C-16), 118.7 (C-31), 117.3 (C-38), 114.2 (C-51, C-51’), 109.0 (C-27, 
C-28), 102.9 (C-19), 95.1 (C-42), 79.4 (C-15), 75.1 (C-11), 75.1 (C-9), 75.0 (C-5), 72.9 
(C-26), 72.2 (C-48), 71.8 (C-20), 71.7 (C-3), 69.6 (C-43), 69.4 (C-25), 68.7 (C-23), 55.5 
(C-53), 51.8 (C-41), 51.3 (C-40), 49.5 (C-2), 46.1 (C-18), 42.8 (C-10), 42.4 (C-4), 42.2 (C-
24), 41.4 (C-6), 40.9 (C-8, C-14), 40.6 (C-12), 35.3 (C-35), 33.2 (C-22), 26.2 (C-56), 24.2 
(C-29), 24.2 (C-29’), 22.1 (C-36), 18.4 (C-55), 13.9 (C-37), -3.7 (C-54), -4.4 (C-54’);  
FTIR (neat): νmax 2930, 2856, 1721, 1643, 1614, 1514, 1463, 1436, 1382, 1361, 1303, 1249, 
1166, 1106, 1043, 892, 836, 777 cm-1; 








methylenetetrahydro-2H-pyran-2-yl)-3-((4-methoxybenzyl)oxy)butanoic Acid (2.94): 
To a stirred solution of aldehyde 2.93 (69.4 mg, 62.3 umol, 1.0 equiv) in CH3CN (3.1 mL, 
0.02 M) was added t-BuOH (3.1 mL, 0.02M) and isoamylene (3.1 mL, 0.02 M).  With an 
ice-water bath, a solution of NaH2PO4∙H2O (87 mg, 0.63 mmol, 10.0 equiv) and NaClO2 
(70 mg, 0.62 mmol, 10.0 equiv) in D.I. H2O (1.6 mL, 0.4 M) was added into this reaction.  
It was stirred for 2 hours at this temperature, and then quenched by addition of a saturated 
197 
 
Na2S2O3 solution (10 mL).  This mixture was stirred for 10 minutes at ambient temperature, 
and then EtOAc (10 mL) was added before being poured into a saturated NH4Cl solution 
(15 mL).  The aqueous layer was extracted with EtOAc (4 x 5 mL).  The combined organic 
layers were washed with brine (15 mL) and dried over anhydrous Na2SO4.  The solution 
was filtered and concentrated under reduced pressure to provide a pale yellow oil (78.3 
mg).  The crude product was used in next step without any further purification.   









(2.94a): To a stirred solution of crude acid 2.94 (crude 78.3 mg, theoretically 62.3 umol, 
1.0 equiv) in THF (6.2 mL, 0.01 M) was added 30% HF•Py (1.2 mL, 18 mmol, 300 equiv) 
at  room temperature.  It was stirred for 32 hours, then diluted with EtOAc (10 mL) before 
being poured into a saturated NH4Cl solution (15 mL).  The aqueous layer was extracted 
with EtOAc (4 x 5 mL).  The combined organic layers were washed with brine (10 mL) 
and dried over anhydrous Na2SO4.  The solution was filtered and concentrated under 
reduced pressure to provide a yellow oil (110 mg).  The crude product was used directly in 
next step without any further purification.   
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tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl Octa-2,4-dienoate (2.95): To a 
stirred solution of crude seco-acid 2.94a (crude 110 mg, theoretically 62.3 umol, 1.0 equiv) 
in THF (12.5 mL, 0.005 M) was added N,N-diisopropylethylamine (DIEPA) (110 uL, 632 
umol, 10.0 equiv) and 2,4,6-trichlorobenzoyl chloride (30.0 uL, 188 umol, 3.0 equiv) at 
room temperature, subsequently.  It was stirred for 3 hours under an atmosphere of N2.  
Then, this reaction was added into a stirred solution of DMAP (77 mg, 62 umol, 10.0 equiv) 
in anhydrous toluene (62 mL, 0.001 M) via a syringe pump at the rate of 1 mL/h at 40 oC, 
under an atmosphere of N2.  The flask of mixed anhydride was rinse 3 times with anhydrous 
toluene (3 x 1 mL), which was added into flask containing DMAP solution.  After addition, 
the reaction was stirred further 3 hours before being poured into a saturated NaHCO3 
solution (50 mL).  The aqueous layer was extracted with EtOAc (4 x 10 mL).  The 
combined organic layers were washed with brine (50 mL) and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure.  The 
remainder was purified by flash chromatography on silica gel eluting with 10-20 vol% of 
EtOAc in hexanes to provide the titled compound (59.3 mg, 59.5 umol, 95.5% yield) as a 
yellow oil.   
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TLC:  Rf = 0.81 (MeOH/EtOAc/Hex = 1: 4:5, v/v/v); 
[α]20 D +22.1 (c 0.36, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.37-7.31 (m, 4H, H-45, H-45’, H-46, H-46’), 7.31-7.25 (m, 
2H, H-47, H-32), 7.22 (d, J = 8.8 Hz, 2H, H-50, H-50’), 6.83 (d, J = 8.6 Hz, 2H, H-51, H-
51’), 6.22 (d, J = 15.8 Hz, 1H, H-17), 6.20-6.14 (m, 2H, H-33, H-34), 5.98 (d, J = 1.8 Hz, 
1H, H-38), 5.77 (d, J = 15.1 Hz, 1H, H-31), 5.59 (dddd, J = 11.9, 4.7, 4.7, 2.9 Hz, 1H, H-
25), 5.34 (dd, J = 15.8, 8.6 Hz, 1H, H-16), 5.26 (s, 1H, H-20), 4.75 (d, J = 1.8 Hz, 1H, H-
28a), 4.74 (d, J = 1.8 Hz, 1H, H-28b), 4.72-4.70 (m, 2H, H-27a, H-27b), 4.69 (d, J = 6.7 
Hz, 1H, H-42a), 4.62 (d, J = 6.7 Hz, 1H, H-42b), 4.57 (ABq, J = 11.9 Hz, Δν = 24.8 Hz, 
2H, H-43), 4.48 (ABq, J = 10.8 Hz, Δν = 14.8 Hz, 2H, H-48), 4.15 (dddd, J = 10.0, 6.6, 
6.6, 3.5 Hz, 1H, H-3), 3.90 (ddd, J = 11.1, 8.7, 2.3 Hz, 1H, H-15), 3.81-3.73 (m, 1H, H-
23), 3.75 (s, 3H, H-53), 3.71 (dd, J = 10.5, 4.3 Hz, 1H, H-26a), 3.69 (s, 3H, H-40), 3.71-
3.67 (m, 1H, H-22eq), 3.62 (dd, J = 10.4, 4.9 Hz, 1H, H-26b), 3.48 (dddd, J = 11.5, 7.4, 2.3, 
2.1 Hz,, 1H, H-11), 3.36 (tt, J = 10.8, 2.6 Hz, 1H, H-5), 3.12 (s, 3H, H-41), 3.15-3.06 (m, 
1H, H-9), 2.63 (dd, J = 15.3, 2.6 Hz, 1H, H-2a), 2.48 (dd, J = 15.3, 10.1 Hz, 1H, H-2b), 
2.31 (ddd, J = 12.7, 1.8, 1.4 Hz, 1H, H-12eq), 2.23-2.00 (m, 8H, H-14eq, H-6eq, H-35, H-
22ax, H-8eq, H-24a, H-14ax), 2.00-1.80 (m, 5H, H-8ax, H-12ax, H-6ax, H-24b, H-4a), 1.75 
(ddd, J = 14.3, 10.6, 2.1 Hz, 1H, H-10a), 1.55 (ddd, J = 14.3, 7.3, 1.6 Hz, 1H, H-10b), 1.48 
(ddd, J = 17.1, 10.6, 6.6 Hz, 1H, H-4b), 1.46 (sext, J = 7.4 Hz, 2H, H-36), 1.11 (s, 3H, H-
29), 1.10 (s, 3H, H-29’), 0.93 (t, J = 7.3 Hz, 3H, H-37);  
125 MHz 13C NMR (CDCl3) δ 172.5 (C-1), 167.0 (C-39), 165.6 (C-30), 159.3 (C-52), 
151.6 (C-21), 146.7 (C-32), 145.9 (C-34), 144.5 (C-13), 144.4 (C-7), 142.0 (C-17), 138.1 
(C-44), 131.0 (C-49), 129.5 (C-50, C-50’), 128.6 (C-46, C-46’), 128.6 (C-33), 128.0 (C-
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45, C-45’), 127.9 (C-47), 125.5 (C-16), 119.5 (C-38), 118.7 (C-31), 113.9 (C-51, C-51’), 
109.1 (C-27), 109.0 (C-28), 103.4 (C-19), 95.1 (C-42), 81.7 (C-15), 76.5 (C-5), 76.5 (C-
11), 76.4 (C-9), 75.6 (C-3), 73.5 (C-20), 71.9 (C-48), 69.8 (C-43), 69.4 (C-26), 68.6 (C-
25), 67.2 (C-23), 55.5 (C-53), 52.8 (C-41), 51.4 (C-40), 45.3 (C-18), 44.3 (C-10), 43.1 (C-
2), 41.9 (C-12), 41.5 (C-4), 41.1 (C-6), 41.1 (C-8), 41.0 (C-14), 37.2 (C-24), 35.3 (C-35), 
31.0 (C-22), 26.5 (C-29), 22.1 (C-36), 20.4 (C-29’), 13.9 (C-37); 
FTIR (neat): νmax 2928, 2856, 1725, 1643, 1614, 1581, 1550, 1514, 1463, 1437, 1379, 1249, 
1161, 1108, 1049, 891, 859, 820 cm-1; 







tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl Octa-2,4-dienoate (2.95a): To a 
stirred solution of compound 2.95 (59.3 mg, 59.5 umol, 1.0 equiv) in CH2Cl2 (12 mL, 
0.005M) was added a 0.1 M phosphate pH = 6 buffer solution (1.2 mL, 0.05 M).  Then, 
this reaction was cooled down to 0 oC, and DDQ (41.5 mg, 179 umol, 3.0 equiv) was added 
in one portion.  It was stirred for 3 hours at this temperature.  Then, this reaction was diluted 
with EtOAc (10 mL), and poured into a saturated NaHCO3 solution (20 mL).  The aqueous 
layer was extracted with EtOAc (3 x 5 mL).  The combined organic layers were washed 
with brine (20 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
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concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 15-25 vol% of EtOAc in hexanes to provide the 
titled compound (38.6 mg, 44.0 umol, 74.0% yield) as a pale yellow oil.   







12-yl octa-2,4-dienoate (2.54): To a stirred solution of compound 2.95a (10.1 mg, 11.5 
umol, 1.0 equiv) in CH3CN (1.2 mL, 0.01 M) was added deionized water (60 uL, 0.2M) 
and LiBF4 solid (55 mg, 579 umol, 50 equiv).  This reaction was stirred at 80 oC overnight 
(ca. 8 hours) and then cooled to room temperature before being concentrated.  The 
remainder was purified by flash chromatography on silica gel eluting with 25-35 vol% of 
EtOAc in hexanes to provide the titled compound (5.9 mg, 7.9 umol, 69.1% yield) as a 
colorless oil. 
TLC:  Rf = 0.36 (EtOAc/Hex = 5:5, v/v); 
[α]20 D -7.0 (c 0.16, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.32-7.21 (m, 1H, H-32), 6.27-6.08 (m, 2H, H-33, H-34), 
6.03 (d, J = 2.0 Hz, 1H, H-38), 5.79 (d, J = 15.2 Hz, 1H, H-31), 5.76 (d, J = 16.2 Hz, 1H, 
H-17), 5.42-5.33 (m, 1H, H-25), 5.33 (dd, J = 15.6, 8.3 Hz, 1H, H-16), 5.23 (br. s, 1H, H-
20), 5.20 (br. s, 1H, 19-OH), 4.82-4.65 (m, 4H, H-28a, H-27a, H-28b, H-27b), 4.47 (d, J 
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= 12.2 Hz, 1H, 3-OH), 4.31-4.17 (m, 1H, H-3), 4.10 (tt, J = 11.5, 2.5 Hz, 1H, H-23), 3.94 
(ddd, J = 11.3, 8.3, 2.4 Hz, 1H, H-15), 3.85 (dd, J = 12.0, 3.2 Hz, 1H, H-26a), 3.75-3.69 
(m, 1H, H-22eq), 3.68 (s, 3H, H-40), 3.69-3.60 (m, 1H, H-26b), 3.55 (app. ddd, J = 11.7, 
7.3, 2.4 Hz, 1H, H-11), 3.52-3.45 (m, 2H, H-5, 26-OH), 3.42 (tt, J = 11.3, 2.2 Hz, 1H, H-
9), 2.50 (dd, J = 12.7, 2.9 Hz, 1H, H-2a), 2.45 (dd, J = 12.7, 10.8 Hz, 1H, H-2b), 2.26-1.92 
(m, 13H, H-35, H-8eq, H-6eq, H-12eq, H-22ax, H-14eq, H-4a, H-12ax, H-24a, H-6ax, H-14ax, 
H-8ax), 1.87 (ddd, J = 15.4, 11.3, 7.3 Hz, 1H, H-10a), 1.81 (ddd, J = 11.7, 11.3, 2.7 Hz, 
1H, H-24b), 1.61 (ddd, J = 15.2, 3.4, 3.4 Hz, 1H, H-4b), 1.52 (app. dd, J = 15.6, 2.4 Hz, 
1H, H-10b), 1.47 (sext, J = 7.4 Hz, 2H, H-36), 1.14 (s, 3H, H-29), 1.02 (s, 3H, H-29’), 
0.93 (t, J = 7.3 Hz, 3H, H-37); 
125 MHz 13C NMR (CDCl3) δ 172.6 (C-1), 167.3 (C-39), 165.8 (C-30), 152.2 (C-21), 
146.5 (C-32), 145.6 (C-34), 144.0 (C-13), 143.5 (C-7), 138.8 (C-17), 129.9 (C-6), 128.6 
(C-33), 119.9 (C-38), 118.9 (C-31), 109.3 (C-27), 108.8 (C-28), 99.3 (C-19), 80.3 (C-15), 
79.6 (C-9), 77.7 (C-11), 76.6 (C-5), 74.3 (C-20), 71.9 (C-25), 68.7 (C-3), 66.0  (C-26), 64.6 
(C-23), 51.3 (C-40), 45.2 (C-18), 43.3 (C-10), 42.8 (C-2), 42.4 (C-12), 41.6 (C-14), 41.0 
(C-6), 40.9 (C-8), 40.1 (C-4), 36.2 (C-24), 35.3 (C-35), 31.4 (C-22), 25.0 (C-19), 22.1 (C-
36), 19.9 (C-19’), 13.9 (C-37); 
FTIR (neat): νmax 3449 (br), 2931, 2857, 1725, 1614, 1514, 1462, 1382, 1249, 1108, 1046, 
890 cm-1; 




































1 2.4 x 10 -5 0.89 52-96% 10-70 13 
2 6.2 x 10 -7  60% 30 15 
3 1.6 x 10 -7  63% 30 16 
4 8.9 x 10 -5 6.7 x 10 -4 62% 46 17 
5 2.8 x 10 -5 1.3 x 10-3-2.6 x 10 -4 88% 185 18 
6 1.2 x 10 -4 3.0 x 10 -3 82% 185 18 
7 6.2 x 10 -5 2.6 x 10 -5 77% 92 18 
8 4.2 x 10 -6 1.3 x 10 -3 74% 110 19 
9 2.7 x 10 -5 1.2 x 10 -3 40% 80 20 
10 6.7 x 10 -7 7.6 x 10 -4 34% 10 21 
11 1.7 x 10 -5 1.8 x 10 -5 64% 92.5 21 
12 3.7 x 10 -7 1.4 x 10 -2 47-68% 30-50 22 
13 7.0 x 10 -8 5.4 x 10 -3   22 
14 1.02 x 10 -5 0.33   23 
15 8.6 x 10 -7 1.4   23 
16 4.3 x 10 -6 9.3 x 10 -3   24 
17 3.4 x 10 -6 1.9 x 10 -2   24 
18 6.7 x 10 -6 3.3 x 10 -3   24 
19 1.4 x 10 -5 2.8 x 10 -3 (U937)   25 
20     26 













































Table 2.2 Synergistic Effects of Bryostatin 1105  
Cell line Synergized Drug Result 
HL-60 Ara-C65 Doubled the amount of apoptotic cells 
U937 Taxol Doubled the amount of apoptotic cells 
P388 Tamoxifen Increased growth inhibition 200 times 
Reh Auristatin PE Enhanced the amount of apoptotic cells 
 Vincristine Enhanced the amount of apoptotic cells 
WSU-CLL 2-CdA Tumor growth delay from 37 days to 76 days 






















































































































































































(respect to aldehyde) 
Time Product(Yield) 
1 - -. 30 min 2.74 (57%) 
2 NEt3 0.2 equiv 1 h 2.74 (43%) 
3 iPr2NEt 0.2 equiv 1 h 2.74 (39%) 
4 Py 0.1 equiv 30 min. 2.74 (79%) 
5 Py 0.2 equiv 30 min. 2.74 (93%) 
6 Py 0.3 equiv 30 min. 2.74 (89%) 
7 Py 0.4 equiv 30 min. 2.74 (59%) 
8 Py 0.4 equiv 3 h 2.74 (87%) 
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CHAPTER 3  
 
THE DESIGN AND SYNTHESIS STUDY OF THE BRYOSTATIN 
ANALOGUE WITH C-9 HEMIKETAL 
 
Introduction 
Bryostatin 1 is a naturally occurring macrolide lactone isolated from marine organisms.  
It displays significant and unique antineoplastic activity, and has been a focus of the 
biological and chemical research community.  Bryostatin 1 is a potent modulator of protein 
kinase Cs (PKCs).  PKCs are a group of enzymes that control phosphorylation of proteins.  
They play fundamental roles in signal transduction pathways that regulate cellular 
proliferation, differentiation, and apoptosis.  Consequently, PKCs are attractive targets for 
several ailments, such as cancer, Alzheimer’s disease, and HIV.  As a PKC activator, 
bryostatin 1 is a promising therapeutic candidate in this area.  However, most other PKC 
ligands demonstrate opposing biological responses.  For instance, PMA competes against 
bryostatin 1 in binding to the cysteine-rich C1 modules of PKCs, but promotes cancers.  
The detailed mechanism is uncertain.   
To identify the mechanism, early research was focused on the binding affinity.  Based 
on a computer model, Wender proposed that the northern hemisphere of bryostatin 1 was 
a mere “spacer domain” to retain appropriate spatial orientation, and all the 




helped find out three critical binding sites, which he called a triad.  Later, the Keck group 
and others demonstrated that the C-19 hemiketal and C-21 exo-enoate were as important 
as the triad in retaining the potency to PKC.  Keeping the southern hemisphere almost 
intact, the Keck group prepared several bryostatin analogues with a simplified upper half.  
Their biological properties were evaluated in U937 cell lines and LNCaP cell lines.  Rather 
than displaying bryostatin-like properties, these molecules displayed PMA-like properties.  
The results revealed that substituents on the A- and B-rings of bryostation 1 are critical 
elements for bryostatin-like activity.   
 
Biological Properties of Keck’s Analogues 
As a continual project in our group, the roles of the substituents on the A- and B-rings 
of bryostatin 1 were investigated.  Merle 23 demonstrated a PMA-like pattern in growth 
inhibition and attachment in U937 cells, and differed from bryostatin 1 only at four 
positions, namely the C-7 acetate, C-8 gem-dimethyl, C-9 hydroxyl and C-13 exo-enoate 
(Figure 3.1).1  Therefore, a series of bryostatin derivatives was designed, in which the 
substituents were progressively reintroduced. 
Merle analogues used in structural-feature identification are shown in Figure 3.2.  
Merle 32 differs from Merle 23 in the C-8 gem-dimethyl group and the C-20 side chain.2  
Previously, Merle 22 and 23 already demonstrated that the effect of difference on the side 
chain was trifling on both binding affinity and biological response.1  Merle 27 reintroduces 
the C-7 acetate on Merle 23,3 and Merle 33 further introduces the C-13 exo-enoate.4  In the 
absence of the C-30 carbomethoxy group, Merle 28 is almost a natural bryostatin.  The 




The binding experiments were performed in vitro with mouse PKC-, and almost all 
the analogues maintained their binding affinities at the nanomolar level.  These binding 
results are consistent with our understanding of the relationships between the structure and 
binding affinity, namely that binding largely depends on interactions at the lower half of 
the molecule and is independent of the A- and B-rings at the upper part.   
The relationships between the substitution pattern and biological behavior were 
investigated using U937 leukemia cell assays, because U937 cells respond to PMA and 
bryostatin 1 quite differently.  PMA inhibited cell growth and increased attachment, 
whereas bryostatin 1 caused little growth inhibition and attachment (Figure 3.3).  Merle 
21-23 resembled PMA in both proliferation and attachement.1  Merle 32, which had an 
additional nonpolar gem-dimethyl group, behaved more as PMA in proliferation, but 
showed more biphasic properties in attachment.2  Merle 27 demonstrated that the C-7 
acetate group alone had little change to the bryostatin-like activity (not shown on Figure 
3.3).3  But with two polar groups, Merle 33 displayed more biphasic nature in both 
responses and began to resemble bryostatin 1.4  The two “almost bryostatin” analogues 
(Merle 28 and 30) and bryostatin 2 closely resembled bryostatin 1.5,6  The results of the 
treatments at 72 h are shown in Figure 3.4.7  Obviously, the substituents on the A- and B-
rings altered the biological properties of the molecule.  Substitution patterns determined 
whether the activity was bryostatin-like or PMB-like.  The bryostatin-like or PMB-like 
activity was not all-or-none, and intermediate patterns of activity were also observed.  The 
different extents of bryostatin-like activity indicated that the biological activity could not 
be ascribed to a single substituent or substituents.  It would be the complex integral result 




The effects of these analogues on the induced gene expression of six of the phorbol 
ester regulated genes were investigated in U937 cells.  The genes were treated with the 
analogues at the concentration of 1000 nM (100 nM in the instance of bryostatin 2).  The 
results were detected by qPCR analysis after 24 hours’ treatment.  The U937 cells 
responded to the various analogues to the extents between that of PMA and that of 
bryostatin 1, or a little below for certain instances (Figure 3.5A ).7  The averaged gene 
expression data for all of the genes are shown in Figure 3.5B.  Similar behavior was 
observed in the LNCaP cells after 8 hours’ treatment with the same concentration (Figure 
3.6).  Both systems showed a strong correlation between the bryostatin-like patterns of 
gene expression and the bryostatin-like patterns of biological response, especially in the 
LNCaP cell lines.7   
TNF- secretion is an important contributor to the inhibition of LNCaP cell growth in 
response to PMA.  The same series of analogues were evaluated in the induced secretion 
of TNF- in the LNCaP cell lines.  PMA induced the most TNF- secretion, while 
bryostatin 1 induced the least secretion.  All the other compounds induced the secretion at 
the levels intermediate between that of Merle 23 and bryostatin 1 at 8 h.  Similar general 
behavior was observed in U937 cells.  The compounds’ effectiveness was shown to be 
similar in each experiment.  This further supported our theory that the substitution patterns 
on the A- and B-rings had significant effect on the biological activities of the molecule.   
 
Polarity-Lipophilic Hypothesis 
Previous study of Blumberg et al. revealed that a phorbol ester binding to PKC did not 




3, C-4 and C-20 phorbol ester oxygens form hydrogen bonds with the main-chain groups 
of PKC-δ in the groove of binding.  Phorbol binding capped the groove and forms a 
contiguous hydrophobic surface covering one third of the domain.  The long-chain lipid 
tail of PMA did not interact with PKC in binding, but instead retained itself with the 
membrane.  Thus, the favorable free energy of protein-phorbol binding could be used to 
drive the insertion of the protein into the membrane.  A 2.2 Å resolution X-ray crystal 
structure demonstrated the clear image of the complex of a murine PKC-δ and PMA.  It 
unambiguously exhibited that PMA sits in the binding groove with the long continuous 
hydrophobic surface extending over one third of the complex protein (Figure 2.8).   
Modeling studies have revealed a different mechanism of bryostatin 1 binding to PKC.  
Although bryostatin 1 bound to the same strands of PKC with northern hemisphere capping 
the top of the groove, it bound to both the C1A and C1B modules of the C1 domain.  In 
contrast, PMA selectively bound to the C1B module.  Additionally, PMA caused initial 
translocation of PKC-δ to the plasma membrane, while the highly oxygenated bryostatin 1 
made the translocation of PKC-δ directly to the internal membrane.9,10  The detailed 
mechanism is still uncertain; the polarity of the upper part of bryostatin 1 is probably 
partially responsible for the difference.   
Computational modeling suggested that the surface generated by bryostatin 1 at the top 
of the C1 domain was different from that generated by PMA.  This surface drove novel 
interactions, whether intramolecular interactions with another portion of the PKC molecule 
or intermolecular interactions with other enzymes, adapters or PKC substrate.  Further 
computational study of Merle analogues found that the A- and B-ring regions of bryostatin-




on the evidence, it is reasonable to assume that the appropriate amount of hydrophilicity in 
the A and B-rings makes the special surface at the top of C1 domain, which in turn 
determines the translocalization and protein-protein interactions of the activated PKCs, 
rendering them unique biological functions.  
New-generation analogues are needed to verify this hypothesis.  Beyond that, there are 
several questions.  What is the appropriate amount of hydrophilicity?  What is the specific 
role of the substituents on the upper half of the molecule?  Or, are there conformation 
requirements for the northern hemisphere?  Actually, the des-A ring analogue Merle 29u 
acted as PMA, but it retained high binding affinity and comparable hydrophilicity to Merle 
33 (Figure 3.2).11  In addition, Merle 34 and Merle 38, which were expected to behave 
more towards bryostatin 1, turned out to be PMA-like analogues.12  In these instances, the 
absence of the rigid B-ring was suspected to be the reason. 
 
Sythetic Efforts towards the C-9 Hemiketal Analogue 
The hemiketal hydroxyl group is the most polar group in the upper half of the natural 
molecule.  As a free hydroxyl group, it is also a hydrogen bond donor.  Therefore, it not 
only increases the hydrophilicity of the molecule but also might alter the conformation via 
H-bonding.  To validate the polarity-lipophilic hypothesis, the analogue with the C-9 
hemiketal hydroxyl group was designed.  Besides investigating the role of this functional 
group, we also wish to provide a convergent and efficient synthetic route to access 






SmI2-Medicated Cyclization Strategy 
Previously, our lab developed a strategy to achieve a 2-alkoxytetrahydropyran ring via 
an acylation-reductive cyclization sequence (Scheme 3.1).13  The initial reaction in this 
sequence is to access chiral homoallylic alcohol 3.3.  Taking advantage of the well-
established Keck’s catalytic asymmetric allylation reaction, either enantiomeric 3.3 is 
obtainable in high yield with excellent enantioselectivity.  After an esterification reaction, 
the resulting allyl chloride 3.4 is converted to the more reactive allyl iodide 3.5 by halogen 
exchanging with Finkelstein’s protocol.14  The allyl halide serves as a “stored” allyl 
carbanion, which is available with SmI2 under almost neutral conditions.  Then, the 
diastereomeric mixture hemiketal 3.6 is protected as a relatively stable ketal 3.8 in alcohol 
via an oxocarbenium intermediate 3.7.  Both the anomeric effect and stereoelectronic effect 
favor the most thermodynamically stable isomer 3.8.   
 
Retrosynthetic Plan of Analogue 3.9 
The retrosynthetic analysis of analogue 3.9 is outlined in Figure 3.7.  To fulfill the goal 
of using the SmI2-mediated cyclization strategy, one disconnection was made at the A-ring 
next to the hemiketal.  Once again, the B-ring was planned to be constructed by pyran-
annulation.  Yamaguchi esterification was designed to link the upper and lower halves 
together at the other site.  Therefore, the analogue 3.9 was disconnected into three equally 
important segments, namely 3.10, 3.11, and 3.12.  Based on experience learned from model 
studies, the SmI2-mediated cyclization was planned to be applied at a late stage, since the 
reaction conditions were almost neutral.  To the best of our knowledge by that time, ketals, 




of any additive at room temperaute.15  We wished to take advantage of its chemoselectivity 
to avoid protecting group replacements.  Another reason for this disconnection was to 
obtain the maximum benefits from the previous synthetic work.   
Enal aldehyde 3.10 was prepared with the previous route described in Chapter 2, but 
using modified and scaled approaches with easier manipulations.  Allylchloride 3.12 was 
prepared from the advanced intermediate 2.39.  The route to β-hydroxyallylsilane 3.11 was 
revised, and started with the commercially available compound (S)-(+)-aspartic acid 3.14.  
In the previous route, at least 2 equivalents of β-TMSmethyl-allylstannane 2.21 were 
required to force the CAA reaction into completion, or the product 3.11 could not be 
isolated from the starting materials. In addition, 2.21 was in turn prepared from β-
hydroxyallylsilane over four steps.  Last, the revised route was more environmentally 
friendly.  
 
Results and Discussion  
The synthesis of aldehyde 3.21 began with protection of the commercial chiral 
compound 3.13 with BOMCl under solvent-free conditions (Scheme 3.2).  The BOMCl 
was prepared freshly as previously described, and the sterically hindered Hünig’s base was 
utilized to prevent epimerization.  Ester 3.14 was reduced into aldehyde 3.15 in an almost 
quantitative yield.  A chelation-controlled allylation reaction provided the anti-Felkin 
product 3.16 as a single diastereomer.16  It was protected by PMB-Br and oxidatively 
cleaved with ozone to furnish aldehyde 3.18, which was in turn subjected to a second 
allylation reaction.  Though both chelation-controlled and nonchelation-controlled 1,3-




moderate diastereomeric selectivity was obtained with a variety of chelating and 
nonchelating Lewis acids.  The best result was achieved with MgBr2·OEt2 to afford 6-7:1 
selectivity, favoring the desired isomer 3.19.  After a TBS protection, the olefin 3.20 was 
elongated into terminal aldehyde 3.21 by hydroformylation.19    
Using zinc dust instead of indium metal, prenylation afforded alcohol 3.22 as a 
diasteromeric mixture (Scheme 3.3).20,21   In addition, the usage of relatively expensive 
prenyl bromide was also cut in half.  After a normal workup, no chromatography was 
further needed.  This racemic mixture of alcohol was then converted to ketone 3.23 by 
Swern oxidation in 95% yield over two steps.22  The olefin was oxidatively cleaved by 
ozonolysis.  Since the intermediate 3.24 was partially decomposed on silica gel, by-product 
triphenylphosphine oxide was largely removed from the reaction as precipitate using 1: 4 
Et2O/Hexanes solvent system.  Next was a Horner-Emmons reaction.23 
Thiophosphonoacetate was used at this point, because an ,β-unsaturated thioester, in 
contrast to an ,β-unsaturated alkoxyl ester, could be reduced to ,β-unsaturated aldehyde 
with DIBAL.  Subsequently, the crude product 3.24 was subjected to a Horner-Emmons 
reaction, and the desired ,β-unsaturated thioester 3.25 was obtained as a single 
geometrical isomer in 93% yield over two steps.  Then, the TBS protecting group was 
removed with aqueous HF buffered by pyridine, and a dehydrative cyclization reaction was 
performed with CSA in toluene at reflux to afford 3.27 with 86.3% yield over two steps.  
The major by-product in this step was spiral ketal, which came from the hemiketal 
intermediate.  Finally, enal 3.10 was furnished by DIBAL half-reduction. 
An attempt of olefin metathesis was also made to install the C16-17 internal olefin 




with acrylic ester under various conditions, including with Lewis acids at elevated 
temperature.  A wide variety of reagents, such as crotonic esters, protected allylic alcohol 
and protected crotyl alcohol, were also under investigation but with no success.  
Fortunately, 3.23 was able to be recovered in most situations.  This also implied that 3.23 
was inert to the catalyst because of the sterically hindered gem-dimethyl group.  A similar 
obstacle was reported by Thomas et al.26  In their bryostatin analogue synthesis, ring-
closure metathesis was designed to complete macrocyclization at a late stage.  Compound 
3.28 did not undergo ring-closure metathesis with Grubbs’ II, Hoveyda, or Schrock 
catalysts, but destroyed the olefin connecting to the tetrahydropyran B-ring (Figure 3.8).  
Later, compound 3.30 without gem-dimethyl group at C-18 was prepared, and it was 
successfully macrocyclized with Grubbs’ II catalyst.    
In the revised route, β-hydroxylallylsilane 3.11 was prepared from the commercially 
available (S)-aspartic acid 3.14.  It was converted to bromosuccinate 3.32 by HNO2-
mediated deamination in the presence of potassium bromide (Scheme 3.4).27  Its 
configuration was completely retained under the aid of neighboring group participation of 
the -carboxyl group.28  Diacid 3.32 was subsequently reduced to the corresponding diol 
3.33 with borane-DMS complex in almost quantitative yield.  Using the modified 
Rapoport’s protocol, the oxirane 3.34 was obtained by one-pot reaction of epoxidation and 
silyl ether protection in sequence.27  The freshly prepared Grignard reagent derived from 
3.3529 attacked the less hindered site of the oxirane to afford the allylsilane compound 3.11.  
All the physical data matched those of the compound prepared from the previous route. 
With both enal 3.10 and β-hydroxyallylsilane 3.11 in hand, the simplified B-ring was 




3.5).30  The excess of allylsilane 3.11 was recovered by chromatography.  The syn-
relationship between the C-11 proton and the C-15 proton was proved by NOESY1D 
experiment.  Epoxidation with m-CPBA in methanol followed by epimerization with PPTS 
provided alcohol 3.37 in 90% yield over two steps.  This alcohol was then oxidized to 
ketone 3.38 by DMP in quantitative yield.31   
Prior to Dess-Martin perodinane (DMP), several other oxidants were attempted to 
oxidize 3.37 into 3.38.  TPAP-NMO,32 which achieved success in almost all our analogue 
syntheses, but surpringly failed to do so at room temperature, as did TEMPO-BAIB 
oxidation.33  A variety of activated DMSO oxidations suffered from either incomplete 
reactions, such as Parikh-Doering,34 Swern35 and Corey-Kim,36 or being accompanied with 
significant side products, such as Albright-Goldman oxidation.37  Both PCC38 and PDC39 
could complete the transformation with approximately 80% yield after 10 hours.  The best 
result was obtained with DMP, which provided the desired product in quantitative yield 
after 1 hour.  The IBX, the precursor of DMP, had no success in this transformation.40   
Next, aldol condensation with freshly distilled methyl glyoxylate afforded the 
exclusive E-geometrical isomer 3.39 in presence of K2CO3.  At this point, the syn-
relationship between the C-19 methoxy group and the C-23 proton was confirmed by 
NOESY1D experiment.  A Luche reduction reaction followed by an esterification reaction 
provided the compound 3.41.41  The E-geometry of the C-21 exocyclic enoate was 
confirmed by NOE experiment.  In addition, the chemical shift variation of the enoate 
proton was consistent with its own geometry.   
Synthesis of allylchloride 3.12 was from the intermediate 2.39 (Scheme 3.6).  A 




allylchloride 3.42 in 79% yield and 97% diastereomeric selectivity.  This reaction set the 
desired stereochemistry at the newly formed chiral center, which was proved by Mosher 
ester analysis later.  Next, the hydroxyl group of 3.42 was protected as a TBS ether, and 
the primary TBDPS ether was selectively cleaved with NH4F in MeOH at 60 oC.42  The 
newly liberated alcohol 3.44 was converted to carboxylic acid 3.12 in two sequential 
oxidations.43  
Before the combination of 3.12 and 3.41, some minor modifications were made on the 
latter segment (Scheme 3.7).  The deprotection of the TBDPS ether followed by a DMP 
oxidation reaction converted the silyl ether 3.41 to a corresponding aldehyde.  Then, DDQ-
mediated deprotection of PMB-ether liberated the alcohol at C-25 to afford 3.48 in 93% 
yield.    
Next, the alcohol 3.48 was esterified with 3.12 under Yamaguchi esterification 
conditions to afford compound 3.49 in 92% yield (Scheme 3.8).  According to the SmI2-
mediated cyclization strategy, an esterification between C-5 and C-9 was needed.  
Therefore, the C-9 aldehyde of 3.48 was converted to corresponding acid under Lindgren 
oxidation conditions,43 and the C-5 TBS-protected alcohol was liberated with pyridine-
buffered HF.  Using the high-dilution technique, macrolactonization under Yamaguchi 
esterification conditions was achieved to furnish compound 3.51 in 75% over two steps.  
Subsequently, the relatively inert allylchloride moiety was converted into more reactive 
allyliodide 3.52 with Finkelstein’s protocol in a straightforward fashion.44    
Unfortunately, SmI2-mediated cyclization failed in installing the A-ring on 3.52 under 
the standard conditions previously developed.  The reaction was completed in seconds at 




attempted at -78 oC, but no desired product was observed.  However, using a limited 
amount of SmI2, the decomposed C-20 side chain was identified.  To our great surprise, a 
crude 1H NMR experiment demonstrated that the allyliodide moiety, which was generally 
considered more labile, was intact.  Further investigations revealed that an elimination 
reaction occurred in γ-functionalized ,β-unsaturated carbonyl moiety, which was in the 
C-ring.  This elimination reaction was faster than the planned reductive-cyclization 
reaction.  The detailed discussion is in Chapter 1. 
Thus, an attempt was made to construct the A-ring via a 1,5-hydroxyketone 
intermediate.  The plan was to furnish a ketone at C-11 by an allylation reaction followed 
by an oxidization reaction.  Then the C-11 ketone could react with the C-7 alcohol to form 
the desired hemiketal.  Several metals, including Mg, Zn, In, Pd, Cr and B, were used in 
an attempt to accomplish allylation under a variety of conditions.  Unfortunately, in the 
presence of sensitive functional groups on the C-ring, all the attempts failed because of 
either the decomposition of the C-ring or the dehalogenation of allyl iodide.  Additionally, 
the microscale of this reaction at the late stage of synthesis greatly increased the difficulty 
of manipulations.  
At this point, an attempt was made to make an analogue without an A-ring, which 
would be used to investigate the effect of the absence of an A-ring on the biological 
property of bryostatin 1.  Then, the PMB group was removed from 3.51 with DDQ, and 
the resulting compound was treated with LiBF4 in aqueous acetonitrile at reflux.  The final 
product, 3.56, was unexpected and more complex.  After LiBF4 treatment, the BOM group 
was removed. Instead of staying as free hydroxyl, the newly liberated alcohol at C-26 




turn underwent a Michael addition reaction with exocyclic enoate at C-21 to form a fused 
6-membered ring.  Meanwhile, the C-19 methoxy group was eliminated to furnish a glycal 
moiety.   
Because the C-26 hydroxyl, which is part of an ester, does not exist as a free alcohol, 
it cannot bind to PKCs.  In addition, the elimination of the C-19 hemiketal results in the 
loss of H-bond, which is critical in retaining the optimized conformation of the molecule 
for binding.  Thus, 3.56 is not potent to PKCs.  It is proved by the binding affinity, and no 
further biological evaluation is needed.  
 
Conclusion 
Previous bryostatin analogues demonstrated that the substation patterns on the A- and 
B-rings determined the biological profiles of the molecules.  To investigate the role of the 
C-9 hemiketal and to verify the polarity-lipophilic hypothesis, analogue 3.9 with the C-9 
hemiketal group was designed.  In the designed route, the SmI2-mediated cyclization 
developed in our lab was the key step to install the A-ring at the late stage.  Unfortunately, 
it failed in the attempts because of the elimination of the C-20 side chain.  The failure also 
led us to a discovery of an unreported reaction, which could be applied to deconjugation.  
Its scope of application was further investigated.   
An absent A-ring analogue was finally produced.  In the absence of A-ring, the normal 
size macrolactone was expanded under the deprotection conditions.  This was probably due 
to the favorable conformation for the transesterification.  Since the C-26 alcohol was part 
of an ester, the whole molecule lost PKC potency.  This negative result also proved the C-




The role of C-9 hemiketal in the biological activity of bryostatin 1 is still of interest.  It 
will help us understand the mechanism of how bryostatin 1 regulates PKCs.  Thus analogue 
3.9 is still an important analogue to synthesize. A revised convergent route accessing to 3.9 
is needed for future synthesis.   
 
Experimental Section 
All solvents were dried and distilled according to the guidelines in Purification of 
Laboratory Chemicals, 6th Ed. (Armarego and Chai, Butterworth-Heinemann: Oxford, 
U.K., 2009).  Diisopropylamine, diisopropylethylamine, triethylamine, pyridine, 
dichloromethane and ethyl acetate were distilled from CaH2 under an atmosphere of N2.  
Ether solvents (THF and Et2O) were distilled under N2 from sodium benzophenone ketyl.  
Benzene and toluene were distilled from molten sodium metal under N2.  Solvents and 
reagents were deoxygenated where necessary by Freeze-Pump-Thaw technique and 
refilled with nitrogen prior to use.  Titanium tetrachloride and titanium isopropoxide were 
distilled prior to use.  Deuterated solvents were purchased from Cambridge Isotope 
Laboratories (all ≥ atom% D).  Reagents were purchased from Acros, Aldrich and Alfa, 
and used as received unless stated otherwise.  Argon, oxygen, and syngas (1:1 mixture of 
H2 and CO) were acquired from Airgas and used as received.  Glassware for reactions was 
oven dried at 110 oC for 4 hours and cooled down under a dry atmosphere prior to use, or 
flame-dried under an atmosphere of N2.  All air- and moisture-sensitive manipulations were 
performed by using oven-dried glassware, standard Schlenk techniques and glovebox 
under an atmosphere of N2.  Analytical thin-layer chromatography was performed on 




to UV light (254 nm), and stained with either an ethanolic solution of 12-
molybdophosphoric acid or a solution of KMnO4/K2CO3/NaOH.  Organic solutions were 
concentrated on a rotovap at aspirator pressure at 20-30 oC.  Flash column chromatography 
was performed on SiliaFlash® F60 silica gel (230-400 mesh, 60Å), and eluted with solvents 
indicated.  Melting points were recored using open capillary tubes on a Mel-Temp 
electrochemical melting point apparatus and were uncorrected.  Nuclear magnetic 
resonance (NMR) spectra were acquired on a Variann Inova 500 spectrometer operating at 
500 MHz and 125 MHz for 1H and 13C separately.  All 1H NMR chemical shifts were 
quoted in parts per million (ppm) relative to the line of the CDCl3 residual singlet at 7.27 
ppm (or the C6D6 residual singlet at 7.16 ppm), and 13C NMR chemical shifts were relative 
to the center line of CDCl3 triplet at 77.23 ppm (or the center line of C6D6 triplet at 128.62 
ppm).  Multiplicities in the 1H NMR spectra were described as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, ABq = AB quartet, quin = quintet, sext = sextet, m = 
multiplet, br =broad.  Coupling constants were reported in Hz.  The structural assignments 
of 1H and 13C NMR spectra were elucidated with the aid of gCOSY, gDQCOSY, TOCSY, 
DEPT, HMQC and HMBC experiments.  Stereochemical assignments were based on 
coupling constants where possible, and with the aid of NOSEY1D, ROSEY1D, NOSEY 
and ROSEY experiments.  AA’BB’ systems were reported as doublets.  Infrared (IR) 
spectra were recored from a Perkin Elmer FT-IR Paragon 1000 PC spectrometer using a 
thin film supported between NaCl plates.  Optical rotations were acquired on a Perkin 
Elmer Model 343 polarimeter using Na D-line with a 10 cm path length micro cell at 20 
oC from CHCl3 solutions.  Ozone was generated by a Welsbach model T-816 generator.  





(3.14): To a solution of commercial available isobutyl 
(R)-(+)-lactate 3.13 (25.0 mL, 0.161 mol, 1.0 equiv) in 
freshly distilled N, N-diisopropylethylamine (84.2 mL, 0.483 mol, 3.0 equiv) was added 
benzyl chloromethyl ether (33.2 mL, 0.242 mol, 1.5 equiv) dropwise via syringe at 0 oC.  
This reaction was allowed to warm to room temperature and stirred under an atmosphere 
of N2 for 24 hours.  It was then quenched with 1N HCl solution (150 mL).  The aqueous 
layer was extracted with ethyl ether (3 x 30 mL).  The combined organic layers were 
washed with brine (100 mL) and dried over anhydrous Na2SO4.  The solution was filtrated, 
and concentrated in vacuo.  The yellow crude product was purified by flash 
chromatography on silica gel eluting with 1-3 vol% of ethyl acetate in hexanes to provide 
the tilted compound (40.2 g, 0.151 mol, 93.8% yield) as a yellowish oil. 
TLC:  Rf = 0.54 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +67.3 (c 1.946, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.41-7.27 (m, 5H, H-7, H-7’, H-8, H-8’, H-9), 4.85 (s, 2H, 
H-4), 4.66 (s, 2H, H-5), 4.33 (t, J = 6.8 Hz, 1H, H-2), 3.98-3.83 (m, 2H, H-10), 2.02-1.86 
(m, 1H, H-11), 1.45 (d, J = 6.8 Hz, 3H, H-1), 0.93 (d, J = 6.7 Hz, 6H, H-12a, H-12b); 
125 MHz 13C NMR (CDCl3): δ 173.3 (C-3), 137.9 (C-6), 128.6 (C-8, C-8’), 128.1 (C-7, C-
7’), 127.9 (C-9), 94.1 (C-4), 71.8 (C-2), 71.1 (C-10), 70.1 (C-5), 27.9 (C-11), 19.2 (C-12a), 
19.2 (C-12b), 18.8 (C-1);  
FTIR (neat): νmax 2963, 2893, 1750, 1456, 1379, 1275, 1176, 1121, 1081, 1050, 989, 740, 
699 cm-1; 




(R)-2-(Benzyloxymethoxy)propanal (3.15): To a solution 
of ester 3.14 (4.44 g, 16.7 mmol, 1.0 equiv) in CH2Cl2 (170 
mL, 0.1 M) was introduced DIBAL solution (1.0 M in 
CH2Cl2, 20.0 mL, 20.0 mmol, 1.2 equiv) by a syringe pump at 15 mL/h at -78 oC under an 
atmosphere of N2.  When the reaction was completed (monitored by TLC), methanol (10 
mL) was added to quench this reaction by a syringe pump at 15 mL/h at -78 oC.  The cold 
bath was then removed.  A saturated Rochelle’s salt solution (50 mL) was added, and the 
mixture was stirred vigorously overnight (ca. 8 hours).  The separated aqueous layer was 
extracted with Et2O (3 x 20 mL).  The combined organic layers were washed brine (100 
mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo.  The crude 
colorless oil was purified by flash chromatography on silica gel eluting with 8-10 vol% of 
ethyl acetate in hexanes to provide the titled compound (3.215 g, 16.55 mmol, 99.3% yield) 
as a colorless oil.   
TLC:  Rf = 0.36 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +12.7 (c 1.99, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 9.66 (d, J = 1.5 Hz, 1H, H-3), 7.42-7.28 (m, 5H, H-7, H-7’, 
H-8, H-8’, H-9), 4.88 (s, 2H, H-4), 4.69 (ABq, J = 12.0 Hz, Δν = 22.7 Hz, 2H, H-5), 4.12 
(qd, J = 7.0, 1.5 Hz, 1H, H-2), 1.34 (d, J =7.0 Hz, 3H, H-1);  
125 MHz 13C NMR (CDCl3): δ 202.7 (C-3), 137.5 (C-6), 128.7 (C-8, C-8’), 128.1 (C-9), 
128.0 (C-7, C-7’), 94.4 (C-4), 78.4 (C-2), 70.3 (C-5), 15.5 (C-1);  
FTIR (neat): νmax 3065, 3033, 2938, 2892, 2813, 2718, 1737, 1498, 1454, 1380, 1176, 1108, 
1042, 909, 741 cm-1; 




 (2R,3R)-2-(Benzyloxymethoxy)hex-5-en-3-ol (3.16): 
To a solution of aldehyde 3.15 (3.616 g, 18.62 mmol, 1.0 
equiv) in CH2Cl2 (100 mL, 0.2 M) was added MgBr2·OEt2 
(9.62 g, 37.3 mmol, 2.0 equiv) in one portion.  This reaction was then stirred at room 
temperature for 20 minutes under an atmosphere of N2.  It was cooled down to -15 oC, and 
allyltributyltin 2.59 (6.9 ml, 22 mmol, 1.2 equiv) was introduced dropwise via syringe.  It 
was stirred for a further 6 hours, then quenched with saturated NaHCO3 solution (100 mL) 
at -15 oC.  This reaction was allowed to warm to room temperature.  The aqueous layer 
was extracted with ethyl ether (3 x 30 mL).  The combined organic layers were washed 
with brine (100 mL) and dried over anhydrous Na2SO4.  The solution was filtrated and 
concentrated by rotary evaporation.  The residue was dissolved in acetonitrile (150 ml), 
and washed with hexanes (50 mL).  The solution of acetonitrile was concentrated to provide 
a colorless oil.  The crude product was purified by flash chromatography on silica gel 
eluting with 0-6 vol% of acetone in hexanes to provide titled compound (3.982 g, 16.85 
mmol, 90.5% yield, single diastereomer) as a coloress oil. 
TLC:  Rf = 0.32 (EtOAc/Hex = 3:7, v/v); 
[α]20 D -31.9 (c 0.765, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.39-7.29 (m, 5H, H-10, H-10’, H-11, H-11’, H-12), 5.91 
(dddd, J = 6.5, 7.6, 10.3, 17.1 Hz, 1H, H-5), 5.15 (dddd, J = 1.2, 1.5, 1.5, 17.1 Hz, 1H, H-
6a), 5.12 (dddd, J = 1.2, 1.2, 1.5, 10.3 Hz, 1H, H-6b), 4.86 (ABq, J = 7.3 Hz, Δν = 20.7 
Hz, 2H, H-7), 4.66 (ABq, J = 12.0 Hz, Δν = 17.0 Hz, 2H, H-8), 3.68 (dq, J = 5.9, 6.4 Hz, 
1H, H-2), 3.56 (dddd, J = 4.1, 4.4, 5.9, 8.1 Hz, 1H, H-3), 2.60 (d, J = 4.4 Hz, 1H, -OH), 




14.4 Hz, 1H, H-4b), 1.24 (d, J = 6.4 Hz, 3H, H-1);  
125 MHz 13C NMR (CDCl3): δ 137.8 (C-9), 134.9 (C-5), 128.7 (C-11, C-11’,), 128.1 (C-
10, C-10’), 128.0 (C-12), 117.6 (C-6), 94.1 (C-7), 77.5 (C-2), 74.4 (C-3), 70.0 (C-8), 37.8 
(C-4), 16.9 (C-1);  
FTIR (neat): νmax 3461 (br), 3070, 3032, 2977, 2891, 1642, 1497, 1381, 1285, 1208, 1104, 
1042, 915, 739, 699 cm-1; 
HRMS(ESI-TOF) m/z: [M+Na+] Calcd for C14H20O3Na 259.1310; found 259.1311. 
Determination of Absolute Configuration of the New Stereocenter of (2R,3R)-2-
(Benzyloxymethoxy)hex-5-en-3-ol (3.16) via Mosher Ester Method:  
(2R,3R)-2-(Benzyloxymethoxy)hex-5-en-3-yl (S)-
α-Methoxy-α-(trifluoromethyl)phenylacetate 
(3.16-S-MTPA): To a screw-capped vial equipped 
with a stirring bar was added alcohol 3.16 (30.5 mg, 
0.129 mmol, 1.0 equiv), (S)-(-)-MTPA-OH acid (34.1 mg, 0.143 mmol, 1.1 equiv), DMAP 
(15.9 mg, 0.129 mmol, 1.0 equiv) and subsequently toluene (2.5 mL, 0.05 M), at room 
temperature.  Freshly distilled NEt3 (90 uL, 0.65 mmol, 5.0 equiv) was then added to this 
mixture.  This reaction was cooled down to 0 oC, 2,4,6-trichlorobenzoylchloride (22.6 uL, 
0.142 mmol, 1.1 equiv) was then added dropwise via syringe.  The reaction turned cloudy 
and precipitated immediately.  The vial was tightly capped.  The reaction was allowed to 
warm to room temperature slowly, and stirred for 6 hours.  Then, the resulting yellow 
mixture was concentrated and purified by flash chromatography on silica gel eluting with 
5-7 vol% of ethyl ether in hexanes to provide the titled compound (56.0 mg, 0.124 mmol, 




TLC:  Rf = 0.55 (EtOAc/Hex = 3:7, v/v); 
[α]20 D -22.5 (c 2.47, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.61-7.53 (m, 2H, Ph-2, Ph-2’), 7.42-7.29 (m, 8H, H-10, 
H-10’, H-11, H-11’, H-12, Ph-3, Ph-3’, Ph-4), 5.79 (dddd, J = 5.9, 7.8, 10.2, 17.1 Hz, 1H, 
H-5), 5.21 (ddd, J = 4.1, 5.9, 8.3 Hz, 1H, H-3), 5.14 (dddd, J = 1.5, 1.5, 2.0, 17.1 Hz, 1H, 
H-6a), 5.12 (dddd, J = 1.2, 1.5, 1.5, 10.2 Hz, 1H, H-6b), 4.63 (s, 2H, H-7), 4.53 (ABq, J = 
11.7 Hz, Δν = 18.0 Hz, 2H, H-8), 3.87 (dq, J = 5.9, 6.3 Hz, 1H, H-2), 3.58 (s, 3H, -OMe), 
2.58 (ddddd, J = 1.5, 2.0, 4.1, 5.9, 14.9 Hz, 1H, H-4a), 2.41 (ddddd, J = 1.2, 1.5, 7.8, 8.3, 
14.9 Hz, 1H, H-4b), 1.12 (d, J = 6.3 Hz, 3H, H-1);  
125 MHz 13C NMR (CDCl3): δ 166.4 (C=O), 137.9 (C-9), 133.3 (C-5), 132.4 (Ph-1), 129.7 
(Ph-4), 128.6 (C-11, C-11’), 128.5 (Ph-2, Ph-2’), 128.0 (C-10, C-10’), 127.9 (C-12), 127.6 
(Ph-3, Ph-3’), 123.5 (q, JC-F = 288.7 Hz, -CF3), 118.8 (C-6), 94.1 (C-7), 84.7 (q, JC-F = 
27.7 Hz, -CC=O), 78.1 (C-2), 73.3 (C-3), 69.7 (C-8), 55.9 (-OMe), 34.2 (C-4), 16.1 (C-1);  
FTIR (neat): νmax 3033, 2950, 2361, 1747, 1453, 1267, 1170, 1113, 1081, 1024, 720, 698 
cm-1; 
HRMS(ESI-TOF) m/z: [M+Na+] Calcd for C24H27O5F3Na 475.1708; found 475.1700. 
(2R,3R)-2-(Benzyloxymethoxy)hex-5-en-3-yl (R)-
α-Methoxy-α-(trifluoromethyl)phenylacetate 
(3.16-R-MTPA): To a screw-capped vial equipped 
with a stirring bar was added alcohol 3.16 (26.5 mg, 
0.112 mmol, 1.0 equiv), (R)-(+)-MTPA-OH acid (29.2 mg, 0.126 mmol, 1.1 equiv), DMAP 
(13.9 mg, 0.113 mmol, 1.0 equiv) and subsequently toluene (2.5 mL, 0.05 M), at room 




mixture.  This reaction was cooled down to 0 oC, 2,4,6-trichlorobenzoylchloride (19.7 uL, 
0.124 mmol, 1.1 equiv) was then added dropwise via syringe.  The reaction turned cloudy 
and precipitated immediately.  The vial was tightly capped.  The reaction was allowed to 
warm to room temperature slowly, and stirred for 6 hours.  Then, the resulting yellow 
mixture was concentrated and purified by flash chromatography on silica gel eluting with 
5-7 vol% of ethyl ether in hexanes to provide the titled compound (43.6 mg, 0.0964 mmol, 
85.9% yield) as a colorless oil. 
TLC:  Rf = 0.53 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +24.0 (c 1.825, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.63-7.54 (m, 2H, Ph-2, Ph-2’), 7.45-7.28 (m, 8H, H-10, 
H-10’, H-11, H-11’, H-12, Ph-3, Ph-3’, Ph-4), 5.68 (dddd, J = 6.1, 8.1, 10.3, 17.1 Hz, 1H, 
H-5), 5.20 (ddd, J = 3.9, 5.9, 7.8 Hz, 1H, H-3), 5.05 (dddd, J = 1.2, 1.5, 1.5, 17.1 Hz, 1H, 
H-6a), 5.03 (dddd, J = 1.2, 1.5, 1.5, 10.3 Hz, 1H, H-6b), 4.78 (ABq, J = 7.1 Hz, Δν = 20.5 
Hz, 2H, H-7), 4.61 (ABq, J = 11.7 Hz, Δν = 24.1 Hz, 2H, H-8), 3.93 (dq, J = 5.9, 6.4 Hz, 
1H, H-2), 3.55 (s, 3H, -OMe), 2.55 (ddddd, J = 1.5, 1.5, 3.9, 6.1, 14.6 Hz, 1H, H-4a), 2.36 
(ddddd, J = 1.2, 1.2, 7.8, 8.1, 14.6 Hz, 1H, H-4b), 1.25 (d, J = 6.4 Hz, 3H, H-1);  
125 MHz 13C NMR (CDCl3): δ 166.4 (C=O), 137.8 (C-9), 132.8 (C-5), 132.3 (Ph-1), 129.8 
(Ph-4), 128.7 (C-11, C-11’), 128.5 (Ph-2, Ph-2’), 128.1 (C-10, C-10’), 128.0 (C-12), 127.9 
(Ph-3, Ph-3’), 123.6 (q, JC-F = 288.6 Hz, -CF3), 118.8 (C-6), 94.1 (C-7), 84.9 (q, JC-F = 
27.7 Hz, -CC=O), 78.2 (C-2), 73.5 (C-3), 69.8 (C-8), 55.6 (-OMe), 34.4 (C-4), 16.5 (C-1);  
FTIR (neat): νmax 3068, 2949, 1748, 1644, 1497, 1453, 1381, 1255, 1171, 1115, 1044, 921, 
851, 699 cm-1; 




The chemical shift differences (in ppm) between the (S)- and (R)-MTPA Mosher esters 
of the alcohol 3.16 were consistent for a (R)-configuration of the new formed stereocenter.  
(4R,5R)-5-(Benzyloxymethoxy)-4-(4-
methoxybenzyloxy)hex-1-ene (3.17): To a 1L rb. flask 
was charged KH (dispersion in mineral oil ~35%, 7.99g, 
69.7 mmol, 1.5 equiv) and freshly distilled THF (140 mL, 
0.5 M).  With an ice-water bath, a solution of alcohol 3.16 (10.97 g, 46.41 mmol, 1.0 equiv) 
in dry THF (230 mL, 0.2 M) was added into the reaction flask dropwise via cannula over 
30 minutes.  After addition, it was then stirred under an atmosphere of N2 for 10 minutes.  
A solution of PMB-Br (14.09 g, 70.09 mmol, 1.5 equiv) in dry THF (140 mL, 0.5 M) was 
added into this reaction via cannula over 30 minutes.  This reaction was stirred in this 
condition for 30 minutes, and quenched with ice cubes carefully.  It was poured into a 
saturated NaHCO3 solution (300 mL).  The aqueous layer was extracted by ether (3 x 50 
mL).  The combined organic layers were washed with brine (200 mL) and dried over 
anhydrous Na2SO4.  The solution was filtrated and concentrated by rotary evaporation.  The 
residue was purified by flash chromatography on silica gel eluting with 3-10 vol% of ethyl 
ether in hexanes to provide a coloress oil (16.54 g, 46.41 mmol, 100% yield). 
TLC:  Rf = 0.47 (EtOAc/Hex = 3:7, v/v); 




500 MHz 1H NMR (CDCl3): δ 7.38-7.32 (m, 4H, H-10, H-10’, H-11, H-11’), 7.32-7.29 
(m, 1H, H-12), 7.27 (d, J = 8.8 Hz, 2H, H-15, H-15’), 6.87 (d, J = 8.8 Hz, 2H, H-16, H-
16’), 5.88 (dddd, J = 6.8, 7.3, 10.3, 17.1 Hz, 1H, H-5), 5.12 (dddd, J = 1.0, 1.5, 2.0, 17.1 
Hz, 1H, H-6a), 5.06 (dddd, J = 1.0, 1.2, 2.0, 10.3 Hz, 1H, H-6b), 4.84 (ABq, J = 7.1 Hz, 
Δν = 12.0 Hz, 2H, H-7), 4.63 (s, 2H, H-8), 4.55 (ABq, J = 11.5 Hz, Δν = 10.2 Hz, 2H, H-
13), 3.90 (dq, J = 4.9, 6.3 Hz, 1H, H-2), 3.80 (s, 3H, H-18), 3.44 (ddd, J = 4.4, 4.9, 7.3 Hz, 
1H, H-3), 2.43 (ddddd, J = 1.0, 1.5, 4.4, 6.8, 14.4 Hz, 1H, H-4a), 2.31 (ddddd, J = 1.0, 1.2, 
7.3, 7.3, 14.4 Hz, 1H, H-4b), 1.21 (d, J = 6.3 Hz, 3H, H-1);  
125 MHz 13C NMR (CDCl3): δ 159.3 (C-17), 138.1 (C-9), 135.6 (C-5), 130.9 (C-14), 129.7 
(C-15, C-15’), 128.6 (C-11, C-11’), 128.0 (C-10, C-10’), 127.8 (C-12), 117.0 (C-6), 113.9 
(C-16, C-16’), 94.1 (C-7), 81.3 (C-3), 74.2 (C-2), 72.4 (C-13), 69.7 (C-8), 55.4 (C-18), 
34.7 (C-4), 16.2 (C-1);  
FTIR (neat): νmax 2953, 2924, 2854, 1614, 1587, 1514, 1463, 1377, 1302, 1248, 1172, 1112, 
1043, 911, 820, 776, 734, 666, 590 cm-1; 
HRMS(ESI-TOF) m/z: [M+Na+] Calcd for C22H28O4Na 379.1885; found 379.1891. 
(3R,4R)-4-Benzyloxymethoxy-3-(4-
methoxybenzyloxy)pentalal (3.18): To a solution of 
olefin 3.17 (6.404 g, 17.97 mmol, 1.0 equiv) in CH2Cl2 
(180 mL, 0.1 M) was purged with O3 (3 Psi, 60 Volts) at -
78 oC.  When the colorless reaction turned pinkish, the O3 was turned off, and O2 flushed 
through the reaction until it turned colorless again.  Triphenylphospine (5.724 g, 21.82 
mmol, 1.2 equiv) was then was added into this reaction.  It was allowed to warm to room 




was purified by flash chromatography on silica gel eluting with 8-15 vol% of ethyl acetate 
in hexanes to provide the titled compound (5.443 g, 15.19 mmol, 84.5% yield) as a 
yellowish oil. 
TLC:  Rf = 0.24 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +1.1 (c 1.74, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.75 (dd, J = 1.5, 2.4 Hz, 1H, H-5), 7.41-7.28 (m, 5H, H-9, 
H-9’, H-10, H-10’, H-11), 7.24 (d, J = 8.8 Hz, 2H, H-14, H-14’), 6.87 (d, J = 8.8 Hz, 2H, 
H-15, H-15’), 4.79 (ABq, J = 7.1 Hz, Δν = 21.6 Hz, 2H, H-6), 4.60 (s, 2H, H-7), 4.53 
(ABq, J = 11.2 Hz, Δν = 11.5 Hz, 2H, H-12), 4.04 (ddd, J = 4.4, 4.4, 7.8 Hz, 1H, H-3), 
4.00 (dq, J = 4.4, 6.3 Hz, 1H, H-2), 3.80 (s, 3H, H-17), 2.68 (ddd, J = 1.5, 4.4, 16.6 Hz, 
1H, H-4a), 2.62 (ddd, J = 2.4, 7.8, 16.6 Hz, 1H, H-4b), 1.21 (d, J = 6.3 Hz, 2H, H-1);  
125 MHz 13C NMR (CDCl3) δ 201.6 (C-5), 159.5 (C-16), 137.9 (C-8), 130.2 (C-13), 129.8 
(C-14, C-14’), 128.7 (C-10, C-10’), 128.0 (C-9, C-9’), 128.0 (C-11), 114.0 (C-15, C-15’), 
93.7 (C-6), 75.6 (C-3), 73.1 (C-2), 72.3 (C-12), 70.0 (C-7), 55.5 (C-17), 44.4 (C-4), 15.1 
(C-1);  
FTIR (neat): νmax 2891, 1725, 1613, 1514, 1458, 1384, 1302, 1249, 1175, 1039, 822, 741, 
699, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C21H26O5Na 381.1678; found 381.1680. 
(4S,6R,7R)-7-(Benzyloxymethoxy)-6-(4-
methoxybenzyloxy)oct-1-en-4-ol (3.19): To a stirred 
solution of aldehyde 3.18 (4.999 g, 13.95 mmol, 1.0 equiv) 
in CH2Cl2 (150 mL, 0.1 M) was added MgBr2·OEt2 




It was stirred under an atmosphere of N2 for 20 minutes, and then cooled down to -78 oC 
and stirred for further 15 minutes.  Then, allyltributyltin 2.59 (6.5 ml, 21 mmol, 1.5 equiv) 
was introduced dropwise via syringe.  It was allowed to warm to 0 oC slowly over 10 hours.  
A saturated solution of NaHCO3 (100 mL) was added into this reaction.  The aqueous layer 
was extracted with EtOAc (3 x 30 mL).  After being washed with brine (100 mL), the 
combined organic layers were stirred with salt of KF·2H2O and anhydrous Na2SO4 for 30 
minutes at room temperature.  The solution was filtrated and concentrated by rotary 
evaporation.  The pale yellow residue was purified by flash chromatography on silica gel 
eluting with 5-15 vol% of acetone in hexanes to provide the titled compound as a yellowish 
oil (5.262 g, 13.14 mmol, 94.2% yield, dr = 6-7:1 in favor of the desired product). 
TLC:  Rf = 0.24 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +34.6 (c 0.89, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.41-7.35 (m, 4H, H-12, H-12’, H-13, H-13’), 7.35-7.30 
(m, 1H, H-14), 7.28 (d, J = 8.7 Hz, 2H, H-17, H-17’), 6.88 (d, J = 8.7 Hz, 2H, H-18, H-
18’), 5.84 (dddd, J = 7.3, 7.3, 11.7, 16.8 Hz, 1H, H-7), 5.12 (td, J = 1.5, 16.8 Hz, 1H, H-
8a), 5.12 (td, J = 1.0, 11.7 Hz, 1H, H-8b), 4.86 (ABq, J = 6.8 Hz, Δν = 11.8 Hz, 2H, H-9), 
4.65 (ABq, J = 6.8 Hz, Δν = 4.9 Hz, 2H, H-10), 4.63 (d, J = 11.0 Hz, 1H, H-15a), 4.54 (d, 
J = 11.0 Hz, 1H, H-15b), 4.02 (dq, J = 4.1, 6.4 Hz, 1H, H-2), 3.86 (app. quin, J = 6.3 Hz, 
1H, H-5), 3.80 (s, 3H, H-20), 3.77 (app. dt, J = 4.3, 6.3 Hz, 1H, H-3), 2.37 (br. s, 1H, -
OH), 2.26 (ddd, J = 5.9, 6.8, 14.2 Hz, 1H, H-6a), 2.22 (ddd, J = 6.3, 7.3, 14.2 Hz, 1H, H-
6b), 1.68 (dd, J = 5.4, 6.8 Hz, 1H, H-4a), 1.68 (dd, J = 5.4, 6.8 Hz, 1H, H-4b), 1.22 (d, J = 
6.4 Hz, 3H, H-1);  




129.7 (C-17, C-17’), 128.5 (C-13, C-13’), 127.9 (C-12, C-12’), 127.8 (C-14), 117.9 (C-8), 
113.9 (C-18, C-18’), 93.8 (C-9), 78.3 (C-3), 73.9 (C-2), 72.6 (C-15), 69.6 (C-10), 67.8 (C-
5), 55.3 (C-20), 42.6 (C-6), 36.5 (C-4), 15.6 (C-1); 
FTIR (neat): νmax 3453 (br.), 2974, 2933, 2837, 2060, 1999, 1883, 1613, 1514, 1455, 1382, 
1302, 1249, 1175, 1113, 1063, 1040, 820, 748, 699, 666, 586, 535 cm-1; 
HRMS(ESI-TOF) m/z: [M+Na+] Calcd for C24H32O5Na 423.2147; found 423.2153. 
Determination of Absolute Configuration of the New Stereocenter of (4S,6R,7R)-





MTPA):To a screw-capped vial equipped with a 
stirring bar was added alcohol 3.19 (25.9 mg, 64.7 umol, 1.0 equiv), (S)-(-)-MTPA-OH 
acid (17.3 mg, 72.4 umol, 1.1 equiv), DMAP (8.7 mg, 71 umol, 1.0 equiv), and 
subsequently toluene (1.5 mL, 0.05 M), at room temperature.  Freshly distilled NEt3 (45.0 
uL, 323 umol, 5.0 equiv) was then added to this mixture.  This reaction was cooled down 
to 0 oC, 2,4,6-trichlorobenzoylchloride (11.5 uL, 72.1 umol, 1.1 equiv) was then added 
dropwise via syringe.  The reaction turned cloudy and precipitated immediately.  The vial 
was tightly capped.  The reaction was allowed to warm to room temperature slowly, and 
stirred overnight (ca. 10 hours).  Then, the resulting white mixture was concentrated and 
purified by flash chromatography on silica gel eluting with 10-15 vol% of ethyl ether in 





TLC:  Rf = 0.47 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +22.3 (c 1.87, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.58 (dd, J = 2.4, 8.3 Hz, 2H, Ph-2, Ph-2’), 7.44-7.30 (m, 
8H, H-12, H-12’, H-13, H-13’, H-14, Ph-3, Ph-3’, Ph-4), 7.28 (d, J = 8.3 Hz, 2H, H-17, 
H-17’), 6.88 (d, J = 8.3 Hz, 2H, H-18, H-18’), 5.67 (dddd, J = 6.8, 6.8, 11.0, 15.9 Hz, 1H, 
H-7), 5.46 (dddd, J = 2.9, 5.4, 5.9, 9.5 Hz, 1H, H-5), 5.02 (dt, J = 10.7, 1.5 Hz, 1H, H-8a), 
5.02 (dt, J = 16.1, 1.6 Hz, 1H, H-8b), 4.76 (ABq, J = 7.1 Hz, Δν = 26.1 Hz, 2H, H-9), 4.60 
(ABq, J = 12.0 Hz, Δν = 23.2 Hz, 2H, H-10), 4.53 (d, J = 10.7 Hz, 1H, H-15a), 4.38 (d, J 
= 10.7 Hz, 1H, H-15b), 3.98 (dq, J = 4.9, 6.3 Hz, 1H, H-2), 3.80 (s, 3H, H-20), 3.52 (s, 3H, 
-OMe), 3.47 (ddd, J = 2.0, 4.9, 10.7 Hz, 1H, H-3), 2.43 (tddd, J = 1.5, 5.4, 6.8, 14.2 Hz, 
1H, H-6a), 2.38 (tddd, J = 1.6, 5.9, 6.8, 14.2 Hz, 1H, H-6b), 1.92 (ddd, J = 2.0, 9.8, 14.9 
Hz, 1H, H-4a), 1.73 (ddd, J = 2.9, 10.7, 14.9 Hz, 1H, H-4b), 1.17 (d, J = 6.3 Hz, 3H, H-
1);   
125 MHz 13C NMR (CDCl3): δ 166.4 (-C=O), 159.5 (C-19), 138.0 (C-11), 132.9 (C-7), 
132.2 (Ph-1), 130.5 (C-16), 129.9 (C-17, C-17’), 129.8 (Ph-4), 128.7 (C-13, C-13’), 128.6 
(C-12, C-12’), 128.0 (Ph-2, Ph-2’), 127.9 (C-14), 127.8 (Ph-3, Ph-3’), 123.6 (q, JC-F = 
288.4 Hz, -CF3), 118.8 (C-8), 114.1 (C-18, C-18’), 93.3 (C-9), 84.8 (q, JC-F = 28.2 Hz, -
CC=O), 77.1 (C-3), 73.9 (C-5), 72.8 (C-2), 72.6 (C-15), 69.6 (C-10), 55.6 (-OMe), 55.5 
(C-20), 39.3 (C-6), 34.1 (C-4), 14.9 (C-1);  
FTIR (neat): νmax 3066, 2936, 1744, 1613, 1514, 1250, 1169, 1114, 1040, 991, 820, 698, 
666, 631, 538 cm-1; 







To a screw-capped vial equipped with a stirring bar 
was added alcohol 3.19 (25.6 mg, 63.9 umol, 1.0 equiv), (R)-(+)-MTPA-OH acid (17.6 mg, 
74.4 umol, 1.1 equiv), DMAP (9.7 mg, 78.6 umol, 1.0 equiv), and subsequently toluene 
(1.5 mL, 0.05 M) at room temperature.  Freshly distilled NEt3 (45.0 uL, 323 umol, 5.0 
equiv) was then added to this mixture.  This reaction was cooled down to 0 oC, 2,4,6-
trichlorobenzoylchloride (11.5 uL, 72.1 umol, 1.1 equiv) was then added dropwise via 
syringe.  The reaction turned cloudy and precipitated immediately.  The vial was tightly 
capped.  The reaction was allowed to warm to room temperature slowly, and stirred for 6 
hours.  Then, the resulting yellow solution was concentrated and purified by flash 
chromatography on silica gel eluting with 8-15 vol% of ethyl ether in hexanes to provide 
the titled compound (39.4 mg, 63.9 umol, 100% yield) as a colorless oil. 
TLC:  Rf = 0.53 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +56.7 (c 1.75, CHCl3); 
500 MHz 1H NMR (CDCl3): δ 7.59 (dd, J = 2.4, 8.3 Hz, 2H, Ph-2, Ph-2’), 7.43-7.31 (m, 
8H, H-12, H-12’, H-13, H-13’, H-14, Ph-3, Ph-3’, Ph-4), 7.29 (d, J = 8.8 Hz, 2H, H-17, 
H-17’), 6.90 (d, J = 8.8 Hz, 2H, H-18, H-18’), 5.77 (dddd, J = 7.1, 7.1, 11.8, 17.8 Hz, 1H, 
H-7), 5.47 (dddd, J = 2.4, 5.9, 5.9, 10.5 Hz, 1H, H-5), 5.11 (dq, J = 11.2, 1.5 Hz, 1H, H-
8a), 5.10 (dq, J = 17.6, 1.5 Hz, 1H, H-8b), 4.67 (ABq, J = 7.1 Hz, Δν = 34.7 Hz, 2H, H-9), 
4.57 (ABq, J = 12.2 Hz, Δν = 31.4 Hz, 2H, H-10), 4.50 (d, J = 10.3 Hz, 1H, H-15a), 4.34 




(s, 3H, -OMe), 3.33 (ddd, J = 2.0, 4.9, 10.7 Hz, 1H, H-3), 2.48 (app. tt, J = 1.5, 7.1 Hz, 2H, 
H-6), 1.86 (ddd, J = 2.0, 10.3, 14.6 Hz, 1H, H-4a), 1.70 (ddd, J = 2.4, 10.5, 14.6 Hz, 1H, 
H-4b), 1.12 (d, J = 6.3 Hz, 3H, H-1);   
125 MHz 13C NMR (CDCl3): δ 166.5 (-C=O), 159.5 (C-19), 138.0 (C-11), 133.1 (C-7), 
132.4 (Ph-1), 130.6 (C-16), 129.8 (C-17, C-17’, Ph-4), 128.6 (C-13, C-13’), 128.6 (C-12, 
C-12’), 128.0 (Ph-2, Ph-2’), 127.9 (C-14), 127.6 (Ph-3, Ph-3’), 123.6 (q, JC-F = 288.8 Hz, 
-CF3), 118.9 (C-8), 114.1 (C-18, C-18’), 93.2 (C-9), 84.5 (q, JC-F = 27.7 Hz, -CC=O), 77.1 
(C-3), 73.9 (C-5), 73.0 (C-15), 72.5 (C-2), 69.5 (C-10), 55.7 (-OMe), 55.5 (C-20), 39.5 (C-
6), 34.1 (C-4), 14.9 (C-1);  
FTIR (neat): νmax 3065, 2935, 1745, 1681, 1613, 1514, 1454, 1251, 1167, 1113, 1064, 1041, 
990, 922, 821, 698 cm-1; 
HRMS(ESI-TOF) m/z: [M+Na+] Calcd for C34H39O7F3Na 639.2546; found 639.2548. 
The chemical shift differences (in ppm) between the (S)- and (R)-MTPA Mosher esters 
of the (4S,6R,7R)-7-(benzyloxymethoxy)-6-(4-methoxybenzyloxy)oct-1-en-4-ol 3.16 were 
consistent for a (S)-configuration of the new formed stereocenter.  
(4S,6R,7R)-7-(Benzyloxymethoxy)-4-(tert-
butyldimethylsilyloxy)-6-(4-methoxybenzyloxy)oct-
1-ene (3.20): To a stirred solution of alcohol 3.19 (5.135 




added imidazole (3.583 g, 52.10 mmol, 4.0 equiv), and subsequently TBSCl (3.989 g, 
25.67 mmol, 2.0 equiv) at room temperature.  This reaction was stirred under an 
atmosphere of N2 for 24 hours.  Then, it was diluted with Et2O (100 mL), and the reaction 
was poured into a saturated solution of NaHCO3 (200 mL).  The aqueous layer was 
extracted by Et2O (3 x 30 mL).  The combined organic layers were washed with brine (100 
mL) and dried over anhydrous Na2SO4.  The solution was filtered and concentrated under 
reduced pressure to provide a yellowish oil.  The crude product was purified by flash 
chromatography on silica gel eluting with 2-6 vol% of ethyl acetate in hexanes to provide 
the titled compound (6.426 g, 12.48 mmol, 97.4% yield) as a yellowish oil.   
TLC:  Rf = 0.67 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +26.7 (c 1.62, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.41-7.29 (m, 5H, H-12, H-12’, H-13, H-13’, H-14), 7.27 
(d, J = 8.8 Hz, 2H, H-17, H-17’), 6.89 (d, J = 8.8 Hz, 2H, H-18, H-18’), 5.85 (dddd, J = 
7.1, 7.1, 9.5, 17.8 Hz, 1H, H-7), 5.06 (app. dt, J = 9.5, 1.5 Hz, 1H, H-8a), 5.06 (app. dt, J 
= 17.8, 2.0 Hz, 1H, H-8b), 4.83 (ABq, J = 6.8 Hz, Δν = 10.1 Hz, 2H, H-9), 4.65 (ABq, J = 
12.9 Hz, Δν = 16.9 Hz, 2H, H-10), 4.61 (d, J = 11.0 Hz, 1H, H-15a), 4.49 (d, J = 11.0 Hz, 
1H, H-15b), 4.03 (dq, J = 4.9, 6.3 Hz, 1H, H-2), 4.00 (dddd, J = 3.4, 4.9, 6.3, 7.7 Hz, 1H, 
H-5), 3.82 (s, 3H, H-20), 3.68 (ddd, J = 3.4, 4.9, 8.8 Hz, 1H, H-3), 2.36-2.25 (m, 2H, H-
6), 1.68 (ddd, J = 3.4, 7.7, 14.2 Hz, 1H, H-4a), 1.63 (ddd, J= 3.4, 8.8, 14.2 Hz, 1H, H-4b), 
1.20 (d, J = 6.3 Hz, 3H, H-1), 0.92 (s, 9H, H-23), 0.10 (s, 3H, H-21a), 0.08 (s, 3H, H-21b);  
125 MHz 13C NMR (CDCl3) δ 159.3 (C-19), 138.1 (C-11), 134.9 (C-7), 131.1 (C-16), 
129.3 (C-17, C-17’), 128.6 (C-13, C-13’), 128.0 (C-12, C-12’), 127.8 (C-14), 117.3 (C-8), 




5), 55.5 (C-20), 43.1 (C-6), 37.4 (C-4), 26.1 (C-23), 18.3 (C-22), 15.3 (C-1), -3.6 (C-21a), 
-4.3 (C-21b);   
FTIR (neat): νmax 3068, 2954, 2857, 1613, 1514, 1463, 1381, 1302, 1250, 1173, 1100, 1042, 
914, 835, 775, 698 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C30H46O5SiNa 537.3012; found 537.3022.  
(5S,7R,8R)-8-(Benzyloxymethoxy)-5-(tert-
butyldimethylsilyloxy)-7-(4-
methoxybenzyloxy)nonanal (3.21): To an oven-
dried flask equipped with a stirring bar was added 
dicarbonylacetylacetonatorhodium (I) (9.3 mg, 0.036 mmol, 0.5 mol%), BIPHEPHOS 
(113 mg, 0.144 mmol, 2.0 mol%) and freshly distilled degassed THF (70 mL).  This flask 
was evacuated and refilled with N2 by 3 times.  It was then stirred at room temperature 
under an atmosphere of N2 for 10 minutes, whereupon the mixture was dissolved.  The 
solution of olefin 3.20 (3.699 g, 7.185 mmol, 1.0 equiv) in degassed THF (7 mL, 1.0 M) 
was added into this flask via cannula.  This flask was unsealed and put into Parr autoclave 
quickly.  Then the Parr pressure vessel was sealed tightly.  The atmosphere of this reaction 
vessel was exchanged with 100 psi of CO/H2 (1:1 mixture) three times by being evacuated 
with an oil pump and refilled with syngas.  Then, the reaction vessel was pressurized with 
CO/H2 (1:1 mixture) at 100 psi, and stirred at 57 oC for 36 hours.  After cooling to room 
temperature, the reaction was depressurized and concentrated by rotary vacuum.  The 
remainder was purified by flash chromatography on silica gel eluting with 10-16 vol% of 
ethyl acetate in hexanes to provide titled compound (3.776 g, 6.932 mmol, 96.5% yield) as 




TLC:  Rf = 0.50 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +23.7 (c 0.76, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.75 (t, J = 1.5 Hz, 1H, H-9), 7.39-7.28 (m, 5H, H-13, H-
13’, H-14, H-14’, H-15), 7.25 (d, J = 8.8 Hz, 2H, H-18, H-18’), 6.87 (d, J = 8.8 Hz, 2H, 
H-19, H-19’), 4.82 (ABq, J = 7.1 Hz, Δν = 12.0 Hz, 2H, H-10), 4.64 (ABq, J = 12.0 Hz, 
Δν = 18.1 Hz, 2H, H-11), 4.60 (d, J = 10.7 Hz, 1H, H-16a), 4.45 (d, J = 10.7 Hz, 1H, H-
16b), 4.03 (dq, J = 4.6, 6.8 Hz, 1H, H-2), 3.92 (dddd, J = 3.6, 4.9, 5.4, 8.1 Hz, 1H, H-5), 
3.81 (s, 3H, H-21), 3.64 (ddd, J = 2.4, 4.6, 9.5 Hz, 1H, H-3), 2.40 (app. dt, J = 1.5, 7.3 Hz, 
2H, H-8), 1.71 (ddd, J = 2.4, 8.1, 14.2 Hz, 1H, H-4a), 1.67 (app. ddt, J = 6.4, 10.4, 7.3 Hz, 
2H, H-7), 1.56 (ddd, J = 3.6, 9.5, 14.2 Hz, 1H, H-4b), 1.58-1.39 (m, 2H, H-6a, H-6b), 1.19 
(d, J = 6.8 Hz, 3H, H-1), 0.90 (s, 9H, H-24), 0.06 (s, 6H, H-22);  
125 MHz 13C NMR (CDCl3) δ 202.7 (C-9), 159.3 (C-20), 138.1 (C-12), 131.1 (C-17), 
129.4 (C-18, C-18’), 128.6 (C-14, C-14’), 128.0 (C-13, C-13’), 127.9 (C-15), 114.0 (C-19, 
C-19’), 93.4 (C-10), 78.2 (C-3), 72.9 (C-2), 72.1 (C-16), 69.5 (C-11), 69.5 (C-5), 55.5 (C-
21), 44.2 (C-8), 37.7 (C-6), 37.3 (C-4), 26.1 (C-24), 18.3 (C-23), 17.4 (C-7), 15.2 (C-1), -
3.7 (C-22a), -4.2 (C-22b);  
FTIR (neat): νmax 3032, 2952, 2893, 2857, 2718, 1726, 1613, 1556, 1514, 1463, 1383, 1250, 
1173, 1112, 1064, 937, 834, 774, 736, 698, 578 cm-1; 








g, 9.266 mmol, 1.0 equiv), 1-bromo-3-methylbut-2-ene (1.70 mL, 14.0 mmol, 1.5 equiv), 
THF (18.5 mL, 0.5 M) and saturated NH4Cl (90 mL, 0.1 M) aqueous solution was added 
Zn dust (0.932 g, 14.0 mmol, 1.5 equiv) in one portion at room temperature.  It was stirred 
overnight (ca. 12 hours), then Et2O (50 mL) was poured into this reaction.  The aqueous 
layer was extracted with Et2O (3 x 20 mL).  The combined organic layers were washed 
with brine (50 mL) and dried over anhydrous Na2SO4.  Filtered, it was then concentrated 
by rotary vacuum to give a yellow oil (5.571 g, 9.271 mmol, 100% yield), which was used 
in the next step without further purification.    




one (3.23): With a –78 oC bath, to a stirred solution 
of oxalyl chloride (0.70 mL, 80 mmol, 1.5 equiv) in dry CH2Cl2 (40 mL, 0.2 M) was added 
a solution of DMSO (1.1 mL, 16 mmol, 3.0 equiv) in dry CH2Cl2 (30 mL, 0.5 M) dropwise 
via cannula under an atmosphere of N2.  After 30 minutes, the solution of alcohol 3.22 
(3.172 g, 5.158 mmol, 1.0 equiv) in dry CH2Cl2 (50 mL, 0.1 M) was added dropwise via 
cannula.  This reaction was stirred for 1 hour in this condition.  Then, NEt3 (3.60 mL, 25.8 
mmol, 5.0 equiv) was introduced dropwise via syringe.  After 5 minutes, the cooling bath 
was removed, and the reaction was stirred at room temperature for 1.5 hours.  The solution 
was poured into a saturated solution of NH4Cl (150 mL).  The aqueous layer was extracted 
with Et2O (3 x 30 mL).  The combined organic layers were washed with brine (200 mL) 




The remainder was purified by flash chromatography on silica gel eluting with 5-12 vol% 
of ethyl acetate in hexanes to provide the titled compound (3.016 g, 4.920 mmol, 95.4% 
yield over two steps) as a colorless oil.    
TLC:  Rf = 0.62 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +44.9 (c 2.06, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.40-7.29 (m, 5H, H-17, H-17’, H-18, H-18’, H-19), 7.26 
(d, J = 8.8 Hz, 2H, H-22, H-22’), 6.88 (d, J = 8.8 Hz, 2H, H-23, H-23’), 5.91 (dd, J = 10.7, 
17.3 Hz, 1H, H-11), 5.15 (d, J = 10.7 Hz, 1H, H-12a), 5.15 (d, J = 17.3 Hz, 1H, H-12b), 
4.82 (ABq, J = 7.1 Hz, Δν = 10.8 Hz, 2H, H-14), 4.65 (ABq, J = 11.7 Hz, Δν = 19.1 Hz, 
2H, H-15), 4.61 (d, J = 10.9 Hz, 1H, H-20a), 4.48 (d, J = 10.9 Hz, 1H, H-20b), 4.03 (dq, 
J = 4.8, 6.8 Hz, 1H, H-2), 3.91 (dddd, J = 3.4, 5.4, 5.4, 8.8 Hz, 1H, H-5), 3.81 (s, 3H, H-
25), 3.66 (ddd, J = 2.4, 4.8, 9.5 Hz, 1H, H-3), 2.46 (ddd, J = 6.8, 7.3, 17.5 Hz, 1H, H-8a), 
2.42 (ddd, J = 7.3, 7.3, 17.5 Hz, 1H, H-8b), 1.70 (ddd, J = 2.4, 8.8, 14.2 Hz, 1H, H-4a), 
1.60 (ddd, J = 3.4, 9.5, 14.2 Hz, 1H, H-4b), 1.61-1.54 (m, 2H, H-7a, H-7b), 1.51-1.41 (m, 
2H, H-6a, H-6b), 1.23 (s, 6H, H-13), 1.20 (d, J = 6.8 Hz, 3H, H-1), 0.91 (s, 9H, H-28), 
0.072 (s, 3H, H-26a), 0.068 (s, 3H, H-26b);  
125 MHz 13C NMR (CDCl3) δ 212.9 (C-9), 159.3 (C-24), 142.8 (C-11), 138.2 (C-16), 
131.2 (C-21), 129.3 (C-22, C-22’), 128.6 (C-18, C-18’), 128.0 (C-17, C-17’), 127.8 (C-19), 
114.3 (C-12), 113.9 (C-23, C-23’), 93.4 (C-14), 78.3 (C-3), 73.1 (C-2), 72.1 (C-20), 69.7 
(C-15), 69.5 (C-5), 55.4 (C-25), 50.9 (C-10), 37.9 (C-6), 37.7 (C-8), 37.4 (C-4), 26.2 (C-
28), 23.7 (C-13a), 23.7 (C-13b), 19.5 (C-7), 18.3 (C-27), 15.2 (C-1), -3.6 (C-26a), -4.2 (C-
26b); 




921, 835, 775, 738, 698, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C36H56O6SiNa 635.3744; found 635.3750. 
(7S,9R,10R)-10-(Benzyloxymethoxy)-7-(tert-
butyldimethylsilyloxy)-9-(4-methoxybenzyloxy)-2,2-
dimethyl-3-oxoundecanal (3.24): With an acetone/dry ice 
bath (–78 oC), a steam of O3 (3.0 psi, 60 Volts) purged through a solution of olefin 3.23 
(2.794 g, 4.559 mmol) in CH2Cl2 (45 mL, 0.1 M) until the colorless solution turned pinkish, 
whereupon the O3 was turned off, and a stream of N2 flushed the solution until the color 
faded.  Then, triphenylphosphine (1.812 g, 6.839 mmol) was added in one portion.  The 
reaction was stirred at room temperature for 6 hours.  The resulting yellow solution was 
concentrated under reduced pressure.  Then, an ice-cold solution of 30 vol% Et2O in 
pentane (45 mL, 0.1 M) was added into the remainder.  It was stirred at 0 oC for 10 minutes.  
The white precipitate was filtrated, and washed with an ice-cold solution of 10 vol% Et2O 
in pentane (3 x 10 mL).  The solution was concentrated by rotary evaporation to give a 
yellow oil which was used directly in the next step without further purification.  





oxotridec-2-enethioate (3.25): To a round-
bottomed flask was charged NaH (60% dispersion in mineral oil, 0.274 g, 6.85 mmol, 1.5 




ethylthiocarbonylmethylphosphonate (1.645 g, 6.847 mmol, 1.5 equiv) in THF (20 mL, 0.4 
M) was added dropwise via cannula.  This reaction was then stirred under an atmosphere 
of N2 for 10 minutes, whereupon a solution of abovementioned crude aldehyde 3.24 
(theoretically 4.559 mmol, 1.0 equiv) in THF (10 mL, 0.5 M) was added via a cannula.  It 
was kept stirring in this condition for 2 hours.  Then, a saturated NaHCO3 solution (100 
mL) was added.  The separated aqueous layer was extracted with ethyl ether (3 x 20 mL).  
The combined organic layers were washed with brine (100 mL) and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure to provide a 
yellowish oil.  The crude product was purified by flash chromatography on silica gel eluting 
with 4-10 vol% of ethyl acetate in hexanes to afford the titled compound (2.968 g, 4.233 
mmol, 92.9% yield over two steps) as a yellowish oil. 
TLC:  Rf = 0.57 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +22.9 (c 1.02, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.39-7.28 (m, 5H, H-20, H-20’, H-21, H-21’, H-22), 7.25 
(d, J = 8.8 Hz, 2H, H-25, H-25’), 6.96 (d, J = 15.6 Hz, 1H, H-11), 6.87 (d, J = 8.8 Hz, 2H, 
H-26, H-26’), 6.14 (d, J = 15.6 Hz, 1H, H-12), 4.81 (ABq, J = 7.1 Hz, Δν = 11.4 Hz, 2H, 
H-17), 4.63 (ABq, J = 11.7 Hz, Δν = 19.7 Hz, 2H, H-18), 4.53 (ABq, J = 11.0 Hz, Δν = 
67.7 Hz, 2H, H-23), 4.02 (dt, J = 4.9, 6.4 Hz, 1H, H-2), 3.89 (dddd, J = 3.4, 5.1, 5.1, 8.8 
Hz, 1H, H-5), 3.80 (s, 3H, H-28), 3.64 (ddd, J = 2.4, 4.9, 9.3 Hz, 1H, H-3), 2.97 (q, J = 
7.3 Hz, 2H, H-14), 2.42 (dd, J = 7.3, 8.8 Hz, 1H, H-8a), 2.42 (dd, J = 5.9, 7.3 Hz, 1H, H-
8b), 1.69 (ddd, J = 2.4, 8.8, 14.1 Hz, 1H, H-4a), 1.64-1.52 (m, 3H, H-4b, H-7), 1.50-1.38 
(m, 2H, H-6), 1.30 (t, J = 7.3 Hz, 3H, H-15), 1.28 (s, 6H, H-16), 1.18 (d, J = 6.4 Hz, 3H, 




125 MHz 13C NMR (CDCl3) δ 210.6 (C-9), 190.0 (C-13), 159.2 (C-27), 142.3 (C-11), 
138.1 (C-19), 131.1 (C-24), 129.3 (C-25, C-25’), 128.6 (C-21, C-21), 128.0 (C-20, C-20’), 
127.8 (C-12), 127.7 (C-22), 113.9 (C-26, C-26’), 93.3 (C-17), 78.2 (C-3), 72.9 (C-2), 72.0 
(C-23), 69.6 (C-5), 69.5 (C-18), 55.4 (C-28), 50.6 (C-10), 38.6 (C-8), 37.8 (C-6), 37.3 (C-
4), 26.1 (C-31), 23.6 (C-16), 23.5 (C-14), 19.2 (C-7), 18.2 (C-30), 15.2 (C-1), 14.9 (C-15), 
-3.6 (C-29a), -4.2 (C-29b);  
FTIR (neat): νmax 2932, 1713, 1672, 1623, 1514, 1463, 1381, 1250, 1174, 1040, 835, 775, 
739, 698, 665 cm-1; 




oxotridec-2-enethioate (3.26): To an ice-cold 
solution of TBS ether 3.25 (0.9042 g, 1.290 
mmol, 1.0 eq) in MeCN (13 mL, 0.1 M) was added pyridine (13 mL, 0.1 M) and DI H2O 
(0.8 mL, 2.0 M).  Then, a solution of HF (48 wt% in H2O, 2.0 mL, 55 mmol, 40 equiv) was 
added dropwise.  This reaction was allowed to warm to room temperature for 3 hours, and 
another portion of HF solution (48 wt%, 2.0 mL, 55 mmol, 40 equiv) was added dropwise.  
A portion of HF solution (48 wt%, 2.0 mL, 55 mmol, 40 equiv) was added into this reaction 
every 6 hours until total 200 equiv of HF was added.  This reaction was stirred for 36 hours, 
whereupon it was diluted with ether (50 mL) and slowly poured into a stirred ice-cold 
suspension of NaHCO3 (32.8 g, 390 mmol, 300 equiv) and H2O (200 mL) in 5 portions.  




30 mL).  The combined organic solutions were washed with brine (200 mL), a saturated 
solution of Cu2SO4 (200 mL), and then brine (200 mL).  The organic solution was dried 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to provide a 
yellow oil (crude 0.781 g, 1.33 mmol, 100% yield), which was used directly in the next 
step without further purification. 





(3.27): To a solution of abovementioned crude 
alcohol 3.26 (0.781 g, theoretically 1.29 mmol, 1.0 equiv) in toluene (26 mL, 0.05 M) was 
added CSA (9 mg, 0.04 mmol, 0.03 equiv) in  one portion at room temperature.  This 
reaction was refluxed with a dean-stark apparatus for an hour under an atmosphere of N2.  
Then, freshly distilled pyridine (0.10 mL, 1.2 mmol) was added into this reaction.  It was 
cooled down to room temperature under an atmosphere of N2, and poured into a saturated 
NaHCO3 solution (50 mL).  The aqueous layer was extracted by ethyl ether (3 x 20 mL).  
The combined organic layers were washed with brine (100 mL), and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure to provide a 
yellow oil.  The crude product was purified by flash chromatography on silica gel eluting 
with 10-20 vol% of ethyl ether in hexanes to afford the titled compound (0.633 g, 1.11 
mmol, 86.3% yield over two steps) a yellowish oil. 




[α]20 D +42.4 (c 1.96, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.38-7.33 (m, 4H, H-20, H-21), 7.30 (tt, J = 4.4, 7.8 Hz, 1H, 
H-22), 7.25 (d, J = 8.6 Hz, 2H, H-25), 6.97 (d, J = 16.1 Hz, 1H, H-11), 6.86 (d, J = 8.6 Hz, 
2H, H-26), 6.09 (d, J = 16.1 Hz, 1H, H-12), 4.83 (ABq, J = 7.1 Hz, Δν = 7.1 Hz, 2H, H-
17), 4.64 (ABq, J = 12.2 Hz, Δν = 10.4 Hz, 2H, H-18), 4.61 (d, J = 10.7 Hz, 1H, H-23a), 
4.59 (dd, J = 2.9, 5.4 Hz, 1H, H-8), 4.49 (d, J = 10.7 Hz, 1H, H-23b), 4.00 (dddd, J = 2.0, 
2.4, 9.8, 10.3 Hz, 1H, H-5), 3.96 (dq, J = 4.9, 6.3 Hz, 1H, H-2), 3.80 (ddd, J = 2.4, 4.9, 9.8 
Hz, 1H, H-3), 3.80 (s, 3H, H-28), 2.89 (q, J = 7.5 Hz, 2H, H-14), 2.09 (dddd, J = 2.9, 5.9, 
9.8, 16.8 Hz, 1H, H-7a), 1.99 (dddd, J = 2.9, 5.4, 6.4, 16.8 Hz, 1H, H-7b), 1.80 (ddd, J = 
2.0, 9.8, 14.3 Hz, 1H, H-4a), 1.76 (dddd, J = 2.4, 2.9, 5.9, 13.4 Hz, 1H, H-6a), 1.61 (ddd, 
J = 2.4, 10.3, 14.3 Hz, 1H, H-4b), 1.50 (dddd, J = 6.4, 9.8, 9.8, 13.4 Hz, 1H, H-6b), 1.22 
(t, J = 7.5 Hz, 3H, H-15), 1.22 (s, 3H, H-16a), 1.21 (s, 3H, H-16b), 1.20 (d, J = 6.3 Hz, 
3H, H-1);  
125 MHz 13C NMR (CDCl3) δ 190.7 (C-13), 159.3 (C-27), 157.1 (C-9), 152.0 (C-11), 
138.2 (C-19), 131.1 (C-24), 129.7 (C-25), 128.6 (C-21), 128.0 (C-20), 127.9 (C-22), 125.7 
(C-12), 114.0 (C-26), 94.6 (C-8), 93.6 (C-17), 77.8 (C-3), 73.9 (C-2), 73.7 (C-23), 72.0 (C-
5), 69.6 (C-18), 55.5 (C-28), 41.4 (C-10), 36.2 (C-4), 28.2 (C-6), 25.3 (C-16a), 25.2 (C-
16b), 23.3 (C-14), 20.5 (C-7), 15.6 (C-1), 14.9 (C-15);  
FTIR (neat): νmax 2933, 1711, 1668, 1623, 1513, 1456, 1381, 1249, 1174, 1039, 822, 740, 
699 cm-1; 







With a –78 oC bath, to a stirred solution of 
thioester 3.27 (2.982 g, 5.243 mmol, 1.0 equiv) in fresh distilled CH2Cl2 (50 mL, 0.1 M) 
was added a DIBAL solution (1.0 M solution in CH2Cl2, 7.90 mL, 7.90 mmol, 1.5 equiv) 
at the rate of 15 mL/h via syringe pump under an atmosphere of N2.  After addition, it was 
stirred for 1 hour, and EtOAc (5 mL) was then added into the reaction at the same rate 
above.  Then, a saturated Rochelle’s salt solution (100 mL) was added, and the mixture 
was stirred vigorously for 3 hours, whereupon two clear phases appeared.  The aqueous 
layer was extracted by Et2OAc (3 x 20 mL).  The combined organic layers were washed 
with brine (100 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure.  The crude product was purified by flash 
chromatography on silica gel eluting with 5-15 vol% of ethyl acetate in hexanes to provide 
the titled compound (2.245 g, 4.414 mmol, 84.2% yield) as a colorless oil.   
TLC:  Rf = 0.49 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +44.9 (c 2.06, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.48 (d, J = 7.8 Hz, 1H, H-13), 7.39-7.28 (m, 5H, H-18, H-
18’, H-19, H-19’, H-20), 7.24 (d, J = 8.8 Hz, 2H, H-23, H-23’), 6.86 (d, J = 8.8 Hz, 2H, 
H-24, H-24’), 6.86 (d, J = 16.1 Hz, 1H, H-11), 6.10 (dd, J = 7.8, 16.1 Hz, 1H, H-12), 4.82 
(ABq, J = 6.8 Hz, Δν = 10.7 Hz, 2H, H-15), 4.63 (s, 2H, H-16), 4.63 (dd, J = 2.9, 3.4 Hz, 
1H, H-8), 4.62 (d, J = 10.7 Hz, 1H, H-21a), 4.47 (d, J = 10.7 Hz, 1H, H-21b), 4.03 (dddd, 




26), 3.78 (ddd, J = 2.4, 4.9, 10.2 Hz, 1H, H-3), 2.10 (dddd, J= 2.9, 6.8, 9.8, 17.1 Hz, 1H, 
H-7a), 2.01 (dddd, J= 3.4, 4.9, 5.9, 17.1 Hz, 1H, H-7b), 1.82 (ddd, J= 2.9, 10.2, 14.2 Hz, 
1H, H-4a), 1.80 (dddd, J= 2.4, 4.9, 6.8, 13.2 Hz, 1H, H-6a), 1.62 (ddd, J = 2.4, 10.7, 14.2 
Hz, 1H, H-4b), 1.52 (dddd, J= 5.9, 9.8, 9.8, 13.2 Hz, 1H, H-6b), 1.26 (s, 3H, H-14a), 1.25 
(s, 3H, H-14b), 1.20 (d, J = 6.3 Hz, 3H, H-1);  
125 MHz 13C NMR (CDCl3) δ 194.7 (C-13), 165.7 (C-11), 159.4 (C-25), 156.7 (C-9), 
138.1 (C-17), 130.9 (C-22), 129.8 (C-12), 129.5 (C-23, C-23’), 128.6 (C-19, C-19’), 128.0 
(C-18, C-18’), 127.9 (C-20), 114.0 (C-24, C-24’), 94.9 (C-8), 93.6 (C-15), 77.7 (C-3), 73.7 
(C-2), 73.4 (C-21), 72.2 (C-5), 69.6 (C-16), 55.5 (C-26), 42.1 (C-10), 36.0 (C-4), 28.2 (C-
6), 25.3 (C-14a), 25.1 (C-14b), 20.5 (C-7), 15.5 (C-1);  
FTIR (neat): νmax 2931, 1691, 1613, 1514, 1458, 1381, 1297, 1248, 1173, 1098, 1040, 822, 
739, 699, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C31H40O6Na 531.2723; found 531.2725. 
(S)-2-Bromosuccinic Acid (3.32): To the mixture of (S)-(+)-
aspartic acid 3.14 (10.40 g, 76.57 mmol, 1.0 equiv) and KBr (41.9 
g, 345 mmol, 4.5 equiv) was added H2SO4 solution (2.5 M, 200 
mL, 500 mmol, 6.5 equiv) at -10 oC.  A solution of NaNO2 (9.40 g, 135 mmol, 1.8 equiv) 
in D.I. H2O (22.5 mL, 6.0 M) was added to this mixture via an additional funnel dropwise 
over 1 hour, while keeping the temperature below 0 oC.  After 4 hours, the resulting brown 
mixture was extracted with EtOAc (4 x 50 mL).  The combined organic layers were dried 
over anhydrous MgSO4.  The solution was filtered and concentrated under reduced pressure 
to provide the titled compound (14.02 g, 71.17 mmol, 93.0% yield) as a white solid (mp: 




further purification.   
mp:  168-170 oC; 
[α]20 D -41.5 (c 1.17, H2O); 
500 MHz 1H NMR (CD3OD) δ 4.93 (br. s, 2H, -OHa, -OHb), 4.56 (dd, J = 8.8, 6.2 Hz, 
1H, H-3), 3.19 (dd, J = 17.2, 8.8 Hz, 1H, H-2a), 2.95 (dd, J = 17.2 6.2 Hz, 1H, H-2b); 
125 MHz 13C NMR (CD3OD) δ 173.3 (C-4), 172.5 (C-1), 40.9 (C-2), 40.3 (C-3);  
FTIR (neat): νmax 3011, 2903, 2530,, 1693, 1420, 1403, 1289, 1245, 1211, 1184, 932, 766, 
706, 647, 585 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C4H5O6BrNa 218.9269; found 218.9274. 
(S)-2-Bromo-1,4-butanediol (3.33): At -10 oC, under an 
atmosphere of N2, to the solution of diacid 3.32 (3.975 g, 20.18 
mmol, 1.0 equiv) in dry THF (70 mL, 0.3 M) was added a solution of BH3•DMS complex 
(10.0 M, 6.1 mL, 61 mmol, 3.0 equiv) in THF (30 mL, 2.0 M) dropwise via addition funnel 
over 80 minutes.  Then, this reaction was allowed to warm to room temperature slowly 
over 4 hours.  After stirred at room temperature for 1.5 hours, it was cooled down to 0 oC.  
Then, H2O (5 mL) was added dropwise into this reaction to quench the excess borane, 
followed by addition of K2CO3 (5.0 g).  The mixture was stirred at room temperature for 
10 minutes, and filtered through a pad of Celite®.  The residue was washed by ether (4 x 
20 mL).  The combined organic solution was concentrated in reduced pressure.  The residue 
was purified by quick flash chromatography on silica gel eluting with 40-60% v/v EtOAc 
in hexanes with 3 vol% MeOH to provide the titled compound (3.392 g, 20.07 mmol, 99.4% 
yield) as a yellowish oil.   




[α]20 D -31.0 (c 1.705, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 4.35 (dq, J = 7.8, 5.2 Hz, 1H, H-3), 3.96-3.76 (m, 4H, H-1a, 
H-1b, H-4a, H-4b), 2.41 (br. s, 2H, 2 x -OH), 2.23-2.07 (m, 2H, H-2a, H-2b); 
125 MHz 13C NMR (CDCl3) δ 67.3 (C-4), 60.3 (C-1), 55.4 (C-3), 38.0 (C-2);  
FTIR (neat): νmax 3317 (br), 2932, 1420, 1234, 1164, 1053, 1026, 930, 820, 642, 568 cm-1. 
(R)-tert-Butyl-(2-(oxiran-2-yl)ethoxy)diphenylsilane 
(3.34): To a suspension of NaH (60% in mineral oil, 5.84 g, 
146 mmol, 3.00 equiv) in freshly distilled THF (300 ml, 0.5 
M) was added a solution of diol 3.33 (8.189 g, 48.45 mmol, 
1.00 equiv) in THF (100 ml, 0.5 M) via cannula at –15 °C under an atmosphere of N2.  
After 20 minutes, a solution of TBDPSCl (13.5 mL, 50.1 mmol, 1.05 equiv) in THF (50.0 
ml, 1.0 M) was added at that temperature, and the reaction was allowed to warm to room 
temperature.  It was stirred overnight (ca. 14 hours).  Then, the reaction was quenched with 
ice cubes and poured into a saturated NaHCO3 solution (200 mL).  The aqueous layer was 
extracted with Et2O (3 x 30 ml). The combined organic extracts were dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The residue was purified by flash 
chromatography eluting with 2-8 vol% Et2O in hexanes to provide the titled compound 
(12.82 g, 39.25 mmol, 81.0% yield) as a yellow oil.  
TLC:  Rf = 0.61 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +6.2 (c 0.97, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.72-7.65 (m, 4H, H-8, H-8’, H-12, H-12’), 7.48-7.36 (m, 
6H, H-9, H-9’, H-13 H-13’, H-10, H-14), 3.89-3.78 (m, 2H, H-1a, H-1b), 3.12 (dddd, J = 




Hz, 1H, H-4a), 1.84-1.74 (m, 2H, H-2a, H-2b), 1.07 (s, 9H, H-6); 
125 MHz 13C NMR (CDCl3) δ 135.8  (C-8, C-8’, C-12, C-12’), 133.9 (C-7), 133.8 (C-11), 
129.9 (C-10, C-14), 127.9 (C-9, C-9’, C-13, C-13’), 61.1 (C-1), 50.3 (C-3), 47.5 (C-4), 
35.9 (C-2), 27.0 (C-6), 19.4 (C-5); 
FTIR (neat): νmax 3071, 3049, 2931, 2858, 1590, 1472, 1428, 1390, 1362, 1257, 1112, 910, 
866, 824, 740, 703 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C20H26O2SiNa 349.1600; found 349.1599. 
2-Bromoallyltrimethylsilane (3.35): To an oven-dried 300-mL 
round-bottomed flask equipped with a reflux condenser and a 
pressure-equalizing additional funnel was added CuCl (0.524 g, 4.92 mmol, 0.05 equiv), 
anhydrous Et2O (70 mL, 1.5 M) and freshly distilled NEt3 (14.5 mL, 104 mmol, 1.0 equiv) 
subsequently.  The mixture of 2,3-dibromopropane (12.0 mL, 104 mmol, 1.0 equiv) and 
trichlorosilane (12.0 mL, 117 mmol, 1.1 equiv) was added dropwise to the mixture at the 
rate maintaining a gentle reflux.  A voluminous white precipitate formed when the addition 
started.  After addition, this reaction was kept stirring over night (ca. 16 hours) at room 
temperature.  It was then cooled down to 0 oC, and MeMgBr (3.0 M solution in Et2O, 160 
mL, 480 mmol, 4.5 equiv) was added slowly. The reaction turned dark black, and it was 
stirred for a further 18 hours at room temperature.  Then, it was carefully quenched with 
ice cubes at 0 oC.  A saturated solution of NH4Cl (300 mL) was added into this reaction, 
and the mixture was poured into a mixture of Et2O (100 mL) and H2O (100 mL).  The 
separated organic layer was washed with H2O (2 x 50 mL).  The combined aqueous layers 
were extracted with Et2O (3 x 30 ml).  The combined organic layers were washed with 




CH2Cl2 three times.  The solvent was removed by normal pressure distillation, and the 
residue further distilled under reduced pressure of aspirator.  The titled compound was 
obtained as a colorless oil (11.54 g, 59.74 mmol, 57.4% yield) collected at 76.0-82.0 
oC/aspirator.  
(S)-1-(tert-Butyldiphenylsilyl)oxy-5-
((trimethylsilyl)methyl)hex-5-en-3-ol (3.11): To a 
100-mL 3-necked flask equipped with a reflux 
condenser, a pressure-equalizing additional funnel, a 
rubber septum and a magnetic stirring bar, was added magnesium turnings (2.304 g, 94.80 
mmol, 3.0 equiv).  This apparatus was flame-dried under a flow of N2.  Then, anhydrous 
THF (50 mL) was added into this flask at room temperature, followed by addition of a 
catalytic amount 1,2-dibromoethane (50 uL, 0.57 mmol, 1.3 mol%) to activate the 
magnesium turnings.  It was refluxed for 10 minutes, then a solution of allylsilane 3.35 
(8.64 g, 44.7 mmol, 1.4 equiv) in THF (9.0 mL, 5.0 M) was added at the rate maintaining 
a gentle reflux.  This reaction was kept refluxing for further 30 minutes after addition.  
To another 250-mL flask, anhydrous CuCl (0.913 g, 4.79 mmol, 0.15 equiv) was mixed 
with a solution of oxirane 3.34 (10.43 g, 31.95 mmol, 1.0 equiv) in freshly distilled THF 
(65 mL, 0.5 M) at -78 oC. Then, the abovementioned Grignard reagent was quickly 
transferred into this mixture via cannula.  Then, it was allowed to warm to room 
temperature over 2 hours.  It was then quenched with a saturated NH4Cl solution (100 mL) 
carefully.  The aqueous layer was extracted with Et2O (3 x 20 mL).  The combined organic 
layers were washed with brine (100 mL) and dried over anhydrous Na2SO4.  The solution 




chromatography on silica gel eluting with 2-5 vol% of ethyl ether in hexanes to provide 
the desired product (4.153 g, 9.422 mmol, 80.1% yield) as a colorless oil. 
TLC:  Rf = 0.51 (Acetone/cHex = 1:9, v/v); 
[α]20 D +4.1 (c 1.045, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.76-7.62 (m, 4H, H-12, H-16), 7.49-7.34 (m, 6H, H-13, H-
14, H-17, H-18), 4.69 (ddd, J = 1.0, 1.0, 2.0 Hz, 1H, H-8a), 4.66 (ddd, J = 1.0, 1.0, 2.0 Hz, 
1H, H-8b), 4.06 (ddddd, J = 2.4, 3.9, 5.4, 6.3, 7.8, Hz, 1H, H-3), 3.91 (ddd, J = 5.4, 5.4, 
10.5 Hz, 1H, H-1a), 3.85 (ddd, J = 5.4, 6.8, 10.5 Hz, 1H, H-1b), 2.94 (d, J = 2.4 Hz, 1H, -
OH), 2.19 (ddd, J = 1.0, 7.8, 13.7 Hz, 1H, H-4a), 2.13 (ddd, J = 1.0, 5.4, 13.7 Hz, 1H, H-
4b), 1.73 (app. q, J = 5.7 Hz, 2H, H-2), 1.58 (dABq, J = 1.0, 13.2 Hz, Δν = 15.7 Hz, 2H, 
H-6), 1.07 (s, 9H, H-10), 0.05 (s, 9H, H-7); 
125 MHz 13C NMR (CDCl3) δ 144.7 (C-5), 135.8 (C-12, C-16), 133.5 (C-11), 133.4 (C-
15), 130.0 (C-14, C-18), 128.0 (C-13, C-17), 110.3 (C-8), 68.8 (C-3), 63.1 (C-1), 46.7 (C-
4), 38.6 (C-2), 27.0 (C-10), 26.9 (C-6), 19.3 (C-9), -1.1 (C-7);  
FTIR (neat): νmax 3516 (br), 3072, 2955, 2859, 1631, 1471, 1427, 1249, 1157, 1110, 851, 
738, 703, 613 cm-1; 










With a –78 oC bath, to a stirred mixture of aldehyde 3.10 (403.1 mg, 0.7925 mmol, 1.0 
equiv), and β-hydroxyl allylsilane 3.11 (523 mg, 1.19 mmol, 1.5 equiv) in fresh distilled 
Et2O (16 mL, 0.05 M) was added pyridine (19.0 uL, 0.235 mmol, 0.3 equiv) via syringe 
under an atmosphere of N2.  Then, a solution of 1.0 M TMSOTf in Et2O (0.96 mL, 0.96 
mmol, 1.2 equiv) was introduced into this reaction dropwise via syringe.  It was stirred for 
25 minutes and quenched with DIPEA (1.5 mL, 8.6 mmol, 10 equiv) at this temperature.  
It was stirred further 30 minutes, and poured into a saturated NaHCO3 solution (30 mL).  
The aqueous layer was extracted by Et2O (3 x 10 mL).  The combined organic layers were 
washed with brine (50 mL) and dried over anhydrous Na2SO4.  The solution was filtered 
and concentrated under reduced pressure to provide a colorless oil.  The crude product was 
purified by flash chromatography on silica gel eluting with 5-10 vol% of Et2O in hexanes 
to provide the titled compound (600 mg, 0.698 mmol, 88.1% yield) as a colorless oil.   
TLC:  Rf = 0.33 (Et2O/Hex = 3:7, v/v); 
[α]20 D +21.9 (c 1.56, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.74-7.64 (m, 4H, H-37, H-37’, H-41, H-41’), 7.47-7.28 (m, 
11H, H-25, H-25’, H-26, H-26’, H-27, H-38, H-38’, H-39, H-42, H-42’, H-43), 7.26 (d, 
J = 8.8 Hz, 2H, H-30, H-30’), 6.86 (d, J = 8.8 Hz, 2H, H-31, H-31’), 5.80 (dd, J = 1.0, 
16.1 Hz, 1H, H-11), 5.53 (dd, J = 6.1, 16.1 Hz, 1H, H-12), 4.84 (ABq, J = 7.1 Hz, Δν = 4.8 
Hz, 2H, H-22), 4.72 (d, J = 2.0 Hz, 1H, H-21a), 4.71 (d, J = 2.0 Hz, 1H, H-21b), 4.65 
(ABq, J = 12.0 Hz, Δν = 9.7 Hz, 2H, H-23), 4.64 (d, J = 10.7 Hz, 1H, H-28a), 4.55 (dd, J 
= 3.4, 4.4 Hz, 1H, H-8), 4.54 (d, J = 10.7 Hz, 1H, H-28b), 4.03 (dddd, J = 2.0, 2.4, 9.8, 
10.2 Hz, 1H, H-5), 3.97 (dq, J = 5.1, 6.3 Hz, 1H, H-2), 3.90-3.82 (m, 2H, H-3, H-19a), 




1H, H-17), 2.25 (app. t. J = 13.4 Hz, 1H, H-14a), 2.25 (app. t. J = 13.4 Hz, 1H, H-16a), 
2.14-1.97 (m, 2H, H-7a, H-16b), 2.02-1.80 (m, 4H, H-4a, H-7b, H-14b, H-18a), 1.83-1.69 
(m, 2H, H-6a, H-18b), 1.62 (ddd, J = 2.4, 10.7, 14.1 Hz, 1H, H-4b), 1.50 (dddd, J = 6.4, 
9.8, 9.8, 13.2 Hz, 1H, H-6b), 1.21 (d, J = 6.3 Hz, 3H, H-1), 1.19 (s, 6H, H-20), 1.06 (s, 9H, 
H-35);  
125 MHz 13C NMR (CDCl3) δ 159.4 (C-32), 159.0 (C-9), 144.9 (C-15), 139.1 (C-11), 
138.1 (C-24), 135.7 (C-37, C-37’, C-41, C-41’), 134.2 (C-36), 134.1 (C-40), 131.1 (C-29), 
129.7 (C-30, C-30’, C-39, C-43), 128.6 (C-26, C-26’ ), 128.0 (C-25, C-25’), 127.8 (C-27, 
C-38, C-38’, C-42, C-42’), 127.6 (C-12), 114.0 (C-31, C-31’), 108.7 (C-21), 93.6 (C-22), 
93.4 (C-8), 79.2 (C-13), 78.0 (C-3), 75.4 (C-17), 74.1 (C-2), 73.7 (C-28), 71.7 (C-5), 69.6 
(C-23), 60.5 (C-19), 55.5 (C-33), 41.3 (C-16), 40.9 (C-14), 40.7 (C-10), 39.2 (C-18), 36.4 
(C-4), 28.3 (C-6), 27.1 (C-35), 26.1 (C-20a), 25.9 (C-20b), 20.5 (C-7), 19.4 (C-34), 15.8 
(C-1); 
FTIR (neat): νmax 3070, 2932, 2887, 2857, 1660, 1613, 1514, 1463, 1428, 1381, 1248, 1111, 
1086, 1041, 892, 822, 739, 702 cm-1; 











0.311 mmol, 1.0 equiv) in fresh distilled CH2Cl2 (16 mL, 0.02 M) and MeOH (8.0 mL, 
0.04 M) was added a solution of mCPBA (105 mg, 0.470 mmmol, 1.5 equiv) in CH2Cl2 
(5.0 mL, 0.1 M) via cannula.  This reaction was stirred at this temperature under an 
atmosphere of N2 for 3 hours.  Then, a saturated solution Na2S2O3 (15 mL) was added.  It 
was stirred at room temperature for 30 minutes.  It was then poured into a saturated solution 
of NaHCO3 (15 mL).  The aqueous layer was extracted by EtOAc (3 x 10 mL).  The 
combined organic layers were washed with brine (50 mL) and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure to provide a 
colorless oil.   
To the solution of the crude product abovementioned in MeOH (30 mL, 0.01 M) was 
added a 0.1 M solution of PPTS in MeOH (310 uL, 0.0310 mmol, 0.1 equiv) at room 
temperature.  It was stirred under an atmosphere of N2 for 1 hour.  It was then poured into 
a saturated solution of NaHCO3.  The aqueous layer was extracted with EtOAc (3 x 10 mL).  
The combined organic layers were washed with brine (30 mL) and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated by rotary evaporation.  The remainder 
was passed through a pack of sica gel eluting with 15-25 vol% of EtOAc in hexanes to 
provide a colorless oil.  









methylbut-3-en-2-yl)-2-methoxydihydro-2H-pyran-3(4H)-one (3.38): To a stirred 
solution of alcohol 3.37 (257.3 mg, 0.2836 mmol, 1.0 equiv) in dry CH2Cl2 (30 mL, 0.01 
M) was added t-BuOH (35.0 uL, 0.366 mmol, 1.5 equiv) and freshly distilled pyridine 
(69.0 uL, 0.853 mmol, 3.0 equiv).  Then, this reaction was cooled down to 0 oC, and Dess-
Martin periodinane (182.4 mg, 0.4171 mmol, 1.5 equiv) was added in one portion.  The 
cooling bath was removed, and the reaction was stirred at room temperature for 1 hour 
under an atmosphere of N2, whereupon the reaction was diluted with Et2O (20 mL), and a 
saturated NaHCO3 solution (30 mL) was added, followed by a saturated Na2S2O3 solution 
(30 mL).  This mixture was stirred for 10 minutes at room temperature.  The aqueous layer 
was extracted by Et2O (3 x 20 mL).  The combined organic layers were washed with brine 
(50 mL) and dried over anhydrous Na2SO4.  The solution was filtered and concentrated 
under reduced pressure.  The remainder was purified by flash chromatography on silica gel 
eluting with 10-20% of EtOAc in hexanes to provide the titled compound (256.7 mg, 
0.2836 mmol, 96% yield over two steps) as a colorless oil.   
TLC:  Rf = 0.49 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +14.1 (c 0.685, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.68 (ddd, J = 1.6, 3.4, 8.1 Hz, 4H, H-37, H-37’, H-41, H-
41’), 7.47-7.28 (m, 11H, H-25, H-25’, H-26, H-26’, H-27, H-38, H-38’, H-39, H-42, H-
42’, H-43), 7.23 (d, J = 8.7 Hz, 2H, H-30, H-30’), 6.86 (d, J = 8.7 Hz, 2H, H-31, H-31’), 
6.03 (dd, J = 1.3, 16.1 Hz, 1H, H-11), 5.50 (dd, J = 6.0, 16.1 Hz, 1H, H-12), 4.86 (ABq, J 
= 6.9 Hz, Δν = 6.9 Hz, 2H, H-22), 4.75 (br. s, 2H, H-21), 4.67, (s, 2H, H-23), 4.64 (d, J = 
10.9 Hz, 1H, H-28a), 4.47 (d, J = 10.9 Hz, 1H, H-28b), 4.15 (dddd, J = 2.6, 2.9, 9.7, 10.1 




3), 3.85 (ddd, J = 5.2, 7.8, 10.1 Hz, 1H, H-19a), 3.80 (s, 3H, H-33), 3.80-3.73 (m, 2H, H-
13, H-19b), 3.55 (dddd, J = 2.1, 4.9, 7.3, 11.4 Hz, 1H, H-17), 3.25 (s, 3H, H-44), 2.41 (dd, 
J = 6.8, 9.1 Hz, 1H, H-7a), 2.41 (dd, J = 4.7, 8.1 Hz, 1H, H-7b), 2.30-2.19 (m, 2H, H-14a, 
H-16a), 2.03 (dd, J = 11.7, 12.2 Hz, 1H, H-14b), 1,99-1.81 (m, 5H, H-4a, H-6a, H-6b, H-
16b, H-18a), 1.76 (dddd, J = 2.1, 5.2, 6.9, 14.0 Hz, 1H, H-18b), 1.66 (ddd, J = 2.9, 10.4, 
14.3 Hz, 1H, H-4b), 1.22 (d, J = 6.5 Hz, 3H, H-1), 1.17 (s, 3H, H-20a), 1.12 (s, 3H, H-
20b), 1.07 (s, 9H, H-35);  
125 MHz 13C NMR (CDCl3) δ 207.5 (C-8), 159.4 (C-32), 144.7 (C-15), 138.0 (C-24), 
136.7 (C-11), 135.7 (C-37, C-37’, C-41, C-41’), 134.2 (C-36), 134.1 (C-40), 130.8 (C-29), 
129.7 (C-30, C-30’), 129.5 (C-12), 129.4 (C-26, C-26’), 128.6 (C-39, C-43), 128.0 (C-25, 
C-25’), 127.9 (C-27), 127.8 (C-38, C-38’, C-42, C-42’), 114.0 (C-31, C-31’), 108.8 (C-21), 
104.2 (C-9), 93.6 (C-22), 79.0 (C-13), 77.4 (C-3), 75.5 (C-17), 72.7 (C-2), 72.2 (C-28), 
69.9 (C-5), 69.7 (C-23), 60.6 (C-19), 55.4 (C-33), 52.4 (C-44), 44.3 (C-10), 41.2 (C-14), 
40.9 (C-16), 39.3 (C-18), 37.7 (C-7), 36.4 (C-4), 30.3 (C-6), 27.1 (C-10), 23.0 (C-20a), 
22.0 (C-20b), 19.4 (C-34), 15.0 (C-1);  
FTIR (neat): νmax 3070, 3031, 2934, 2889, 2858, 1960, 1886, 1822, 1723, 1613, 1514, 1463, 
1428, 1382, 1249, 1173, 1111, 1042, 894, 822, 739, 703 cm-1; 










(3.39): To a stirred solution of ketone 3.38 (83.8 mg, 0.0926 mmol, 1.0 equiv) in dry MeOH 
(1.0 mL, 0.1 M) was added K2CO3 solid (68 mg, 0.49 mmol, 5.0 equiv).  Then a solution 
of freshly distilled methyl glyoxylate in dry THF (3.0 M, 1.0 mL, 3.0 mmol, 50 equiv) was 
added into this reaction via syringe in one portion at room temperature.  It was stirred under 
an atmosphere of N2 for 2.5 hours, whereupon the reaction was diluted with Et2O (20 mL).  
It was poured into a saturated NaHCO3 solution (30 mL).  The aqueous layer was extracted 
by Et2O (3 x 10 mL).  The combined organic layers were washed with brine (30 mL) and 
dried over anhydrous Na2SO4.  The solution was filtered and concentrated under reduced 
pressure.  The remainder was purified by flash chromatography on silica gel eluting with 
20-30% of Et2O in hexanes to provide the titled compound (76.1 mg, 0.0780 mmol, 84.3% 
yield, E:Z > 95:5) as a yellow oil.   
TLC:  Rf = 0.36 (Et2O/Hex = 5:5, v/v); 
[α]20 D -28.2 (c 2.675, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.68 (ddd, J = 1.6, 3.4, 8.1 Hz, 4H, H-37, H-37’, H-41, H-
41’), 7.47-7.28 (m, 11H, H-25, H-25’, H-26, H-26’, H-27, H-38, H-38’, H-39, H-42, H-
42’, H-43), 7.19 (d, J = 8.6 Hz, 2H, H-30, H-30’), 6.83 (d, J = 8.6 Hz, 2H, H-31, H-31’), 
6.57 (dd, J = 1.7, 3.3 Hz, 1H, H-45), 5.83 (dd, J = 1.0, 16.0 Hz, 1H, H-11), 5.40 (dd, J = 
6.1, 16.1 Hz, 1H, H-12), 4.86 (ABq, J = 7.0 Hz, Δν = 9.7 Hz, 2H, H-22), 4.73 (br. s, 1H, 
H-21a), 4.71 (br. s, 1H, H-21b), 4.67, (s, 2H, H-23), 4.62 (d, J = 11.2 Hz, 1H, H-28a), 
4.42 (d, J = 11.2 Hz, 1H, H-28b), 4.21-4.08 (m, 1H, H-5), 4.14 (dq, J = 4.6, 6.5 Hz, 1H, 
H-2), 3.91 (ddd, J = 2.1, 4.6, 10.1 Hz, 1H, H-3), 3.84 (ddd, J = 5.5, 7.8, 10.3 Hz, 1H, H-




H-13), 3.51 (dddd, J = 2.0, 5.2, 7.4, 11.4 Hz, 1H, H-17), 3.32 (ddd, J = 2.1, 2.1, 18.7, 1H, 
H-6eq), 3.23 (s, 3H, H-44), 2.87 (ddd, J = 3.4, 12.5, 18.7, 1H, H-6ax), 2.23 (ddd, J = 1.6, 
2.0, 13.0 Hz, 1H, H-16eq), 2.10 (ddd, J = 1.6, 1.9, 13.0 Hz, 1H, H-14eq), 1.99 (ddd, J = 2.1, 
9.1, 14.6 Hz, 1H, H-4a), 1,96-1.88 (m, 2H, H-14ax, H-16ax), 1.86 (dddd, J = 5.5, 5.5, 7.4, 
13.8 Hz, 1H, H-18a), 1.77 (ddd, J = 2.9, 10.1, 14.6 Hz, 1H, H-4b), 1.74 (dddd, J = 5.2, 5.7, 
7.8, 13.8, 1H, H-18b), 1.23 (d, J = 6.5 Hz, 3H, H-1), 1.14 (s, 3H, H-20a), 1.07 (s, 9H, H-
35), 1.06 (s, 3H, H-20b);  
125 MHz 13C NMR (CDCl3) δ 197.7 (C-8), 166.2 (C-46), 159.4 (C-32), 148.2 (C-7), 144.6 
(C-15), 138.0 (C-24), 135.8 (C-11), 135.7 (C-37, C-37’, C-41, C-41’), 134.2 (C-36), 134.1 
(C-40), 130.6 (C-29), 130.3 (C-12), 129.7 (C-39), 129.7 (C-43), 129.3 (C-30, C-30’), 128.6 
(C-26, C-26’), 128.0 (C-25, C-25’), 127.9 (C-27), 127.8 (C-38, C-38’, C-42, C-42’), 123.1 
(C-45), 114.0 (C-31, C-31’), 108.8 (C-21), 104.7 (C-9), 93.6 (C-22), 79.0 (C-13), 76.9 (C-
3), 75.5 (C-17), 72.3 (C-2), 71.7 (C-28), 69.7 (C-23), 69.6 (C-5), 60.5 (C-19), 55.4 (C-33), 
52.3 (C-44), 51.9 (C-47), 44.9 (C-10), 40.8 (C-16), 40.5 (C-14), 39.2 (C-18), 36.3 (C-4), 
36.1 (C-6), 27.1 (C-35), 22.6 (C-20a), 21.5 (C-20b), 19.4 (C-34), 14.7 (C-1); 
FTIR (neat): νmax 3069, 2930, 2856, 1724, 1706, 1514, 1463, 1429, 1249, 1207, 1176, 1111, 
1064, 1040, 895, 822, 737, 706, 666, 585 cm-1; 










(3.40): To a stirred solution of ketone 3.39 (218 mg, 0.224 mmol, 1.0 equiv) in toluene (1.0 
mL, 0.2 M) was added MeOH (25.0 mL, 0.01 M) and then CeCl3∙7H2O (857.8 mg, 2.300 
mmol, 10.0 equiv) at room temperature.  Until all the solid was dissolved, this reaction was 
cooled down to -78 oC, and NaBH4 (61 mg, 1.6 mmol, 7.0 equiv) was added in one portion.  
It was stirred for 2.5 hours at -78 oC, and then stirred for 10 minutes at 0 oC.  The reaction 
was diluted with EtOAc (10 mL), and poured into a cold saturated NaHCO3 solution (30 
mL).  The aqueous layer was extracted with EtOAc (4 x 10 mL).  The combined organic 
layers were washed with brine (50 mL) and dried over anhydrous Na2SO4.  The solution 
was filtered and concentrated under reduced pressure to provide a colorless oil (219 mg, 
0.224 mmol, 100% yield).  The crude product was used in the next step immediately 
without further purification.    
TLC:  Rf = 0.36 (EtOAc/Hex = 3:7, v/v); 








methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl Octa-2,4-dienoate (3.41): 




dry toluene (13.5 mL, 0.05 M) was added freshly distilled NEt3 (320 uL, 2.30 mmol, 10.0 
equiv), followed by 2,4,6-trichlorobenzoylchloride (108 uL, 0.677 mmol, 3.0 eq) at 0 oC.  
After 10 minutes, the cooling bath was removed, and the reaction was stirred at room 
temperature under an atmosphere of N2 for 2 hours.   
Then this reaction was transferred to a solution of crude alcohol 3.40 (crude 219 mg, 
theoretically 0.224 mmol, 1.0 equiv) in toluene (2.5 mL, 0.1 M) via cannula at 0 oC.  Then, 
a solution of DMAP (42 mg, 0.34 mmol, 1.5 equiv) in toluene (3.5 mL, 0.1 M) was added 
into this mixture via cannula.  After 10 minutes, the cooling bath was removed, and this 
reaction was stirred at room temperature for 3 hours.  Then, methanol (1 mL, 24.7 mmol) 
was added at room temperature.  This reaction was stirred further 2 hours.  It was diluted 
with ether (10 mL) and poured into a saturated NaHCO3 solution (20 mL).  The aqueous 
layer was extracted with ether (3 x 10 mL).  The combined organic layers were washed 
with brine (20 mL).  The organic layer was dried over anhydrous Na2SO4.  The solution 
was filtered and concentrated under reduced pressure.  The reminder was purified by flash 
chromatography on silica gel eluting with 10-15 vol% of EtOAc in hexanes to provide a 
single diastereomer (226 mg, 0.206 mmol, 91.9% yield over two steps, dr > 95:5) as a 
colorless oil. 
TLC:  Rf = 0.51 (EtOAc/Hex = 3:7, v/v); 
[α]20 D -1.8 (c 0.47, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.66 (ddd, J = 1.6, 2.1, 8.1 Hz, 4H, H-37, H-37’, H-41, H-
41’), 7.45-7.23 (m, 11H, H-25, H-25’, H-26, H-26’, H-27, H-38, H-38’, H-39, H-42, H-
42’, H-43), 7.27 (dd, J = 10.1, 15.1 Hz, 1H, H-50), 7.21 (d, J = 8.6 Hz, 2H, H-30, H-30’), 




Hz, 1H, H-11), 5.91 (s, 1H, H-45), 5.78 (d, J = 15.1 Hz, 1H, H-49), 5.58 (s, 1H, H-8), 5.40 
(dd, J = 5.5, 16.0 Hz, 1H, H-12), 4.84 (ABq, J = 7.0 Hz, Δν = 5.4 Hz, 2H, H-22), 4.71 (br. 
s, 1H, H-21a), 4.68 (br. s, 1H, H-21b), 4.66, (s, 2H, H-23), 4.62 (d, J = 10.9 Hz, 1H, H-
28a), 4.45 (d, J = 10.9 Hz, 1H, H-28b), 4.18-4.11 (m, 1H, H-5), 4.10 (dq, J = 4.9, 6.5 Hz, 
1H, H-2), 3.90 (ddd, J = 2.1, 4.7, 10.1 Hz, 1H, H-3), 3.83 (ddd, J = 5.7, 7.8, 10.1 Hz, 1H, 
H-19a), 3.79-3.72 (m, 1H, H-19b), 3.78 (s, 3H, H-33), 3.72-3.66 (m, 1H, H-13), 3.68 (s, 
3H, H-47), 3.55-3.45 (m, 1H, H-17), 3.49 (dd, J = 2.6, 16.1 Hz, 1H, H-6eq), 3.24 (s, 3H, 
H-44), 2.37 (dd, J = 10.7, 16.1 Hz, 1H, H-6ax), 2.25-2.20 (m, 1H, H-16eq), 2.22-2.17 (m, 
1H, H-14eq), 2.14 (dt, J = 7.2, 7.3 Hz, 2H, H-53), 1,99 (dd, J = 12.2, 12.5 Hz, 1H, H-14ax), 
1.95-1.80 (m, 3H, H-4a, H-16ax, H-18a), 1.80-1.67 (m, 2H, H-4b, H-18b), 1.45 (sex, J = 
7.4 Hz, 2H, H-54), 1.22 (d, J = 6.5 Hz, 3H, H-1), 1.14 (s, 6H, H-20), 1.05 (s, 9H, H-35), 
0.92 (t, J = 7.4 Hz, 3H, H-55);  
125 MHz 13C NMR (CDCl3) δ 166.7 (C-46), 165.7 (C-48), 159.4 (C-32), 153.0 (C-7), 
146.7 (C-50), 145.9 (C-52), 144.8 (C-15), 138.3 (C-11), 138.1 (C-24), 135.7 (C-37, C-37’, 
C-41, C-41’), 134.2 (C-36), 134.1 (C-40), 130.8 (C-29), 129.7 (C-39, C-43), 129.5 (C-30, 
C-30’), 128.7 (C-26, C-26’), 128.6 (C-51), 128.0 (C-25, C-25’), 127.9 (C-27), 127.8 (C-
38, C-38’, C-42, C-42’), 127.0 (C-12), 118.7 (C-49), 117.2 (C-45), 114.0 (C-31, C-31’),  
108.7 (C-21), 102.9 (C-9), 93.6 (C-22), 79.0 (C-13), 77.1 (C-3), 75.6 (C-17), 72.7 (C-2), 
72.2 (C-28), 71.8 (C-8), 69.7 (C-23), 68.3 (C-5), 60.7 (C-19), 55.5 (C-33), 51.5 (C-44), 
51.3 (C-47), 46.2 (C-10), 40.9 (C-16), 40.8 (C-14), 39.3 (C-18), 36.6 (C-4), 35.3 (C-53), 
33.2 (C-6), 27.1 (C-35), 24.3 (C-20a), 24.1 (C-20b), 22.0 (C-54), 19.4 (C-34), 15.010 (C-
1), 13.9 (C-55); 




704, 613 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C66H86O12SiNa 1121.5786; found 1121.5793.  
(4S,6S)-8-(tert-Butyldiphenylsilyloxy)-2-
(chloromethyl)-6-(4-methoxybenzyloxy)oct-1-en-4-ol 
(3.42): To a stirred solution of  aldehyde 2.39 (524 mg, 
1.10 mmol, 1.0 equiv) in freshly distilled CH2Cl2 (22 mL, 
0.05 M) was added MgBr2∙Et2O (576 mg, 2.23 mmol, 2.0 
equiv) in one portion at –15 oC under an atmosphere of N2.  
After 15 minutes, the mixture was then cooled down to –78 oC, and stirred for further 30 
minutes, whereupon a solution of 2-(trimethylsilylmethyl)allyltributylstannane (570 uL, 
1.67 mmol, 1.5 eq) in CH2Cl2 (5.5 mL, 0.3 M) was introduced via cannula over 5 minutes.  
It was stirred for 4 hours in this condition before being poured into a saturated NaHCO3 
solution (30 mL).  The aqueous layer was extracted with Et2O (3 x 10 mL).  The combined 
organic layers were washed with brine (50 mL) and dried over anhydrous Na2SO4.  The 
solution was filtered and concentrated under reduced pressure to provide a colorless oil.  
The crude product was purified by flash chromatography on silica gel eluting with 2-8 vol% 
of EtOAc in hexanes to provide the titled compound (494 mg, 0.870 mmol, 79.2% yield, 
dr = 97:3) as a yellowish oil, and its diastereomer (15.1 mg, 0.0266 mmol, 2.4% yield, dr 
= 97:3). 
TLC:  Rf = 0.46 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +8.9 (c 1.495, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.74-7.65 (m, 4H, H-17, H-17’, H-21, H-21’), 7.50-7.44 (m, 




H-12, H-12’), 6.87 (d, J = 8.4 Hz, 2H, H-13, H-13’), 5.24 (d, J = 1.0 Hz, 1H, H-9a), 5.06 
(d, J = 1.0 Hz, 1H, H-9b), 4.48 (ABq, J = 11.3 Hz, Δν = 6.9 Hz, 2H, H-10), 4.14-4.07 (m, 
2H, H-8), 4.11-4.04 (m, 1H, H-5), 3.99 (dddd, J = 6.6, 6.6, 6.6, 3.7 Hz, 1H, H-3), 3.88-
3.80 (m, 1H, H-1a), 3.81 (s, 3H, H-15); 3.80-3.73 (m, 1H, H-1b), 2.87 (bs, 1H, -OH), 2.39-
2.24 (m, 2H, H-6a, H-6b), 1.99 (dddd, J = 13.9, 6.1, 6.1, 6.1 Hz, 1H, H-2a), 1.79 (app. dq, 
J = 14.3, 6.4 Hz, 1H, H-2b), 1.77 (ddd, J = 14.7, 9.3, 3.4 Hz, 1H, H-4a), 1.63 (ddd, J = 
14.6, 6.8, 2.5 Hz, 1H, H-4b), 1.10 (s, 9H, H-25); 
125 MHz 13C NMR (CDCl3) δ 159.5 (C-14), 142.7 (C-7), 135.8 (C-17, C-17’, C-21, C-
21’), 133.9 (C-16), 133.9 (C-20), 130.4 (C-11), 129.9 (C-19, C-23), 129.8 (C-12, C-12’), 
127.9 (C-18, C-18’, C-22, C-22’), 117.2 (C-9), 114.0 (C-13, C-13’), 74.0 (C-3), 71.3 (C-
10), 66.9 (C-5), 60.7 (C-1), 55.4 (C-15), 48.6 (C-8), 41.6 (C-6), 40.1 (C-4), 36.7 (C-2), 
27.1 (C-25a, C-25b, C-25c), 19.4 (C-24); 
FTIR (neat): νmax 3480 (br), 3071, 2933, 2859, 1829, 1614, 1588, 1514, 1467, 1428, 1389, 
1361, 1301, 1250, 1176, 1108, 912, 831, 739, 704, 666 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C33H43O4ClSiNa 589.2517; found 589.2526. 
(4S,6S)-4-(tert-Butyldimethylsilyloxy)-8-(tert-
butyldiphenylsilyloxy)-2-(chloromethyl)-6-(4-
methoxybenzyloxy)oct-1-ene (3.43): With a -10 oC 
bath, to a stirred solution of alcohol 3.42 (1.110 g, 
1.957 mmol, 1.0 equiv) in freshly distilled CH2Cl2 
(40.0 mL, 0.05 M) was added 2,6-lutidine (700 uL, 5.95 mmol, 3.0 equiv) via syringe.  
Then, TBSOTf (690 uL, 2.94 mmol, 1.5 eq) was added dropwise via syringe.  This reaction 




solution (50 mL) .  The aqueous layer was then extracted with Et2O (3 x 15 mL).  The 
combined organic layers were washed with brine (50 mL), and dried over anhydrous 
Na2SO4.  The solution was filtered and concentrated under reduced pressure.  The 
remainder was purified by flash chromatography on silica gel eluting with 3 vol% of ethyl 
acetate in hexanes to provide the desired product (1.276 g, 1.872 mmol, 95.7% yield) as a 
yellowish oil. 
TLC:  Rf = 0.63 (EtOAc/Hex = 3:7, v/v); 
[α]20 D +12.0 (c 1.635, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.69 (app. td, J = 6.8, 1.5 Hz, 4H, H-20, H-20’, H-24, H-
24’), 7.49-7.34 (m, 6H, H-21, H-21’, H-22, H-25, H-25’, H-26), 7.20 (d, J = 8.5 Hz, 2H, 
H-15, H-15’), 6.86 (d, J = 8.5 Hz, 2H, H-16, H-16’), 5.17 (d, J = 1.2 Hz, 1H, H-9a), 4.98 
(d, J = 1.2 Hz, 1H, H-9b), 4.41 (ABq, J = 10.9 Hz, Δν = 29.9 Hz, 2H, H-13), 4.11-4.02 (m, 
1H, H-5), 4.06 (br. s, 2H, H-8), 3.85-3.78 (m, 2H, H-1), 3.81 (s, 3H, H-18), 3.83-3.72 (m, 
1H, H-3), 2.44 (dd, J = 14.2, 5.1 Hz, 1H, H-6a), 2.34 (dd, J = 14.2, 7.1 Hz, 1H, H-6b), 
1.88-1.75 (m, 2H, H-2), 1.74 (ddd, J = 14.2, 8.5, 4.2 Hz, 1H, H-4a), 1.52 (ddd, J = 14.3, 
7.8, 4.0 Hz, 1H, H-4b), 1.08 (s, 9H, H-28), 0.91 (s, 9H, H-12), 0.10 (s, 3H, H-10a), 0.08 
(s, 3H, H-10b); 
125 MHz 13C NMR (CDCl3) δ 159.3 (C-17), 142.4 (C-7), 135.8 (C-20, C-20’, C-24, C-
24’), 134.0 (C-19, C-23), 131.2 (C-14), 129.8 (C-22, C-26), 129.3 (C-15, C-15’), 127.9 (C-
21, C-21’, C-25, C-25’), 117.5 (C-9), 114.0 (C-16, C-16’), 73.4 (C-3), 70.7 (C-13), 68.2 
(C-5), 61.0 (C-1), 55.5 (C-18), 48.7 (C-8), 42.8 (C-4), 41.7 (C-6), 37.6 (C-2), 27.1 (C-28a, 
C-28b, C-28c), 26.2 (C-12), 19.4 (C-27), 18.2 (C-11), -3.8 (C-10a), -4.3 (C-10b); 




1251, 1176, 1108, 1006, 912, 831, 775, 739, 704, 666, 614, 536 cm-1. 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C39H57O4ClSi2Na 703.3382; found 703.3384. 
(3S,5S)-5-(tert-Butyldimethylsilyloxy)-7-(chloromethyl)-
3-(4-methoxybenzyloxy)oct-7-en-1-ol (3.44): To a solution 
of silyl ether 3.43 (379 mg, 0.556 mmol, 1.0 equiv) in MeOH 
(30 mL, 0.02 M) was added NH4F solid (409 mg, 11.0 mmol, 
20 equiv) in one portion at room temperature.  This reaction 
was heated at 60 oC with stirring for 6 hours, and quenched 
with a saturated solution of NaHCO3 (100 mL).  It was diluted with EtOAc (50 mL) and 
extracted with EtOAc (3 x 20 mL).  The combined organic layers were washed with brine 
(100 mL) and dried over anhydrous Na2SO4.  The solution was filtered and concentrated 
under reduced pressure.  The colorless crude product was purified by flash chromatography 
on silica gel eluting with 18-25 vol% of ethyl acetate in hexanes to provide the desired 
product (243 mg, 0.548 mmol, 98.6% yield) as a colorless oil. 
TLC:  Rf = 0.27 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +4.3 (c 1.06, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.26 (d, J = 8.5 Hz, 2H, H-15, H-15’), 6.89 (d, J = 8.5 Hz, 
2H, H-16, H-16’), 5.21 (d, J = 1.0 Hz, 1H, H-9a), 5.01 (d, J = 1.2 Hz, 1H, H-9b), 4.48 
(ABq, J = 10.9 Hz, Δν = 23.3 Hz, 2H, H-13), 4.07 (ABq, J = 11.7 Hz, Δν = 9.5 Hz, 2H, H-
8), 4.03 (dddd, J = 7.3, 7.2, 5.3, 4.8 Hz, 1H, H-5), 3.86-3.80 (m, 1H, H-1a), 3.81 (s, 3H, 
H-18), 3.80-3.75 (m, 1H, H-3), 3.76-3.69 (m, 1H, H-1b), 2.42 (dd, J = 14.2, 5.5 Hz, 1H, 
H-6a), 2.34 (dd, J = 14.2, 7.1 Hz, 1H, H-6b), 2.24 (br. s, 1H, -OH), 1.95 (dddd, J = 14.5, 




14.4, 6.4, 6.1, 4.6 Hz, 1H, H-2b), 1.54 (ddd, J = 14.3, 7.7, 4.8 Hz, 1H, H-4b), 0.90 (s, 9H, 
H-12), 0.09 (s, 3H, H-10a), 0.08 (s, 3H, H-10b);  
125 MHz 13C NMR (CDCl3) δ 159.5 (C-17), 142.2 (C-7), 130.6 (C-14), 129.5 (C-15, C-
15’), 117.7 (C-9), 114.1 (C-16, C-16’), 75.6 (C-3), 70.8 (C-13), 68.4 (C-5), 60.5 (C-1), 
55.5 (C-18), 48.8 (C-8), 41.9 (C-4), 41.624 (C-6), 36.207 (C-2), 26.1 (C-12), 18.2 (C-11), 
-3.9 (C-10a), -4.3 (C-10b); 
FTIR (neat): νmax 3423 (br), 2952, 2858, 1613, 1514, 1466, 1385, 1302, 1251, 1176, 1081, 
913, 834, 776, 665 cm-1; 
HRMS (ESI-TOF) m/z: [M+Na+] Calcd for C23H39O4ClSiNa 465.2204; found 465.2205. 
(3R,5S)-5-(tert-Butyldimethylsilyloxy)-7-(chloromethyl)-3-
(4-methoxybenzyloxy)oct-7-enal (3.45): To a stirred solution 
of alcohol 3.44 (351.4 mg, 0.7931 mmol, 1.0 equiv) in dry 
CH2Cl2 (40 mL, 0.02 M) was added t-BuOH (100 uL, 1.04 
mmol, 1.3 equiv) and freshly distilled pyridine (193 uL, 2.38 
mmol, 3.0 equiv).  Then this reaction was cooled down to 0 oC, 
and Dess-Martin periodinane (519 mg, 1.19 mmol, 1.5 equiv) was added in one portion.  
After 10 minutes, the cooling bath was removed and the reaction was stirred at room 
temperature for 1 hour under an atmosphere of N2.  Then, a saturated NaHCO3 solution (20 
mL) was added into this reaction, followed by a saturated Na2S2O3 solution (20 mL).  This 
mixture was stirred for 10 minutes at ambient temperature.  The aqueous layer was 
extracted with Et2O (3 x 10 mL).  The combined organic layers were washed with brine 
(30 mL) and dried over anhydrous Na2SO4.  The solution was filtered and concentrated 




eluting with 5-12 vol% of EtOAc in hexanes to provide the titled compound (301.4 mg, 
0.6833 mmol, 86.2% yield) as a colorless oil.   
TLC:  Rf = 0.41 (EtOAc/Hex = 3:7, v/v);  
[α]20 D 17.8 (c 1.275, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.81 (dd, J = 2.4, 2.2 Hz, 1H, H-1), 7.24 (d, J = 8.7 Hz, 2H, 
H-15, H-15’), 6.89 (d, J = 8.7 Hz, 2H, H-16, H-16’), 5.20 (d, J = 1.2 Hz, 1H, H-9a), 5.00 
( d, J = 1.2 Hz, 1H, H-9b), 4.47 (ABq, J = 10.7 Hz, Δν = 27.5 Hz, 2H, H-13), 4.14-4.05 
(m, 2H, H-3, H-5), 4.06 (dd, J = 11.7, 1.0 Hz, 1H, H-8a), 4.03 (dd, J = 11.7, 1.0 Hz, 1H, 
H-8b), 3.81 (s, 3H, H-18), 2.69 (ddd, J = 16.1, 5.9, 2.4 Hz, 1H, H-2a), 2.65 (ddd, J = 16.2, 
5.6, 2.2 Hz, 1H, H-2b), 2.46 (ddd, J = 14.2, 4.9, 1.0 Hz, 1H, H-6a), 2.32 (ddd, J = 14.2, 
7.6, 1.0 Hz, 1H, H-6b), 1.87 (ddd, J = 14.3, 8.4, 3.5 Hz, 1H, H-4a), 1.53 (ddd, J = 14.3, 
8.3, 4.0 Hz, 1H, H-4b), 0.90 (s, 9H, H-12), 0.10 (s, 3H, H-10a), 0.09 (s, 3H, H-10b);  
125 MHz 13C NMR (CDCl3) δ 201.4 (C-1), 159.5 (C-17), 142.0 (C-7), 130.4 (C-14), 129.4 
(C-15, C-15’), 117.8 (C-9), 114.1 (C-16, C-16’), 71.8 (C-3), 71.1 (C-13), 68.0 (C-5), 55.5 
(C-18), 48.9 (C-2), 48.7 (C-8), 42.8 (C-4), 41.8 (C-6), 26.1 (C-12), 18.2 (C-11), -3.8 (C-
10a), -4.4 (C-10b);  
FTIR (neat): νmax 2953, 2857, 2725, 1725, 1644, 1613, 1587, 1514, 1466, 1384, 1301, 1251, 
1176, 1093, 915, 834, 776, 665, 571 cm-1; 





(4-methoxybenzyloxy)oct-7-enic Acid (3.12): To a stirred 
solution of aldehyde 3.45 (300 mg, 0.681 mmol, 1.0 equiv) in 
t-BuOH (34 mL, 0.02 M) and isoamylene (17 mL, 0.04 M) was 
added distilled H2O (3.5 mL, 0.2 M) and KH2PO4 (931 mg, 
6.84 mmol, 10 equiv).  This mixture was stirred at room 
temperature for 20 minutes, whereupon it was homogenous.  This reaction was then cooled 
down to 0 oC, and NaClO2 (393 mg, 3.48 mmol, 5.0 equiv) was added in one portion.  It 
was stirred at this temperature for 2 hours and quenched with a saturated NaS2O3 solution 
(15 mL).  After 30 minutes, it was then poured into a mixture of EtOAc (20 mL) and brine 
(30 mL).  The aqueous phase was extracted with EtOAc (3 x 15 mL).  The combined 
organic layers were dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 9-20 vol% of EtOAc in hexanes with 1 vol% 
methanol to provide the titled compound (311 mg, 0680 mmol, 99.9% yield) as a colorless 
oil. 
TLC:  Rf = 0.26 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +16.1 (c 1.045, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 11.01 (br. s, 1H, -CO2H), 7.25 (d, J = 8.7 Hz, 2H, H-15, H-
15’), 6.88 (d, J = 8.7 Hz, 2H, H-16, H-16’), 5.18 (d, J =1.0 Hz, 1H, H-9a), 4.99 (d, J =1.0 
Hz, 1H, H-9b), 4.51 (ABq, J = 10.7 Hz, Δν = 51.1 Hz, 2H, H-13), 4.11-4.02 ( m, 1H, H-
5), 4.04 (dd, J = 11.8, 0.7 Hz, 1H, H-8a), 4.03 (dd, J = 11.7, 1.0 Hz, 1H, H-8b), 4.07-3.99 




6.1 Hz, 1H, H-2b), 2.46 (ddd, J = 14.2, 4.9, 1.0 Hz, 1H, H-6a), 2.32 (ddd, J = 14.2, 7.6, 
0.7 Hz, 1H, H-6b), 1.83 (ddd, J = 14.4, 8.5, 3.4 Hz, 1H, H-4a), 1.57 (ddd, J = 14.4, 8.3, 
3.7 Hz, 1H, H-4b), 0.90 (s, 9H, H-12), 0.10 (s, 3H, H-10a), 0.09 (s, 3H, H-10b); 
125 MHz 13C NMR (CDCl3) δ 177.3 (C-1), 159.5 (C-17), 142.0 (C-7), 130.4 (C-14), 129.5 
(C-15, C-15’), 117.8 (C-9), 114.1 (C-16, C-16’), 73.2 (C-3), 71.3 (C-13), 68.0 (C-5), 55.5 
(C-18), 48.7 (C-8), 42.6 (C-4), 41.8 (C-6), 40.0 (C-2), 26.1 (C-12), 18.2 (C-11), -3.8 (C-
10a), -4.4 (C-10b); 
FTIR (neat): νmax 3338 (br), 2954, 2932, 2858, 1711, 1613, 1514, 1465, 1441, 1386, 1363, 
1302, 1251, 1174, 1083, 1037, 915, 835, 776, 665 cm-1; 







pyran-3-yl Octa-2,4-dienoate (3.46): To a stirred solution of silyl ether 3.41 (331.8 mg, 
0.3018 mmol, 1.0 equiv) in MeOH (30.0 mL, 0.01 M) was added NH4F solid (347 mg, 
9.28 mmol, 30.0 equiv) in one portion at room temperature.  This reaction was stirred at 
60 oC for 24 hours, whereupon it was diluted with EtOAc (20 ml) and poured into a 
saturated NaHCO3 solution (30 mL).  The aqueous layer was extracted with EtOAc (3 x 10 
mL).  The combined organic layers were washed with brine (30 mL) and dried over 




The remainder was purified by flash chromatography on silica gel eluting with 20-30 vol% 
of EtOAc in hexanes to provide the titled compound (254.4 mg, 0.2954 mmol, 97.9% yield) 
as a yellow oil.   
TLC:  Rf = 0.23 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -5.5 (c 1.985, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.40-7.33 (m, 4H, H-37, H-37’, H-38, H-38’), 7.32-7.25 (m, 
2H, H-39, H-24), 7.22 (d, J = 8.8 Hz, 2H, H-42, H-42’), 6.84 (d, J = 8.8 Hz, 2H, H-43, H-
43’), 6.23-6.14 (m, 2H, H-25, H-26), 6.02 (dd, J = 16.0, 1.2 Hz, 1H, H-11), 5.89 (br. s, 1H, 
H-30), 5.79 (d, J = 15.3 Hz, 1H, H-23), 5.61 (br. s, 1H, H-8), 5.36 (dd, J = 16.0, 5.9 Hz, 
1H, H-12), 4.87 (s, 2H, H-34), 4.73 (d, J = 1.8 Hz, 1H, H-21a), 4.70 (dd, J = 2.1, 1.8 Hz, 
1H, H-21b), 4.68 (s, 2H, H-35), 4.63 (d, J = 11.0 Hz, 1H, H-40a), 4.45 (d, J = 11.0 Hz, 
1H, H-40b), 4.16-4.07 (m, 1H, H-5), 4.13 (qd, J = 6.5, 4.7 Hz, 1H, H-2), 3.91 (ddd, J = 
10.3, 4.7, 2.2 Hz, 1H, H-3), 3.84-3.70 (m, 2H, H-19a, H-19b), 3.79 (s, 3H, H-45), 3.71-
3.58 (m, 1H, H-13), 3.67 (s, 3H, H-32), 3.50 (dddd, J = 11.4, 8.7, 3.6, 2.7 Hz, 1H, H-17), 
3.44 (dd, J = 16.1, 2.9 Hz, 1H, H-6eq), 3.24 (s, 3H, H-33), 2.94 (br. s, 1H, -OH), 2.43 (ddd, 
J = 15.8, 11.7, 1.6 Hz, 1H, H-6ax), 2.24-2.12 (m, 4H, H-14eq, H-27, H-16eq), 2.07-1.95 (m, 
2H, H-16ax, H-14ax), 1.94 (ddd, J = 14.3, 9.6, 2.1 Hz, 1H, H-4a), 1.82-1.69 (m, 3H, H-18a, 
H-18b, H-4b), 1.47 (sex, J = 7.3 Hz, 2H, H-28), 1.24 (d, J = 6.2 Hz, 3H, H-1), 1.13 (s, 3H, 
H-20a), 1.11 (s, 3H, H-20b), 0.93 (t, J = 7.4 Hz, 3H, H-29);  
125 MHz 13C NMR (CDCl3) δ 166.8 (C-31), 165.6 (C-22), 159.4 (C-44), 153.4 (C-7), 
146.7 (C-24), 145.9 (C-26), 144.1 (C-15), 138.9 (C-11), 138.1 (C-36), 130.7 (C-41), 129.5 
(C-42, C-42’), 128.6 (C-38, C-38’), 128.6 (C-25), 128.0 (C-37, C-37’), 127.9 (C-39), 126.5 




(C-34), 79.4 (C-13), 78.1 (C-17), 77.0 (C-3), 72.7 (C-2), 72.1 (C-40), 71.6 (C-8), 69.6 (C-
35), 68.3 (C-5), 60.9 (C-19), 55.4 (C-45), 51.3 (C-32, C-33), 46.2 (C-10), 40.9 (C-14), 40.8 
(C-16), 38.4 (C-18), 36.5 (C-4), 35.3 (C-27), 33.4 (C-6), 24.1 (C-20a), 24.0 (C-20b), 22.0 
(C-28), 15.0 (C-1), 13.9 (C-29);  
FTIR (neat): νmax 2936, 1718, 1643, 1614, 1514, 1436, 1248, 1042, 891, 738, 699 cm-1; 







2,4-dienoate (3.47): To a stirred solution of alcohol 3.46 (243.1 mg, 0.2823 mmol, 1.0 
equiv) in dry CH2Cl2 (30 mL, 0.01 M) was added t-BuOH (35 uL, 0.37 mmol, 1.3 equiv) 
and freshly distilled pyridine (70 uL, 0.87 mmol, 3.0 equiv).  Then this reaction was cooled 
down to 0 oC, and Dess-Martin periodinane (186 mg, 0.425 mmol, 1.5 equiv) was added 
in one portion.  After 10 minutes, the cooling bath was removed and the reaction was stirred 
at room temperature for 1 hour under an atmosphere of N2.  Then, a saturated NaHCO3 
solution (20 mL) was added into this reaction, followed by a saturated Na2S2O3 solution 
(20 mL).  This mixture was stirred for 10 minutes at ambient temperature.  The aqueous 
layer was extracted with Et2O (3 x 10 mL).  The combined organic layers were washed 
with brine (30 mL) and dried over anhydrous Na2SO4.  The solution was filtered and 




chromatography on silica gel eluting with 12-20 vol% of EtOAc in hexanes to provide the 
titled compound (236.8 mg, 0.2757 mmol, 97.6% yield) as a yellowish oil.   
TLC:  Rf = 0.32 (EtOAc/Hex = 3:7, v/v);  
[α]20 D -6.1 (c 1.03, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.77 (t, J = 2.2, 1H, H-19), 7.39-7.33 (m, 4H, H-37, H-37’, 
H-38, H-38’), 7.33-7.24 (m, 2H, H-39, H-24), 7.22 (d, J = 8.7 Hz, 2H, H-42, H-42’), 6.84 
(d, J = 8.7 Hz, 2H, H-43, H-43’), 6.24-6.12 (m, 2H, H-25, H-26), 6.02 (dd, J = 16.0, 1.3 
Hz, 1H, H-11), 5.90 (br. s, 1H, H-30), 5.78 (d, J = 15.1 Hz, 1H, H-23), 5.58 (br. s, 1H, H-
8), 5.35 (dd, J = 15.9, 5.9 Hz, 1H, H-12), 4.87 (ABq, J = 7.1 Hz, Δν = 3.8 Hz, 2H, H-34), 
4.76 (dd, J = 3.8, 1.8 Hz, 1H, H-21a), 4.73 (dd, J = 3.8, 2.0 Hz, 1H, H-21b), 4.68 (s, 2H, 
H-35), 4.62 (d, J = 10.7 Hz, 1H, H-40a), 4.44 (d, J = 10.7 Hz, 1H, H-40b), 4.15-4.08 (m, 
1H, H-5), 4.13 (qd, J = 6.5, 4.8 Hz, 1H, H-2), 3.91 (ddd, J = 10.2, 4.8, 2.2 Hz, 1H, H-3), 
3.83-3.75 (m, 1H, H-17), 3.79 (s, 3H, H-45), 3.72 (dddd, J = 11.2, 5.9, 2.3, 1.3, 1H, H-13), 
3.67 (s, 3H, H-32), 3.47 (dd, J = 16.3, 2.7 Hz, 1H, H-6eq), 3.24 (s, 3H, H-33), 2.65 (ddd, J 
= 16.3, 7.3, 2.4 Hz, 1H, H-18a), 2.50 (ddd, J = 16.3, 5.1, 2.0 Hz, 1H, H-18b), 2.39 (ddd, J 
= 16.1, 11.7, 1.9 Hz, 1H, H-6ax), 2.30-2.11 (m, 4H, H-16eq, H-14eq, H-27), 2.04-1.93 (m, 
2H, H-14ax, H-16ax), 1.92 (ddd, J = 14.4, 9.8, 2.2 Hz, 1H, H-4a), 1.74 (ddd, J = 14.4, 10.2, 
2.7 Hz, 1H, H-4b), 1.47 (sex, J = 7.4 Hz, 2H, H-28), 1.23 (d, J = 6.4 Hz, 3H, H-1), 1.13 
(s, 3H, H-20a), 1.12 (s, 3H, H-20b), 0.93 (t, J = 7.3 Hz, 3H, H-29);  
125 MHz 13C NMR (CDCl3) δ 201.2 (C-19), 166.7 (C-31), 165.6 (C-22), 159.4 (C-44), 
153.0 (C-7), 146.7 (C-24), 146.0 (C-26), 143.5 (C-15), 139.0 (C-11), 138.1 (C-36), 130.7 
(C-41), 129.5 (C-42, C-42’), 128.7 (C-38, C-38’), 128.6 (C-25), 128.0 (C-37, C-37’), 127.9 




(C-9), 93.6 (C-34), 79.4 (C-13), 77.0 (C-3), 73.6 (C-17), 72.6 (C-2), 72.1 (C-40), 71.7 (C-
8), 69.7 (C-35), 68.4 (C-5), 55.5 (C-45), 51.5 (C-33), 51.3 (C-32), 49.9 (C-18), 46.2 (C-
10), 40.6 (C-16), 40.5 (C-14), 36.5 (C-4), 35.3 (C-27), 33.2 (C-6), 24.2 (C-20a), 24.1 (C-
20b), 22.1 (C-28), 14.9 (C-1), 13.9 (C-29);  
FTIR (neat): νmax 2936, 1719, 1643, 1614, 1514, 1459, 1382, 1304, 1248, 1042, 892, 858, 
821, 739, 699, 536 cm-1; 







yl Octa-2,4-dienoate (3.48): To a stirred solution of PMB ether 3.47 (69.5 mg, 80.9 umol, 
1.0 equiv) in CH2Cl2 (1.6 mL, 0.05M) was added a 0.1 M phosphate pH = 6 buffer solution 
(0.80 mL, 0.1 M).  Then, this reaction was cooled down to 0 oC, and DDQ (38 mg, 160 
umol, 2.0 equiv) was added in one portion.  It was stirred for 5 hours at this temperature.  
Then, this reaction was diluted with EtOAc (10 mL), and poured into a saturated NaHCO3 
solution (20 mL).  The aqueous layer was extracted with EtOAc (3 x 5 mL).  The combined 
organic layers were washed with brine (20 mL) and dried over anhydrous Na2SO4.  The 
solution was filtered and concentrated under reduced pressure.  The remainder was purified 
by flash chromatography on silica gel eluting with 28-38 vol% of EtOAc in hexanes to 




TLC:  Rf = 0.20 (EtOAc/Hex = 4:6, v/v);  
[α]20 D -14.3 (c 2.06, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.81 (t, J = 2.2, 1H, H-19), 7.39-7.32 (m, 4H, H-37, H-37’, 
H-38, H-38’), 7.32-7.24 (m, 2H, H-39, H-24), 6.23-6.11 (m, 2H, H-25, H-26), 6.02 (dd, J 
= 16.1, 1.2 Hz, 1H, H-11), 5.89 (dd, J = 1.2, 1.0 Hz, 1H, H-30), 5.78 (d, J = 15.4 Hz, 1H, 
H-23), 5.60 (br. s, 1H, H-8), 5.35 (dd, J = 16.0, 6.0 Hz, 1H, H-12), 4.87 (ABq, J = 7.0 Hz, 
Δν = 22.2 Hz, 2H, H-34), 4.76 (dd, J = 3.7, 2.0 Hz, 1H, H-21a), 4.74 (dd, J = 3.8, 1.8 Hz, 
1H, H-21b), 4.66 (ABq, J = 11.7 Hz, Δν = 15.3 Hz, 2H, H-35), 4.22 (dddd, J = 11.7, 7.8, 
3.2, 3.1 Hz, 1H, H-5), 3.93-3.85 (m, 1H, H-3), 3.82 (dddd, J = 11.4, 7.7, 5.1, 2.4 Hz, 1H, 
H-17), 3.72 (dddd, J = 11.3, 5.9, 2.4, 1.2 Hz, 1H, H-13), 3.67 (s, 3H, H-32), 3.69-3.64 (m, 
1H, H-2), 3.44 (ddd, J = 16.1, 2.4, 0.8 Hz, 1H, H-6eq), 3.35 (s, 3H, H-33), 2.77 (d, J = 4.4 
Hz, 1H, -OH), 2.67 (ddd, J = 16.3, 7.6, 2.6 Hz, 1H, H-18a), 2.52 (ddd, J = 16.3, 5.1, 2.0 
Hz, 1H, H-18b), 2.42 (ddd, J = 16.1, 11.7, 2.0 Hz, 1H, H-6ax), 2.25 (ddd, J = 13.2, 2.1, 1.6 
Hz, 1H, H-16eq), 2.21 (ddd, J = 13.2, 2.1, 1.7 Hz, 1H, H-14eq), 2.16 (q, J = 6.6 Hz, 2H, H-
27), 2.04-1.94 (m, 2H, H-14ax, H-16ax), 1.78-1.67 (m, 2H, H-4a, H-4b), 1.46 (sext, J = 7.3 
Hz, 2H, H-28), 1.27 (d, J = 6.3 Hz, 3H, H-1), 1.124 (s, 3H, H-20a), 1.117 (s, 3H, H-20b), 
0.92 (t, J = 7.3 Hz, 3H, H-29);  
125 MHz 13C NMR (CDCl3) δ 201.4 (C-19), 166.7 (C-31), 165.5 (C-22), 153.2 (C-7), 
146.7 (C-24), 145.9 (C-26), 143.5 (C-15), 139.3 (C-11), 137.7 (C-36), 128.7 (C-38, C-38’), 
128.5 (C-25), 128.1 (C-37, C-37’), 128.0 (C-39), 126.0 (C-12), 118.6 (C-23), 116.7 (C-30), 
109.6 (C-21), 102.8 (C-9), 93.9 (C-34), 79.4 (C-13), 78.0 (C-2), 73.5 (C-17), 71.8 (C-8), 
71.1 (C-3), 70.0 (C-35), 68.2 (C-5), 51.4 (C-33), 51.2 (C-32), 49.9 (C-18), 46.1 (C-10), 




22.0 (C-28), 16.9 (C-1), 13.9 (C-29);  
FTIR (neat): νmax 3513 (br), 2933, 1952, 1771, 1718, 1643, 1617, 1496, 1457, 1436, 1382, 
1356, 1313, 1243, 1134, 1105, 1056, 893, 861, 752, 700, 668, 633, 605, 536 cm-1; 









2,4-dienoate (3.49): Under an atmosphere of N2, to a stirred mixture of alcohol 3.48 (181.0 
mg, 0.2450 mmol, 1.0 equiv), acid 3.12 (153.5 mg, 0.3358 mmol, 1.3 equiv) and DMAP 
(33.6 mg, 0.272 mmol, 1.0 equiv) in toluene (12.0 mL, 0.02 M) was added DIPEA (220 
uL, 1.26 mmol, 5.0 equiv) at 0 oC.  Then, 2,4,6-trichlorobenzoylchloride (51.0 uL, 0.339 
mmol, 1.3 equiv) was added dropwise via syringe.  The reaction turned cloudy and white 
precipitate appeared during the addition.  It was allowed to warm to room temperature 
slowly, and stirred overnight (ca. 16 hours).  Then, it was diluted with ethyl ether (10 mL), 
and poured into a saturated NaHCO3 solution (20 mL).  The aqueous layer was extracted 
with ether (3 x 10 mL).  The combined organic layers were washed with brine (30 mL) and 
dried over anhydrous Na2SO4.  The solution was filtered and concentrated under reduced 




18-25 vol% of ethyl acetate in hexanes to provide the tiltled compound (264.3 mg, 0.2244 
mmol, 91.6% yield) as a colorless oil. 
TLC:  Rf = 0.48 (EtOAc/Hex = 4:6, v/v);  
[α]20 D -2.2 (c 2.405, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.80 (t, J = 2.2 Hz, 1H, H-9), 7.43-7.31 (m, 4H, H-46, H-
46’, H-47, H-47’), 7.31-7.25 (m, 2H, H-48, H-33), 7.22 (d, J = 8.5 Hz, 2H, H-51, H-51’), 
6.84 (d, J = 8.5 Hz, 2H, H-52, H-52’), 6.25-6.10 (m, 2H, H-34, H-35), 5.99 (d, J = 16.1 
Hz, 1H, H-17), 5.89 (br. s, 1H, H-39), 5.77 (d, J = 15.4 Hz, 1H, H-32), 5.50 (br. s, 1H, H-
20), 5.41 (ddd, J = 9.8, 4.2, 2.4 Hz, 1H, H-25), 5.33 (dd, J = 16.0, 5.7 Hz, 1H, H-16), 5.18 
(d, J = 0.8 Hz, 1H, H-28a), 4,99 (d, J = 1.0 Hz, 1H, H-28b), 4.83 (ABq, J = 7.0 Hz, Δν = 
6.7 Hz, 2H, H-43), 4.76 (d, J = 2.0 Hz, 1H, H-29a), 4.75 (d, J = 2.0 Hz, 1H, H-29b), 4.65 
(s, 2H, H-44), 4.55 (d, J = 10.9 Hz, 1H, H-49a), 4.41 (d, J = 10.9 Hz, 1H, H-49b), 4.13-
3.99 (m, 2H, H-5, H-3), 4.03 (br. s, 2H, H-8a, H-8b), 3.94 (qd, J = 6.5, 4.0 Hz, 1H, H-26), 
3.88-3.75 (m, 2H, H-23, H-11), 3.77 (s, 3H, H-54), 3.75-3.69 (m, 1H, H-15), 3.66 (s, 3H, 
H-41), 3.39 (dd, J = 15.8, 2.1 Hz, 1H, H-22eq), 3.21 (s, 3H, H-42), 2.66 (ddd, J = 16.4, 7.7, 
2.6 Hz, 1H, H-10a), 2.64 (dd, J = 15.4, 6.1 Hz, 1H, H-2a), 2.54 (dd, J = 15.2, 5.6 Hz, 1H, 
H-2b), 2.50 (ddd, J = 16.4, 5.0, 2.1 Hz, 1H, H-10b), 2.45 (dd, J = 14.2, 4.6 Hz, 1H, H-6a), 
2.40-2.33 (m, 1H, H-22ax), 2.30 (dd, J = 14.4, 7.6 Hz, 1H, H-6b), 2.27-2.20 (m, 2H, H-
14eq, H-12eq), 2.16 (dtd, J = 7.4, 5.1, 2.7 Hz, 2H, H-36), 2.02-1.82 (m, 4H, H-12ax, H-14ax, 
H-24a, H-24b), 1.79 (ddd, J = 14.3, 8.7, 3.4 Hz, 1H, H-4a), 1.51 (ddd, J = 14.3, 8.5, 3.9 
Hz, 1H, H-4b), 1.47 (sext, J = 7.3 Hz, 2H, H-37), 1.18 (d, J = 6.3 Hz, 3H, H-27), 1.11 (s, 
6H, H-30a, H-30b), 0.93 (t, J = 7.4 Hz, 3H, H-38), 0.89 (s, 9H, H-57), 0.092 (s, 3H, H-




125 MHz 13C NMR (CDCl3) δ 201.4 (C-9), 170.9 (C-1), 166.7 (C-40), 165.5 (C-31), 159.3 
(C-53), 152.9 (C-21), 146.7 (C-33), 146.0 (C-35), 143.6 (C-13), 142.1 (C-7), 139.0 (C-17), 
138.0 (C-45), 130.7 (C-50), 129.1 (C-51, C-51’), 128.6 (C-47, C-47’), 128.6 (C-34), 128.1 
(C-46, C-46’), 127.9 (C-48), 126.2 (C-16), 118.6 (C-32), 117.7 (C-28), 117.0 (C-39), 114.0 
(C-52, C-52’), 109.7 (C-29), 102.9 (C-19), 93.6 (C-43), 79.4 (C-15), 73.6 (C-11), 73.3 (C-
26), 73.1 (C-3), 71.9 (C-20, C-25), 71.1 (C-49), 69.8 (C-44), 68.1 (C-23), 67.8 (C-5), 55.4 
(C-54), 51.5 (C-42), 51.3(C-41), 49.9 (C-10), 48.7 (C-8), 46.1 (C-18), 42.6 (C-4), 41.8 (C-
6), 40.5 (C-12, C-14), 40.3 (C-2), 36.3 (C-24), 35.3 (C-36), 32.9 (C-22), 26.1 (C-57), 24.2 
(C-30a), 24.0 (C-30b), 22.1 (C-37), 18.2 (C-56), 15.8 (C-27), 13.9 (C-38), -3.8 (C-55a), -
4.4 (C-55b); 
FTIR (neat): νmax 2933, 2858, 1723, 1643, 1615, 1514, 1463, 1382, 1303, 1250, 1102, 1041, 
911, 835, 776, 745, 700, 665, 536 cm-1; 








methylbut-1-en-1-yl)-4-methylenetetrahydro-2H-pyran-2-yl)acetic Acid (3.50): To a 
stirred solution of aldehyde 3.49 (80.1 mg, 0.0680 mmol, 1.0 equiv) in CH3CN (3.5 mL, 




ice-water bath, a solution of NaH2PO4∙H2O (97 mg, 0.70 mmol, 10.0 equiv) and NaClO2 
(80 mg, 0.71  mmol, 10.0 equiv) in D.I. H2O (1.7 mL, 0.04 M) was added into this reaction.  
It was stirred for 3 hours, and then quenched by addition of a saturated Na2S2O3 solution 
( 10 mL).  This mixture was stirred for 10 minutes at ambient temperature.  The reaction 
was diluted by EtOAc (10 mL) and poured into a mixture of a saturated NH4Cl solution 
(10 mL) and brine (10 mL).  The aqueous layer was extracted with EtOAc (4 x 5 mL).  The 
combined organic layers were dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 15-35 vol% of EtOAc in hexanes to provide the 
titled compound (76.3 mg, 0.0639 mmol, 94.0% yield) as a colorless oil.   
TLC:  Rf = 0.53 (MeOH/EtOAc/Hex = 1:4:5, v/v/v);  
[α]20 D -10.1 (c 1.475, CHCl3); 
500 MHz 1H NMR (CDCl3) δ -CO2H not observed, 7.41-7.31 (m, 4H, H-46, H-46’, H-47, 
H-47’), 7.31-7.24 (m, 2H, H-48, H-33), 7.22 (d, J = 8.8 Hz, 2H, H-51, H-51’), 6.84 (d, J 
= 8.8 Hz, 2H, H-52, H-52’), 6.23-6.13 (m, 2H, H-34, H-35), 6.08 (dd, J = 16.1, 1.2 Hz, 
1H, H-17), 5.90 (br. s, 1H, H-39), 5.76 (d, J = 15.4 Hz, 1H, H-32), 5.43 (br. s, 1H, H-20), 
5.41 (ddd, J = 9.9, 4.1, 2.3 Hz, 1H, H-25), 5.30 (dd, J = 16.0, 5.7 Hz, 1H, H-16), 5.17 (d, 
J = 1.0 Hz, 1H, H-28a), 4.98 (d, J = 1.2 Hz, 1H, H-28b), 4.84 (ABq, J = 7.1 Hz, Δν = 5.6 
Hz, 2H, H-43), 4.75 (ABq, J = 6.8 Hz, Δν = 11.8 Hz, 2H, H-29), 4.67 (ABq, J = 11.8 Hz, 
Δν = 9.2 Hz, 2H, H-44), 4.54 (d, J = 10.9 Hz, 1H, H-49a), 4.41 (d, J = 10.9 Hz, 1H, H-
49b), 4.11-3.99 (m, 4H, H-5, H-3, H-8), 3.95 (qd, J = 6.4, 4.1 Hz, 1H, H-26), 3.85-3.75 
(m, 1H, H-23), 3.77 (s, 3H, H-54), 3.79-3.69 (m, 2H, H-11, H-15), 3.66 (s, 3H, H-41), 




H-2a), 2.61 (dd, J = 15.0, 7.7 Hz, 1H, H-10a), 2.56 (dd, J = 15.0, 5.5 Hz, 1H, H-2b), 2.52 
(dd, J = 15.2, 4.8 Hz, 1H, H-10b), 2.44 (dd, J = 14.0, 4.5 Hz, 1H, H-6a), 2.36-2.26 (m, 2H, 
H-22ax, H-6b), 2.28-2.19 (m, 2H, H-12eq, H-14eq), 2.16 (td, J = 7.3, 5.7 Hz, 2H, H-36), 
2.04-1.95 (m, 3H, H-12ax, H-14ax, H-24a), 1.91 (ddd, J = 14.6, 9.9, 2.6 Hz, 1H, H-24b), 
1.79 (ddd, J = 14.3, 8.7, 3.4 Hz, 1H, H-4a), 1.51 (ddd, J = 14.2, 8.4, 3.9 Hz, 1H, H-4b), 
1.46 (sex, J = 7.3 Hz, 2H, H-37), 1.18 (d, J = 6.4 Hz, 3H, H-27), 1.11 (s, 3H, H-30a), 1.10 
(s, 3H, H-30b), 0.92 (t, J = 7.4 Hz, 3H, H-38), 0.89 (s, 9H, H-57), 0.088 (s, 3H, H-55a), 
0.071 (s, 3H, H-55b);  
125 MHz 13C NMR (CDCl3) δ 173.2 (C-9), 171.3 (C-1), 166.8 (C-40), 165.5 (C-31), 159.3 
(C-53), 152.5 (C-21), 146.7 (C-33), 146.0 (C-35), 143.2 (C-13), 142.1 (C-7), 140.0 (C-17), 
137.8 (C-45), 130.6 (C-50), 129.2 (C-51, C-51’), 128.7 (C-47, C-47’), 128.6 (C-34), 128.1 
(C-46, C-46’), 127.9 (C-48), 125.2 (C-16), 118.6 (C-32), 117.7 (C-28), 117.5 (C-39), 114.0 
(C-52, C-52’), 109.9 (C-29), 102.9 (C-19), 93.5 (C-43), 79.3 (C-15), 74.6 (C-11), 73.5 (C-
26), 73.1 (C-3), 72.1 (C-20), 72.1 (C-25), 71.1 (C-49), 69.8 (C-44), 68.2 (C-23), 67.8 (C-
5), 55.4 (C-54), 51.8 (C-42), 51.3 (C-41), 48.7 (C-8), 46.0 (C-18), 42.5 (C-4), 41.8 (C-6), 
41.1 (C-10), 40.5 (C-14), 40.2 (C-2), 40.1 (C-12), 36.5 (C-24), 35.3 (C-36), 32.4 (C-22), 
26.1 (C-57), 24.0 (C-30a), 23.9 (C-30b), 22.0 (C-37), 18.2 (C-56), 15.8 (C-27), 13.9 (C-
38), -3.9 (C-55a), -4.4 (C-55b);  
FTIR (neat): νmax 3353 (br), 2933, 1718, 1643, 1615, 1514, 1437, 1382, 1303, 1249, 1159, 
1103, 911, 835, 776, 737, 699, 665, 591, 536 cm-1; 












To a stirred solution of acid 3.50 (143.9 mg, 120.5 umol, 1.0 equiv) in THF (6.0 mL, 0.02 
M) and MeOH (2.0 mL, 0.06 M) was added HF•Py solution (50 vol%, 0.60 mL, 0.20 M) 
at 0 oC.  It was allowed to warm to room temperature and stirred for 1 day.  Then, it was 
poured into a solution of brine (20 mL).  The separated aqueous layer was extracted with 
EtOAc (5 x 5 mL).  The combined organic layers were dried over anhydrous Na2SO4.  The 
solution was filtered and concentrated under reduced pressure.  The remainder was purified 
by flash chromatography on silica gel eluting with 10-25 vol% of EtOAc in hexanes with 
2 vol% MeOH to provide a colorless oil (117.3 mg, 108.6 umol, 90.2% yield).   
With an ice-water bath, to a stirred solution of abovementioned seco acid (117.3 mg, 
108.6 umol, 1.0 equiv) in toluene (11.0 mL, 0.01 M) was added 2,4,6-
trichlorobenzoylchloride (23.0 uL, 144 umol, 1.3 equiv) followed by DIPEA (95.0 uL, 545 
umol, 5.0 equiv) under an atmosphere of N2.  After 3 hours, this reaction was transferred 
to another flask containing 10 mL of toluene and DMAP (13.3 mg, 109 umol, 1.0 equiv) 
via syring pump at the rate 1mL/1h.  It was stiired for 2 hours after addition.  Then, it was 




ether (3 x 10 mL).  The combined organic layers were washed with brine (30 mL) and dried 
over anhydrous Na2SO4.  The solution was filtered and concentrated under reduced 
pressure.  The reminder was purified by flash chromatography on silica gel eluting with 
18-30 vol% of ethyl acetate in hexanes to provide the desired product (95.5 mg, 90.0 umol, 
74.7% yield over two steps) as a colorless oil. 
TLC:  Rf = 0.55 (MeOH/EtOAc/Hex = 1:3:6, v/v/v);  
[α]20 D +20.3 (c 0.34, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.48-7.33 (m, 4H, H-46, H-46’, H-47, H-47’), 7.33-7.27 (m, 
2H, H-48, H-33), 7.26 (d, J = 8.3 Hz, 2H, H-51, H-51’), 6.86 (d, J = 8.5 Hz, 2H, H-52, H-
52’), 6.34 (d, J = 15.9 Hz, 1H, H-17), 6.27-6.11 (m, 2H, H-34, H-35), 5.98 (br. s, 1H, H-
39), 5.77 (d, J = 15.1 Hz, 1H, H-32), 5.60 (ddd, J = 10.1, 4.3, 0.7 Hz, 1H, H-25), 5.35 (dd, 
J = 15.7, 8.2 Hz, 1H, H-16), 5.31 (s, 1H, H-20), 5.25-5.16 (m, 1H, H-5), 5.16 (s, 1H, H-
28a), 4.96 (s, 1H, H-28b), 4.85 (ABq, J = 7.1 Hz, Δν = 9.9 Hz, 2H, H-43), 4.76 (br. s, 1H, 
H-29a), 4.72 (br. s, 1H, H-29b), 4.67 (s, 2H, H-44), 4.51 (d, J = 10.7 Hz, 1H, H-49a), 4.39 
(d, J = 10.7 Hz, 1H, H-49b), 4.03 (ABq, J = 12.0 Hz, Δν = 36.6 Hz, 2H, H-8), 4.04-3.95 
(m, 2H, H-15, H-3), 3.90 (dq, J = 6.6, 6.3 Hz, 1H, H-26), 3.80 (s, 3H, H-54), 3.69 (s, 3H, 
H-41), 3.76-3.64 (m, 2H, H-23, H-22eq), 3.58 (app. t, J = 10.1 Hz, 1H, H-11), 3.12 (s, 3H, 
H-42), 2.79 (dd, J = 17.6, 4.6 Hz, 1H, H-2a), 2.55 (dd, J = 15.0, 9.1 Hz, 1H, H-10a), 2.46-
2.36 (m, 2H, H-6), 2.33 (dd, J = 17.7, 7.7 Hz, 1H, H-2b), 2.28 (app. d, J = 14.6 Hz, 1H, 
H-10b), 2.23-2.08 (m, 5H, H-22ax, H-12eq, H-36, H-14eq), 2.07-1.98 (m, 1H, H-24a), 1.99 
(t, J = 13.4 Hz, 1H, H-14ax), 1.97 (t, J = 13.1 Hz, 1H, H-12ax), 1.90 (td, J = 14.1, 9.7 Hz, 
1H, H-24b), 1.58 (ddd, J = 13.5, 11.8, 2.0 Hz, 1H, H-4a), 1.45 (sext, J = 7.3 Hz, 2H, H-




3H, H-30b), 0.92 (t, J = 7.2 Hz, 3H, H-38);  
125 MHz 13C NMR (CDCl3) δ 171.8 (C-9), 171.1 (C-1), 167.0 (C-40), 165.5 (C-31), 159.4 
(C-53), 151.7 (C-21), 146.9 (C-33), 146.1 (C-35), 143.7 (C-13), 141.4 (C-7), 141.2 (C-17), 
137.9 (C-45), 130.5 (C-50), 130.1 (C-51, C-51’), 128.7 (C-47, C-47’), 128.6 (C-34), 128.1 
(C-46, C-46’), 128.0 (C-48), 125.7 (C-16), 119.4 (C-39), 118.6 (C-32), 117.9 (C-28), 114.1 
(C-52, C-52’), 109.4 (C-29), 103.3 (C-19), 93.5 (C-43), 80.5 (C-15), 75.1 (C-11), 73.9 (C-
26), 73.0 (C-20), 71.9 (C-49), 71.5 (C-3), 71.1 (C-25), 69.9 (C-44), 69.7 (C-5), 67.4 (C-
23), 55.5 (C-54), 52.7 (C-42), 51.4 (C-41), 48.1 (C-8), 45.1 (C-18), 42.7 (C-10), 41.5 (C-
12), 41.2 (C-14), 40.9 (C-4), 39.8 (C-2), 38.7 (C-6), 36.0 (C-24), 35.3 (C-36), 30.8 (C-22), 
26.8 (C-30a), 22.0 (C-37), 21.0 (C-30b), 16.1 (C-27), 13.9 (C-38); 
FTIR (neat): νmax 2926, 2855, 1722, 1641, 1613, 1513, 1459, 1381, 1249, 1160, 1090, 1044, 
739, 700, 666, 590 cm-1; 







12,18,25,26-tetraoxatricyclo[19.3.1.15,9]hexacos-2-en-6-yl Octa-2,4-dienoate (3.52): 
To a stirred solution of allylchloride 3.51 (26.5 mg, 25.0 umol, 1.0 equiv) in dry acetone 
(5.0 mL, 0.005 M) was added NaI solid (32.4 mg, 385 umol, 15 equiv) in one portion at 




was added Et2O (10 mL) and poured into brine (15 mL).  The aqueous layer was extracted 
by Et2O (4 x 5 mL).  The combined organic layers were dried over Na2SO4.  The solution 
was filtered and concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 18-27 vol% of EtOAc in hexanes to provide the 
titled compound (26.4 mg, 0.229 umol, 91.7% yield) as a pale yellow oil.   
TLC:  Rf = 0.38 (Et2O/CH2Cl2/Hex = 1:1:2, v/v/v);  
[α]20 D +16.0 (c 1.31, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.45-7.33 (m, 4H, H-46, H-46’, H-47, H-47’), 7.33-7.27 (m, 
2H, H-48, H-33), 7.27 (d, J = 8.7 Hz, 2H, H-51, H-51’), 6.86 (d, J = 8.7 Hz, 2H, H-52, H-
52’), 6.33 (d, J = 15.9 Hz, 1H, H-17), 6.26-6.11 (m, 2H, H-34, H-35), 5.98 (d, J = 2.0 Hz, 
1H, H-39), 5.77 (d, J = 15.4 Hz, 1H, H-32), 5.59 (ddd, J = 10.9, 4.8, 1.8 Hz, 1H, H-25), 
5.35 (dd, J = 15.8, 8.3 Hz, 1H, H-16), 5.31 (s, 1H, H-20), 5.26 (br. s, 1H, H-28a), 5.19 
(dddd, J = 8.6, 6.5, 6.5, 2.2 Hz, 1H, H-5), 4.91 (app. d, J = 1.0 Hz, 1H, H-28b), 4.85 (ABq, 
J = 7.0 Hz, Δν = 9.1 Hz, 2H, H-43), 4.76 (app. q, J = 1.8 Hz, 1H, H-29a), 4.72 (app. td, J 
= 1.8, 1.7 Hz, 1H, H-29b), 4.67 (s, 2H, H-44), 4.52 (d, J = 10.6 Hz, 1H, H-49a), 4.40 (d, J 
= 10.8 Hz, 1H, H-49b), 4.05-3.96 (m, 2H, H-3, H-15), 3.92 (ABq, J = 9.7 Hz, Δν = 35.6 
Hz, 2H, H-8), 3.89 (qd, J = 6.4, 4.8 Hz, 1H, H-26), 3.80 (s, 3H, H-54), 3.69 (s, 3H, H-41), 
3.75-3.65 (m, 2H, H-23, H-22eq), 3.59 (dddd, J = 10.8, 9.4, 2.1, 1.7 Hz, 1H, H-11), 3.13 
(s, 3H, H-42), 2.78 (dd, J = 17.4, 4.6 Hz, 1H, H-2a), 2.56 (dd, J = 14.9, 9.1 Hz, 1H, H-
10a), 2.48 (dd, J = 14.9, 7.2 Hz, 1H, H-6a), 2.44 (dd, J = 14.6, 5.4 Hz, 1H, H-6b), 2.33 
(dd, J = 17.5, 7.6 Hz, 1H, H-2b), 2.29 (dd, J = 14.9, 3.6 Hz, 1H, H-10b), 2.23-2.07 (m, 5H, 
H-22ax, H-12eq, H-36, H-14eq), 2.07-1.93 (m, 3H, H-24a, H-14ax, H-12ax), 1.89 (ddd, J = 




7.3 Hz, 2H, H-37), 1.47-1.39 (m, 1H, H-4b), 1.23 (d, J = 6.5 Hz, 3H, H-27), 1.13 (s, 3H, 
H-30a), 1.10 (s, 3H, H-30b), 0.92 (t, J = 7.4 Hz, 3H, H-38);  
125 MHz 13C NMR (CDCl3) δ 171.8 (C-9), 171.1 (C-1), 167.0 (C-40), 165.5 (C-31), 159.4 
(C-53), 151.7 (C-21), 146.9 (C-33), 146.1 (C-35), 143.7 (C-13), 142.8 (C-7), 141.2 (C-17), 
137.9 (C-45), 130.5 (C-50), 130.1 (C-51, C-51’), 128.7 (C-47, C-47’), 128.6 (C-34), 128.1 
(C-46, C-46’), 128.0 (C-48), 125.7 (C-16), 119.3 (C-39), 118.6 (C-32), 117.1 (C-28), 114.1 
(C-52, C-52’), 109.4 (C-29), 103.2 (C-19), 93.5 (C-43), 80.4 (C-15), 75.2 (C-11), 73.9 (C-
26), 72.9 (C-20), 71.9 (C-49), 71.5 (C-3), 71.1 (C-25), 69.9 (C-44), 69.7 (C-5), 67.4 (C-
23), 55.5 (C-54), 52.7 (C-42), 51.4 (C-41), 45.1 C-18), 42.8 (C-10), 41.5 (C-12), 41.2 (C-
14), 40.9 (C-4), 39.8 (C-2), 39.6 (C-6), 36.0 (C-24), 35.3 (C-36), 30.8 (C-22), 30.5 (C-30a), 
29.9 (C-30b), 22.0 (C-37), 16.1 (C-27), 13.9 (C-38), 10.5 (C-8); 
FTIR (neat): νmax 2929, 2856, 1721, 1628, 1461, 1378, 1259, 1134, 1090, 1062, 913, 838, 
734, 667, 618 cm-1; 






3(27),5-dien-27-yl octa-2,4-dienoate (3.56):  
To a stirred solution of compound 3.51 (5.3 mg, 5.3 umol, 1.0 equiv) in CH2Cl2 (5 mL, 
0.001M) was added a 0.1 M phosphate pH = 6 buffer solution (0.5 mL, 0.01 M).  Then, 




in one portion.  It was stirred for 3 hours at this temperature.  Then, this reaction was diluted 
with EtOAc (10 mL), and poured into a saturated NaHCO3 solution (20 mL).  The aqueous 
layer was extracted with EtOAc (3 x 5 mL).  The combined organic layers were washed 
with brine (20 mL), and dried over anhydrous Na2SO4.  The solution was filtered and 
concentrated under reduced pressure.  The remainder was purified by flash 
chromatography on silica gel eluting with 15-25 vol% of EtOAc in hexanes.   
To a stirred solution of abovementioned alcohol CH3CN (6 mL) was added deionized 
water (60 uL) and LiBF4 solid (24.4 mg, 260 umol).  This reaction was stirred at 80 oC 
overnight (ca. 8 hours), and then cooled to room temperature before being concentrated.  
The remainder was purified by flash chromatography on silica gel eluting with 25-35 vol% 
of EtOAc in hexanes to provide the titled compound (2.5 mg, 3.2 umol, 61% yield over 
two steps) as a colorless oil. 
TLC:  Rf = 0.48 (EtOAc/Hex = 3:7, v/v);  
[α]20 D +26.0 (c 0.065, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.03 (dd, J = 15.2, 11.2 Hz, 1H, H-33), 6.42 (dd, J = 15.1, 
11.1 Hz, 1H, H-34), 6.11 (dt, J = 14.9, 7.3 Hz, 1H, H-35), 5.93 (dd, J = 15.9, 1.7 Hz, 1H, 
H-17), 5.79 (d, J = 15.2 Hz, 1H, H-32), 5.49 (dddd, J = 12.7, 6.8, 4.9, 1.7 Hz, 1H, H-5), 
5.79 (dd, J = 16.1, 3.9 Hz, 1H, H-16), 5.19 (br. s, 1H, H-28a), 5.02 (br. s, 1H, H-28b), 4.84 
(app. ddd, J = 13.2, 7.8, 3.4 Hz, 1H, H-25), 4.69 (br. s, 2H, H-29a, H-29b), 4.54 (dq, J = 
12.2, 6.3 Hz, 1H, H-26), 4.41 (app. t, J = 6.4 Hz, 1H, H-23), 4..22 (dd, J = 11.7, 1.0 Hz, 
1H, H-8a), 4.08 (d, J = 11.6 Hz, 1H, H-8b), 4.14-4.00 (m, 1H, H-3), 3.76 (ddd, J = 9.5, 
8.8, 2.0 Hz, 1H, H-11), 3.65 (s, 3H, H-41), 3.60 (dddd, J = 11.7, 3.4, 2.4, 2.0 Hz, 1H, H-




13.4 Hz, 1H, H-22eq), 2.64 (dd, J = 17.6, 10.3 Hz, 1H, H-10a), 2.54 (dd, J = 14.2, 4.9 Hz, 
1H, H-6a), 2.48-2.38 (m, 2H, H-2a, H-2b), 2.34 (dd, J = 14.2, 7.3 Hz, 1H, H-6b), 2.27 (d, 
J = 17.1 Hz, 1H, H-10b), 2.20 (d, J = 17.1 Hz, 1H, H-22ax), 2.24-2.13 (m, 3H, H-36, H-
14eq), 2.09 (ddd, J = 13.2, 2.0, 1.5 Hz, 1H, H-12eq), 2.00 (dd, J = 13.2, 12.2 Hz, 1H, H-
12ax), 1.83-1.73 (m, 2H, H-14ax, H-24a), 1.66 (ddd, J = 14.2, 10.5, 1.7 Hz, 1H, H-4a), 1.56 
(ddd, J = 14.2, 1.7, 1.5 Hz, 1H, H-4b), 1.48 (sext, J = 7.3 Hz, 2H, H-37), 1.46-1.41 (m, 1H, 
H-24b), 1.24 (d, J = 6.5 Hz, 3H, H-27), 1.13 (s, 3H, H-30a), 1.10 (s, 3H, H-30b), 0.93 (t, 
J = 7.3 Hz, 3H, H-38); 
125 MHz 13C NMR (CDCl3) δ 171.5 (C-1), 170.7 (C-9), 170.5 (C-40), 166.1 (C-31), 147.4 
(C-33), 145.1 (C-35), 144.5 (C-13), 141.7 (C-7), 141.4 (C-20), 133.8 (C-17), 129.9 (C-34), 
126.5 (C-16), 122.8 (C-21), 118.8 (C-32), 118.1 (C-28), 108.6 (C-29), 97.9 (C-19), 78.0 
(C-15), 74.2 (C-11), 68.2 (C-5), 68.1 (C-26), 67.1 (C-25), 65.7 (C-23), 63.5 (C-3), 52.3 (C-
41), 48.1 (C-8), 45.0 (C-2), 43.4 (C-18), 42.0 (C-4, C-14), 40.5 (C-10), 40.3 (C-12), 39.1 
(C-6), 35.3 (C-35), 35.1 (C-39), 33.8 (C-22), 32.1 (C-24), 25.6 (C-30a), 22.4 (C-37), 21.3 
(C-30b), 14.2 (C-27), 14.1 (C-38).   
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